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Structure of the Thesis 
Chapter 1 is the introductory chapter of the thesis. It describes the natural history and 
epidemiology of tuberculosis and the role of cytokines.  It also describes tools for diagnosing 
Mycobacterium tuberculosis (Mtb) infection with a particular focus on Interferon-gamma release 
assays (IGRAs) such as Quantiferon-TB Gold In-Tube (QFT) as an emerging alternative to the 
Tuberculin skin test (TST). This chapter also describes the aims and objectives as well as the 
conceptual framework of the study.  
Chapter 2 provides a literature review of the studies related to the objectives of this thesis. In 
this chapter I collate and review the most relevant analytical studies on the association between 
the magnitude of T-cell Interferon-γ responses to Mtb specific antigens and risk of progression 
to disease. I critically review this evidence with regard to whether IGRAs are better than the TST 
at predicting individuals who have a high risk of progression to active TB and whether Mtb 
infected individuals with strongly elevated IFN-γ levels are most likely to progress to active 
disease. I also review studies examining concordance between IGRAs and TST results and the 
effect of HIV on IGRAs.  
 Chapter 3 describes the study methods. This chapter first describes the background study, 
(ZAMSTAR trial) within which the cohort study under discussion in this thesis (QFT cohort study) 
is nested. The rest of the chapter describes details of the QFT-GIT cohort study with regard to 
the following: sample size, study duration, study population, measurement tools, baseline and 
follow-up activities, data collection and statistical analyses.  
 In Chapter 4 the results of four small studies examining the performance and operational 
characteristics of QFT-GIT in a field setting are presented. The first study addresses the 
sensitivity and test-retest reproducibility of QFT-GIT as well as the effect of CD4+ T-lymphocyte 
counts and delayed incubation of blood samples on IFN-γ responses. The second study 
addresses the effect of power outages during incubation on IFN-γ responses. The third study 
addresses the effect of increased storage temperature on IFN-γ responses. Lastly, the fourth 
study addresses the financial cost of diagnosing Mtb infection using QFT-GIT. 
 In Chapter 5 the baseline results of the study are presented. These include a description of the 
socio-demographic and clinical characteristics of the study population, the prevalence of 
tuberculous infection as measured by QFT-GIT and TST as well as risk factors associated with 
positive QFT-GIT and TST results at baseline. Lastly, this chapter presents results on the level of 
agreement between QFT-GIT and TST results. 
In Chapter 6, I present survival analysis results whose main aim is to determine incidence rates 
of TB in HHCs with positive and negative QFT-GIT results; also stratified by HIV status. A similar 
analysis for TST is presented as a comparison. Results on risk factors associated with incident TB 
and a sensitivity analysis are also presented in chapter 6. 
 In Chapter 7, I answer the main research question of the thesis: whether individuals with high 
(≥ 10 IU/ml) levels of IFN-γ in response to Mtb specific antigens in the QFT-GIT assay (ESAT-6, 
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CFP-10 or TB 7.7) are at higher risk of developing TB compared to those with low levels (≥ 
0.35<10 IU/ml). 
In Chapter 8 I present results of other exploratory cut-offs points in a sensitivity analysis, in 
addition to using a cut-off point of ≥ 10 IU/ml. 
In Chapter 9 the main study findings are discussed. A discussion of the main question is 
presented in addition to a discussion addressing each of the specific objectives of the result 
chapters outlined above. Objectives are discussed in view of previous research. The study 
limitations, potential biases and conclusions are also described here.  
Lastly in Chapter 10 a summary of the evolving IGRAs research is presented including other 
biomarkers for disease progression. In addition, the potential role and use of IGRAs as diagnostic 
tests in high TB/HIV endemic resource constrained settings is described as well suggestions for 
future research. 
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Abstract 
Background 
Household contacts (HHCs) of pulmonary TB patients are at high risk of 
Mycobacterium tuberculosis (Mtb) infection and early disease development. 
Tuberculin skin test (TST) has been traditionally used to identify infected individuals; 
however, its use is limited by low specificity in populations with high levels of BCG 
vaccination or significant exposure to non-tuberculosis mycobacteria (NTM), and 
reduced sensitivity in immunocompromised individuals. Interferon-gamma release 
assays (IGRAs) such as QuantiFERON-TB Gold In-Tube (QFT-GIT) using Mtb specific 
antigens provide an alternative to TST for infection detection. IGRAs are now widely 
used for the detection of Mtb infection and are included in the guidelines of many 
countries with a low incidence of TB. Despite a growing body of literature on IGRAs, 
the relationship between the magnitude of T-cell Interferon-γ responses to Mtb 
specific antigens and risk of progression to disease has not been studied. 
Objective  
 The main objective of this study was to determine whether HHCs with high (≥10 IU/ml) levels of 
IFN-γ in response to Mtb specific antigens (ESAT-6, CFP-10 or TB 7.7) in the QFT-GIT assay are at 
higher risk of developing TB compared to those with low (> 0.35-<10 IU/ml) levels. Other 
secondary objectives included to determine the following:  the performance and operational 
characteristics of QFT-GIT in a field setting; risk factors associated with positive QFT-GIT results; 
concordance between the two tests; incidence rates of TB in HHCs with positive and negative 
QFT-GIT and TST results at baseline as well as positive and negative predictive values. 
 
Method 
This study was nested within a large community randomized trial called ZAMSTAR implemented 
in 16 communities in Zambia and 8 communities in the Western Cape Province of South Africa. A 
cohort of HIV-positive and HIV-negative adult (≥ 15 years) HHCs were prospectively followed for 
2-4 years. Consenting HHCs had blood drawn for HIV antibodies. QFT-GIT test was performed 
according to the manufacturer's instructions. TST were performed according to the standard 
IUATLD protocol. A standardized questionnaire was used to collect information on risk factors 
for TB and TB treatment information (for those with TB). 
Results 
The feasibility studies showed three main findings. Firstly, the sensitivity of QFT-GIT was greater 
than that of TST overall, at all the standard TST cut-offs and when stratified by HIV status. The 
sensitivity of QFT-GIT was 85.6% (95%CI: 77.0-91.9) (indeterminate results excluded) compared 
to that of TST at 51.6% (95% CI: 40.9-62.2) at a cut-off of ≥ 10 mm. Secondly, test-retest 
reproducibility of QFT-GIT was high at 91.74% (ICC: 0.90; 95% CI 0.82-0.97). Thirdly, in this 
setting, some biological and operational factors that affected the performance of QFT-GIT were 
identified such as HIV positivity, low CD4+ T-lymphocytes, delayed incubation of blood samples 
and power outages.  
 8
For the main study, the study population at baseline consisted of 1,789 HHCs who were 
predominantly women (71%); median age was 28 years (IQR: 21-43); HIV positivity rate was 
27.9%. Prevalence of tuberculous infection was 63.7% as measured by QFT-GIT and 39.6% by 
TST. There was a low level of agreement between the tests regardless of TST cut-off point (% 
agreement=59.7%; kappa=0.24). QFT+/TST- discordance (575/719; 80%) was more frequent 
than QFT-/TST+ discordance (144/719; 20%) at TST ≥10 mm. 
Risk factors associated with QFT-GIT positivity were identified at baseline. In multivariable 
analysis adjusted for sex, age, and community, HIV status was negatively associated with QFT-
GIT positivity (aOR: 0.48; 95% CI: 0.37–0.63; p<0.001) whereas residing in an urban area (aOR: 
2.37; 95% CI: 1.10–5.13; p<0.03), smear status of index (OR: 1.26; 95% CI: 0.91-1.76; p=0.15) and 
country (aOR: 1.93; 95% CI: 1.48–2.51; p<0.001) were positively associated with QFT-GIT 
positivity. Similar results were obtained for TST. 
From a total of 1789 HHCs seen at baseline, 1113 (62.2%) HHCs entered follow-up and were 
included in the main analysis. The overall incidence rate of TB was 20.96/1000 pyrs (95% CI: 
15.93-27.58). TB incidence rate was higher among test positive HHCs compared to those who 
were negative (IRR for QFT-GIT: 1.65; 95% CI: 0.86-3.37; p=0.06) and for TST (IRR: 1.88; 95%CI: 
1.04-3.41; p=0.01). Results were similar in univariable analysis (QFT-GIT: 1.66 (95%CI: 0.88-3.11; 
p=0.11) and TST: 1.89 (95%CI: 1.09-3.28; p=0.02)) and multivariable analysis adjusted for sex, 
age and HIV (QFT-GIT: 2.20 (95%CI: 1.14-4.25; p=0.02) and TST: 2.19 (95%CI: 1.24-3.86; 
p=0.007)). Overall, PPV for QFT-GIT was 5.38% (95%CI: 3.84-7.31), compared to TST, 6.57% (95% 
CI: 4.41- 9.36). 
 
Overall for QFT-GIT, the IRR was higher among HIV negative HHCs (IRR: 3.85; 95%CI: 0.90-34.51; 
p=0.07) compared to HIV positives (IRR; 1.93; 95%CI: 0.88-4.57; p=0.04). Overall for TST, the IRR 
for HIV negatives (IRR: 2.21; 95%CI: 0.78-6.72; p=0.05) was similar to that among HIV positives 
(IRR: 2.32; 95%CI: 1.09-5.00; p=0.009). Univariable analysis showed similar results for both tests. 
In multivariable analyses adjusted for age, sex and country as an effect modifier, the HR for 
developing TB was 4.72 (95%CI: 1.35-16.46; p=0.01) in HIV positive QFT-GIT positives compared 
to 2.13 (95%CI: 0.81-5.60; p=0.12) in HIV positives TST positive HHCs. 
Risk factors for TB were identified. In multivariable analyses, adjusted for age, sex , HIV status 
and country there was strong evidence that  occasional smoking, (HR: 4.07; 95%CI:1.31-12.63), 
HIV positivity (HR: 4.60; 95%CI:2.48-8.56), smear  positivity of the index (HR: 2.00 ; 95%CI:1.04-
3.87)  and country (HR: 1.79 ; 95%1.02-3.15; p=0.04) ) were associated with incidence of TB.   
Out of the 1,113 HHCs who entered follow-up, 406 HHCs had IFN-γ levels <0.35 IU/ml and were 
excluded leaving 707 HHCs in analysis for the primary objective. Out of these 536 (75.8%) had 
IFN-gamma levels ≥ 0.35 and <10 IU/ml (low IFN-γ levels) while 171 (24.2%) HHCs had ≥ 10 IU/ml 
(high IFN-γ levels). 
Out of the 707 HHCs that entered follow-up, 38 (5.4%) HHCs developed active TB over 1558.0 
person-years (pyrs) of follow-up, giving an incidence rate of 24.39/1000 pyrs (95% CI: 17.75-
33.52).TB incidence rates were 24.51/1000 pyrs (9 cases/367.2 pyrs) in HHCs with high levels 
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and 24.35 (29 cases/1190.7 pyrs) among those with low levels of IFN-γ, giving an IRR of 1.0 (95% 
CI: 0.42-2.18; p=0.48). 
Overall, unadjusted HR in HHCs with high IFN-γ levels was 1.02 (95%CI: 0.48-2.15; p=0.96) while 
in multivariable analysis adjusted for age, sex, country and HIV as an effect modifier, HR was 
1.74 (95%CI: 0.63-4.79; p=0.29). 
TB incidence rates in HIV positives was 51.94/1000 pyrs (3 cases/57.8 pyrs) in HHCs with high 
levels and 65.29/1000 pyrs (19 cases/291.0 pyrs) among those with low levels of IFN-γ, giving an 
IRR of 0.79 (95%CI: 0.15-2.70; p=0.38).TB incidence rates in HIV negatives were 19.56/1000 pyrs 
(6 cases/306.7 pyrs) in HHCs with high levels and 11.47 (10 cases/871.7 pyrs) among those with 
low levels of IFN-γ, giving an IRR of 1.70 (95%CI: 0.51-5.18, p=0.16). 
Unadjusted HR among HIV negative HHCs was 1.73 (95%CI: 0.63-4.77; p=0.29) and 0.75 
(95%0.22-2.55; p=0.65) among HIV positive ones respectively. In multivariable analysis adjusted 
for age, sex and country, the HR remained similar as unadjusted analysis for both HIV negatives 
and positives. 
For all the groups used for sensitivity analysis of the primary question, HHCs with the highest 
IFN-γ levels had increased IRRs ranging from 1.5 to 2 compared to the reference sub-group. For 
HIV negatives, HHCs with the highest IFN-γ levels had the highest IRRs in all groups apart from 
one group. HIV negative HHCs with the highest IFN-γ levels had increased IRRs ranging from 4 to 
5-fold compared to the reference sub-group. In comparison, HIV positive HHCs with the highest 
IFN-γ levels had increased IRRs ranging from 1.6 to 2.6 compared to the reference sub-group. 
Conclusions 
The principal finding in this study is that there was no difference in incidence rates between 
HHCs with low and high levels (overall IRR: 1.0 (95% CI: 0.42-2.18)).  
Another principal finding was that there was strong evidence of a five-fold increased risk of TB in 
HIV positive QFT-GIT positive HHCs compared to HIV positive QFT-GIT negative ones (aHR : 4.72; 
95%CI: 1.35-16.46; P=0.01). For all the groups used in the sensitivity analysis of the primary 
question, HHCs with the highest IFN-γ levels had increased IRRs ranging from 1.5 to 2 compared 
to the reference sub-group. The feasibility studies emphasized the need for stringent sample 
collection and processing techniques to ensure the accuracy of QFT-GIT results. 
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Glossary of terms and abbreviations 
ART   Antiretroviral therapy 
 
AFB  Acid-Fast Bacilli 
AIDS  Acquired Immune Deficiency Syndrome 
BCG  Bacille Calmette-Guérin 
CFP-10  Culture Filtrate Protein 10 
CI Confidence interval 
DTH  Delayed-type Hypersensitivity 
ELISA  Enzyme linked Immunosorbent assay 
ELISPOT  Enzyme linked immunospot assay 
ESAT-6  Early secretory antigenic target 6  
HHCs  Household contacts 
HIV  Human Immunodeficiency Virus 
HR Hazard ratio 
IGRAs   Interferon-gamma release assays 
IFN-γ  Interferon-gamma 
IPT  Isoniazid Preventive therapy 
IP-10  IFN-γ-inducible protein 10  
IRR Incidence rate ratio 
IQR Interquartile range 
LTBI Latent TB infection (Used as quoted by other authors although not preferred) 
Mitogen-nil  Interferon-gamma response to phytohaemagglutinin (a mitogen) 
Mtb  Mycobacterium tuberculosis  
MDR TB  Multidrug-resistant tuberculosis 
NPV Negative predictive value 
NTM  Non-Tuberculous mycobacteria 
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Glossary of terms and abbreviations continued… 
PHA  Phytohaemagglutinin 
PLWH  People living with HIV 
PPD  Purified Protein derivative 
PPV  Positive Predictive value 
PYRS Person-years 
QFT-G  QuantiFERON®-TB Gold 
QFT -GIT QuantiFERON®-TB Gold In-tube  
RR Rate ratio 
OR  Odds ratio 
SA  South Africa 
SOCS  Secondary outcome cohorts 
RD1 Region of Difference-1 
TB  Tuberculosis 
TBI  Tuberculous Infection (used by this author)  
TB antigen-nil   Interferon- gamma response to TB antigens (ESAT-6/CFP-10/TB7.7)  
TH1  T helper 1 cells 
T-SPOT  T-SPOT®.TB 
TST  Tuberculin skin test 
TST-/QFT-    Negative results on both tests 
TST+/TST+  Positive results on both tests 
TST+/QFT-  TST Positive but QFT-GIT negative result   
TST-/QFT+ TST Negative but QFT-GIT positive result 
ZAMSTAR   Zambia and South Africa TB and AIDS Reduction trial 
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Definitions 
Biomarker: a biological characteristic that is objectively measured and evaluated as an indicator 
of physiological or pathological processes, for example as a response to a therapeutic (e.g. drug) 
or preventive (e.g. vaccine) measure (1). 
Cytokines: a varied group of small secreted proteins that mediate cellular interactions in 
immune and inflammatory responses, cell proliferation and differentiation, and various other 
processes. 
Disease (Tuberculosis):  AFB smear-positive or positive culture for Mycobacterium tuberculosis. 
Exposed: An exposure, leading with a reasonably measurable risk to acquisition of infection with 
M.tuberculosis.  
Mtb infection: Is demonstrated by immune responsiveness of the host to Mtb antigens (using 
the tuberculin skin test or interferon-γ release assays).  
Positive predictive value: the proportion of individuals with a positive test result who actually 
have the disease. It reflects the probability that a positive test reflects the underlying condition 
being tested for. 
Negative predictive value: is the proportion of individuals with a negative test result who do not 
have disease 
Sensitivity: the proportion of individuals with disease who will have a positive result  
Specificity: the proportion of individuals without the disease who will have a negative result  
Reproducibility of a test is an assessment of the extent to which the same tester achieves the 
same results on repeated testing of the same samples, or the extent to which different testers 
achieve the same results on the same samples. 
Test-retest reproducibility: the ability of the test to produce consistent results when performed 
under similar circumstances. 
Incidence: the number of new cases of disease that develop in a population during a specified 
period of time. 
Prevalence: the proportion of a given population with an infection at a given time. 
Performance: How well or badly a test works.   
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1.0 Introduction 
 
The aim of this chapter is to describe the study objectives, provide a justification and a detailed 
description of the TB epidemiology and describe the conceptual framework from which the 
study hypotheses originate. 
The specific objectives of this chapter are:  
1.  To discuss the traditional and current theoretical paradigms of TB immune responses.  
2.  To give a brief description of the epidemiology of TB with regard to risk factors for 
exposure, infection and disease. 
3.  To describe the TB and HIV epidemics in Zambia and SA. 
4. To describe tools for diagnosing Mtb infection with a particular focus on Interferon-gamma 
release assays (IGRAs) as an emerging alternative to the TST.  
5. To outline the specific primary and secondary objectives for this study.  
1.1 Tuberculosis: Infection and Disease 
 
Tuberculosis (TB) is transmitted when a person with infectious TB coughs or sneezes, releasing 
droplets containing Mycobacterium tuberculosis (Mtb) into the air. A susceptible individual can 
become infected with Mtb when breathing in these droplets. Much of the available evidence on 
infection and progression to disease comes from the pre-HIV era. The most important source of 
infection is a person with smear-positive pulmonary TB even though those with smear negative 
TB can transmit infection as well. Left untreated, a smear positive patient on average infects 
approximately 10-15 individuals per year, for an average duration of infectiousness of 2 years, 
before becoming noninfectious (due to spontaneous cure or death) (2). 
A smear-positive patient on average infects approximately 20 people during their lifetime and 
creates two new cases of TB, at least one of which will be infectious (3). As long as at least one 
new case of TB is created by each existing case the cycle of transmission within a community is 
maintained. Traditionally, three possible outcomes of Mtb exposure have been well recognised 
(Figure 1.1). 
Figure 1.1:  Innate Response to Mycobacterium Tuberculosis. 
 
 
Modified from (4) 
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In some individuals, Mtb is eliminated by the host immediately upon inhalation (spontaneous 
healing). In a small number of infected individuals, adaptive immunity fails and they develop 
primary TB. Approximately 5–10% of recently exposed individuals develop clinically active TB 
within the first two years after exposure and another 5% in later life as a result of exogenous re-
infection or reactivation of a previously acquired latent infection (3). Reactivation of latent 
infection can occur due to factors such as aging or the immune compromised status of the host. 
In the third and the largest group of individuals, infection is contained as a result of successful 
granuloma formation, a function of strong innate and adaptive immune response by the host, 
which results in latent infection. In the absence of HIV, most people (around 90%) who become 
infected with Mtb do not develop disease either because their immune system has persistently 
controlled the mycobacteria or they are no longer infected with Mtb (5). 
1.1.1 Theoretical Paradigms of TB Immune Responses 
 
There is  growing evidence showing that the nature of the relationship between Mtb and the 
human host represents a spectrum of immune responses, mycobacterial metabolic activity, and 
organism load (6). Traditionally, the outcome of infection by Mtb was generally represented as a 
bimodal distribution between active disease and latent TB on the basis of the presence or 
absence of clinical symptoms. However, this traditional view is now being challenged. An 
alternative paradigm has been suggested; it  involves viewing Mtb infection as a continuous 
spectrum extending from sterilizing immunity to active infection and clinical disease (7, 8). In 
three reviews, Young, Barry, Lawn and colleagues (6-8) have divided this spectrum into five 
different states that represent a dynamic spectrum ranging from immunity to disease (Figure 
1.2)  
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Figure 1.2:  A Theoretical framework of Mtb infection as a Spectrum of Immune responses. 
 
Modified from (6-8)  
Below is a brief description of how these suggested immune responses are likely to correlate 
with Interferon-gamma release assays (IGRAs) results. It should be remembered that IGRAs just 
like TST are designed to identify an adaptive immune response against Mtb. A positive result is 
primarily a measure of an immunologic response to stimulation by mycobacterial antigens that 
should not be equated with the presence of live Mtb in the human host (6-9). 
a) Innate immune response.  
Following exposure to Mtb, infection may either be eliminated by the innate immune response 
without the need for T-cell priming. For such individuals IGRA results are negative i.e. there is no 
immunodiagnostic evidence of T-cell priming (6-8). 
b) Acquired immune response 
 Alternatively, infection may also be eliminated following development of an acquired immune 
response. The adaptive immune response involves effector memory T-cells (which may be 
transiently present in the blood if bacteria are cleared) and central memory T-cells (which may 
remain for life but may not provide protection in all individuals). For such individuals there is T-
cell priming and IGRA results are often positive although they may be negative. 
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c) Quiescent infection 
 Among those who are unable to eliminate infection following exposure, a majority establishes 
and maintains immune control. Such individuals typically have evidence of T-cell priming and 
maintain low bacillary numbers (non-replicating) which may persist for life (6-8). In this state, 
IGRA results are often positive but may be negative. 
d) Active infection 
A subsequent shift in the host-pathogen response for an individual with quiescent infection may 
permit active mycobacterial replication, leading to subclinical active infection. The relationship 
between “quiescent” and “active” infection is likely to be a dynamic one over time with 
bidirectional shifts between the two (6-8). 
e) Disease 
 Loss of immune control and escalating mycobacterial load, however, may subsequently lead to 
the development of symptoms and overt clinical disease. For individuals with TB (disease), IGRA 
response is often positive but may be negative; approximately 30% of TB patients have a 
negative IGRA result probably due to immune-suppression. Therefore, there is a poor 
correlation between disease phenotype and immunodiagnostic test results (10). 
 The impact of HIV on the proposed host-pathogen relationship has also been reviewed. It has 
been suggested  that “rather than increasing the risk of transition between compartmentalized 
disease states, HIV co-infection has a fundamental impact on the spectrum of the host-pathogen 
relationship with a general shift towards poor immune control, high bacillary numbers, and 
subsequent development of active infection and symptomatic disease”. It has been further 
suggested that recurrent exogenous re-exposure to Mtb in high TB prevalence settings is also 
likely to play an important role, further increasing bacillary numbers and increasing the 
likelihood of progression to disease .  
1.1.2 Cytokines and Mtb infection 
 
T-cell mediated immune responses are important in the host control of Mtb infection (11). Mtb 
infection results in the induction of a large number of cytokines, and a subset of these have 
been demonstrated to be essential for control of the infection. Immunologic control of Mtb 
infection is based on a Th-1-type immune response which induces cytokines such as interferon-
gamma (IFN-γ), tumour necrosis factor alpha (TNFα), interleukin (IL) -2 and IL-12. Besides, CD4+ 
T cells, other  cytokines  may be necessary in TB immunity like CD8+ and natural killer T (NKT) 
cells (12). The source and biological function of some cytokines involved in Mtb control are 
summarized in Table 1.1 below: 
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Table 1.1:  Cytokines Involved in Mtb infection control (11, 12)  
Biomarker Cell source Biological activity 
IL2 Activated  Th1 cells (T cells), 
CD4+,CD25+, FoxP3+ 
T- Cell growth factor (T-cell proliferation). 
 
Central role in regulating Th1 T cell production 
of IFN-γ 
IFN-γ Activated  Th1 cells, natural 
killer cells 
Activates macrophages for mycobacterial 
killing, stasis & granuloma formation. 
TNFα Activated Th1 cells and 
macrophages, NK cells 
Involved in localization of infection 
Enhances the proliferation of T-cells 
Activates macrophages for mycobacterial 
killing and granuloma formation. 
IL4↑ Th2 cells and B cells (mast cells) B- cell growth factor 
IL6 T cell and macrophages  T & B cell growth & differentiation 
IL10↑ T regulatory cells (Tr1/Th3), 
macrophages and B cells 
B-cell differentiation 
Inhibit macrophage activation 
Inhibit secretion of inflammatory cytokines 
 (decreases IFN-γ production) 
Reduces collateral damage 
IL-17 CD4 memory cells Induce cytokine production by epithelia, 
endothelia & fibroblasts. 
CXCL10/ IP-
10 
Activated T cells, monocytes Immunostimulant; promotes Th1immunity 
All are cytokines except CXCL10 which is a chemokine. 
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1.1.3 The role of IFN-γ in protective immunity and as a marker of disease. 
 
IFN-γ is a key T helper (Th) type 1 pro-inflammatory cytokine produced primarily by natural killer 
cells and T cells (Th1-type CD4 T cells; CD8 T cells). It is important in restricting the replication of 
Mtb in the macrophages and a determinant of susceptibility to mycobacterial infections in 
humans (13). Its main functions include macrophage activation (which in turn kill or inhibit 
growth of the pathogen), increased expression of MHC molecules and antigen processing 
components, immunoglobulin class switching and suppression of TH2 (14). 
The ability of CD4+ T cells to produce IFN-γ is central in protection against disease (15-17) and 
the frequency of IFN-γ producing cells has been widely used as a correlate of protection against 
Mtb. This is evident from the increased risk of TB in individuals with deficiencies in their IFN-γ 
and interleukin-12 (18). Individuals defective in genes for IFN-γ or IFN-γ receptors are 
susceptible to serious mycobacterial infections, including Mtb (19). For instance, although very 
rare, a number of individuals with mutations in the IFN-γ R1 or IFN-γ R2 chains of the IFN-γ 
receptor have been identified, and these individuals are more susceptible to infection with 
mycobacterial (19, 20). In mice, IFN-γ knockout strains are the most susceptible to virulent Mtb 
infection(16, 17). Further evidence is given by the  association between CD4+ T- cell depletion 
and elevated susceptibility to active TB in HIV-infected individuals (11).  
In addition, TB patients have been shown to demonstrate depressed IFN-γ producing CD4+ T-cell 
responses (62) with increased expression of IFN-γ after successful completion of  therapy (21). 
The increased IFN-γ expression  in healthy, latently infected individuals suggest that it might be a 
promising biomarker of protective immunity (22). In practice, though, it has proved 
disappointing (23). Therefore, although IFN-γ is key to protection against TB, its value as a 
correlate of protection is not sufficient (20). Its detection in isolation is not a sufficient indicator 
of a protective immune phenotype as those with LTBI  and a positive IFN-γ release assay status 
can progress to active disease and IFN-γ secretion can also be detected in samples from patients 
with active disease (24). The complexity of the immune response against TB makes it more than 
likely that additional biomarkers are required for a reliable correlate of protection (25). 
Although  IFN-γ may be required for protection, it is a marker of disease as well as immunity 
(20). Mtb has developed mechanisms to limit the activation of macrophages by IFN-γ suggesting 
that the amount of IFN-γ produced by T cells may be less predictive of outcome than the ability 
of the cells to respond to this cytokine (26). In this regard, it has been shown that the level of 
IFN-γ produced by a mouse in response to a candidate vaccine does not always correlate with 
the effectiveness of the vaccine during Mtb challenge (26). Similarly, evaluation of the efficacy of 
human BCG vaccination using several assays demonstrated that mycobacterial growth inhibition 
did not correlate with IFN-γ response (27).  
When IFN-γ production is present, there are situations where “more is not better, more IFN-γ 
production may mean more pathology or less protection e.g. bovine TB in calves”(20). Thus, 
although IFN-γ is essential for the development of an immune response that prolongs the life 
span of an infected animal, it is not sufficient to eliminate an Mtb infection. Therefore, much 
work is still needed to understand what IFN-γ production actually reflects.  
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1.1.4 Can we use the immune response as a surrogate measure of bacterial load? 
 
Accurate diagnosis of TBI is scientifically challenging because of the low burden of tubercle 
bacilli, which are not directly detectable or quantifiable. However, the strong cellular immune 
response triggered by TBI serves as a signal for the presence of these bacilli. 
There is limited direct evidence on the correlation between immune response and bacterial load 
and pathology can only be inferred. The magnitude of the IFN-γ T-cell response to infecting Mtb 
is proposed to be proportional to the antigenic load of the infecting organism in human and 
animal models (28, 29). Hence the level of IFN-γ production is  thought  to be related to the 
bacterial load in the host (30). Although plausible and supported by some indirect evidence (31), 
there is no consensus yet, partly due to lack of a quantitative absolute measure of bacterial or 
antigen load in TB. 
Studies have shown a correlation between infectious doses to which contacts have been 
exposed and the magnitude of their response to PPD and ESAT in vitro (32, 33). A rising ELISPOT 
count in a TB case contact with Mtb infection prior to onset of full-blown active disease showed 
how the quantitative ELISPOT read-out related to level of exposure, reflecting the infectious 
load (34). Other studies support this hypothesis as well (34-36). 
Changes in the level of T-cell responses in persons undergoing treatment of both active and LTBI 
indicate some relationship to antigen load (37). Most studies have shown that TB patients 
produce lower concentration of IFN-γ in response to ESAT-6 than HHCs, community controls or 
recent converters (38-40). Significant qualitative and quantitative reversions of T cell responses 
to ESAT-6 and CFP-10 antigens following treatment of LTBI and active TB in different settings 
(37, 41-45) have been found. In two studies in the Gambia, a significant proportion of individuals 
who successfully completed TB treatment changed from a positive to a negative ELISPOT (46, 
47). Similarly, in Cape Town, 81% HIV-negative patients who had successfully completed TB 
treatment were ELISPOT negative (48). While it is believed that most reversion cases indicate 
sterile cure of infection or active disease, other reasons may apply (49). Similarly, other studies 
have found that frequencies of ESAT-6 -specific IFN-γ secreting CD4 T cells were higher in 
infected healthy contacts and subjects with minimal disease and than in patients with advanced 
active TB (43). 
Although such evidence examining the relationship between immune response and bacterial 
load is present, its interpretation remains unclear and contradictory. One interpretation of these 
findings is that, at the time of initial infection with Mtb, HHCs mount a strong, high frequency T 
cell response to Mtb and so limit bacterial replication (infection may be controlled). Limited 
bacterial replication induces a low IFN- γ response. Individuals who go on to develop active 
disease, in contrast, make a weak T-cell response, and the bacteria are allowed to reach a higher 
equilibrium bacterial load, resulting in disease. Disease is associated with progressive bacterial 
replication and a high IFN- γ response. Figure 1.3 shows a schematic of the postulated 
correlation between bacterial load, T-cell responses, and clinical outcomes (50). 
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Reproduced from [50]. 
Initial infection might be controlled at its onset with minimal bacterial replication (measured as colony-
forming units (CFU)) and induction of ESAT-6 responses (A and D). In such cases, the T -cell response may 
be below the diagnostic cut-off. However, in most cases, initial bacterial replication reaches a point at 
which it induces an ESAT-6 specific IFN-γ response to increase above the established cut-off value 
(infection threshold), enabling the diagnosis of an individual as latently infected (B and E).In most cases, 
individuals control the infection, resulting in latent infection, but some develop active TB disease 
associated with progressive bacterial replication. This is accompanied by increasing and strong ESAT-6 
responses and, as hypothesized here, an incipient (higher) disease cut-off value may predict development 
of progressive disease (C and F).    
Other interpretations suggest that in TB patients with advanced disease, a high bacterial load 
stimulates weaker, less efficient proliferation of Ag-specific T cells in vivo (43). This model is 
analogous to that proposed for certain chronic viral infections, in which virus-specific CD8 T cells 
are believed to mediate protective immunity (43). 
 However, there is evidence suggesting that disease is associated with a defect in IFN-γ 
production that is improved by TB treatment (38, 39).  A recent study done in Singapore among 
275 sputum culture-positive, HIV negative TB patients showed significant declines in the 
positivity rates and quantitative results of IGRAs with treatment (42). It has been suggested that 
the progressive decline of IFN-γ response measured by IGRAs reflects the reduction of 
mycobacterial burden following a successful TB treatment.  However, measurements using 
peripheral blood  may be  complicated by the sequestration of reactive cells to disease sites 
(20). Cytokines such as IFN-γ and the IL4/ IL4δ2 ratio have been shown to vary with treatment of 
 
Figure 1.3:  A Schematica of the Postulated Correlation between bacterial load, T cell responses 
and clinical outcomes. 
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LTBI and active disease; these changes, however, are not always consistent and may be 
confounded by the natural variation in stimulated cytokine responses over time (51). Recent 
studies suggest that a profile using several cytokines, rather than one biomarker, may be more 
useful. 
Despite this evidence there is no agreed consensus as studies have been inconsistent regarding 
whether T-cell responses in TB patients change during and after treatment. Thus while some 
studies have demonstrated that IFN-γ response decreased or became negative (41-44), others 
have reported persistently positive or even stronger responses during and after TB treatment 
(39, 52, 53). 
1.1.5 Risk factors for TB: From exposure to disease 
 
Acquisition of active TB depends on the succession of various factors influencing:  
1) The risk of exposure 
2) The risk of infection and  
3) The risk of developing disease.  
 
While most factors that affect the risk of infection (such as crowding, urban residence, and low 
socioeconomic status (SES) are extrinsic to the susceptible host and are related to the 
environment, many that affect the risk of disease after infection are host related and also a 
consequence of human interaction with the environment (54, 55). Environmental factors may 
have an impact on the incidence of TB in a given population as a result of their effect on both 
the risk of infection and the risk of disease once a person is infected (55). A model of TB 
epidemiology showing risk factors for exposure, infection and disease is shown in Figure 1.4 
below:  
Figure 1.4:  Model of TB epidemiology showing risk factors for exposure, infection and disease. 
 
Modified from (3) 
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1) Risk factors for exposure to Mtb  
 Risk of exposure to Mtb depends primarily on encountering an airspace that contains the 
tubercle bacilli. There are three major factors that determine the risk of becoming exposed to 
tubercle bacilli (3) which are as follows: 
a) The number of incident infectious cases within a community 
Without the presence of infectious cases, no relevant exposure can occur. The more new cases 
of infectious disease there are, the greater the likelihood that a susceptible individual will inhale 
the organism in a given space. Nevertheless, there are other factors that need to be considered 
for any fixed number of incident cases. They are principally: how “infectious” a case is and how 
“susceptible” an individual (or population) is. 
b) The duration of infectiousness of the individual case 
The risk of becoming exposed is greatly enhanced if infectiousness is prolonged, as compared 
with a short duration of infectiousness. On average, around 30-40% of contacts are infected 
around the time of diagnosis of a sputum smear-positive index case (56). Early intervention with 
chemotherapy reduces the time of infectiousness while inadequate treatment can prolong 
infectiousness. 
c)  The number and nature of case-contact interactions per unit of time. 
The number and nature of possible case-contact interactions will vary greatly according to 
individual behavior and opportunities for interacting with other people in a community. 
Important factors include: 
 Population density 
The nature of the dwelling in which people live and the number of persons who share that 
dwelling have an important impact on the risk of exposure, given that a case of  TB lives in that 
dwelling. The number of possible contacts of a TB patient in a rural area may be smaller per unit 
of time than that of a patient living in an urban setting (given a similar dwelling and family size) 
because urban areas have a much higher population density than rural areas. Therefore, the 
likelihood that a susceptible person will be exposed to an infectious tuberculosis patient 
increases with population density, even if the incidence is the same. 
 Family size and social arrangements within families. 
 The most intense exposure is likely to occur among individuals who share the same household 
or who spend long periods of time in the same room with an infectious source case. The larger 
the size of the family, the greater the number of individuals at risk of exposure given that an 
infectious case of TB is part of the family and other factors considered like infectiousness of the 
case. Of further importance are social arrangements within the family, i.e., the sleeping 
proximity to the index case (sharing the same room or bed with the index case). Household 
studies conducted more than 30 or 40 years ago both in industrialized and non-industrialized 
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countries showed that the risk of becoming infected increased with intimacy of contact with a 
tuberculosis case (55). This may be enhanced by overcrowding and inadequate ventilation. 
Places of social networks in countries with a high burden of disease have been shown to be 
“hotspots”(57) for TB transmission. Although historically, household contacts (HHCs) were 
thought to have been infected mainly from within the households, it is now well recognized that 
transmission of TB occurs within households as well as the community (58). 
 Differences in climatic conditions 
In a warm climate, outdoor social activities are much more common than in a colder climate. 
Tubercle bacilli expelled outdoors are dispersed rapidly, and exposed to sunlight they die very 
quickly due to the sun’s ultraviolet rays. In contrast, tubercle bacilli expelled indoors by a patient 
in a confined space with poor ventilation may retain viability, and thus the potential to cause 
infection, for a prolonged period of time. A cold climate causes people to congregate inside, 
thus increasing the likelihood of exposure if there is a case of TB in the group. In contrast, indoor 
activities might be reduced in tropical climates, and indoor ventilation might be better, because 
windows can be kept open for much longer periods than in colder climates. 
 Age of sources of infection  
Parents may expose their children to a much larger extent compared to other individuals. It is a 
common notion that people tend to socialize with those of their own age. 
 Gender 
The degree of social interactions differs by gender to a great extent in different societies. The 
opportunity of becoming exposed to an infectious case will differ for men and women because 
of the different roles played by the two (see further details in section 1.1.5). 
2) Risk factors for Mtb infection 
Risk factors for becoming infected given that exposure has occurred are largely exogenous in 
nature (3). The probability of becoming infected with Mtb depends on the number of infectious 
droplet nuclei per volume of air (infectious particle density) and the duration of exposure of a 
susceptible individual to that particle density i.e. 
 
 
 
 
 
 
Particles 
Volume 
X Exposure time 
 
Key 
Particles: Production of infectious droplet nuclei 
Volume: Volume of air and ventilation 
Exposure time: Time of inhaling air with droplet Nuclei 
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a)  Air density of Mtb (infectious particle density) 
To be transmissible through the medium of air, TB must remain airborne after being expelled 
from an infectious case. Successful transmission requires airborne infectious droplet nuclei, 
small enough to reach an alveolus in the periphery of the lung.  Such droplets can remain 
suspended in air for several hours.  
b) Nature of the infectious case 
Patients with sputum smear-positive tuberculosis are by far the most potent sources of infection 
in the community. However, various studies have demonstrated, that patients classified as 
smear-negative can also transmit infection. A study in San Francisco, California, using molecular 
fingerprinting techniques demonstrated that 17 per cent of transmissions were attributable to 
index cases with sputum smears negative at diagnosis, and that the relative transmission rate 
from smear-negative compared to smear-positive TB was 0.22, or roughly one fifth of all 
transmissions (59). Household studies conducted more than 30 or 40 years ago both in 
industrialized and non-industrialized countries showed that the risk of becoming infected 
increased with intimacy of contact with a tuberculosis case (55). 
c)  Air circulation and ventilation 
Given a defined number of tubercle bacilli expelled into the air, the volume of air into which the 
bacilli are expelled determines the probability that a susceptible individual breathing that air will 
become infected.  Adequate ventilation plays an important role in diluting the concentration of 
bacilli. 
d) Host immune response 
The macrophage is the first cell from the immune system to encounter and ingest the TB 
bacillus. Macrophage function may vary due to genetic or acquired factors (3). Data from 
nosocomial outbreaks of TB in HIV-infected subjects suggest that susceptibility to infection is 
dependent on the health status of the person (55) and recent studies suggest that susceptibility 
to mycobacterial infection might be genetically modulated (60). 
e) Age and sex 
Age and sex variations in the prevalence of infection and disease have been reported worldwide, 
in both developed and developing countries (55, 61). The prevalence of tuberculin sensitivity is 
usually similar in males and females until adolescence, after which prevalence is higher among 
males (55). This difference after adolescence may reflect greater exposure among adult males 
because of differentiated social roles and economic activities, but it also may reflect a genuine 
sex difference in susceptibility to tuberculosis infection related to a different predisposition to 
responsiveness to delayed-type hypersensitivity. 
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f) Socio-economic factors 
Crowding and urban dwelling have long been established as risk factors for exposure to TB 
infection (62). Housing conditions often reflect socio-economic status and can affect infection 
risk and outcomes through such mediators as poor ventilation and air quality in the home (62).  
 There is evidence that socio economic status (SES) is associated with risk of infection.  Several 
studies  have shown an association of socio economic status (SES) and infection with Mtb (55). A 
recent study done in two communities in Zambia (63) aimed to assess the association between 
household socioeconomic position and tuberculosis infection. In this study, higher socio-
economic position, rather than lower, was associated with significantly higher risk of TB 
infection. None of the traditional risk factors for Mtb infection mediated this association, 
suggesting that in these two communities TB transmission occurred through exposure to as yet 
undefined risk factors that were associated with higher socioeconomic position. These results 
suggested emerging new patterns of TB transmission and a role of socioeconomic position on 
the risk of TB infection opposite to was expected. 
3) Risk factors for tuberculosis 
The most important risk factor for tuberculosis is infection with tubercle bacilli. Social, 
environmental and biological determinants of health have long been recognized as risk factors 
for TB (62).  While the risk of becoming infected is largely exogenous in nature, the risk of 
developing TB given that infection has occurred is largely endogenous, determined by the 
integrity of the cellular immune system. 
a) Time elapsed since becoming infected 
The temporal association between infection and progression to disease has been well 
recognized. The risk is elevated in the first years following infection, rapidly falls off and then 
remains low, but measurable for a prolonged period of time (3). Only 5–10% of recently exposed 
individuals develop clinically active TB in the first two years after exposure.  Preventive therapy 
trials using placebos have shown that the incidence of TB is highest in the first few years 
following infection and then rapidly falls off (64). Furthermore, studies have shown that 
individuals with recent TB infection rapidly progress to disease (64-66) and that recent infection 
is ten times more likely to produce a case than a long standing infection (3) in the absence of 
HIV infection.  
b) Infection with HIV 
HIV is the most powerful known risk factor for reactivation of latent TB infection to active TB. 
HIV fuels the TB epidemic in several ways. HIV promotes progression to active TB both in people 
with recently acquired and with latent Mtb infections. HIV increases the rate of recurrent TB, 
which may be due to either endogenous reactivation (true relapse) or exogenous re-infection 
(67). In populations at high risk of infection, re-infection might be a major contributor to the 
overall rate of TB in adults, whereas, in populations that have a low risk of infection, most cases 
of post primary disease in adults probably result from reactivation (55). 
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Studies from Sub-Saharan Africa have recorded HIV sero-prevalence rates of up to 50% in 
patients with TB (68). An HIV-positive person infected with Mtb has up to a 50% lifetime risk of 
developing disease as compared to an HIV-negative person who has only a 10% risk (69). 
A TB prevalence survey conducted among 8044 adults sampled from 2 sub-districts in Lusaka 
province, Zambia, demonstrated that 36% of all prevalent TB cases in these communities were 
attributable to HIV. HIV appeared to have overshadowed previously described risk factors for 
prevalent TB such as male sex, urban environment and previous TB such that it was identified as  
the major driving force behind prevalent TB (68). Low CD4 and high viral loads have been found 
to be further risk factors for disease, while treatment with highly active antiretroviral therapy 
(ART) reduces risk (62). 
c) Age 
Large differences in TB incidence are often observed by age, with higher incidence of disease 
with increasing age due to the cumulatively increasing prevalence of tuberculous infection. 
Disease risk after primary infection with Mtb is greatest in children younger than 4 years, and 
declines slowly to its lowest at age 5–10 years (70). During adolescence (age 15–19 years), there 
is a rapid increase in risk with a second peak between the ages of 20–30 years (70). 
d) Gender 
 In the pre-HIV era, TB notification rates were  typically male-biased for all ages over 15 (3), but 
in several African countries with high rates of HIV infection, the majority of notified TB cases are 
now women. Women now account for up to 70% of HIV-infected adults in sub-Saharan Africa, 
which has shifted the male-to-female case-notification ratio such that more female than male 
cases of TB are now detected in countries with high HIV prevalence (71). In the pre-HIV era this 
gender disparity was mainly explained by access barriers, such as  socio-cultural 
disempowerment, stigma, different patterns of health-care use, or lack of financial resources 
and  poorly elucidated biological factors (3, 72). Most of these access barriers are still true 
today. A review suggested that not only was TB among women under-reported because of 
cultural and socioeconomic factors, but also these factors increased the chances of women to be 
exposed to TB bacilli and to progress from TB infection to TB disease (through for example 
malnutrition and HIV co-infection) (73).  
e)  Area of residence 
TB tends to be more common in urban settings for reasons probably related to population 
density, crowding, environmental pollution and housing characteristics influencing ventilation 
issues. Living conditions are also known to be quite different between urban and rural areas, 
and are generally lower in rural areas.  
Urbanization has largely increased in many resource-poor countries over the past 30 years and 
has dramatically enhanced HIV transmission at multiple levels; by bringing people closer 
together in time and space and in environments with fewer social control mechanisms, 
urbanization has enabled HIV infection to spread in densely populated areas (55).  
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f) Socio-economic factors 
Historically, TB has been referred to as a "disease of the poor and socially disadvantaged” (see 
also section 1.1.4). Nevertheless, there is contrasting evidence linking SES and TB (74, 75). 
Overall,  most studies (75) have traditionally linked lower SES to TB, including a recent one done 
in Zambia (74).  In a case-control study nested within a population-based TB and HIV prevalence 
survey conducted in 2005–2006 in two Zambian communities, prevalent TB was significantly 
associated with lower household SEP (aOR = 6.2, 95%CI: 2.0–19.2 and aOR = 3.4, 95%CI: 1.8-7.6) 
respectively for low and medium household SEP compared to high (74).  
g) Medical conditions 
In persons infected with Mtb, any condition modifying the balance established in the body 
between the tubercle bacilli and the host's immune defenses can affect risk of developing the 
disease. Such factors include HIV infection, immunosuppressive treatment (corti-costeroid 
medication), malignancies, renal failure, measles, diabetes, malnutrition, and alcoholism, and all 
are considered intrinsic to the susceptible host (55). These factors are likely to reduce the 
efficiency of the body’s means of defense. 
h) Smoking 
Smoking is a well recognized risk factor for both infection and disease (76). Suggested 
mechanisms include decreased immune response, CD4 lymphopenia, defects in macrophage 
immune responses, and mechanical disruption of cilia function in the airways. 
i) Alcohol 
One systematic review has examined this association between TB and alcohol. In 21 studies 
identified, all forms of TB were about three times higher, and pulmonary TB was four times 
more frequent, in heavy drinkers than controls (77). 
j) Body mass index and under-nutrition 
 There is some evidence suggesting a relationship between nutrition or low BMI and TB. One 
review on TB and low BMI has indicated a strong dose-response relationship, with TB incidence 
increasing exponentially as BMI decreased in the six studies summarized (34). On a population 
level, the impact of this risk factor has been predicted to be enormous, due to the widespread 
global prevalence of under-nutrition (78).  
k) Genetic factors 
Evidence indicates that genetic factors may determine differences in host susceptibility to 
infection with mycobacteria and that they might contribute to the pattern of clinical disease (55, 
79). A recent meta-analysis (79) consisting of 36 studies showed that the association between 
SLC11A1 polymorphisms and TB susceptibility supported the hypothesis that NRAMP1 might 
play an important role in the host defense to the development of TB. 
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1.2 Epidemiology and Control of Tuberculosis 
1.2.1 TB and HIV epidemics globally 
 
TB is among the most pressing public health problems globally. In 2009 there were an estimated 
9.4 million incident cases (equivalent to 137 cases per 100 000 population) of TB globally, with 
the majority of these occurring in South-East Asia (35%), Africa (30%) and Western Pacific 
regions (20%)(80). Of the 9.4 million incident cases in 2009, an estimated 1.0–1.2 million (11–
13%) were HIV-positive. Although the total number of incident cases of TB is increasing in 
absolute terms, the number of cases per capita is falling ( less than 1% per year) since a peak of 
142 cases per 100 000 population in 2004 . Sub-Saharan Africa has borne the brunt of the HIV 
and TB co-epidemics, accounting for 70% of the global burden of HIV (Figure 1.5)(81). 
Figure 1.5:  TB notification rates in Southern Africa 
 
In Africa, HIV has been the single most important factor in determining the increased incidence 
of TB in the past 10 years. The risk of developing TB is between 20 and 37 times greater in 
people living with HIV (PLWH),  than among those who do not have HIV infection (68).TB is a 
leading cause of death in PLWH, accounting for almost a quarter of the 1.7 million AIDS deaths 
in 2009 (80). People with HIV infection also face the problems of multidrug-resistant (MDR) and 
extensively drug-resistant TB (XDR)(82). 
The exact prevalence of latent TB is not known, but TST  surveys done by WHO suggest that one- 
third of the world’s population is latently infected with Mtb, corresponding to 2 billion people 
worldwide (83). It is from this reservoir that new cases responsible for transmission emerge. A 
review (64) of published literature and WHO/UN/ CDC databases, showed that the HIV epidemic 
was exacerbating TB transmission. HIV individuals infected with TB were responsible for an 
estimated 7% of all TB transmission in the African region (largely sub Saharan Africa). Of all 
individuals infected worldwide, the largest burden of TBI is in Southeast Asia (prevalence, 46%), 
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the Western Pacific region (32%), Africa (31%), and the Eastern Mediterranean region (27%)(64, 
84). This finding contrasts with the lower prevalence of TBI noted in the Americas (15%) and 
Europe (14%). 
1.2.2 TB and HIV epidemics in Zambia and Western Cape, SA (the study sites) 
 
Globally, WHO reports that new cases of TB have been falling for several years and fell at a rate 
of 2.2% between 2010 and 2011 (85). However, the burden of TB and HIV in sub Sahara Africa 
remains enormous. Zambia has one of the highest incidence rates of TB in the world today (86). 
In 2009 the estimated incidence rate was 482 per 100 000 population according to WHO (86). 
However, TB incidence has never been directly measured at national level, since this would 
require long-term studies among large cohorts of people at high cost and with challenging 
logistics. Estimates of TB incidence have been mostly based on assessments of the fraction of 
incident cases captured in notification data in the late 1990s (86). 70% of all new TB patients are 
co-infected with HIV. In 2007, 14.3 per cent of Zambia’s estimated 12.9 million population was 
infected with HIV. 
 
South Africa (SA) ranks among the worst afflicted countries in the world for both HIV infection 
and TB. This is as a result of the convergence of a major pre-HIV-era TB epidemic, rising numbers 
of TB cases associated with the maturing HIV epidemic, and growing resistance to 
antituberculosis drugs (87). Historically, the social, economic, and environmental conditions 
created by apartheid such as overcrowded squatter settlements, migrant labour, and 
deliberately underdeveloped health services for black people provided a favorable environment 
for efficient transmission of TB and HIV. 
 In 2009, SA was among the five countries worldwide which had the largest number of incident 
cases (0.40-0.59 million) of TB (80). TB case notification rates in South Africa have increased 
almost 4-fold from 163/100,000 in 1986 to 628/100,000 in 2006 (88). Overall, HIV prevalence 
has increased from 15.1% in 2006 to 16.1%  in 2008 (89). HIV prevalence levels vary 
geographically between provinces and within provinces. In 2008, the Western Cape provincial 
HIV prevalence amongst 15-49 antenatal women was 16.1% (Figure 1.6). 
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 Figure 1.6:  HIV prevalence epidemic curve among antenatal women, Western Cape, 1990-
2008 
 
The TB-HIV co-infection rate in SA is also high, with an estimated 73% of new TB patients co-
infected with HIV (Table 1.2). In addition, the numbers of MDR-TB and XDR-TB patients have 
increased due to the concurrent HIV epidemic and inadequate management of TB (90). In 2009 
the National Health Laboratory Services (NHLS) diagnosed 9 070 MDR-TB and 594 XDR-TB cases 
(90).  A summary of the TB and HIV situation in both countries is shown below, Table 1.2. 
Table 1.2:  Selected TB and HIV indicators for 2009 (86, 89, 91, 92) 
  Zambia South Africa  
Indicator   
Population 12.9 million 50.4 million  
Incidence rate in all forms of TB/100 000  482 (433-533) 971 (791-1169) 
Prevalence rate in all forms of TB/100 000 309 (108-562) 808 (362–1288) 
TB patients that are HIV positive 70% (2007) 73% (2007) 
MDR-TB among new TB cases 1.0% (0.4-2.3 %)2 1.8 (1.5–2.3) ( 2008) 
Number of people living with HIV 1.1 million (1-2) 5.6 million (5.4-5.9) 
HIV prevalence in antenatal women 16.4% (93) 29.4 (28.7-30.1) 
Adults aged 15 to 49 HIV prevalence rate 14.3% (2007) 17.8% (17.2-18.3%) 
HIV infected people receiving ART 55.1% (2008) 56% 
All data are for 2009 unless otherwise stated.2 Zambia National Drug resistance survey results, 2008 (unpublished) 
Recent studies in Africa have estimated the annual risk of tuberculosis infection (ARTI) to be in 
the range of 1.5-4%, representing the proportion of the adult population which will be infected 
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with Mtb (94-96). Two recent large TST surveys found that the average ARTI of 24 high burden 
TB/HIV communities in Zambia and SA was between 0.8 and 2.8% and between 2.5% and 4.2% 
respectively (95). This survey provided an important source of data indicating the extent of TB 
transmission in Zambia and Western Cape, SA. The ARTI is an epidemiological index derived 
from TST surveys among children to measure the extent of TB transmission in a community (95).  
The average annual risk of infection with Mtb is a calculated average from an observed 
prevalence of infection, approximating the incidence of infection (97).  
1.2.3 Control of TB infection and disease 
 
One of the targets of the WHO Stop TB Partnership is to reduce the annual incidence of new TB 
cases to less than one per million populations by 2050 (98). For many years, the cornerstone of 
TB control was focused mainly on the DOTS strategy which includes passive detection and 
treatment of infectious cases. Even though this still remains the cornerstone of most TB control 
programs, it is increasingly being accepted that effective TB control in endemic settings requires 
additional approaches. There are three recognized approaches to TB control: (i) early detection 
and treatment of active TB (ii) Prevent progression from  infection to active TB and (iii) Reduce 
HIV transmission (99). Other recent approaches such as pre-exposure and post exposure 
vaccination against TB are being explored. Protection induced by Bacillus Calmette-Guerin (BCG) 
vaccination against adolescent and adult TB, is insufficient. 
Early detection and treatment of active TB reduces transmission, reducing the number of 
carriers, who will later develop active TB. However, WHO has estimated that less than 50 per 
cent of all cases globally are currently diagnosed and treated (80) . These patients continue to 
act as reservoirs for new cases of TB. Limited access to quality health services, over stretched 
staff, stigma, poverty and inability to diagnose smear negative TB especially in HIV infected 
individuals are contributing factors in resource poor settings. 
Reducing the risk of progression from Mtb infection to disease can be achieved through 
accurate diagnosis and treatment of individuals infected with Mtb. Several placebo-controlled 
trials have shown that preventive therapy (PT) substantially reduces the subsequent risk of 
active TB by 60-90% (100-102). Targeted testing and treatment of TBI especially among HIV 
positive individuals is an important strategy to reduce the incidence of TB (103) and contributes 
to closing the tap of new infections. The contribution of HIV positive individuals to the pool of TB 
transmission in high TB prevalence countries though small on a case-to-case basis has huge 
epidemiological implications and has increasingly drawn the attention to the need for PT. 
However, provision of PT to eligible individuals has been of higher priority in low than high TB 
prevalence countries. 
Any strategy that successfully reduces HIV transmission will benefit TB control. The 
implementation of collaborative TB/HIV activities is a well practiced approach in many countries 
affected by the dual TB/HIV epidemic. Early initiation of ART in HIV positive individuals reduces 
plasma levels of HIV, which correlate closely with infectivity. 
 41
1.2.4 Predictive biomarkers for the development of active TB  
 
Over the past decade, real progress has been made in the development of new TB diagnostics 
resulting in WHO endorsing several tests for use in TB endemic countries (104) whilst others are 
still pending. At the community health care level, no single test had been successfully endorsed 
by WHO by 2011 and among these is a predictive biomarker for TBI (Figure 1.7).  
Figure 1.7:  TB diagnostics pipeline and their targets. 
 
Modified from the Global plan to stop TB 2011-2015 (105) and (104). 
However despite this progress the search for a predictive biomarker for the development of TB 
is still on. The need for a better tool than TST that will act as a predictive marker of progression 
to active disease is still among one of the important TB research priorities (106, 107). Several 
longitudinal studies in the recent past have explored whether Interferon Gamma Release Assays 
(IGRAs), such as the QuantiFERON-TB Gold assay (QFT) could provide the much needed answer 
(108) (see further details under literature review). 
A new target to develop a predictive biomarker for active TB has been put forth by the Global 
Plan to Stop TB, 2011-2015 (105). The previous target by the WHO STOP TB New Diagnostics 
Working Group (Strategic Plan 2006-2015), to develop a rapid diagnostic procedure capable of 
predicting the future progression of latent TB infection to active disease, in both HIV-infected 
and uninfected subjects by 2012 now seems unachievable (85) . Therefore, despite the push and 
increase in TB diagnostics in the recent years endorsed by WHO; clearly not much has been 
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achieved for diagnostics for TB infection and disease progression. There is need to put much 
more continued emphasis on diagnostics for the prevention of active TB in high TB endemic 
countries.  
FIND (Foundation for Innovative New Diagnostics) estimates that the largest potential available 
market for a new TB diagnostic would be for a test that both detects latent infection and 
predicts progression to active disease. Such a test, if widely implemented and accompanied by 
successful treatment, could revolutionize TB control (109). Such a test should be cost effective, 
robust enough to be used at peripheral levels of health-care systems, perform equally well in 
HIV infected individuals and should allow sensitive, specific and timely detection (110).  
Even though the evidence so far seems to show that IGRAs have modest predictive ability (108) 
and may be by themselves only unlikely to be sufficient enough to act as predictive markers for 
TBI, longitudinal data especially in HIV infected populations is still lacking. Some of the 
unanswered questions (e.g. within subject conversions and reversions) may be important in 
understanding better platforms of designing and improving similar technologies. Recently WHO 
strongly recommended (111) that IGRAs should not be used as predictive tools because neither 
IGRAs nor the TST can accurately predict the risk of infected individuals developing active TB. 
However, this recommendation was based on three studies (one was submitted as an interim 
report because the study was ongoing-this is the main study under discussion in this thesis) of 
different quality done among individuals with varying risks.  
This thesis is part of the many efforts by investigators to try and focus on issues that are still 
poorly understood about IGRAs due to paucity of longitudinal data. Furthermore, these assays 
have not only gained popularity in high income countries but slowly they are filtering in the 
private sector of high burden countries despite the recommendation by WHO  Some of the key 
unresolved issues are the efficacy of preventive therapy on IGRA results; relationship between 
quantitative IGRA levels and the subsequent development of TB; immunological phenotypes of 
discordant-concordant TST/IGRA pairs and the subsequent rates of TB and the utility of repeated 
or serial IGRA results for predicting subsequent incident active TB (111). In this thesis my focus is 
on the relationship between quantitative IGRA levels and the subsequent development of TB. 
1.3 Diagnosis of Mtb Infection 
 
Introduction 
The tuberculin skin test (TST) was until the past decade, the only test available for the diagnosis 
of TBI. Two commercially available Interferon Gamma Release Assays (IGRAs), the QuantiFERON-
TB Gold assay (QFT-GIT; Cellestis Ltd.) and the enzyme-linked immunospot (ELISPOT)-based T-
SPOT.TB (Oxford Immunotec Ltd, UK) assays have emerged as alternatives to the TST (112). The 
newer generation  of QuantiFERON-TB Gold assay  is called QuantiFERON-TB Gold In-Tube (QFT-
GIT, Cellestis, Australia) and this is a whole-blood based enzyme-linked immunosorbent assay 
(ELISAs) measuring the amount of IFN-γ produced in response to three M. tuberculosis antigens 
(QFT: ESAT-6, CFP-10 and TB7.7). In contrast, the T-SPOT.TB (Oxford Immunotec, UK) measures 
the number of peripheral mononuclear cells that produce IFN-γ after stimulation with ESAT-6 
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and CFP-10 (112). However, both TST and IGRAs cannot distinguish infection from active 
disease. There is still no gold standard for diagnosing tuberculous infection. The only gold 
standard for a test of TBI is the future development of active disease. 
TST and IGRAs are measures of cellular immunity and putative markers of latent infection. Both 
TST and IGRAs are currently available commercially and depend on the elaboration of 
inflammatory cytokines by T-cells previously sensitized to mycobacterial antigens (113) (Figure 
1.8). 
Figure 1.8:  Mechanism of action of TST and IGRAs. 
 
Reproduced from (113) 
Both  tests  simply determine that infection has at some point led to an acquired immune 
response that is detectable following re-challenge with antigen (8). Detection of an adaptive 
immune response towards mycobacterial antigens is only an indirect measure that represents “a 
footprint of a contact of the immune system with these organisms” (5). 
Therefore, a positive IGRA only indicates a long-lasting T cell immune response against Mtb, but 
like the TST does not per se demonstrate the persistence of viable Mtb organisms. It is possible 
that viable Mtb organisms persist only in a fraction of individuals who have a persisting T cell 
immune response to Mtb antigens (114). 
1.3.1 Tuberculin skin test 
 
The principle of the TST is based on the intradermal injection of Purified Protein derivative (PPD) 
producing a cell-mediated immune response in the form of delayed type hypersensitivity 
response. The mycobacterial antigens injected below the epidermal layer, cause infiltration of 
antigen-specific lymphocytes and the elaboration of inflammatory cytokines. This inflammatory 
reaction results in the characteristic indurated area at the site of injection (figure 1.8). 
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TST reactions in humans are measured by the diameter of induration, measured 48-72 h after 
antigen injection. Clinically, the skin reaction may already start a few hours after the injection of 
tuberculin PPD with a white or rose-colored induration of the skin as a type-I or type-III immune 
reaction followed by the DTH reaction, which peaks after 48-72 hours and may last for up to 1 
month, depending on the quality and quantity of the initial reaction. 
The TST is one of the few tests that have been continuously in use for about 100 years in clinical 
medicine. Despite the shortcomings of the TST, large studies have shown that treatment of TBI, 
as defined by the TST, substantially reduces the risk of developing active disease (100-102). 
Several longitudinal clinical randomized trials have demonstrated the positive association 
between TST response and subsequent risk of active TB (115-118). These trials have 
demonstrated the two-year protective effect of PT, which reduces the risk of active disease by 
60%. HIV positive individuals that have a positive TST have a 30% or more lifetime risk of 
developing active TB (119). In a review article by Watkins and others (116) across 10 studies the 
larger TST reactor category was found to have a greater risk of TB than the smallest reactor 
category indicating a positive association between tuberculin reactivity and the risk of TB.  
Although TST has been widely used, it has well-known limitations (116, 120). Limitations in the 
skin test operating characteristics have a long history and have been extensively discussed (121-
123). One such major limitation is that the PPD used in the skin test is a crude mixture of several 
antigens, many of which are shared among Mtb, M.bovis BCG and several non-tuberculous 
mycobacteria (NTM). As a result TST gives false positive and false negative results and has lower 
specificity in populations with high BCG and NTM exposure. In addition its sensitivity may be low 
in individuals with depressed immunity (AIDS, malnutrition, advanced TB, other 
immunosuppressive conditions). In one study in Zambia (124) only 30% of HIV-positive patients 
at a  STI clinic had positive TST compared with 62% of HIV-negative individuals. The 
administration and reading of TST pose many problems such as reader variability and digit 
preference.  
1.3.2 Interferon Gamma Release Assays (IGRAs) 
 
IGRAs are based on the principle that T-cells of individuals sensitized by Mtb produce IFN-γ 
when they reencounter mycobacterial antigens (figure 1.8). These tests measure in vitro IFN-γ 
production by circulating T-cells after 16–20 hours stimulation in response to specific Mtb 
antigens. Specific IFN-γ production in response to mycobacterial antigens, therefore, is 
presumed to be indicative of infection with Mtb and can be measured by the rapid ex vivo 
enzyme-linked immunospot (ELISPOT) assay or by the whole blood ELISA (125). The detection 
and subsequent quantification of IFN-γ is the basis of these tests.  
The genes encoding these antigens are found in the region of difference (RD), either RD1 (CFP-
10 and ESAT-6) or RD11 (TB7.7) of the Mtb genome, which are deleted from the genome of M. 
bovis BCG and not present in most environmental mycobacteria, including the M. avium 
complex(5). However, homologues of the antigens are encoded within the RD-1 of M. leprae, 
wild type M. bovis, and other NTM (including M. kansasii, M. marinum, M. szulgai and M. 
Flavescens (113, 126). 
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It has been suggested that T-cells responding to the RD antigens after 24 hours stimulation are 
predominantly CD4 T-cells of an effector memory phenotype, consistent with having recently 
encountered antigen in vivo (5). In contrast, long-lived central memory T-cells are less likely to 
release IFN- γ after 24 hours of incubation and more likely to produce IL-2 (5). 
Systematic reviews have shown that, compared with the TST, IGRAs have a higher specificity in 
low TB incidence settings, correlate better with surrogate measures of Mtb exposure, and have 
no cross reactivity with the BCG vaccine (127, 128). Although the replacement of the TST by 
IGRAs may not be imminent in resource-limited settings, IGRAs are increasingly being 
recommended in resource-rich countries for the diagnosis of TBI in adults. A comparison of the 
performance and operational characteristics of TST and IGRAS is shown in Table 1.3. 
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Table 1.3:  Comparison of the performance and operational characteristics of TST and IGRAs (5, 127, 129-131)  
Performance &operational 
characteristics 
Tuberculin skin test QuantiFERON -TB Gold In Tube assay (ELISA) T SPOT-TB assay (ELISpot) 
Administration/format In-vivo (intradermal) In-vitro, ELISA based In-vitro, ELISPOT based 
Antigens PPD ESAT-6, CFP-10 and TB 7.7 ESAT-6 and  CFP-10 
Test substrate Skin Whole blood Peripheral blood mononuclear cells 
Cells involved Neutrophils, memory CD4 T cells 
and CD8 
CD4 Tcells in whole blood tubes CD4 Tcells in the wells 
Cytokines involved IFN-γ, TNF-α, IL-4, IL-10,  IFN-γ, TNF-β, TNF-α IFN-γ, TNF-β, TNF-α 
Outcome measure Size of induration Plasma concentration of IFN-γ  Number of IFN-γ producing T cells 
Units of measurement Millimeters of induration International units (IU) of IFN-γ IFN-γ spot forming cells (SFC) 
Positive results 5 mm, 10 mm, or 15 mm ≥0.35IU/ml and >25% of nil ≥8SPU 
Time to result 48-72 hours 16-24 hours ( longer if run in batches) 16-24 hours ( longer if run in batches) 
1Sensitivity (95% CI) 77% (71-82%)  77% (CI: 75% to 80%) 92% (CI: 90% to 93%) 
Sensitivity in HIV positives 60 (50 - 70%) 61% (47-75%)  72% (62%-81%)  
2Specificity (95% CI) 97% (95-99%) non BCG 
vaccinated; 59% BCG vaccinated 
99% (98-100%) Non BCG vaccinated; 96% (94-98%) 
BCG vaccinated 
93% (86-100%) BCG vaccinated 
Cross-reactivity with BCG and 
NTM  
Yes  Less likely but can cross react with some NTM  Less likely but can cross react with some NTM 
Inter-reader variability yes No Variation in counting spots (if manual) 
Laboratory infrastructure No  Requires laboratory expertise & equipment. Requires laboratory expertise & equipment. 
Reliability (reproducibility) Moderate   High Limited evidence but may be high 
Correlation with Mtb exposure Yes  Yes (correlated better than TST) Yes (correlated better than TST  
Association between test 
positivity & risk of active TB 
Moderate to strong positive 
association  
Modest but evidence still limited Modest but evidence still limited 
3Benefits of treating test positives  Yes  No evidence No evidence 
4Boosting phenomenon  Yes No  No  
Potential for conversions and 
reversions  
Yes  Yes  Yes  
Cost per test($)(106) 12.73 41 85 
.1May be positive with M. kansasii and M. marinum species.1Sensitivity: TB patients with active disease, most studies had no HIV positive participants.2Specificity: healthy 
individuals with low risk or without known exposure to TB. 3Based on randomized control trials.4Boosting phenomenon: initial test influencing the subsequent test. 
 47
1.3.3 What is the current use of IGRAs in clinical practice?  
 
IGRAs are now licensed for clinical use in many countries such as USA, UK and Canada (132, 
133). 
There has been growing interest in the use of IGRAs especially in low TB incidence high-resource 
countries(134). There are now 33 guidelines and statements from 25 countries (135) with 
considerable diversity in the approaches. However, these guidelines are predominantly from 
high-income countries with established TBI screening programs. In low TB incidence and high-
resource settings, the higher specificity of IGRAs and their logistical advantages seem to 
enhance their adoption and usage. 
In high TB incidence and low resource countries, the TST is still preferred because there is no 
strong evidence that IGRAs are superior to the TST in such settings, especially given the 
significantly higher costs associated with IGRAs. There is currently no high incidence and low-
resource country that has published guidelines on IGRAs. However, IGRAs are available in some 
countries, such as India and South Africa, although they are being used mostly in the private 
sector and in research settings (135). 
Current guidelines are characterized by four main approaches as shown in Table 1.4 (134): 
1) A two-step approach of TST first, followed by an IGRA for confirmation.  
2) IGRA only, replacing the TST 
3) Both TST and IGRA together 
4) Either the TST or an IGRA, but not both. 
These considerations are based mainly on cost effectiveness calculations. One recent study 
found that  the use of IGRAs as a screening tool, either alone or in conjunction with the TST, for 
detecting TBI  was a more cost effective alternative than using the TST alone (136). 
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Table 1.4:  Recommendations for contact Investigations in adults (134) 
Recommendation   Guideline or position statement* 
TST alone WHO, Brazil, ECDC (high-incidence countries) 
TST followed by IGRA,  
if TST positive (either IGRA only in 
BCG vaccinated persons or 
independent of BCG vaccine) 
Canada (low –risk contacts), Germany, Italy, Switzerland, Spain, 
Saudi Arabia, the Netherlands, Norway, Bulgaria, Portugal, Ireland, 
ECDC (low incidence countries), and for the UK and South Korea 
only in adults <35 years old. 
Both TST and IGRA  
 
Canada (High–risk contacts), Czech Republic, Croatia, Austria, 
Australia (IGRA may be considered in addition). 
Either TST or IGRA USA, Denmark, Finland (IGRA preferred if BCG-vaccinated all three 
countries, South Korea (only adults <35 Years old), Austria. 
IGRA alone  Slovakia, Japan France 
CDC, US Centers for disease control and prevention; ECDC, European centre for disease prevention and 
control:  
*Some countries /organizations are listed more than once because their recommendations vary across 
risk groups 
 
Most of these guidelines are based on expert opinion and not evidence based. Future guidelines 
will need to consider impact of IGRAs on patient outcomes and cost-effectiveness in various 
settings (135). 
1.3.4 Limitations of using IGRAs as diagnostic tests for Mtb infection. 
 
1) As with the TST, both false negative and false positive results can occur with IGRAs such as 
QFT-GIT.  
a) A negative IGRA result does not preclude the possibility of Mtb infection or disease: 
false-negative results can be due to the stage of infection (e.g. specimen obtained prior to 
the development of cellular immune response),  medical conditions which affect immune 
functions, incorrect handling of the blood collection tubes following  venepuncture, 
incorrect performance of the assay or other immunological variables.  
b) A positive IGRA result is not a definitive basis for determining infection with Mtb. 
Incorrect performance of the assay may cause false positive responses. Assessing the 
probability of TBI requires a combination of epidemiological, historical, medical and 
diagnostic findings that should be taken into account when interpreting results.  Therefore, 
additional medical and diagnostic evaluations may be needed to make a diagnosis. 
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c) While ESAT-6 and CFP-10 are absent from all BCG strains and from most known 
nontuberculous mycobacteria, it is possible that a result may be due to infection by M. 
kansasii, M. szulgai or M. marinum.  
 
2) Blood samples must be processed within 8-16 hours after collection while white blood cells 
are still viable.  
 
3) Errors in collecting, transporting and processing blood specimens may influence the actual 
results obtained. For instance, technical issues  that affect results include: 
a)  Time from blood drawing to incubation longer than 16 hours. 
b) Storage of filled blood collection tubes outside the recommended temperature range 
(22° C± 5°C) prior to incubation. 
c) Insufficient mixing of blood collection tubes. 
d) Incomplete washing of the ELISA plate. 
e) Variation to the stated pipetting and washing techniques. 
Variations caused by these factors may be difficult to distinguish from variations caused by 
immunologic responses to Mtb exposure.   
 
4) IGRA results may also be affected by other individual  factors that are a result of 
immunologic responses to Mtb exposure e.g. within-personal biological variation, new 
infection (conversion), transient infection (137)  or reversions. Existing studies suggest that 
IGRAs are highly dynamic tests whose T-cell responses especially weakly positive responses 
tend to fluctuate over time and that just like the TST; they are prone to conversions, 
reversions and non-specific variations (138-140). 
 
5)  IGRAs have higher resource demands when compared to the TST, as they require laboratory 
access, trained personal and implementation of quality-assured procedures. As they are 
technically more demanding, IGRAs are a more costly diagnostic tool. However, the reading 
and analysis of test results can be done by batch, thus reducing the cost but also increasing 
the time until results are known.  
 
6) IGRAs require phlebotomy 
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1.4 Aim and Objectives 
1.4.1 Hypothesis 
 
Household contacts with high (≥10 IU/ml) levels of IFN-γ in response to Mtb specific antigens 
(ESAT-6, CFP-10 and TB 7.7) in the QFT-GIT assay are at higher risk of developing TB compared to 
those with low levels (> 0.35-<10 IU/ml). 
There is data indicating that a high response to ESAT-6 and CFP-10 reflects  Mtb infection . 
However, what constitutes a ’high’ response may be context-dependant and might differ from 
TB endemic to TB non-endemic regions and from HIV uninfected to HIV-infected individuals (50). 
The estimate of 10 IU/ml has been used elsewhere (141) and is the maximum value the QFT-GIT 
ELISA software can read. 
Other literature have defined strong responders or those with high levels as those with IFN-γ 
levels tenfold higher than the cut-off point of 0.35 IU/ml (142). 
1.4.2 Aim 
 
To determine the association between the magnitude of T-cell Interferon-γ response to Mtb 
specific antigens (ESAT-6, CFP-10 and TB 7.7) in the QFT-GIT assay and the risk of progression to 
TB post Mtb exposure.  
1.4.3 Primary Objective 
 
To determine whether household contacts with high (≥10 IU/ml) levels of IFN-γ in response to 
Mtb specific antigens (ESAT-6, CFP-10 or TB 7.7) in the QFT-GIT assay are at higher risk of 
developing TB compared to those with low level (> 0.35-<10 IU/ml). 
1.4.4 Secondary objectives 
 
1) To determine the performance and operational characteristics of QFT-GIT in a field setting. 
2) To determine risk factors associated with positive QFT-GIT and TST results at baseline.  
3) To determine the level of agreement or concordance between QFT-GIT and TST results. 
4) To determine the incidence rates of TB in household contacts with positive and negative 
QFT-GIT and TST results, also stratified by HIV status. 
5) To determine the association between QFT-GIT and TST positivity and the subsequent risk of 
development of TB.  
6) To determine risk factors associated with incident TB.  
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7) To determine the association between the magnitude of QFT-GIT and TST responses and the 
subsequent risk of development of TB. 
1.4.5 Research questions 
 
1) Are household contacts with high (≥10 IU/ml) levels of IFN-γ in response to Mtb specific 
antigens (ESAT-6, CFP-10 or TB 7.7) in the QFT-GIT assay at higher risk of developing TB 
compared to those with low level (> 0.35-<10 IU/ml)? 
2) What is the performance and operational characteristics of QFT-GIT in a field setting? 
3) What risk factors are associated with positive QFT-GIT and TST results at baseline? 
4) What is the level of agreement or concordance between QFT-GIT and TST results? 
5) What are the incidence rates of TB in household contacts with positive and negative QFT-GIT 
and TST results, stratified by HIV status? 
6)  What is the association between QFT-GIT and TST positivity and the subsequent risk of 
development of TB? 
7) What risk factors are associated with incident TB? 
8) What is the association between the magnitude of QFT-GIT and TST responses and the 
subsequent risk of development of TB? 
 
Conceptual Framework 
There are various factors to consider when contextualizing the impact of high levels of 
interferon-γ on TB incidence. It is by setting in place this context that this study will facilitate an 
understanding of how high levels of interferon-γ  in the QFT-GIT assay can affect risk of  
progression to TB.  There is currently limited understanding and evidence of this relationship. 
The suggested conceptual framework is shown in Figure 1.9  
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Figure 1.9:  A conceptual framework showing host immune response following exposure, IFN-γ levels and disease within a 2-3 year period. 
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2.0 Literature Review 
 
An overwhelming publication of IGRA literature 
Research on IGRAs has been ongoing at unprecedented rate with an extremely large number of 
papers cumulating over the recent years.  There are more than 250 published papers on IGRAs 
since 2001 (143). This field has been an extremely rapidly evolving field with large series of 
expert reviews and expert opinions and numerous guidelines issued worldwide as well as 
systematic reviews or meta-analyses. A PubMed survey of studies looking at TB diagnostics: 1st 
January 2008 to 7th August 2011 showed that almost 42% of studies on TB diagnostics focused 
on IGRA (143) (Figure 2.1) 
 
Figure 2.1:  A PubMed survey of studies looking at TB diagnostics: 1st January 2008 to 7th 
August 2011. 
 
 
Modified from (143) 
In this chapter I will attempt to review IGRA evidence in relation to the most relevant and critical 
analytical studies. The objectives of this chapter are: 
1) To collate and review the most relevant analytical studies on the association between the 
magnitude of T-cell Interferon-γ responses to Mtb specific antigens and risk of progression 
to disease. 
2) To critically review the above evidence with reference to the following: 
IGRAS
41.8%
Biomarkers
11.7%
Manual NAAT
8.9%
GenXpert  3.3%
Culture 6.8%
Skin tests 4.9%
Microscopy
3.0%
Serology 3.5%
Point of Care 1.0%
Other 15%
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a) Whether Mtb infected individuals with strongly elevated IFN-γ levels are most likely to 
progress to active disease? 
b) Whether IGRAs are better than the TST at predicting individuals who have a high risk of 
progression to active TB? 
c) The concordance between IGRAs and TST results. 
d) Effect of HIV on IGRAs. 
2.1 What is the performance and operational characteristics of QFT-GIT in a resource-limited 
field setting with a high burden of TB and HIV? 
 
Each time a new product is launched on the market, one of the important questions that 
consumers would want to know is accessibility, practicability, affordability and whether it is 
better than existing products and in what ways. This was no different for IGRAs. The 
development of IGRAs brought a lot of hope for TB diagnostics after a decade of using one test 
for the diagnosis of TB infection, the TST. To be useful, diagnostic tests need to be accurate, 
simple and affordable for the population they are intended. It is still not widely acknowledged 
whether IGRAs represent “true hope for TB diagnostics” as an alternative to the TST for poor 
resource settings with a high burden of TB and HIV.  
The evaluation of any diagnostic test involves assessing performance and operational 
characteristics. Test performance involves determining the sensitivity and specificity, and the 
positive and negative predictive values of a test (144) and reproducibility. In evaluating the 
operational characteristics of a test, important considerations include stability of the test under 
ideal and less ideal conditions, time taken to perform the test, user acceptability, ease of use 
from the field to less specialized laboratories as well as some financial costs.  
In poor resource settings with a high burden of TB and HIV, a lot of factors are at play that may 
determine how IGRAs work. According to WHO, novel technologies successfully introduced into 
developed countries require adaptation to match the needs of developing countries (145), 
which includes feasibility and cost effectiveness considerations. In developing countries 
potential drawbacks include the cost, the need for highly skilled staff and a good laboratory 
infrastructure (with capacity to run ELISA or ELISPOT), the high HIV prevalence as well as 
logistical issues (e.g. power shortages) peculiar to these settings. In addition, stringent control of 
multiple variables, from blood collection, processing and storage in the field to performance of 
the test in the laboratory may be difficult to control in resource-limited settings. QFT-GIT 
indeterminate results can  occur due to improper assay techniques (e.g. time delays that lead to 
loss of viable T cells in the specimens)(146). Many studies have now shown that HIV has an 
effect on the performance of IGRAs (131, 147, 148). 
Many countries with low TB incidence now have guidelines on the use of IGRAs for the diagnosis 
of tuberculous infection. In these settings, IGRAs are believed to have many advantages over TST 
in particular an increase in specificity (127, 128). However, their use is limited in high TB 
incidence countries as there is a dearth of data on their performance in these settings. 
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Systematic reviews have suggested that IGRA performance differs in high versus low TB and HIV 
incidence settings, with relatively lower sensitivity in high-burden settings (149).  
Other factors that affect the immune response and hence the outcome of IGRAs (150) are at 
play in high TB incidence poor resource settings. In particular, the presence of universal BCG 
vaccination, poverty related malnutrition, tropical infections, helminths and widespread 
exposure to NTM might pose unique challenges. Protein-calorie malnutrition is associated with 
impaired cellular and humoral immunity, the basis of immunodeficiency thought to be 
metabolic disturbances, which adversely affect maturation and function of cells of the immune 
system (151). 
Although the specific antigens encoded within the RD-1 of Mtb are absent in many NTM, their 
presence in other species like in M. leprae and M. kansasii can pose challenges if prevalent. 
Theoretically, the presence in the host of some NTM could cause a false-positive IGRA result. 
The presence of environmental mycobacteria in Zambian communities was evident in two 
recent large tuberculin skin test surveys in the ZAMSTAR study (95). A study in Malawi (152)  
found a high rate of  IFN-γ  responses to PPD of atypical mycobacteria, especially to those of 
MAIS complex (M. avium, M .intracellulare, M. scrofulaceum and  M. marinum) which was 
strongly associated with positive TST response to human PPD. Only M. kansasii can cause 
disease similar to tuberculosis and it does so only infrequently (113).  
A small number of cost and cost-effective analysis studies comparing different TBI screening 
strategies have been conducted. However, most studies were conducted from low TB incidence 
settings where TB control effort focuses on high-risk subgroups (153-155) and where healthcare 
costs may be different to high incidence countries. The potential savings from switching to 
IGRAs such as the reduced costs of unread tests, missed cases, preventable cases and reduced 
false positive tests need to be studied further in specific endemic populations. Currently, the 
cost-effectiveness of IGRAs in routine programmatic settings; in high incidence settings is 
unknown.  
Recently WHO strongly recommended (156) that IGRAs should not be used in the diagnosis of 
active TB, diagnosis of TBI in children and HIV infected individuals; screening health care 
workers, contact screening, outbreak investigations and predicting development of TB in low- 
and middle-income countries, typically those with a high TB and/or HIV burden. WHO  noted  
that the majority of IGRA studies had been performed in high-income countries and mere 
extrapolation to low- and middle-income settings with high background TB infection rates was 
not appropriate (156). However, the evidence upon which these recommendations were made 
was insufficient and was of low quality. It was also noted that given the comparable 
performance of IGRAs and TST but increased cost and technical complexity of IGRAs no real 
advantage was seen (156). These recommendations did not apply to high-income countries or 
any national guidelines that may have been written for such settings. 
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2.2 Are Mtb infected individuals with strongly elevated IFN-γ levels most likely to progress to 
active TB? 
 
Despite a growing body of literature on IGRAs, several questions remain unanswered (24, 157). 
There is still a widely recognized need for large longitudinal studies with clinical outcomes to 
determine the prognostic value of positive IGRA results in the development of TB (106,141, 
158). This is particularly important for highly endemic TB settings with large numbers of latently 
infected HIV positive individuals who may require preventive therapy. 
There are few  studies available that describes the association between the changes in IFN- γ 
responses in IGRAs and disease prediction (9). It has been postulated that individuals with 
strong and/or rising IFN-γ responses to QFT-GIT may be at greater risk for progressing to active 
disease (28, 33, 50, 141). Literature from studies done among healthy HHCs suggest that 
recently exposed individuals have different ESAT-6/CFP-10 response levels (22, 28). Some of the 
earliest studies done among HHCs in Ethiopia have demonstrated this (22, 28) and recently 
similar evidence has emerged (35, 141, 142, 159). It is thought that among such an exposed 
group of individuals are those with strong ESAT-6/CFP-10 responses or high levels of IFN-γ in 
response to Mtb specific antigens. It is believed that these recently exposed individuals offer a 
vigorous T-cell response as a result of active bacterial replication (39). 
A study done in the Gambia (39), found increased proportions of responders and intensities of 
responses to ESAT-6 and TST in HHCs than community controls. In addition, higher frequencies 
of lymphocytes producing IFN-γ in response to ESAT-6 and TST were reported in recent 
converters (PPD) than in healthy controls in Germany and the United States (38). In another 
study done in Pakistan among 109 HHCs, CFP-induced IFN-γ showed consistent increases during 
the first 6 months until 12 months post exposure and then dropped to the baseline level at 24 
months (13). 
It has been suggested that such high responses are not only typical of recently exposed  
individuals but are suggestive of an early stage of infection by Mtb, which could in time result in 
overt disease or containment of the infection (160). Consequently, such strong increases in T-
cell response after recent exposure might predict progression to active disease (28, 107). It has 
been hypothesized that IGRAs detect responses of partially activated, effector T cells that have 
recently encountered antigens in vivo, and can therefore rapidly release IFN-γ when stimulated 
in vitro (52). It is plausible that unlike the TST, IGRAs may be measuring recent rather than old 
infection and therefore associated with higher rates of progression to active TB.  
Several studies of HHCs of TB patients suggest that in HIV negative individuals, high or increasing 
concentrations of TB-specific IFN-γ production might predict overt TB, although the numbers of 
cases in these studies are small (28, 33, 141). A recent study done among HHCs in Colombia (35) 
explored whether IFN-γ production in response to CFP-10 and non-specific (CFP) Mtb antigens at 
baseline were predictive of active TB . In this study, individuals with high IFN-γ levels in response 
to CFP-10 were at higher risk of developing TB than those with low levels early after exposure to 
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a pulmonary TB case. The results showed an almost 3-fold difference in incidence rate between 
the highest IFN-γ producers at baseline compared with negative responders. Disease incidence 
was found to be highest in strong responders to CFP-10, whilst those with medium and low 
levels of IFN-γ production had intermediate incidence levels. There was also a significant 
tendency of increasing hazard rates of disease development with increasing IFN-γ production 
levels in response to CFP-10 observed during follow-up. A limitation of this study is that an in-
house assay was used that incorporated a 7 day whole blood culture in contrast to the 24-hour 
incubation used by commercial IGRAs. By virtue of the extended lymphocyte culture times used, 
these measures may primarily detect central memory responses while short incubation IGRAs 
detect mostly effector memory T cell responses of recently activated lymphocytes. 
In a study conducted in Germany (141), all six subjects who developed TB showed a high IFN-γ 
above 10 IU/ml as well as in the follow up study (142) in which a larger cohort was examined. In 
this follow up study, 16 of the 19 people who developed active TB were strong responders in the 
QFT-GIT assay, with IFN-γ levels more than tenfold higher than the cut-off of 0.35 IU/ml. 10 of 
the 19 had levels above the 10IU/ml upper limit for the test’s ELISA. Progression to disease was 
significantly associated with IFN-γ level; the chance of developing TB nearly doubled with every 
unit of IFN-γ /ml. 
In a study done in Senegal (159), there was a quantitative relation between the level of ELISPOT 
response and the risk of development of TB within two years follow-up. HHCs with an ELISPOT 
response of 32 SFC/106 PBMC or greater had nearly a two-fold increased rate of developing TB 
in follow-up compared to those with a response <32 SFC. In a contact investigation study done 
in Japan (161), contacts  with high levels of IFN-γ production in response to either ESAT-6 and/or 
CFP-10 had a higher risk of developing active TB than those with lower levels. In this study there 
was an increasing trend of disease risk with increasing quartile (odds ratio of 4th quartile 
compared to 1st quartile was 4.04). However, the study was not based on a pure prospective 
design, the diagnosis of TB was done using radiological findings only and the sample size was 
small. In addition the authors did not specific the quantitative values of IFN-γ for the quartiles 
indicated. 
Other studies have found contrasting findings. In the study in Turkey in children contacts (158), 
although a positive ELISpot result was prognostic of progression to TB, the magnitude of this 
response did not further refine the risk for progression. Within ELISpot-positive contacts, the 
size of the baseline IFN-γ response to peptides did not significantly differ between contacts who 
developed TB and those who did not. 
Some studies that have looked at the prognostic ability of IGRAs have used a  single test showing 
an elevated IFN-γ response which does not provide information on when the response became 
elevated (whether this was recently or in the past) or whether it has stayed elevated for a long 
time (whether it has been persistently elevated or not)(162). 
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There have been suggestions to use quantitative as well as qualitative results of IGRAs. 
However, the significance of the quantitative test results is unclear at present, especially 
whether very high test results could indicate an increased risk of progression. The quantitative 
results from IGRAs have not yet been shown to have prognostic value. Hence it is important to 
determine whether quantitative IFN-γ responses are predictive of those who have a high risk of 
progression to active TB. Evidence provided by studies described in this section suggest that this 
approach is worth exploring (107). 
2.3 Are IGRAs better than the TST at predicting individuals who have a high risk of 
progression to active TB? 
 
Much has been speculated about the possible advantages of IGRAs over the TST in diagnosing TB 
infection. However, few studies to date have addressed the actual purpose of these assays, 
namely, the prognostic ability of IGRAs to accurately identify individuals with latent infection 
who are at the highest risk for progression to active TB (24, 157, 163). This is particularly 
important for highly endemic TB settings with large numbers of latently infected HIV positive 
individuals who may require preventive therapy. If an IGRA has better sensitivity of predicting 
active TB than the TST, its use would lead to fewer people being ‘‘identified’’ as positive and, 
thereby, fewer people to evaluate for active TB and fewer being offered  preventive therapy 
(141) . Such an outcome would focus scarce TB-control resources on those individuals most 
likely to progress to active TB and reduce transmission (107, 157). 
To date, 13 longitudinal studies have been published assessing the predictive value of IGRAs (35, 
159, 164-166). However, some of these are designed as contact investigation studies (8-12) in 
low TB burden countries. Out of the 13 studies, only five are large cohorts with over 2000 
participants. Only two studies have been done from countries with a high burden of TB and HIV; 
one among adolescents in SA and another among pregnant HIV infected women in Kenya (166, 
167). Given the paucity of data from such high burden countries, the present study was 
conducted in two countries with high burden of TB and HIV. 
The evidence from studies evaluating the predictive value of IGRAs  has been conflicting .The 
value of IGRAs in predicting the development of active TB has been reported to be higher than 
the TST in some studies (141, 168) and similar (158, 164, 169, 170) in others. The positive 
predictive value for the development of TB is most likely to be higher with an IGRA than with the 
TST because of the higher test specificity and sensitivity (although this is similar in high TB 
burden settings). It is unclear if these different outcomes can be attributed to the different 
IGRAs used, different cut-offs used for TST, the different populations, or to differences in TB 
prevalence. 
Some studies have shown that IGRAs perform similarly to the TST in predicting risk of 
subsequent TB. The largest prospective study investigating the predictive value of TST versus an 
IGRA was conducted among 5244 adolescents in Cape Town, SA (169). This study showed that 
adolescents with either a positive QFT-GIT or TST result at baseline had a three-fold increased 
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risk of active TB than those who were negative. Another large longitudinal study (164) done in 
Gambia among 2348 HHCs found that the presence of either a positive ELISPOT or TST result at 
baseline was associated with  a two-fold increased risk of developing active TB compared to 
those who were ELISPOT or TST negative. These findings  are similar to those of a study among 
2679 HHCs in Senegal (159). However, the studies done in Gambia and Senegal used in house EC 
ELISPOT assays in contrast to the commercial types reported in other studies. Among child 
contacts of persons with active TB in Turkey, positive ELISpot or TST predicted a three-fold 
increased risk of active TB compared to those that had negative results, although the evidence 
was stronger for ELISPOT than for TST. 
Other studies have shown that IGRAs perform better than the TST in predicting risk of 
subsequent TB. A study following 601 exposed HHCs in a German metropolis found a 
progression rate to active TB in QFT-IT positive individuals of 14.6% compared with 2.3% in 
those who were TST positive (141). However, all TB cases occurred in persons who refused PT. In 
another study done in China among 308 silicosis patients, a positive T-SPOT test independently 
predicted the subsequent development of active TB while TST did not, irrespective of  the cutoff 
values (168). However, silicosis patients have a much higher  risk (2.8 to 39 times higher, 
depending on the severity of the silicosis) of developing TB compared to healthy controls (171). 
In a systematic review done by WHO on the use of IGRAs in low- and middle-income countries 
(111), both IGRAs and the TST appeared to have only modest predictive value and did not help 
to identify those who were at highest risk of progression to active disease. The vast majority of 
individuals (>95%) with a positive IGRA results did not progress to active  disease during follow-
up, although a modest but statistically insignificant increase in incidence rates of TB in IGRA- 
positives compared to IGRA-negatives was observed. However, the quality of evidence used to 
determine the predictive value of IGRAs was poor. 
There are only three large studies that have evaluated IGRAs for prediction of active TB in HIV 
positive adults (167, 172, 173). All of these studies were done among HIV positive individuals 
within a clinic or hospital setting and lacked a comparison group of HIV negative individuals. 
Therefore, these results cannot be extrapolated to immunocompetent populations. However, 
the studies do show that IGRA positivity at baseline is associated with a much greater risk of 
active TB, in comparison to studies involving immunocompetent HHCs.  
The largest longitudinal study among 822 HIV positive individuals was conducted in Austria 
(172). Of 37 individuals who were QFT-IT positive, three (8.1%) developed active TB during a 
follow-up period of 19 months. None of the QFT-GIT-negative individuals progressed to active 
TB, indicating a very high negative predictive value. Limitations of this study are that 60% of 
individuals were on ART at enrolment hence lowering the risk of active TB. In addition, even 
though all individuals were screened for TB symptoms at baseline, more intensive screening 
with chest X-ray, smear, culture, PCR & TST were done in those who were QFT-GIT positives.   
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This additional work up introduced verification (work-up bias) making QFT-GIT positive 
individuals more likely to have disease than negatives.  
Similar results were observed in a study done in Kenya among 333 HIV positive pregnant women 
(167). In multivariate analysis, adjusting for baseline CD4 count, IGRA positivity was associated 
with an almost 5-fold increased risk of active TB. Among women with baseline CD4 cell counts of 
less than 250 cells/mL, IGRA positivity was associated with a 5-fold greater risk of active TB or 
death. In the study done in Gambia described above (164) similar results were obtained despite 
the small number of HIV positive HHCs (2%) i.e. ELISPOT positivity was associated with a 6-fold 
greater risk of active TB. 
Although IGRAs seem to predict subsequent active TB better than or similar to the TST, the 
majority of the high risk people with positive tests will not develop active TB (142). Thus, studies 
so far have shown that IGRAs have a low-modest positive predictive value (PPV)(142). The PPV 
for active TB represents the probability that an individual who tests positive is truly at risk of 
developing active TB disease later in life. In a systematic review, PPV was determined among 
individuals who had refused PT in two-year follow up studies (141, 170, 172, 174). The PPV 
range for QFT-GIT, T-SPOT and TST was 2.8%  to 14.6% ; 3.3%  to 10% and 2.3%to 3.1%, 
respectively (175). However, only four studies were included, the study designs varied widely 
and all of them were done in low TB burden settings. Nevertheless, the results fall within similar 
range when compared to studies done in high TB prevalence settings.  For instance, the PPV for 
IGRAs for the studies done in Kenya among HIV positive pregnant women and among 
adolescents in SA were 5.5% and 1.7% respectively (166, 167). 
A NPV for active TB reflects a test’s ability to correctly predict that an IGRA negative individual 
will not develop active TB in later life, provided they have no further exposure to infection. In 
HIV negative individuals, the NPV of IGRAs for active TB is very high either alone or combined 
with a negative result of the TST. The NPV of IGRAs seems  similar to that of TST, falling within a  
range of 98%-99.8% (142). Hence, among individuals with negative IGRA results, subsequent 
active TB in the next 2-3 years following infection seems to be extremely low (142, 164). 
Despite the evidence presented above, there is still no consensus yet. This is because 
comparison between studies is limited by diagnostic flaws. Some of these flaws include studies 
with small number of participants, verification bias, lack of blinding leading to interpretation 
bias, short duration of follow-up, incorporation bias, use of an inappropriate reference standard 
and failure to report design features. The PPV is influenced by the prevalence of disease in the 
population that is being tested. If the test is done in a high prevalence setting, it is more likely 
that individuals who test positive truly have disease than if the test is performed in a population 
with low prevalence. 
NPV and PPV for IGRAs remain to be established in the pediatric population and in 
immunocompromised individuals especially in HIV positive individuals (131).In contrast, 
randomized controlled trials in HIV infected persons demonstrate that PT confers a 20% to 60% 
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reduction in the risk of active TB among persons with positive TST (115, 131). Unfortunately, 
similar high-quality data on predictive value of IGRA testing are currently lacking. The studies 
evaluating the predictive value of IGRAs are summarized in table 2.1. 
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 Table 2.1:  The association between positive IGRAs results and progression to active TB in selected studies  
Author, year of publication, 
country 
Study population  Follow up 
 time (years) 
 Assay  
used 
Positive test  n/N (%) 
or baseline prevalence 
1aHR for positive IGRA 
results (IRR or PPV (95% CI) 
aHR for positive  
TST (≥ 10 mm)  
High TB incidence       
Mahomed et al, 2011, SA 5244 adolescents 2.4(median) QFT 
TST10  
51% (2669/5244) 
42% (2214/5244) 
IRR: 2.9 (1.6-5.2)  IRR: 2.7 (1.4-5.0) 
Jonnalagadda et al, 2010, Kenya 333 HIV-+ve 
pregnant women 
2 T-SPOT.TB  36% (120/333) 4.5 (1.1-18.0)  
Medium TB incidence       
Lienhardt et al, 2010, Senegal 2679 HHCs adults & 
children 
2  ELISPOT (20 SFC) 
 TST10  
65% (615/952) 
65% (1591/2458) 
2.0 (0.8-5.1)  1.6 (0.7-3.2)  
del Corral, 2009, Columbia 2060 HHCs adults & 
children 
2-3 ELISA ( CFP-10) 
TST10 
66.3% (1310/1977) 
66% (331/502) 
1.8 (0.79-4.20)  
Hill et al, 2008, Gambia 2348 HHCs adults & 
children 
2 ELISPOT 
TST10 
37% (649/1736) 
38% 
1.8 (0.8-4.2) 
HIV +ve:6.2 (1.7-22.5) 
1.8 (0.8-4.1)  
Doherty et al, 2002, Ethiopia 24 HHCS  adults 2 ELISA (PPD) 9/24 (38)   
Low TB incidence       
 Diel et al, 2010, Germany  954 contact adults & 
children 
4 QFT-GIT 
TST10 
21% (198/954)  
25%(242/954) 
PPV:12.9% PPV:4.8% 
Yoshiyama et al, 2010, Japan  3102 contacts adults 
& children 
19 months  QFT-G 
TST many cutoffs 
13.5% (419/3102)  6.7 ( 3.6-12.6) (RR)  
Harstad et al, 2010, Norway1 823 asylum seekers 23-32 months QFT-G 30% (246/823) IRR: 18.8 (2.4-149)  
Leung, et al, 2010, Hong Kong  308 silicosis patients  2.5 T-SPOT.TB 
TST10 
66% (204/308) 
66% (203/308) 
4.55 (1.1-20.4) 1.8 (0.5-6.0)  
Aichelburg  et al, 2009, Austria 830 HIV positives 1.6 QFT-GIT 5.6% (44/783) PPV :8.3% (1.8-22)  
Kik et al, 2009, Netherlands 
 
 339 contact 
immigrant adults 
2 QFT-GIT 
T-SPOT.TB 
TST10 
54% (178/327) 
61% (181/299) 
85% (288/339) 
PPV: 2.8% (1.0-4.6) 
PPV: 3.3% (1.3-5.3) 
PPV: 3.1% (1.3-5.0) 
Diel et al, 2008,  Germany 601 close contacts 2 QFT-GIT 
TST10 
11% (66/601) 
18% (110/601) 
PPV: 14.6% (6.9-28.4) PPV:5.6% 
Bakir et al, 2008, Turkey  908 contact children 1.3 T-SPOT.TB 
TST10 
42% (381/908) 
61% (550/908) 
IRR: 3.4 (1.1-10.7) IRR:2.6 (0.7-14.6) 
Notes: In all studies TB diagnosis was largely based on smear and culture results.IRR: incidence rate ratio. 1 HR: Hazard ratios of positive IGRAs/TST in comparison to negative IGRAs/TST at 
baseline. If aHR is not reported then IRR (incidence rate ratio) or PPV (positive predictive value) is used. 
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2.4 Concordance between IGRAs and TST results 
 
Evaluating the strength of agreement (concordance) between TST and IGRAs avoids the use of 
either test, as the gold standard (129) and comparisons cannot demonstrate which test is 
superior. Discrepancies encountered may be the result of limitations in the TST or limitations in 
the IFN-γ assays.  
There are several studies that have looked at concordance between TST and IGRAs (129, 176, 
177). However, evidence so far is conflicting. Comparison between studies is difficult due to 
differences in the type of assays (in-house assays vs. commercial, different formants); 
incubation times, type of antigenic preparations, TST cut offs, PPD dose, BCG status, HIV status, 
other predisposing individual risk factors for Mtb infection as well as prevalence of TB and NTM 
in the population. Like TST, IGRAs are susceptible to factors affecting host immune responses, 
although the degree of susceptibility may differ between the two tests. Overall, such factors 
may influence concordance between assays and need to be taken in consideration when 
comparing studies.  
Agreement studies comparing TST and IGRAs have commonly used the percent agreement and 
kappa statistics. However, there is wide disagreement about the usefulness of kappa statistics to 
assess rater agreement (178, 179). Although Kappa statistics are appropriate for testing whether 
agreement exceeds chance levels for binary and nominal ratings, controversy still exists. Others 
argue that kappa statistics should not be viewed as the unequivocal standard or default way to 
quantify agreement due to various reasons. Kappa is not really a chance-corrected measure of 
agreement and it does not make distinctions among various types and sources of disagreement. 
It is also influenced by trait prevalence (distribution) and base-rates. As a result, kappas should 
be compared with caution across studies, procedures, or populations. Furthermore, kappa may 
be low even though there are high levels of agreement and even though individual ratings are 
accurate. There is not, however, agreement about what to do about all these issues and 
meanwhile studies have continued reporting kappa statistics. 
A systematic review (24) comparing TST with different interferon-γ assays among 17 studies 
found modest to high agreement (60% to 80%) even though the kappa statistics were highly 
inconsistent ranging from –0.03 to 0.87. In this review, QFT-TB assay (PPD) was used as a 
comparison in 59% of the studies; none of these studies used QFT-GIT and those using TSPOT 
were of small sample size apart from one (180). Another review among HCWs found poor levels 
of agreement between TST and QFT-G in 25 studies and a predominant pattern of TST+/QFT- 
results (181). In a recent community survey among 652 apparently healthy adult pastoralists in 
Ethiopia, there was poor agreement between TST and QFT-GIT (66%; k=0.2) (182). In a study in 
Cape Town among 43 HIV positive adults and children there was moderate agreement between 
the TST and QFT-GIT (k=0.46) in adults (147).  
 
A study (129) conducted in India among 726 health care workers in a rural hospital reported a 
high degree of agreement (81%, k=0.61) as compared to the poor agreement rates reported in 
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most studies from high TB incidence settings (176, 183, 184). Similarly in a study done in 
hospitalized children in India, substantial concordance between TST and QFT-GIT (95.2%; k= 
0.73) was reported (177) despite the high level of malnutrition in these children. Results from 
these two studies showed much higher levels of agreement compared to most studies probably 
due to differences in PPD dose (TU was used in both studies). 
Agreement levels have been shown to be better among HIV positive individuals compared to 
HIV negative ones. However, most of such studies, especially from high TB incidence settings are 
limited by small sample sizes. A small study done in Zambia using TSPOT among 49 healthy 
adults (29% were HIV positive) found a higher concordance rates in HIV positives (64%, kappa 
0.26) compared to HIV negative individuals (185). In a study done in Cape Town (186) among 
160 adults (74 HIV infected), fair agreement between the TST and the IGRAs was seen in HIV-
infected people (k= 0.52–0.6). In contrast, poor agreement between the TST and QFT-GIT tests 
was observed in the HIV- negative group (k= 0.07-0.30). The pattern was similar for T-SPOT.TB 
(k= 0.18–0.24). 
A recent systematic review conducted in HIV positive individuals (131) among 15 studies from 
various countries evaluated agreement between TST and IGRAs. In this review, results were 
reported according to whether the study was done in a low/middle income (Sub-Sahara Africa, 
China, and South Africa) or high income country (Switzerland, Italy, Spain, Germany, USA).  
Overall, estimates of percent concordance were higher in high income countries compared to 
low/middle income countries. In high income countries TSPOT and TST results were concordant 
in 89% (95% CI, 81–98%) of cases and QFT and TST results were concordant in 94% (95% CI, 91–
96%). Eight of the nine studies that reported test agreement using kappa values reported poor 
or moderate agreement (kappa 0.4-0.6). 
 In low/middle income countries, TSPOT and TST results were concordant in 77% (95% CI, 67–
88%) of cases but there was significant heterogeneity among individual studies. Two of three 
studies that reported test agreement using kappa values reported poor or moderate agreement 
(kappa 0.4–0.6). In addition, IGRA+/TST- results were more common than IGRA-/TST+, as shown 
elsewhere in HIV negative populations (181, 187). However, in this review the exact proportions 
of discordant results were not given. The authors in the review did not discuss the reasons 
behind differences in percent concordance between low/middle and high income countries 
which could have been a result of differences in test performances in the different settings.  
In 12 studies (meta-analysis) comparing TST with IGRAs in healthy populations with varying risk 
for LTBI, (157), IGRA−/TST+ discordance (24%) was more common than IGRA+/TST-(5%), similar 
to findings of a community survey in Ethiopia (182). However, in this meta-analysis overall 
concordance rates and kappa statistics were not reported, making comparison difficult. 
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It is increasingly being accepted that concordance between IGRAs and TST in high TB incidence 
settings is lower than that seen in low TB incidence settings. Many factors that modulate the 
sensitivity of IGRAs may explain this difference in addition to those already mentioned. 
Additional factors include high exposure to Mtb; transmission dynamics and repeat exposures; 
high exposure RD-1 homologue producing NTM, disease phenotype and severity(188). 
More recently it has been shown that just like for TST, QFT-GIT has a window period as well (the 
time between infection with Mtb and the test becoming positive). Agreement between the TST 
and QFT-GIT, and the correlation with the intensity of exposure to Mtb, are thought to be better 
after the window period (189). It has been suggested that the test should be carried out 2 
months after exposure, either for the first time or as a confirmatory analysis in cases with a 
positive TST. Although this sounds plausible, this is restricted to contact tracing in low TB 
incidence settings. In high incidence settings, the repeated exposure and re-infection makes it 
difficult to know exactly when an individual was exposed. 
Agreement between IGRAs and TST should not be expected to be excellent because they may be 
measuring different aspects of cell mediated immune response (new vs. old infection) as well as 
using different antigens. It is not yet understood to what extent a positive IGRA result suggests 
previous (remote) infection (either cleared or still persistent) versus recent infection (190). 
However, even though some literature suggests that QFT positivity is related to relatively recent 
acquisition of Mtb infection, there is still no consensus (61). 
Concordance may be maximized by choosing the appropriate cut-off (191). Studies have shown 
that agreement between QFT-GIT and TST increases at higher TST cutoffs (150, 192). Agreement 
between the two tests improved markedly if a > 10mm cut-off was used for the TST, but 
resulted in a large number of QFT+/TST- contacts (193). Three studies showed that agreement 
could be improved by employing a more stringent TST cut-off i.e. 15 mm vs. 10 mm (181). 
2.5 Discordance between IGRAs and TST results 
 
Discordance between IGRA and TST and its interpretation (24) is still an area of considerable 
confusion. Discordance analysis is helpful since there is no gold standard for TB infection. Flaws 
in discordance studies have been observed, some studies assume IGRAs results are “gold 
standard” and that it is more likely to be true and that any discordance (TST+/IGRAs-) is because 
of TST false positives. This approach ignores the fact that this century old test, subjected to 
dozens of very large studies pertaining to its diagnostic and prognostic abilities still performs 
well in certain populations where BCG is given at birth (194-196). Although some discordance 
may be explained by superior specificity of IGRAs, it would be overly simplistic to assume that 
the results of IGRAs were always correct and those of TST were always incorrect. 
Discordance between IGRA and TST has been frequently observed. In a meta-analysis  
comparing TST with IGRAs in healthy populations with varying risk for LTBI, discordant results 
were found in 21% (T-SPOT) or 29% (QFT) of participants (157). In a study in Spain among 135 
 66
HIV positive individuals and controls, TST+/QFT- results (78.1% of discordant results) 
predominated in the control group. Contrary, the HIV group showed a predominance of 
QFT+/TST- (75% of discordant results). HIV was negatively associated with a QFT-/ TST+ result. 
The reason for discordance has been generally explained by BCG vaccination or NTM infection in 
cases where TST is positive and the QFT-GIT test is negative and by a past history of TB infection, 
poor TST sensitivity or false positive IGRA where TST is negative and that of QFT-GIT test to be 
positive (197). 
Beyond this common explanation for discordance, few studies have gone a step further by 
looking at other reasons for discordance (198). Discordance, especially one where TST ≥ 15mm 
and QFT-G assay negative has been reported. Studies in South Africa (183) India (129) and Italy 
(199) have found that among those with large TST reactions (≥ 15mm and therefore, high 
likelihood of infection) approximately 31%, 43%, and 11% were negative by QFT-G respectively. 
In contrast, the community survey among 652 adult pastoralists in Ethiopia found that those 
with TST ≥ 10 mm were 13.6 times more likely to have positive results using QFT-GIT than 
individuals with skin indurations of 0 mm (182). 
While false positives TST (due to BCG, NTM) could be an explanation is it still possible that IGRAs 
are measuring only a fraction of those with latent TB infection (recent versus remote infections). 
The possibility of false positive results due to NTM infections is greater using TST than IGRAs but 
in settings where NTM are prevalent, this may explain QFT-GIT false positives results (182). One 
study in Ethiopia attributed IGRAs false positives due to the present cut-off value recommended 
by the manufacturer which is thought to be too high (182). Some of this observed discordance 
may in part be resolved through further exploration of IGRAs cut-off points and by analyzing the 
results of both tests as continuous outcomes. Discordance of the reverse type (TST-/IGRAs +) 
has been documented as well (182, 199) but not well explained. 
Explaining discordance should be context specific taking into account the epidemiological and 
individual factors contributing to infection. For example, confounding factors, such as 
birthplace, may be a risk factor for TST+/IGRA− discordance in low TB incidence sebngs but not 
in high incidence settings. In low incidence settings, it is currently well accepted that most of the 
TST+/QFT− discordant results can be explained by BCG vaccination or birth in a foreign country 
(usually a high incidence setting). In a pooled analysis of two studies conducted in Germany, 
being foreign-born and BCG-vaccinated explained 95.7% of the TST+/QFT− results (198). 
Furthermore, age explained 49.1% of all TST-/QFT+ discordance. The influence of age on IGRA 
outcomes may be explained either by IGRA ability to detect recent infection and also reflect age-
related differences in immune maturation and IFN-γ production (147). In high incidence settings, 
where BCG is given at birth and hardly repeated in adolescence, its effect on TST results several 
years after the vaccination is minimal (95). Summaries and agreement levels of selected studies 
are shown in Tables 2.2 and 2.3. 
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Table 2.2:  Concordance of QuantiFERON-TB Gold with TST in low incidence countries in adult individuals 
Authors, Year, country , reference 
 
Population 
enrolled 
1Total  with 
both TST & 
QFT results 
(% BCG) 
PPD  
 dose, 
10mm  
Concordant results 
 
 
Discordant results %  overall 
concordance 
(95% CI)  
Kappa  
statistic 
    TST+QFT+ 
n (%) 
TST- QFT- 
n (%) 
TST-QFT+ 
n (%) 
TST+ QFT- 
n (%) 
  
Healthy individuals 
*Lee et al,2006, Korea (157, 200)  224 adults 131 (100) 2TU  3 (2) 95 (73) 8 (6) 25 (19) 73.3  0.43 
Santin et al, 2011, Spain(173) 135 135 2 IU, 5mm 22 (16.3) 81 (60) 7  (5.2) 25 (18.5)   
Contacts of TB patients (high risk groups) 
*Brock et al, 2004, Denmark (157, 201) 85 45 (0) 2TU  23 (51)    19 (42)   1 (2) 2 (4) 94 ( 89-99) 0.87 
*Kang et al,2005, Korea (106, 202) 273  120 (73) 2TU  24 (20) 40 (33) 4 (3) 53 (44) 53.3 0.16 
Diel et al, 2006, Germany(150, 176) 311  309 (50.8) 5TU  28 (9) 169 (55) 3 (1) 109 (35) 63.8 0.20 
Arend, 2007, Netherlands,(192) 909  785 (0) 2TU 74 (9) 518 (66) 7 (1) 186 (24) 75.4 0.33. 
Diel et al, 2008, Germany(141) 629 601 (67) 2TU, 5 mm 62 (10) 354 (59) 4 (1) 181 (30) 69 0.28 
 Diel et al, 2011, Germany(142) 1414 954 5 TU & 2 TU 138 (15) 652 (68) 60 (6) 104 (11) 82.8 0.52 
Anibarro, 2011, Spain(203) 152  136 (0) 2TU, 5 mm 50 (37) 37 (27) 4 (3) 10 (7)  0.73 
HIV positive individuals 
Luetkemeyer, et al, 2007, USA(204) 294 196 5TU, 5 mm 8 (4) 167(85) 11 (6) 10 (5) 89 (84-93) 0.37 
Jones et al, 2007(205) 207 191 5TU, 5 mm 5 (3) 172 (90) 6 (3) 8 (4) 93 (88-96) 0.38 
Balcells et al, 2008, Chile (206) 116  109 (88)   2TU, 5 mm 9 (8) 90 (83) 8 (7) 2 (2) 91 (84-96) 0.59  
*Stephan et al, 2008, Germany (207) 286 275 (6.9) 2 IU, 5mm      0.33 
Talati et al, 2009, USA(208) 336 273 (9.2) 5TU, 5 mm 2 (1) 259 (95) 7 (2) 5 (2) 96 (92-98) 0.23 
Richeldi et al, 2009 (209) 369  116 (6) 5TU, 5 mm     95.4 (90-98) 0.52  
Santin et al, 2011, Spain(173) 135 135 2 IU, 5mm 7 (5) 118 (89) 6 (4) 2(1)   
1 Excludes QFT indeterminates and TST not read;* QFT-G as used 
  
 68
Table 2.3:  Concordance of QuantiFERON-TB Gold with TST in moderate-high TB incidence countries in adult individuals 
Authors, Year , country 
 
Population 
enrolled 
1Total  with 
both TST & 
QFT results (% 
BCG) 
PPD,dose, 
10mm 
Concordant results Discordant results %  overall 
concordance 
(95% CI)  
Kappa  
statistic 
    TST+QFT+ 
n (%) 
TST-QFT- 
n (%) 
TST-QFT+ 
n (%) 
TST+QFT- 
n (%) 
  
Healthy individuals 
Legesse et al, 2011(182) 652  271 2TU  151 (56) 28 (10) 76 (28) 16 (6) 66 0.2 
Mahomed et al, SA, 2006 (183)  367  358 (81) 2TU  189 (53) 57 (16) 12 (3) 100 (28) 69 0.32 
*Rangaka et al, 2007, SA (186) 160 (86 HIV –ve) 74 (71)  2TU  32 (43) 9 (12) 4 (6) 29 (39) 55 0.12  
2Chapman et al, 2002, Zambia (185) 49 (29% HIV +ve) 49 (67) 5TU  22 (45) 8 (16) 8 (16) 11 (22) HIV +ve:64 
HIV –ve:60 
0.26 
0.03 
Contacts of TB patients 
Machado et al, 2009, Brazil(210) 301 (28% 
children) 
255 (76) 2TU  100 (39) 94 (37) 17 (7) 44 (17) 76 0.53 
*Hesseling et al, 2008, SA (211) 82  53 adults (62) 2TU    0% 36% 60 0.34 
Adetifa et al, 2007, Gambia (212) 194 175 (48) 2TU  69(39) 57 (33) 33 (19) 16 (9)  0.43 
2Hill et al, 2006, Gambia(213) 775 693 (46)  165 (24) 413 (60) 55 (8) 60 (9) 75 0.43 
2Hill et al, 2004, Gambia(214) 856 735 (45) 2TU  162 (22) 382 (52) 58 (8) 139 (19) 74 0.43 
Health Care workers 
Costa et al, 2009, Portugal(187) 1686 1686 (100) 2 TU 525 (31) 332(20) 33 (2) 792 (47) 54 0.22 
Lien et al,2009, Vietnam(215) 300 (37) 255 5 TU 114 (45) 71(28) 21 (8) 49(19) 72 0.44 
Pai et al, 2005, India(129) 1081 726 (71 )3 1 TU 226 (31) 359 (50) 62 (9) 72 (10) 81 0.64 
HIV positive individuals 
Mandalakas et al, 2008(147) 43 (53% 
children) 
43  2TU   0% 26.9%  0.49 
*Rangaka et al, 2007, SA (186) 160 (74 HIV +ve) 74 (51)  2TU, 5 
mm 
    76 0.52 
1 Excludes QFT indeterminates and TST not read* QFT-G was used. 2ELISPOT used. 3BCG scars. 
Note: The following risk groups were excluded: prisoners, army personnel, drug users, individuals with other causes of immunosuppression.
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2.6 Effect of HIV on IGRAs 
 
The effect of HIV on the interpretation of IGRAs is now widely discussed (157, 216). There is 
little doubt that the performance of IGRAs is affected by immunosuppression just like TST. High 
rates of indeterminate results and lower sensitivity of IGRAs in immunocompromised people 
have raised concern about their applicability in routine clinical practice (209, 217). As an 
advantage, IGRAs contain an internal positive control allowing the reader to discriminate true 
negative from false negative results. The TST lacks an internal control to distinguish false-
negative results due to anergy from true negative results, leading to a poor diagnostic accuracy, 
especially in HIV positive individuals (121). 
Earlier studies in HIV positive individuals from a variety of settings had shown that ELISpot 
results were robust in HIV infection and independent of CD4 cell count (186, 218, 219). ELISPOT 
was found to be relatively unimpaired in the detection of either TBI or active TB in patients with 
moderately advanced HIV infection (186, 220, 221). A study done in Zambia using ELISPOT assay 
(185) showed high sensitivity in all of HIV-negative (100%) and HIV-positive (90%) TB patients 
although the study was small. In another study of HIV-infected individuals routinely attending a 
HIV-clinic in a high-prevalence setting, the ELISA was found to have a lower rate of positivity 
than either the ELISpot or the TST (147). Previously, it has been generally accepted that the TST 
has a lower sensitivity than IGRAs in HIV-positive individuals and that IGRAs (especially ELISPOT) 
are less prone, but not unaffected by T-cell anergy at lower CD4 cell counts (186, 218).  
This picture seems to be changing as data coming from recent studies appears less convincing 
(131). Data from a meta-analysis that identified 37 studies (5736 HIV infected individuals) 
showed that although TSPOT.TB appeared to be less affected by immunosuppression than QFT-
GIT and the TST, overall, differences among the three tests were small or inconclusive. 
Sensitivity estimates (using culture confirmed TB as a surrogate reference standard for LTBI) 
were higher for T-SPOT (72%) than for QFT-GIT (61%) in low-/middle-income countries. The 
results were similar for high income countries but sensitivities were higher than those in 
low/middle countries (T-SPOT: 94%; QFT-GIT: 67%). However, in this meta-analysis, apart from 
two studies all studies were done in low/middle income countries. In addition, neither IGRA was 
consistently more sensitive than TST in head-to-head comparisons. 
Furthermore, studies done in SA, Uganda and China showed a large reduction in the proportion 
of positive test results for both QFT-GIT and T-SPOT in HIV-infected individuals with advanced 
immunosuppression . Reasons for the stronger impact of immunosuppression on IGRA 
performance in low/middle-income vs. high-income settings were unclear but may be related to 
disease severity and anti-retroviral treatment status.  
Other authors have found that in HIV positive individuals with very low CD4 cell counts, the 
ELISA’s performance is adversely affected, as exemplified by a higher proportion of negative and 
indeterminate results. In a study done in Zambia (222) using QFT-GIT, low CD4+ counts in HIV 
positive TB patients were associated with increases in both indeterminate and false-negative 
results. A number of studies have also found that indeterminate results increase in severe 
immune-suppression, a fact that may affect the diagnostic utility of the ELISA in HIV-positive 
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individuals (147). In a study conducted in Zambia among TB patients, a marked decrease in 
sensitivity was observed in HIV positives compared to HIV negative (63% v 84%, p=0.027) (148). 
In addition, low CD4+ count (<200 cells) was associated with increases in both indeterminate 
and false-negative results, similar to findings in other studies (129, 217, 222-224). 
Both IGRAs are known to suffer from indeterminate results. A high response to the nil or a low 
response to the mitogen will give an indeterminate result. However, in HIV positive individuals 
indeterminate results most commonly arise due to a failed positive control, which usually 
reflects underlying cellular immune suppression. Technical errors during the testing process can 
also result in indeterminate results as well. There is now sufficient evidence showing an increase 
in indeterminate results in HIV positive individuals with advanced immune-suppression (222, 
225) as well as in those with other immunosuppressive disorders (226). 
A recent systematic review and meta-analysis (131) assessed the proportion of indeterminate 
IGRA results among healthy HIV-infected individuals screened for TBI. The proportion of 
indeterminate results was less than 5% in nine of 13 studies evaluating T-SPOT (range,0–13%) 
and six of 10 studies evaluating QFT-GIT (range, 2–11%). Indeterminate ELISA results seem to be 
associated with young (<5 years) and old age (>80 years) and immune-suppression, either due to 
HIV infection or immuno-suppressant medication (130). Co-morbidities such as malaria or 
hepatitis in children have been associated with indeterminate results (227). Other studies have 
found a significant relationship between increasing age and IFN-γ response to the mitogen 
(228). 
2.7 QFT-GIT cut offs 
 
The recommended cut-off values for positive IGRA results are probably not optimally related to 
the risk for disease progression. The determination of new cut-off values for QFT-GIT may 
improve the assay sensitivity, especially in high endemic populations (229). The challenge is not 
to identify positive responses per se but to establish a cut-off point within the positive category 
that predicts subsequent development of TB (107).  
Current cut-off values for commercially available IGRA assays are set at relatively low levels in 
order to maximize the detection of individuals with Mtb infection who might benefit from 
chemoprophylaxis, especially amongst contacts of TB cases (159). 
The cut off value of QFT-GIT is based on receiver operating characteristics curve analysis and just 
like the TST can only be meaningfully discussed in a specific context. The suggested 
manufacturer’s cut off points are increasingly being questioned as to whether they should be 
applied universally regardless of the context. It has been postulated that IGRA cut off points 
should perhaps be used in the same way as TST taking into consideration the epidemiological 
status and underlying diseases like HIV (200, 230). Authors that have evaluated new cut off 
points (229) pointed out that the determination of new cut-off values for QFT-GIT may improve 
the assay sensitivity, especially in high endemic populations.  
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It has been suggested that the cut-off value for QFT-GIT should be reset at a lower level when 
the test is used in high-prevalence situations (231). Lee and others (200) investigated new cut-
off values for the QFT-G and T-SPOT assays in 87 active TB and 131 healthy control subjects in 
South Korea. They found that for QFT-GIT, the cut-off value of >0.13 IU/ml of IFN-γ increased the 
sensitivity of the test from 70.1% to 86.2%, with a minor decrease in specificity (from 91.6% to 
87%). Similarly, another study (229) showed that using a cut-off value of ≥0.818 IU/ml of IFN-γ 
improved the sensitivity of QFT-GIT with no decrease in specificity. This finding suggests that 
using a lower cut-off value in the QFT-GIT assay may increase the sensitivity in diagnosing Mtb 
infection, especially in immune-compromised patients and children (229). Arend and others 
(192) also evaluated new cut-off values for the QFT-GIT and T-SPOT assays in TB contact tracing. 
Experience with the QFT-IT indicates that individuals can have variability in IFN-γ responses 
(232). Some patients with positive results, particularly at or near the cutoff point, can revert to 
negative if retested (and vice-versa) (232). Similar to interpretation of the TST, higher values are 
more likely to be truly positive than values near or below this cutoff point and lower negative 
values are more likely to be truly negative than values that are closer to the cutoff point (232). 
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3.0 Methods 
 
Introduction 
The aim of this chapter is to give a detailed description of the study methods. This chapter first 
describes the background study (ZAMSTAR trial) within which the cohort study under discussion 
in this thesis, the QFT cohort study was nested. The rest of the chapter describes the QFT cohort 
study with regard to sample size, study duration, study population, measurement tools, baseline 
and follow-up activities, data collection and statistical analyses. The specific objectives of this 
chapter are to: 
1. To give a brief description of the background studies within which the QFT cohort was 
nested i.e. the ZAMSTAR and SOCS studies 
2. To describe study procedures and activities in the enrolment and follow-up of HHCs in 
the QFT cohort study.  
3. To describe the statistical analyses used to answer primary and secondary study 
objectives. 
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3.1 Background Studies 
3.1.1 The ZAMSTAR Study 
 
The ZAMSTAR (The Zambia South Africa TB and AIDS Reduction) study was a community 
randomised trial involving 24 communities with a total population of over 1,000,000, in Zambia 
and the Western Cape Province of South Africa. The ZAMSTAR study was the background study 
within which the cohort study under discussion in this thesis, the QFT cohort study was nested. 
 ZAMSTAR primary objectives 
The ZAMSTAR study evaluated two public health interventions that aimed to reduce the 
prevalence of TB at community level. These interventions were community-based enhanced 
case finding for tuberculosis and household counselling and provision of combined TB/HIV 
prevention services at the household level. The ZAMSTAR study was conducted from 2005-2010. 
The primary study questions in the ZAMSTAR study were: 
1 Does enhanced tuberculosis case finding (ECF) by a strategy of community mobilisation and 
enhanced access to sputum microscopy, reduce prevalence of tuberculosis in the 
community? 
2 Does a strategy of combined TB/HIV activities at the household level (HH), that includes 
active case-finding, Isoniazid preventive therapy, psychosocial and adherence support for 
both treatment and prevention of tuberculosis and HIV, reduce the prevalence of 
tuberculosis in the community?  
Institutions involved in the ZAMSTAR study 
This study was conducted by ZAMBART (Zambia AIDS Related TB) Project, a collaboration 
between the University of Zambia and the London School of Hygiene and Tropical Medicine) and 
the Desmond Tutu TB centre from the University of Stellenbosch Cape Town. In addition it was 
also implemented in close collaboration with the departments of Health in Zambia and SA, 
NGOs, civil society and community advisory boards. 
Study setting 
The ZAMSTAR study was conducted in Zambia and South Africa, two countries highly affected by 
the TB and HIV epidemics. A total of 24 communities, 16 communities in Zambia and 8 
communities in the Western Cape Province of South Africa were selected for the study. Study 
communities were selected based on TB notification rates greater than 400/100,000 per annum, 
high HIV seroprevalence and proximity to a TB diagnostic centre. A ‘‘community’’ was  defined 
as the population (minimum size of 25,000) accessing one TB diagnostic centre and was the unit 
of randomization for the ZAMSTAR trial (233). The communities selected were in five provinces 
of Zambia and in Western Cape Province of SA and included both urban and rural communities 
(Figures 3.1 and 3.2).   
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Figure 3.1:  Study communities in Zambia 
 
 
Figure 3.2:  Study communities in Western Cape, SA 
 
 
ZAMSTAR study sampling and randomization. 
The communities formed the primary sampling units. The design and randomization of the 
ZAMSTAR study is described in detail elsewhere (233, 234). However, briefly for the 
randomization, stratification and restriction was used to randomize 24 communities into four 
intervention arms with 6 communities in each arm in a 2x2 factorial design. To ensure that 
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intervention effects were not distorted due to enrolment imbalances between intervention 
groups, communities were ranked according to their TBI prevalence within each country. TBI 
prevalence estimates within each community were determined through a  TST survey done 
among primary school children (95). Stratification was by country and TBI prevalence and 
restriction by HIV prevalence, TBI prevalence, urban/rural, social context, and geographical 
location. 
The 24 communities were randomly allocated to one of 4 trial arms, with 6 communities in each 
arm (Figure 3.3). 
Arm A: Strengthened TB/HIV activities at the clinic only (Clinic) 
Arm B: Clinic plus enhanced case finding (ECF) 
Arm C: Clinic plus household intervention (HH) 
Arm D: Clinic plus ECF and HH interventions 
Figure 3.3:  Interventions randomly allocated into four arms. 
 
 
 
 
 
 
 
 
 
3.1.2 ZAMSTAR study secondary objectives 
 
To determine the secondary objectives of the ZAMSTAR trial, a cohort of consecutive TB 
patients and their household members were followed up for the duration of the interventions to 
allow analysis of household-level outcomes, using both epidemiological and social science 
methods (234).  
These cohorts of TB patients and their household members were called secondary outcome 
cohorts (SOCS). The aim of SOCS was to recruit a cohort of 350 adults from 150-200 households 
in each community in order to be able to measure the secondary outcomes of ZAMSTAR. 
Random allocation of 
interventions for 16 sites
Optimal 
Clinic based 
TB/HIV
(A)
(A)
+
Household 
based 
TB/HIV activities
(B)
(A)
+
Community 
based
enhanced case
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+
(B)
+
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Specific secondary outcomes of the ZAMSTAR trial at household level, as measured on this 
cohort of households were: 
• Cumulative HIV incidence measured by serial HIV testing among those over 15 years old. 
• Uptake of HIV testing and counselling and uptake and adherence to tuberculosis preventive 
therapy among household members of TB patients. 
• TB transmission within the household measured by TST.  
• Cumulative incidence of TB disease in household HHCs.  
• Stigma levels measured using a quantitative stigma score. 
 
SOCS study population 
Adults ≥ 15 years and children < 5 years old were invited to participate in the SOCS study.  
SOCS sample size 
From each of the 24 communities, 150 adult TB index cases were expected to be enrolled into 
the study. A household with one TB index case was expected to have at least 2 adult HHCs, 
giving a total of 7,200 adults (150 indexes x 24 communities x 2 HHCs). Therefore, the SOCS was 
designed to enroll a total of at least 7,200 adults across all communities at enrolment. 
SOCS study duration  
Enrolment of study participants was done between July 2006-2008 (SOCS1). Follow-up visits 
were scheduled at 18 months after enrolment (SOCS2) and 36 months after enrolment (SOCS3). 
3.2 The Quantiferon (QFT) Cohort Study 
 
The QFT cohort study is the study under discussion in this thesis, described in detail in the 
subsequent sections of the methods. The QFT cohort study focuses on adult HHCs enrolled in 
the SOCS study and accepting to have a QFT-GIT test performed. 
After being enrolled into the SOCS study HHCs were free to choose whether or not to take part 
in the QFT cohort study (details below). HHCs had to be enrolled in the SOCS study first before 
being offered being invited to participate in the QFT cohort study. 
Since the QFT cohort was nested within SOCS, the enrollment and follow up of HHCs described 
in the subsequent section of this thesis are similar to those of SOCS (apart from adults being 
offered QFT-GIT and TST tests). 
3.2.1 Study setting 
 
The study setting of the QFT cohort study was as for the ZAMSTAR trial described above. 
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3.2.2 Study duration 
 
The QFT cohort study began approximately 10 months after the SOCS study had started 
enrolment of study participants. Study duration was from April 2007 to December 2010. In 
Zambia, the study began at different times in some communities (difference in the range of 3-4 
weeks because training was done in phases by one multidisciplinary team to ensure quality 
assurance). The first QFT-GIT test in Zambia was done on April 2007. In SA, however, the study 
largely began at the same time in all communities on January 2007. 
3.2.3 Sample size 
 
The sample size for the QFT cohort study was approximately one third of the HHCs recruited in 
SOCS at visit 1 (1,600 and 800 HHCs from Zambia and SA respectively) giving a total of 
approximately 2,400 HHCs. The sample size was also estimated following various considerations 
including logistical feasibility; some resources were shared.  
Based on data from other longitudinal studies (35, 159, 235) sample size was estimated 
expecting a 3% TB incidence and risk ratio of 3 among HHCs with high IFN-γ responders during 
the 2-3 years following exposure. Approximately 20% of HHCs were expected to have high IFN-γ 
responses (≥10 IU/ml based on a similar study done in Colombia (35)and data on community 
controls from a rural district in Zambia (unpublished). 
Under these conditions, an approximate cohort of 2,374 was adopted, consisting of 1,899 
individuals with low interferon-γ levels and 475 with high interferon-γ levels. A cohort of 2,374 
HHCs was expected to detect a minimal significant difference (2-sided p < 0.05) of 2% in TB 
incidence in the two groups of IFN-γ producers (high-responders vs. low responders) at 80% 
power,95% confidence level and significance level α = 0.05.  
Figure 3.4 shows power as a function of sample size. Power curves were obtained for the cohort 
study where the rate ratio (RR) in the exposed group is 3 and the two sided level of statistical 
significance is 5% as the hypothesis. Two different hypothetical scenarios are shown. The lower 
curve shows the power to detect RR of 2 and the upper curve a RR of 3. If the RR is 3 as 
hypothesized in the study, and the aim is to achieve a minimum of 80% power this suggests that 
the sample size of approximately 2500 would be required (Figure 3.4).  
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Figure 3.4: Power as a function of sample size for the QFT cohort study 
 
 
3.3 Primary and Secondary Exposures and Outcomes  
3.3.1 Primary exposure  
 
High interferon-γ levels (≥ 10 IU/ml) at enrolment in response to Mtb specific antigens (either 
ESAT-6 and/or CFP-10). 
3.3.2 Secondary exposure  
 
The secondary exposure variables included the following: 
1. Age 
2. Sex 
3. Level of education 
4. Socioeconomic status 
5. Alcohol 
6. Smoking 
7. HIV status 
8. Smear status of the index 
9. Sleeping proximity to the index TB patient 
10. Country of residency  
3.3.3 Primary outcome 
 
TB incidence rate in HHCs with high IFN-γ responses  
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3.3.4 Secondary outcomes 
 
1. Performance and operational characteristics of QFT-GIT in a field setting. 
2. Risk factors associated with positive QFT-GIT and TST results at baseline. 
3. Level of agreement or concordance between QFT-GIT and TST results.  
4. TB incidence rates in HHCs with: 
a. Positive and negative QFT-GIT and TST results, stratified by HIV status, 
b. Concordant and discordant QFT-GIT and TST results. 
5. Positive and negative predictive values of QFT-GIT and TST tests.  
6. The association between QFT-GIT and TST positivity and the subsequent development of 
TB. 
7. Risk factors associated with incident TB. 
3.4 Ethical Considerations 
 
The study protocols for the ZAMSTAR and QFT cohort study were approved by the Ethics 
committees of the University of Zambia and Stellenbosch University as well as the London 
School of Hygiene and Tropical Medicine (Appendix 1 and Appendix 2). Participation was 
voluntary. All HHCs involved in the study gave written informed consent. Participation in this 
study was not independent from participation in the SOCS study as HHCs were requested to fill 
in one consent form. 
Ministries of Health, Community leaders, district and local health staff and neighbourhood 
health committees agreed to the study taking place. 
3.5 Instruments and Tools 
3.5.1 Study population 
 
The study population was comprised of adult HHCs of newly notified TB cases at least 15 years 
of age who were enrolled in SOCS and in whom QFT-GIT was performed.  
Definition of Household contacts 
HHCs were defined as individuals, who generally slept in the home, ate with the index case and 
who identified a common household head. 
Eligibility criteria 
1. HHCs who were ≥ 15 years of age. 
2.  Had QFT-GIT performed at enrolment  
3. Was not on TB treatment at enrolment 
4. Provided informed written consent 
Note: HHCs on TB preventive therapy and on antiretroviral therapy were also eligible for 
inclusion in the study.  
The following HHCs were excluded from the study at enrolment 
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1.  Did not have QFT-GIT results at enrolment. 
2.  Were less than 15 years of age 
3. On TB treatment at enrolment 
 
3.5.2 Baseline Activities 
The clinic visit by index TB patients 
Newly notified adult TB patients (index cases) were used as entry points into households where 
HHCs were invited to participate. Index cases (pulmonary smear positive, smear negative or 
extrapulmonary) recruited within a month after being notified in the TB register were 
consecutively enrolled into the study from a government clinic by study nurses.  
The household visit 
Permission was sought from index cases to visit their households where HHCs were invited to 
participate. Household visits were done either on the same day the index was recruited or on 
another day by appointment. Once in the household, the study was fully explained to HHCs; 
these were enumerated and individual (name, sex, age, consent) and household (address and 
GPS coordinates) data recorded on an enumeration form (Appendix 3). The address and GPS 
coordinates were important in relocating the same household at a later stage, during follow-up 
visits. Information about the study was given to household members individually and in some 
instances, as a household, if they so preferred (Appendix 4). All HHCs were asked for individual 
signed consent before participating in the study (Appendix 5). 
The consent form and information sheet used in this study were originally designed for use in 
the SOCS study. These were modified for the QFT cohort study to include information on getting 
blood for QFT-GIT and having a TST done in adults.  
Baseline measures  
In summary, the following measures were done at enrolment:  
a. A standardized questionnaire (Appendix 6) was administered to all consenting HHCs by 
trained research assistants (see details under data collection). 
b. Blood was drawn for HIV antibodies and QFT-GIT testing (see details below).  
c. TST were performed on the same day, after blood for QFT-GIT testing was drawn (see 
details below).  
Enrolment screening for active TB was not conducted because the ZAMSTAR study design 
allowed little flexibility to accommodate this. 
HIV Testing 
HIV status was both self-reported (through the questionnaire) and laboratory-reported. The HIV 
results from the laboratory were used to determine the prevalence of HIV infection in this study.  
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Consenting HHCs had blood drawn for HIV antibodies. For each contact, 6 mls of venous blood 
was drawn into a vacutainer tube labeled with an individual barcode. The blood was sent to 
central laboratories in Lusaka and Stellenbosch University where it was tested in batches. HIV 
testing (Appendix 7) was done using the Abbot Axsym system HIV Ag/Ab Combo Assay (4th 
generation assay) (Max-Planck-Ring 2, Germany) and confirmed with the Vironostika algorithm. 
For HHCs who wanted to know their HIV results a small sample of blood was tested either on 
the spot or at the clinic using routine rapid HIV tests.  Determine (Determine™ HIV-1/2) was 
used as the first line test and Uni-Gold (Uni-Gold™ HIV) as the confirmatory test for individuals 
with a positive result. HHCs referred to the clinic for HIV testing were encouraged to attend 
counseling and HIV testing before the test was done.  
HHCs that tested HIV positive on Determine had a confirmatory test using Unigold. If the 2 tests 
were discordant the study staff took the participant to the clinic to allow re-testing and 
confirmation using a tie-breaker test.  
 Management of HIV positive HHCs was done according to the standard of care in the clinics. In 
South Africa, HIV positive individuals were advised to go for TB preventive therapy in 
accordance with National TB Control Program guidelines (91) while in Zambia this was not yet 
government policy. However, in Zambia, preventive therapy was offered to eligible HHCs 
through collaboration with another study operating in the ZAMSTAR sites.   
QuantiFERON-TB Gold In Tube (QFT-GIT) assay testing 
 
QFT-GIT testing was performed according to the manufacturer's instructions (Cellestis Ltd, 
Victoria, Australia) (236) (Appendix 8). 1 ml of blood was drawn into each of the three blood 
collection tubes coated with either heparin (negative control) or Phytohemagglutinin (PHA, a T-
cell-activating mitogen (positive control) or peptides of ESAT-6, CFP-10 and TB 7.7. Samples 
were mixed vigorously by hand and delivered to the laboratory within 16 hours of collection. 
Tubes were incubated for 16- 24 hours at 37°C and plasma was harvested and frozen at –20°C. A 
Quantiferon recording form (Appendix 9) was used to record data (details in data collection 
section). ELISA was performed using standard kits supplied from the manufacturer. The test 
results were interpreted using the software supplied by the manufacturer. The raw data were 
entered into the QFT-GIT analysis software which reported results as negative, positive and 
indeterminate (Table 3.1). 
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Table 3.1: Interpretation criteria for QFT-GIT  
TB antigen minus Nil (IU/mL) Nil 
(IU/Ml) 
Mitogen minus 
Nil(IU/Ml) 
QFT-GIT Result Report/ interpretation 
<0.35 or >0.35 and<25% of Nil value <8.0 >0.5 Negative 
 
Mtb  infection NOT likely 
>0.35 and>25% of Nil value <8.0 Any Positive Mtb infection likely 
<0.35 or >0.35 and< 25% of Nil value <8.0 <0.5 Indeterminate Results cannot be interpreted 
as a result of low mitogen 
response 
Any >8.0 Any Indeterminate Results cannot be interpreted 
as a result of high background 
response 
 
QuantiFERON®-TB Gold IT Analysis Software (version 2.17 and latter version) was used to 
analyze raw data and calculate results (237). The software performed a Quality Control 
assessment of the assay, generated a standard curve and provided a test result for each subject. 
The software reported all concentrations greater than 10 IU/mL as “>10” as such values fell 
beyond the validated linear range of the ELISA. 
Results were calculated by subtracting the IFN-γ level of the negative control tube from the IFN- 
γ level of the respective TB-antigen and mitogen tubes. A test result was positive if the net IFN-γ 
response to the TB antigens was  ≥0.35 IU/mL, regardless of the mitogen response; a test result 
was negative if the net IFN-γ value was  <0.35 IU/mL and there was sufficient mitogen response 
( > 0.50 IU/mL); and a test result was indeterminate if there was excessive IFN-γ production 
from the negative control tube (>8.0 IU/mL) or an insufficient net mitogen response (< 0.50 
IU/mL) plus insufficient net TB antigen response (< 0.35 IU/mL)(236).  
For four Zambian and all the South African communities, QFT-GIT processing was done centrally 
at the research laboratories in Lusaka and Stellenbosch University Medical School respectively. 
However, for twelve Zambian remote communities, QFT-GIT processing was decentralized. In 
these communities, blood samples were collected, incubated, separated and stored locally. 
Frozen samples from these sites were transported monthly to the central laboratory in Lusaka 
where the ELISA was performed manually in batches. 
Feedback of QFT-GIT results to participants 
Feedback of QFT-GIT results was given to HHCs within a period of less than 4-8 weeks since 
results were centrally processed and had to be sent back to individual sites. Study staff was 
trained to give standard explanations of the results as shown in Appendix 10.  
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Quality Assurance of QFT-GIT process and results  
 A multi-disciplinary Quality Assurance (QA) team was constituted in Zambia due to the 
decentralized nature of sample collection, incubation, separation and storage.  The aim of the 
QA team was to ensure that sample processing was done accurately as well as identify and 
correct gaps and weaknesses. A QA monitoring tool was designed which captured the following 
data on various aspects of the process and the test itself (Appendix 11). There were also other 
routine laboratory checks each time samples arrived at the central laboratories and these 
included: checking for leakages during transportation, quality of the sample, correct use of 
barcodes, type of specimen bottles and packaging used 
Tuberculin skin testing 
Skin tests were carried out using 2 TU (Tuberculin Units) of PPD RT23 with Tween, supplied by 
the Statens Serum Institute (Copenhagen, Denmark). A dose of 0.1 ml was injected 
intradermally on the left forearm. Skin reactions were read using calipers 72 hours later as the 
largest palpated transverse diameter. The TST was considered positive if the induration was 
>=10 mm (even for HIV positive HHCs) unless otherwise stated. A  TST recording form (Appendix 
12) was used to record data (details in data collection section). 
Tuberculin skin testing Quality assurance 
All tests were administered and read by nurses who were trained according to the standard 
IUATLD protocol (238). Survey staff was trained in the placement and reading of TST according 
to the standard IUATLD protocol. Training included exchange visits between Zambia and SA so 
that the trainers were using the same methods throughout.  
3.5.3 Follow up Visits 
 After enrolment HHCs were followed up at two time points over the study period. The first 
follow-up visit was at 18 months and the second follow-up visit was at 36 months after 
enrolment into the study.  
All HHCs were followed up regardless of their baseline QFT-GIT and TST results until they 
developed disease or were lost to follow up (due to death, moved or untraceable). Therefore all 
HHCs positive or negative by either test were followed up.  
1st follow up visit 
The following activities occurred at the first follow up visit at 18 months from enrolment 
a) For each household, a print out of the enumeration form filled in at enrolment was given to 
the field teams by the data department at Head Office. The GPS coordinates and the 
address on this form were used to locate households. 
b) Households were revisited and particulars of the households (number and composition) 
were checked against those collected at enrolment. Any HHC who no longer lived in the 
household on a permanent basis was identified and marked and coded on the enumeration 
form. HHCs that were absent but were expected to return within 30 days were still included 
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in the study. Those who were unlikely to return within 30 days were not included at this 
point but were considered for the 2nd follow up visit. Those who had died or who had left on 
a permanent basis to live outside the community were censored at this visit. Those who had 
moved to another house in the same community were retained in the cohort and were 
visited in the house that they currently lived in. 
c) A structured questionnaire was administered to collect information on risk factors for 
tuberculous infection and disease as well as whether individuals were or had been on TB 
treatment since they were last seen (see data collection section).   
d) HHCs were educated on the signs and symptoms of the disease to encourage self-referral to 
the clinic in the event of suspected disease. However, at each follow-up visit no active 
screening for TB was done (HHCs were not queried on signs and symptoms of TB). 
e) At least three attempts were made to visit HHCs who were absent during the 1st follow up 
visit. 
2nd follow-up visit 
The second follow-up visit occurred at 36 months from enrolment 
The procedure for the second follow-up visit was the same as for the 1st follow-up visit including 
the following: 
a) All households recruited at enrolment were revisited at this follow up visit regardless of 
whether HHCs had previously been recorded as died, moved or absent during the1stfollow-
up visit. This was done to minimize losses to follow-up. 
b)  HHCs recorded as moved out in the 1st follow-up visit were revisited to confirm that this was 
truly the case. If they had subsequently returned, but were absent for 6 months or more 
they were censored at this point as “moved out of the community”. If they have returned 
and were absent for a period of less than 6 months they were invited to participate in the 
second follow up visit. 
c) Any HHC who was absent in the 1st follow-up visit was actively followed up on this occasion. 
At least three attempts were made to trace such individuals. If such attempts were not 
successful these HHCs were censored as “absent”. 
d)  If a HHC had died or was recorded as dead in the 1st follow-up visit, condolences were first 
extended after which the research assistant asked for the date of death. This was recorded 
on the enumeration form (Note: the protocol was revised to include the date of death for 
this follow up). No verbal autopsy was conducted to identify whether the causes of death 
were related to the outcome in this study or not. Although the date of death was recorded 
this was not used in this study since death was not an outcome in study. 
e) Sputum specimens were collected from all HHCs and processed using manual MGIT (see 
details below). 
 
3.5.4 Sputum processing, and identification of Mycobacterium tuberculosis complex  
 
All HHCs were asked to produce a respiratory sample on the spot. Instructions were given by the 
study staff to assist individuals to produce the best possible sample for culturing Mtb. Sputum 
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samples were collected from HHCs at home and transported (Appendix 13) to the laboratory in 
cool boxes with ice packs within 72 hours of collection. Sputum sample containers were labeled 
with individual barcodes. Upon receipt, samples were electronically logged and assigned a 
laboratory number before processing (Appendix 13). A work sheet was then printed for each 
sample that was registered. Sample processing was done according to standard laboratory 
procedures for cultures of Mtb (239).   
Digestion and decontamination 
Once sputum specimens were logged in, they were centrifuged. In instances where the volume 
was less than 3mls, it was adjusted with normal saline to 3 mls to create a better 
decontamination and digestion. All sputum samples were processed within 72 hours after arrival 
at the laboratory. The sputum samples were digested and decontaminated using the Sodium 
hydroxide (NaOH)-N-Acetyl L-Cysteine (NALC) method. Commercially prepared NaOH-NALC 
solution (BBL™ MycoPrep™ KIT, BD) was used with a final NaOH concentration of 1.5%. After 
decontamination, the samples were neutralized by adding phosphate buffer up to the 45mls. 
The sample was centrifuged at 3000 rpm for 20 minutes, left to sit for 5 minutes to allow 
aerosols to settle and the supernatant discarded thereafter. The pellet sediment was re-
suspended in 2mls phosphate buffer. The re-suspended pellet was used for making smears and 
for inoculation of MGIT (Mycobacterium growth indicator tube) tubes. 
Inoculation 
Inoculation was performed according to recommended laboratory standard operating 
procedures (239). Each sputum sample was inoculated into two manual mycobacterial growth 
indicator (MGIT BD) tubes.  The two manual MGIT tubes containing OADC (enrichment broth) 
and PANTA (antibiotic mixture) were inoculated with 0.5mls from the 2 ml re-suspended pellet. 
After inoculation the tubes were incubation at 37°C in a standard stand alone incubator for a 
maximum of 6 weeks (42 days). The remainder of the pellet was aliquoted into a labeled 1.5ml 
screw cap tube and stored at -20oC until further need.  
Reading cultures 
 The MGIT instrument was inspected for tubes that were flagged as having growth. Cultures 
were read once a week until 42 days had elapsed using the manual reader. Culture results were 
scored as positive, negative or contaminated.  Once a MGIT tube was flagged as having growth 
by the manual reader it was logged in the database as a “positive MGIT culture”. All MGIT tubes 
that showed no growth after 6 weeks of incubation were scanned into the database as 
“negative MGIT cultures” and discarded. A culture with growth was considered contaminated if 
the ZN stain was negative for AFB.  For the MGIT tubes that were flagged as having growth, a 
slide for Ziehl-Neelsen (ZN) staining was prepared and a MPB64 antigen test (TBc ID) was done. 
At the same time an archive and a DNA sample was prepared and stored at -20 until further 
need.  
Culture isolates that were ZN stain positive and MPB64 antigen strongly positive were defined as 
Mtb isolates. Follow up was initiated for such individuals.  In South Africa, a slightly different 
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SOP was used; follow up was initiated only if the concentrated smear slide was FM (fluorescence 
microscopy) positive for individuals with Mtb isolates as defined above. Cultures with growth 
that were ZN stain negative and MPB64 negative were scored as contaminated (Appendix 14).  
Quality control (QC) 
 All staff was trained according to standard laboratory procedures for cultures of Mtb (239).  
Reference Mtb complex strain-H37Rv stock cultures prepared from the central laboratories 
were used as positive controls for every batch (positive control being scanty” growth of M37RV 
Mtb). These were subjected to the digestion and decontamination process as described above. 
Normal saline was used as a negative control. The control samples were processed in the same 
way as the sputum samples. A randomly selected number of ZN slides were sent to the central 
laboratories for QC to be reread by a second reader in a blinded manner. Discordant slides were 
read by a third reader and the result of this was regarded as final. All readers were experienced 
laboratory scientists. 
Follow-up of culture positive individuals 
Follow up was only conducted in individuals who were AFB positive (with cording) and MPB64 
positive results (Appendix 14). These individuals were revisited so as to refer them to a clinician 
for confirmation of clinical TB and subsequent treatment. Test result forms were automatically 
printed from their respective laboratories and sent to the data department at Head office. A 
follow-up form was generated where an individual’s details were filled in (name, age, individual 
barcode, household barcode, PDA code, and GPS coordinates) (Appendix 15) after which it was 
sent to the site team leader. The site field team then visited all individuals scheduled for follow-
up to explain the results whilst keeping the process and all information confidential. 
 A trained study clinician used a questionnaire to screen individuals for TB symptoms and 
examined anyone suspected of TB. Two further sputum samples (spot and early morning 
sample) were collected from individuals with a culture positive for Mtb. One sputum sample was 
for smear at the local clinic and another one for culture at the central laboratory. TB suspects 
whose smear or culture results were positive for AFB as per algorithm were treated as cases of 
TB and referred for treatment at the local TB diagnostic centre. Counseling and HIV testing were 
offered to all those found to have TB. 
All efforts were made to find individuals with a positive culture. If the house was found but the 
individual was absent, two return visits were made to attempt to find them. If the individual was 
not found on the third attempt a confidential letter was left asking him/her to contact the study 
team and the local health centre. If the individual could not be traced, then the positive result 
and name of person were handed over to the clinic staff for further follow up. 
Definition of incident Cases of TB (Incident Cases) 
Incident TB was defined as self reported TB that was confirmed in the TB treatment register (or 
patient treatment card). In a sensitivity analysis three other definitions of incident TB were 
explored as follows: 
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1. Self-reported TB confirmed in the TB register but excluding co-prevalent cases. Co- prevalent 
TB was defined as active TB diagnosed within 2 months after entry into the study 
2. Bacteriologically confirmed TB (presence of one or more sputum smears positive for acid fast 
bacilli (as notified in the TB register). 
3. Bacteriologically confirmed TB plus one or more positive cultures for M.tuberculosis plus 
positive on MPB64 antigen test. 
3.6 Data Collection Tools 
3.6.1 The Questionnaire 
 
Questionnaires were administered to consenting HHCs at three time points: enrolment, 1st 
follow up visit and 2nd follow up visit. These questionnaires were standardized and 
administered by trained research assistants. Since the questionnaires were originally designed 
for the ZAMSTAR study, they also captured other information that did not pertain to this study. 
All questionnaires were translated and back translated from local languages mainly spoken in 
Zambia (Bemba, Nyanja, Tonga, Lozi or English) and South Africa (Xhosa, Afrikaans or English). 
 
The enrolment questionnaire (Appendix 4) captured data on the following (for the purpose of 
this study): 
1. Demographic characteristics of the cohort (age, sex, marital status, and religion). 
2. Risk factors for tuberculous infection and disease (age, sex, level of education, HIV positivity, 
smoking, alcohol, sleeping proximity to index, household size). 
3. Whether the contact was on TB treatment or not at the time of administering the 
questionnaire 
4. TB treatment registration number (for those on were on treatment). 
5. Whether the contact was taking ARVs (Antiretroviral therapy) or not at the time of 
administering the questionnaire 
6. Date of commencement of ARVs, for individuals taking ARVs.  
The 1st follow up visit questionnaires captured data similar to that administered at enrolment. At 
the 2nd final follow-up visit, the questionnaire was modified to include information from the TB 
treatment card (Appendix 16). 
3.6.2 The TB register and patient TB treatment cards 
 
In addition to the questionnaire, during the 2nd follow up visit, individuals were asked for their 
TB cards from which the research assistant recorded the following (in instances where they 
were recorded): 
 
1. Date TB treatment started, 
2. Type of TB (smear positive, smear negative, extra pulmonary),  
3. Type of patient (new, retreatment),  
4. The name of the TB treatment centre  
5. Number of TB episodes during the study period. 
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The purpose of using the TB register and the patient TB treatment cards was two-fold a) to 
verify that an individual was notified at the clinic b) To collect additional data  that may not have 
been collected using the questionnaire such as date of registration, type of TB and smear 
results. This was especially important for individuals who were only seen at the 1st follow up visit 
as the questionnaire was less detailed. 
To identify individuals who developed TB during each time point the questionnaire data was 
linked to the TB register. Key variables (TB registration number, serial no, name, age, sex and 
date of registration/date treatment) recorded in the questionnaire were used to trace the 
individual in the TB register. 
Manual match with the TB-register data was done. TB registers in 24 communities were 
captured electronically from the beginning of the ZAMSTAR study. Expert judgment was used to 
match the variables: community and sex needed to match exactly, differences in age of up to 2 
years were allowed, differences in date of registration of 3 months were tolerated, misspellings 
of names, TB registration number  and mixing up of the TB registration number and serial 
number were taken into account. The matched records were exported into Stata 11 for analysis. 
3.6.3 HIV recording form 
 
In addition to the data collected through the questionnaire at enrolment, blood for HIV 
antibodies was drawn and recorded on the enumeration form (Appendix 3).  
3.6.4 TST and QFT-GIT recording forms 
 
For QFT-GIT processing a recording form (Appendix 9) captured the following data: date and 
time of sample collection, date and time of incubation start and end, temperature at the 
beginning and end of incubation, date of plasma extraction, storage and delivery to the central 
laboratory. 
A TST recording form captured the dates the TST was administered, read and the size of the 
induration (Appendix 12). 
3.6.5 TB culture recording form 
 
A transport form (Appendix 13) was filled in before sputa were taken to the laboratory for 
processing. This recorded the number of sputum samples sent to the laboratory from the field 
on a particular day. 
Amendment of the data collection tools at the 2nd follow-up visit 
The enumeration form was amended to include a column for sputum. Collection of sputum for 
culture was included at the 2nd follow-up visit.  The consent and information forms were 
amended to include consent and information regarding the need for participants to provide a 
sputum sample. 
3.7 Quality Assurance and Data Management 
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3.7.1 Data quality and management 
 
This study was conducted by local experienced staff that was fluent in most of the commonly 
spoken local languages. This ensured a better acceptance of the study from the local population 
and ensured good knowledge of the study sites. In addition, each study site had community 
advisory boards that ensured that the study procedures and content were locally appropriate 
and acceptable by the community. Both nurses and research assistants were trained in Good 
Clinical Practices (GCP). Data collection was preceded by intensive training. The questionnaire 
was piloted using all major languages spoken in Zambia and SA and was revised following 
unclear issues arising from the piloting.  
During the study, site team leaders checked the quality of data that was collected such as 
whether the questionnaires were filled in correctly, completely or whether bar codes matched 
samples collected. In addition, a multidisciplinary Quality Assurance team was constituted at the 
beginning of the ZAMSTAR study whose roles included assessing compliance with standard 
operating procedures and the quality of the laboratories.  
3.7.2 Data entry and data cleaning 
 
Questionnaire data, laboratory worksheets, HIV results, QFT-GIT and TST results were dually 
entered into a “Microsoft SQL Server” database and checked for errors. Data entry, query 
generation and correction were performed on a daily basis. Data entry differences were 
corrected by referring to the source documents. Data was imported into STATA (version 11.0) 
using Microsoft Access 2000. 
3.8 Confidentiality 
 
All data collected in this study was kept strictly confidential. The study information did not 
identify or disclose any person’s name, status or test result and samples were kept anonymous. 
Bar codes were assigned to individuals. No HIV testing was carried out for the purpose of this 
study but HIV test results were obtained through data collected from the ZAMSTAR study. Data 
security was ensured through password-protected databases accessible only to a selected group 
of people involved in the study.  
3.9 Statistical Analyses  
Data analysis was performed using STATA (version 11.0). Analysis was performed at individual 
level taking into account the effect of clustering at household and country levels due to the 
sampling design of the ZAMSTAR study. A p-value ≤0.05 was defined as statistically significant. 
General description of qualitative and quantitative data analysis 
Frequencies and percentages were used to describe categorical variables and the median and 
interquartile range for quantitative variables. Categorical data were compared by the Pearson’s 
chi-square test (or Fisher’s exact test, when expected sample sizes comprised fewer than five 
individuals). Wilcoxon rank-sum test was used to compare non-parametric distribution of two 
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groups. Kruskal-Wallis test was used to compare non-parametric distributions of more than two 
groups. Non-parametric tests were used to avoid the assumption that data were sampled from a 
normal distribution. 
Prevalence of TB infection  
Prevalence of infection was defined as the number of QFT-GIT or TST positive results divided by 
the total number of HHCs with interpretable (positive and negative) results. Individuals with 
missing TST or indeterminate QFT-GIT results were excluded from the analysis. 
Risk factors associated with positive QFT-GIT and TST results at enrolment 
The distribution of positive reactions to each test in relation to established individual and 
household level risk factors for TBI was described. The strength of relationship between risk 
factors and QFT-GIT / TST positivity was assessed using random effects logistic regression. The 
random effects approach specified the household of residence as the clustering variable. All 
models were adjusted for age, sex, and community of residence. Adjusted odds ratios (ORs) and 
95% confidence intervals (CIs) for each risk factor were calculated. A single “chunk” test was 
performed to assess the significance of all the interaction terms. 
Agreement between TST and QFT-GIT 
Test concordance and discordance were estimated using the kappa statistic and McNemar’s test 
respectively. TST and QFT-GIT results were analyzed as continuous variables and as 
dichotomized binary values. Concordance ( Agreement) between TST and QFT-GIT was 
measured using the Cohen’s Kappa (k) coefficient (240), where κ >0.75 represent excellent 
agreement, κ values from 0.4-0.75 represent fair to good agreement and κ < 0.4 represent poor 
agreement, beyond chance (241). Agreement was explored stratified by different TST cut-off 
points and by HIV status. The concordance rate was determined from individuals positive for 
both plus those negative for both divided by the total, and the discordance rate was the 
complement of the concordance rate.  
Strength of association between two variables (Correlation) 
Correlation coefficients were used to measure the strength of association between two 
variables. Correlation between continuous INF-γ values (IU/ml) and TST induration (mm) was 
assessed using Spearman's correlation coefficient. Spearman rank correlation is a non-
parametric test that is used to measure the degree of association between two numerical 
variables and does not assume any assumptions about the distribution. Pearson correlation was 
used to measure the degree of the relationship between linear related variables, both of which 
were normally distributed and continuous. 
Intraclass correlation (ICC) analysis was also used in the background reproducibility study. 
 
A positive correlation coefficient indicated a positive relationship between the two variables 
while a negative correlation coefficients expressed a negative relationship. A correlation 
coefficient of 0 indicated that no relationship between the variables existed at all. 
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Likelihood Ratio Test (LRT) 
The LRT was used to examine the following 
1. The association of the exposure with the outcome 
2. The association of the exposure with the outcome after adjusting for other variables 
3. Interaction 
4. Linear trend 
5. Departure from linear trend 
Definition of low and high IFN-γ levels 
High and low levels of IFN-γ were defined as ≥ 10 and ≥ 0.35 and <10 IU/ml respectively. IFN-γ 
responses greater than 10 IU/ml were truncated and reported as 10 IU/ml as they fall beyond 
the linear range of most ELISA readers. This is consistent with how the QuantiFERON®-TB Gold IT 
software provided by the manufacturer reports results. Missing data and QFT-GIT indeterminate 
results were excluded from analysis. 
IFN-γ levels were analyzed using dichotomous measures and as per Manufacturer’s 
recommendations. In a sensitivity analysis, different thresholds were explored to determine 
“high levels” of IFN-γ. Continuous measures were converted to quartile category values to 
explore the risk of developing disease with each quartile and the trends with increasing value of 
responses. Further exploration was through use of positive quartile category values. Definition 
of “strong responders” used by other authors were also explored (235). Geometric means and 
medians of IFN-γ levels in high and low responders were tested with Wilcoxon-Mann-Whitney. 
Survival Analysis 
Basic goals of survival analysis were: 
1 To describe, estimate and interpret survival characteristics using Kaplan-Meier survival 
function estimation 
2 To compare survival in different groups using non-parametric tests 
3 To assess the relationship of explanatory variables to survival time using Cox regression 
models. 
Descriptive survival analysis  
The Kaplan-Meier estimates and the generalized log-rank test were used to construct and 
compare the TB-free survival probabilities curves of HHCs with positive and negative QFT-GIT 
and TST results. Survival estimates were analyzed by enrolment test and also stratified by HIV 
status. 
The median survival time was also calculated; this was described as the time with probability of 
survival equal to 0.5 (or the length of time during which the first 50% of the sample developed 
the event, TB). Nelson-Aalen cumulative hazard estimates were also explored as an alternative 
to showing survival using Kaplan-Meier curves. 
Examining the Proportional Hazard Assumption (PHA) in the Cox model 
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A check for departure from the proportional hazard assumption (which assumes that the ratio of 
the hazards in the two groups remains constant over time) was done. This comprised of 
checking whether the HRs estimated by the Cox model change with time or vary over different 
intervals of the time scale. Three general methods were used to examine model adequacy: 
Graphically by using the Kaplan-Meier curves (to check whether survival curves intersect); 
mathematically by using log-minus-log survival plot (Schoenfeld test) and by using time-
dependent variable (test for interactions with time). 
Incidence rates 
 
TB incidence rate was defined as the number of new cases of TB during a specified period of 
time divided by the total person-time-at-risk throughout the observation period.  
The period of risk started at the date of HHCs were enrolled into the study. The period of risk 
ended at either the  second follow-up visit, the midpoint of the last visit seen (if earlier than  
visit 2) and the following scheduled visit date or date of TB diagnosis (defined as the start date 
for treatment) whichever came first. 
TB incidence rate was expressed per 1000 per years as follows: 
TB incidence rate= (Number of new TB cases/Total person years of observation) x 1000 
The incidence rate ratio was defined as the incidence rate in the exposed group divided by the 
incidence rate in the unexposed group. It was expressed as follows:  
Incidence rate ratio: Incidence rate in exposed group/Incidence rate in unexposed group 
TB incidence rates were determined and incidence rate ratios compared for various groups: 
• QFT-GIT positive vs. negative.  
• TST positive vs. TST negative.  
• Concordant QFT-GIT and TST results.  
• Discordant QFT-GIT and TST results  
• High vs. low IFN-γ levels and for the groups used in sensitivity analysis 
TB incidence rates and IRR were stratified by country and HIV for some groups 
Cox regression was used to estimate incidence rates of TB per 1000 person-years of follow-up, 
together with 95% CIs. Incident and non-incident cases were compared with respect to socio-
demographic and clinical characteristics using the chi-square test. 
Positive and negative predictive values 
Positive predictive value was defined as the proportion of HHCs with test positive results and 
had incident TB. Negative predictive value was defined as the proportion of HHCs with test 
negative results and did not have incident TB. These were calculated as follows:  
Positive predictive value = all testing positive and develop TB 
All testing positive 
Negative predictive value = all testing negative and do not develop TB    
     All testing negative 
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Evaluation Of Confounding, Mediation and Effect Modification 
Three concepts about the relationships of variables were examined and these were: 
• Confounding 
• Mediation 
• Effect modification or interaction.  
An assessment of confounding and mediation and etiological pathways was conducted in line 
with the study objectives. Below is a summary of each of these concepts 
1. Potential Confounding Factors 
Confounding factors are variables that produce a mixing of the effect of the exposure under 
study on the disease (outcome) with that of a third factor. Confounders met the following 
criteria: associated with the exposure of interest; independently associated with outcome; not 
on the causal pathway 
2. Mediating Factors 
Mediation has been defined as the totality of processes that explains an observed relationship 
between exposure and disease. A mediator is also associated with both the exposure and 
outcome, but differently from a confounding factor it is part of the causal pathway linking the 
exposure and outcome. A mediator does not bias an association; rather it can help to explain it.  
3. Effect Modifiers  
 Interaction occurs when the presence of one factor modifies the effect of another (the effect of 
the exposure of interest differs according to which category of the other factor is being 
examined). 
Univariable and Multivariable Analysis 
Univariable and multivariable regression models were used to assess the relationship between 
primary exposures variables and outcomes. For survival analysis Cox regression models were 
used. HRs were the main measure of association. P-values were calculated from likelihood ratio 
tests comparing models with and without the factor of interest. The Cox model assumes that all 
covariates act equally (proportionally) on the enrolment hazard over time (i.e. the effects of the 
covariates do not change with time). 
Initially, a univariable analysis was performed among explanatory variables followed by 
multivariable analysis. In multivariable analysis, a hierarchical logistic regression model was used 
to explore the relationship between the study outcome and a range of explanatory variables for 
the primary research question. Since there is no evidence to determine the interrelations 
between HHCs with high IFN-γ levels and other known risk factors for incident TB, the objective 
of the study was to identify this, using a hierarchical approach. In addition it still unknown 
whether the effect of the high IFN-γ levels on TB incidence is direct or mediated through other 
factors. Since there were many explanatory variables, the decision to include risk variables was 
not based on statistical significance only (as in the case of step-wise logistic regression) but was 
determined through a conceptual framework describing the hierarchical relationships between 
them. 
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To construct a hierarchical logistic regression model firstly, I defined the conceptual, hierarchical 
framework for the relationships between the different variables and the disease outcome as 
reflected in the conceptual framework presented in the introduction. Secondly, I identified 
variables that were known a priori to be important confounders based on existing evidence.  
Thirdly, I identified other possible confounders and effect modifiers through exploratory 
analysis. Exposure-confounder interactions were examined paying particular attention to those 
thought a priori to be worth investigating. I used a combination of external knowledge with 
statistical associations in the following strategy summarized in Figure 3.5.  
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Figure 3.5: Evaluation of confounding and interaction 
  
Note: Odds ratio or Hazard ratio 
 96
Lastly, exposure variables were categorized into levels and regression models were fitted as 
shown in the results section. A final model was derived after assessment for interaction 
between the relevant exposures. Exposure-exposure and exposure-confounder interactions 
were examined one at a time, paying particular attention to those thought a priori to be worth 
investigating. In instances were interaction was weak, groups were combined in the interaction 
parameter to try and increase the power of tests for interaction. 
Cluster-level analysis 
After the final model was built, further analysis was performed at individual level taking into 
account the effect of clustering at household level due to the design of the ZAMSTAR study. 
Analysis was also performed at country level. 
Cluster level analysis was considered because of the following reasons: individuals within the 
same cluster are likely to be more similar to each other than they are to individuals in other 
clusters; infectious disease tends to cluster in time and space; clusters may share risk factors for 
infection, and for progression from infection to disease. 
 There are 3 methods that allow individual-level analysis but account for within-cluster and 
between-cluster correlation: “Robust” standard errors (SE); Generalized estimating equations 
(GEE) and Random-effects (multi-level) model. In this analysis Random-effects (RE) was method 
of choice but because the model could not work, the next preferred method was chosen, 
“Robust” standard errors.  
“Robust” SE is expected to work well if the number of clusters is more than 30. Although this 
method is simple and one can always fit this model to the data it does not take account of 
within-cluster correlation. However, this is relatively less important when the size of each 
cluster is similar (as in the design of the ZAMSTAR study). 
Risk factors for incident TB 
 
Risk factors for time to TB episode during follow-up were analyzed using Cox proportional 
hazards regression. The primary risk factors of interest were age, sex, high IFN-γ levels, QFT-GIT 
positivity, TST positivity, HIV positivity, socio-economic status, smear status of index, smoking, 
proximity to the index case and country. 
Risk factors associated with high IFN-γ levels:  
For the analysis in this section and subsequent ones in this chapter some variables (age, 
smoking, education, socioeconomic status and sleeping proximity to the index) were re-coded 
due to small numbers 
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Summary: Methods 
This study, the QFT cohort study was nested within a large community randomized trial called 
ZAMSTAR (Zambia South Africa TB and AIDS Reduction) implemented in 16 communities in 
Zambia and 8 communities in the Western Cape Province of South Africa (SA). More specifically 
it was nested within cohorts of TB patients and their household members called secondary 
outcome cohorts (SOCS) of the ZAMSTAR study whose aim was to determine the secondary 
objectives of the ZAMSTAR study at household-level.   
The sample size for this study was approximately 2400 adult HHCs enrolled in the SOCS. The 
study was conducted from April 2007 to December 2010. The study population was adult HHCs 
of newly notified TB cases at least 15 years of age who were enrolled in SOCS and in whom QFT-
GIT was performed. The study protocols were approved by all the relevant authorities in both 
countries.  
In SA, 4 teams conducted the study in all the 8 communities, while in Zambia, 16 teams (one 
team per community) located in the different geographical areas conducted the study. However, 
training and operating procedures were standardized as much as possible. 
Newly notified adult TB patients (index cases) were used as entry points into households where 
HHCs were invited to participate. QFT-GIT, TST and HIV testing were performed at baseline 
according to standard procedures. HHCs were not screened for active disease at baseline. They 
were followed-up twice at 18 and 36 months post-enrolment to ascertain who was still in the 
cohort and those that were lost to follow-up. A structured questionnaire was administered to 
collect information on risk factors for tuberculous infection and disease. At the final follow-up 
visit HHCs submitted a sputum sample to determine active disease using culture; liquid medium 
(MGIT960 H BD). Quality assurance procedures of all study processes, the tests and data were 
developed and followed. 
Incident TB was defined as self reported TB that was confirmed in the TB clinic register or 
patient treatment card. In a sensitivity analysis three other definitions of incident TB were 
explored as follows: exclusion of HHCs who developed TB within 2 months of enrolment; 
bacteriologically confirmed TB (smear) and smear together with culture. 
Cox regression models were used to assess the relationship between primary and secondary 
exposures and incidence of TB.  
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4.0  Performance and operational characteristics of QFT-GIT in Zambia 
 
Introduction 
The aim of this chapter is to determine the performance and operational characteristics of QFT-
GIT in a field setting. The evaluation of any diagnostic test involves assessing its performance 
and operational characteristics, preferably in a setting where the test will be used. For this 
reason, before we rolled out QFT-GIT on a large scale we decided to do some preliminary 
studies to determine factors that may affect the performance and operational characteristics of 
this test in our setting. Few studies have been published on the performance of QFT-GIT in 
resource limited settings with a high burden of TB and HIV (242).  
 
To assess test performance, we evaluated the sensitivity and test-retest reproducibility of QFT-
GIT as well the effect of CD4+ T-lymphocyte counts on IFN-γ responses. We also looked at some 
process and storage factors affecting the operation of this test.  
More specifically, we aimed to determine the effect of three factors on IFN-γ responses namely; 
delayed incubation of blood samples; power outages during incubation and increased storage 
temperature of blood collection tubes. Lastly, we determined the financial cost of diagnosing TB 
infection using QFT-GIT. 
Four small studies were used to examine these objectives. The first study (study 1) addressed 
four objectives namely; the sensitivity and test-retest reproducibility of QFT-GIT as well as the 
effect of CD4+ T-lymphocyte counts and delayed incubation of blood samples on IFN-γ 
responses. The second study (study 2) addressed the effect of power outages during incubation 
on IFN-γ responses. The third study (study 3) addressed the effect of increased storage 
temperature on IFN-γ responses. Lastly, the fourth study (study 4) addressed the financial cost 
of diagnosing TB infection using QFT-GIT. 
4.1 The performance of QFT-GIT in a field setting in Zambia (Study 1). 
 
Introduction 
The basic performance characteristics of a test designed to distinguish infected from uninfected 
individuals are sensitivity, that is, the probability that a truly infected individual will test positive, 
and specificity, that is, the probability that a truly uninfected individual will test negative (144). 
Since there is no gold standard for the diagnosis of TB infection, both sensitivity and specificity 
cannot be directly measured. For assessing sensitivity, patients with bacteriologically confirmed 
(culture or smear positive) active TB are used as a proxy measure. Sensitivity of IGRAs in active 
TB is considered a surrogate of sensitivity of IGRAs in TB infection, as has been done for the TST 
in the past (190). For assessing specificity, healthy, low risk individuals without known exposure 
to TB are used. An estimate of specificity would be difficult to determine in both Zambia and SA 
due to the high prevalence of TB infection (222). 
 Another important performance characteristic of a test is its reproducibility. The reproducibility 
of a test is an assessment of the extent to which the same tester achieves the same results on 
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repeated testing of the same samples, or the extent to which different testers achieve the same 
results on the same samples (144).  
In this study we aimed to evaluate factors affecting the performance of QFT-GIT in a field 
setting. The specific objectives of this study were four-fold. Firstly, we aimed to determine the 
sensitivity of QFT-GIT in smear positive TB patients and secondly, determine the test-retest 
reproducibility of QFT-GIT. Thirdly, we aimed to determine the effect of CD4+ T-lymphocyte 
count on IFN-γ responses and lastly, determine the effect of a 24-hour delay in incubation of 
blood samples on IFN-γ responses. Some of the results in presented in this study have been 
published (61, 222). 
Sample size 
The sample was limited by time and budget constraints. It was estimated that there were 
around 30 new cases of smear positive TB per month in each of the four large health centers in 
Lusaka. Over a recruitment period of four weeks at the four health centers it was hoped to 
recruit an overall number of 200 people to the study. It was expected that around half of these 
would be HIV positive and up to a third will have a low CD4 count. Assuming overall sensitivity of 
QFT-GIT to be around 80%, with 200 subjects’ sensitivity could be estimated with confidence 
intervals of around +/- 5%. 
Statistical analysis 
Overall, statistical analysis was done as described in the methods (statistical analysis) section of 
the thesis. However, a brief description is given here. 
We determined the sensitivity of QFT-GIT to assess test performance and compared it to that of 
TST using STATA version 11.0. Sensitivity was defined as the proportion of individuals with a 
positive QFT-GIT result among those with smear-positive TB. Sensitivity was defined using two 
methods; firstly, by including indeterminate QFT-GIT results and then secondly, excluding these 
results from the denominator.  
QFT-GIT results in these patients were also examined quantitatively, by looking at the IFN-γ 
responses to TB antigens in relation to grades of smear and duration of TB treatment. This is 
because there is some literature, although inconclusive suggesting that TB antigen-specific IFN-γ 
responses may correlate with antigen (bacterial load)(28).  
To determine test-retest reproducibility of QFT-GIT, test concordance and discordance were 
estimated using the kappa statistic and McNemar's test respectively. Continuous measures were 
also compared using Inter Class Correlations (ICC). 
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4.1.1 Methods 
 
a) Study population 
The study population was adults (over 18 years) with smear-positive TB who are untreated or 
had less than 4 weeks of TB treatment. These patients were enrolled from four government 
clinics in Lusaka from July to October 2007. 
b) Eligibility and recruitment 
TB patients were invited to participate from outpatient chest clinics by study nurses. The study 
nurses explained the study to TB patients and invited them to participate. Informed written 
consent was obtained from all patients using a standard information sheet (Appendix 17 and 
18). This was read out to patients if necessary and they were then given the opportunity to ask 
questions. Patients who were unable to write were asked to provide a thumbprint. Eligible 
patients were identified through the review of TB treatment cards. Patients were defined as 
smear positive if acid-fast bacilli were identified by microscopy in at least one sputum smear. 
Demographic data, information on risk factors for TB infection, height, weight and mid-upper 
arm circumference measurements was recorded for each patient by means of a short 
questionnaire (Appendix 19). 
c) Ethical approval  
Ethical approval was obtained from the London School of Hygiene and Tropical Medicine and 
the University of Zambia ethics committees.  
d) Venepuncture 
Approximately 9 mls of venous blood was drawn into three sets of QFT-GIT collection tubes (3 
ml for one set x 3) which were processed as follows: two sets were handled as duplicates and 
processed according to manufacturer’s instructions (standard incubation 1 and 2) while for the 
third set of tubes, incubation was delayed for 24 hours (delayed incubation).  
One set of the duplicate samples (standard incubation 1) was used to determine sensitivity of 
QFT-GIT and the effect of CD4+ T-lymphocyte count on QFT-GIT performance. To determine 
test-retest reproducibility of QFT-GIT, both duplicates samples were used while the third set 
whose incubation was delayed for 24 hours was used to determine the effect of a 24-hour delay 
in incubation on IFN-γ responses. In cases where the patient was offered and accepted to 
undergo routine diagnostic counseling and testing (DCT) extra blood was drawn for full blood 
count as well as liver and renal function tests in accordance with MoH guidelines at the time of 
the study. 
For the duplicates samples, QFT-GIT was performed according to manufacturer’s instructions 
(see methods section). In brief, whole blood was drawn and placed directly into three 1 ml tubes 
each containing ESAT-6, CFP-10 and TB7.7 or PHA (phytohaemagglutinin-a mitogen used as a 
positive control) or heparin (used as a nil sample to measure the background level of IFN-γ). 
 102
Samples were mixed vigorously and transported to the laboratory within 16 hours. Samples 
were incubated at 37°C for 24 hours, centrifuged and then plasma harvested to perform ELISA. 
One laboratory scientist processed the duplicate samples on the same ELISA plate. 
For the samples whose incubation was delayed for 24 hours, QFT-GIT samples were processed 
as described above (manufacturer’s instructions) except that the incubation period was delayed 
by 24 hours. This was done by leaving the blood collection tubes on the bench at room 
temperature (20-25° C) before incubation.  
T-lymphocyte estimations were done in these patients as a prerequisite to assessing anti-
retroviral therapy (ART) in line with standard Ministry of Health (MoH) guidelines at the time of 
the study. Blood CD4 and CD8 counts were obtained using FACS Count (Becton Dickinson) flow 
cytometric assay according to the manufacturer’s instructions (BD).  
e) Tuberculin Skin Test (TST) 
TST was administered and read as described in the methods section of the thesis. Briefly, TST 
was administered using 2 TU (Tuberculin Units) of PPD RT23 (Copenhagen, Denmark). A dose of 
0.1 ml was injected intradermally on the volar aspect of the left forearm. TST results were read 
using calipers between 48-96 hours after placement. All tests were administered and read by 
study nurses who were trained according to the standard IUATLD protocol (238). 
f) Clinical care 
Clinical standard of care was offered according to MoH national guidelines for patients with TB 
or those co-infected with TB and HIV. As part of the routine health service activity, TB patients 
were given general information on TB and HIV. The MoH recommends that HIV testing be done 
as a routine test for all TB patients in order to maximize the potential for ART referral for those 
found positive. Therefore, diagnostic counseling and testing (DCT) was encouraged and if 
accepted HIV status was recorded. 
HIV status of the TB patients was obtained from VCT and TB registers as well as patient records. 
No HIV testing was done specifically for the study. Patients without documented HIV status 
were encouraged to take DCT and all those found positive were referred for further counseling 
and to discuss treatment options. Those who declined to take part in the study received TB 
treatment in the standard way. Those found to have a low CD4 count (<350 cells/microL) were 
referred for the consideration of ART.  
4.1.2 Results  
 
a) Subject characteristics 
We enrolled 117 TB patients for the study. Of these, 5 patients were excluded due to missing 
data. The remaining 112 adult smear-positive TB patients were included in the analysis of this 
study. Out of the 112 TB patients, 72 (64.3%) were male and the median age was 31 years (IQR: 
25-35) (Table 4.1).  
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Table 4.1:  Demographic and clinical characteristics of TB patients 
 TB patients n (column %) 
Total 112  
Sex  
 Male  72 (64.3) 
Female  40 (35.7) 
Age group (years)  
18-24 27 (24.1) 
25-34 53 (47.3) 
35-44 26 (23.2) 
45-64 6 (5.4) 
Body mass index (kg/m2 ) (WHO definition)  
< 18.5  (underweight) 49 (46.2) 
>18.5 57 (53.8) 
Missing 6 
BCG scar  
No 38 (35.8) 
Yes 68 (64.2) 
Missing 3 
HIV status (n, 96)  
Negative 34 (35.4) 
Positive 62 (64.6) 
Missing 16 
Currently taking ARVs  
No 97 (86.6) 
Yes 15 (13.4) 
CD4 count, cells/ µl (WHO AIDS defining)  
<200 35 (31.2) 
≥200 77 (68.7) 
Smear grade   
Smear 1+  42 (37.5)  
Smear 2+  18 (16.1) 
Smear 3+  52 (46.4) 
Previous TB  
No 53 (72.6) 
Yes 20 (27.4) 
Missing 39 
Period of TB treatment  
Not on TB treatment at enrolment 35 (31.8) 
1-14 days 55 (50.0) 
15-31 days 20 (18.2) 
Missing 2 
 
Using the WHO definition of malnutrition, 46.2% of TB patients were underweight (table 4.1). 
The median body mass index (BMI) was 18.6 kg/m2 (IQR: 17-21).  
As expected in this setting, there was a high rate of TB/HIV co-infection in these patients. HIV 
status was recorded for 96 patients, of these, 64.6% (62/96) were HIV positive (Table 4.1). At the 
time of the study, ART roll-out by the MoH was in its initial stages. Therefore, ART status was 
recorded for 24.2% (15/62) HIV positive TB patients. At enrolment, the median duration of being 
on ART was 7.4 months (95% CI: 2.33-21.2).  
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93.7% (105/112) patients had results available for T-lymphocyte estimations. Overall, the 
median CD4 count was 310 cells/µl (IQR: 153-571) and the median CD4/CD8 ratio was 0.45 
cells/µl (IQR: 0.18-1.15).  
T-lymphocyte estimations were also compared in HIV positive and negative patients. In HIV 
positive patients, the median CD4 count was 205 cells/µl (IQR: 115-312) and the median 
CD4/CD8 ratio was 0.27 cells/µl (IQR: 0.15-0.49). In HIV negative patients, both the median CD4 
count, 537 cells/µl (IQR; 450-689) and the median CD4/CD8 ratio, 1.21 cells/µl (IQR; 0.79-1.80) 
were higher compared to HIV positive patients (Figure 4.1).  
Figure 4.1:  Box plot showing CD4/CD8 cell count ratio by HIV status 
 
There was a significant difference between HIV positive and negative patients in the ratio of 
CD4/CD8 cell count (ranksum, p<0.001).  
Smear status was recorded for all the 112 patients; 37.5% (42/112) had sputum smear recorded 
as 1+, 16.1%  as 2+ and 46.4%  as 3+ (table 4.1). 27.4% (20/73) of TB patients had a history of 
prior TB treatment (relapse cases).  
For the current episode of TB, there were 110/112 (98.2%) patients with accurate TB treatment 
dates recorded. The remaining 2 TB patients were excluded due to errors in dates (dates of 
current TB treatment were earlier than when TB was diagnosed). At enrolment, 31.8% (35/110) 
of patients were not on TB treatment; 50.0% (55/110) were within 1-14 days of treatment and 
the remaining 18.2% (20/110) were within 15-31 days of treatment.  
b) IFN-γ responses  
Overall, the median IFN-γ response to TB antigens was 1.89 IU/ml (IQR: 0.25-5.28). The median 
IFN-γ responses were lower in HIV positive (1.46 IU/ml (IQR: 0.14-5.03)) compared to HIV 
negative (2.63 IU/ml (IQR: 0.77-6.54)) patients (rank-sum; p=0.12), reflecting underlying cellular 
immune suppression in these patients. 
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TB patients who had smear grade 3+ had higher IFN-γ responses (2.08 IU/ml (IQR: 0.45-4.57)) 
compared to those who had smear grade 2+ (1.68 IU/ml (IQR: 0.35-5.02)) or smear grade 1+ 
(1.50 IU/ml (IQR: 0.06-7.07)). However, these differences were not significant (Kruskal-Wallis 
test, p=0.82).  
IFN-γ responses were lower in patients who were not on treatment ((1.30 IU/ml (IQR: 0.18-
5.38)) compared to those who were on treatment for less than 2 weeks (2.8 IU/ml (IQR: 0.37-
5.31)) or greater than 2 weeks (1.34 IU/ml (IQR: 0.2-5.69). However, these differences were also 
not significant (Kruskal-Wallis test, p=0.30). 
c) Sensitivity of QFT-GIT and TST 
Using QFT-GIT, 74.1% (83/112) of TB patients were positive, 12.5% (14/112) were negative and 
13.4% (15/112) had indeterminate results. When patients with indeterminate results were 
included, the sensitivity of QFT-GIT was 74.1% (95%CI: 65.0-81.9). However, QFT-GIT sensitivity 
increased to 85.6% (95% CI: 77.0-91.9) when patients with indeterminate results were excluded. 
Using TST, 47/91 patients were TST positive giving a sensitivity of 51.6% (95% CI: 40.9-62.2) at 
the standard cut-off of ≥ 10 mm. At a TST cut-off of 15 mm, sensitivity of TST was 20.9% (95%CI: 
13.1-30.7%) while it was 65.9% (95%CI: 55.2-75.5) at a TST cut-off of 5 mm. 
In a subgroup analysis of patients with known HIV status, sensitivity was lower in HIV positives, 
62.9% (95%CI: 49.7-74.8) compared to HIV negatives, 85.3% (95%CI: 68.9-95.0) (chi2: p=0.03). 
They were more indeterminate and negative results in HIV positive patients compared to HIV 
negative ones (chi2; p=0.03) (Figure 4.2). All the indeterminate results were due to poor 
response to mitogen (positive control).  
Figure 4.2:  QFT-GIT results in TB patients by HIV status 
 
 
Similarly, when TST results were stratified by HIV status at the cut-off of ≥ 10mm, sensitivity was 
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44.1-81.3)(rank-sum: p=0.05). However, sensitivity improved at a TST cut-off of ≥ 5mm to 55.1% 
(95%CI: 40.2-69.3) in HIV positives and 82.1% (95%CI: 63.1-93.9) in HIV negative patients (rank-
sum: p=0.02). Nevertheless, at TST cut-offs of ≥ 10mm, ≥ 15mm and ≥ 5mm, TST sensitivity was 
lower than that of QFT-GIT overall and stratified by HIV status . 
d) The effect of CD4+ T-lymphocyte cell count on QFT-GIT performance 
Our second objective in this study was to determine the effect of CD4+ T-lymphocyte count on 
QFT-GIT performance. The median CD4 cell count was significantly lower for patients with 
indeterminate results, at 178 cells/µl (IQR: 39-238), than for patients with negative (189 cells/µl 
(IQR: 89-312)) and positive results (428 cells/µl (IQR: 215-615)) results (Kruskal-Wallis test, 
p=0.0003). The difference in median CD4 count remained significantly different between QFT-
GIT positive and negative patients even when indeterminate results were excluded (ranksum, 
p=0.008).  
 With falling CD4 count there was a decrease in sensitivity of QFT-GIT with increases in both 
negative and indeterminate results (chi2, p =0.01) (Figure 4.3). Reduced sensitivity was 
particularly marked at CD4 counts less than 200 cells/ml, where only 18/83 (21.7%) patients had 
a positive QFT-GIT result (Figure 4.3). There was a trend towards an increase in both 
indeterminate and negative results with lower CD4 counts (test for trend, p<0.001).   
Figure 4.3:  The distribution of QFT-GIT results by CD4 cell count 
 
 As expected in this study, the majority of HIV positive patients, 46.8% (29/62) had CD4 counts 
below 200 cells/µl. In contrast, the majority of HIV negative patients, 41.2% (14/34) had CD4 
counts ≥ 600 cells/µl. There was a significant trend towards an increase in both indeterminate 
and negative results with falling CD4 count for HIV positives (test for trend, p=0.03) but not for 
HIV negative patients (test for trend, p=0.2).  
 The median IFN-γ response to TB antigens was significantly lower in patients with a CD4-cell 
count <200 cells/μl than any of the three other groups (Kruskal-Wallis; p=0.01). There was a 
trend towards increased IFN-γ response to TB antigens with increasing CD4 cell count levels (test 
18
19 19
27
8
3
1
2
9
4
1 1
0
5
10
15
20
25
30
<200 200-399 400-599 ≥600
N
u
m
b
e
r 
o
f 
su
b
je
ct
s
CD4 count cells/μl
Positive
Negative
Indeterminate
 107
for trend, p=0.001).  This trend was also found when PHA stimulated IFN-γ response and CD4 
cell counts were examined (Figures 4.4 and 4.5). 
Figure 4.4:  IFN- γ responses to TB antigens (ESAT-6/CFP-10/TB7.7) by CD4 count category 
 
 
Figure 4.5:  IFN- γ responses to PHA (mitogen) by CD4 count category 
 
Figure 4.4 and 4.5: Distribution of IFN-γ responses to TB antigens (ESAT6/CFP10/TB7.7) and 
PHA (mitogen) by CD4 cell count (box plot showing median, IQR and range) respectively. The 
median IFN-γ values within each CD4-cell count interval are indicated with horizontal lines. 
Dotted lines represent cut-off values as recommended by the manufacturer: 0.35 IU/ml for 
TB antigens stimulated IFN-γ response and 0.5 IU/ml for PHA stimulated IFN-γ response. 
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4.2 Reproducibility of QFT-GIT and the effect of a 24-hour delay in incubation 
 
Our third and fourth objectives in this study (study 1) were to determine the test-retest 
reproducibility of QFT-GIT and the effect of a 24-hour delay in incubation of blood samples on 
IFN-γ  responses, respectively. Out of the 112 smear positive TB patients available for analysis, 
we enrolled 109 smear positive TB patients who had duplicate sets of results (standard 
incubation 1 and 2) and one set that was delayed for 24 hours (delayed incubation). 
4.2.1 Test-retest reproducibility of QFT-GIT 
 
Out of the 109 patients, concordance was observed for 91.7% (100/109) and discordance for 
8.3% (9/109) duplicate samples. Overall, the agreement between duplicate samples (standard 
incubation 1 and 2) was high at 91.74% (kappa=0.81 (95% CI: 0.78-0.85)) (Table 4.2).  
Table 4.2:  QFT-GIT results of duplicate samples (standard incubation 1 and 2) 
 Standard incubation 2 
Standard incubation 1 Positive Negative Indeterminate Total 
Positive 77 0 6 83 
Negative 0 10 1 11 
Indeterminate 0 2 13 15 
Total 77 12 20 109 
 
The test-retest agreement between these duplicate samples remained high when continuous 
measures were used (ICC: 0.90; 95% CI 0.82- 0.97) (Figure 4.6), similar to results obtained from 
using dichotomous measures.  
Figure 4.6:  IFN-γ responses to TB antigens for standard incubation 1 and 2 
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Although discordance was observed for 9 patients, all of which included indeterminate results 
(Table 4.3), this was not significant (McNemar test; P =0.18). There was no discordance between 
positive and negative results. 
Of the 9 patients with discordant results, 6 were HIV positive and 3 had unknown HIV status 
(Table 4.3). The IFN-γ responses to TB antigens and PHA of the 9 patients with discordant results 
are shown in table 4.3. All the indeterminate results were due to poor response to PHA and not 
as a result of high background responses detected in the negative control tube (all nil values 
were ≤8.0 IU/ml for both TB antigens and PHA). There was strong evidence of an association 
between HIV positivity and discordant results (OR 1.98, 95%CI 1.06-3.67, p= 0.03). 
Table 4.3:  QFT-GIT results of nine discordant patients 
 Standard 
Incubation 1 
Standard 
Incubation 2 
     
Patient 
No. 
TB  
antigen-nil1 
Mitogen–
nil2 
TB  
antigen-
nil1 
Mitogen–
nil2 
Overall results: 
 Standard incubation 
1/Standard incubation 2 
HIV 
status 
CD4 
count 
1 0.5 0.24 0.00* 0.31 Positive/Indeterminate Unknown 120 
2 0.40 0.10 0.14 0.06 Positive/Indeterminate Unknown 572 
3 0.72 0.38 0.31 0.22 Positive/Indeterminate Unknown 1056 
4 0.00* 1.64 0.1 0.46 Negative/Indeterminate Positive 75 
5 0.14 0.3 0.04 0.62 Indeterminate/negative Positive 26 
6 8.6 1.50 0.00* 0.00 Positive/Indeterminate Positive 246 
7 0.35 0.46 0.15 0.45 Positive/Indeterminate Positive 615 
8 0.57 0.00* 0.01* 0.05 Positive/Indeterminate Positive 342 
9 0.07 0.46 0.02 0.53 Indeterminate/negative Positive 238 
*Negative values recorded as zeros; IFN-gamma response to TB antigens1or mitogen2. 
Overall, the median IFN-γ responses to TB antigens of standard incubation 1 and 2 were 2.06 
IU/ml (IQR 0.39-5.31, mean 5.16) and 1.36 IU/ml (IQR 0.15-5.24, mean 4.52) respectively. 
Although this difference was significant overall (Wilcoxon signed-rank test; p= 0.03), excluding 
the 9 patients with discordant results made this difference insignificant (Wilcoxon signed-rank 
test; p= 0.08). As for the 9 discordant patients, overall, there was a significant difference in the 
median IFN-γ responses to TB antigens of standard incubation 1 and 2 (Wilcoxon signed-rank 
test; p= 0.02) (Figure 4.7).  
  
 110
 
Figure 4.7:  IFN-γ responses to TB antigens for standard and delayed incubation 
 
Figure 4.7: Box plots (log transformations) showing range, inter-quartile range and median Interferon 
gamma responses to TB antigens of standard and delayed incubations. Median IFN-gamma responses 
of delayed incubation are lower than those of either standard incubation 1 or standard incubation 2. 
4.2.2 Effect of delayed incubation on IFN-γ response  
 
The fourth objective in this study was to determine the effect of a 24-hour delay in incubation of 
blood samples on IFN-γ  responses.  
The overall agreement between standard incubation 1 and delayed incubation samples was fair 
to good (kappa= 0.54 (95% CI: 0.49-0.59)) at 77.1%. The sensitivity of QFT-GIT decreased from 
74.1% (95%CI: 65.0-81.9) during standard incubation 1 to 58.7% (95% CI: 48.88- 68.06) during 
delayed incubation with indeterminate results included in the definition (Wilcoxon signed-rank 
test; p=0.002). Similar results were obtained when standard incubation 2 was compared with 
delayed incubation (Wilcoxon signed-rank test; p=0.03). However when indeterminate results 
were excluded in the definition, there was little difference between the sensitivity of standard 
incubation 1 and delayed incubation (standard incubation 1: (85.6% (95% CI: 77.0-91.9)). Vs. 
85.33 (95% CI: 77.27-92.44)) (Wilcoxon signed-rank test; p=0.05). A greater number of 
indeterminate results were observed during delayed incubation, 31.2% (34/109) compared to 
standard incubation 1, 13.8% (15/109) (chi2, p<0.001). 
There was a significant decrease in the median IFN-γ responses to TB antigens of patients from 
2.06 IU/ml during standard incubation 1 to 0.52 IU/ml (IQR -0.04-1.61, mean 1.82) when it was 
delayed (Figure 4.7) (Wilcoxon signed-rank test; p< 0.001). Similar results were obtained 
between standard incubation 2 and delayed incubation (Wilcoxon signed-rank test; p<0.001; 
kappa= 0.57; 77.98%).  
Overall there was a significant decrease in mitogen stimulated IFN-γ responses from 0.68 IU/ml 
(IQR: 0.18-2.52) during standard incubation 1 to 0.23 IU/ml (IQR: 0.07-0.77) when incubation 
was delayed (Wilcoxon signed-rank test; p<0.001). 
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Delaying incubation of QFT-GIT blood collection tubes by 24 hours changed the results of 22.9% 
(25/ 109) of patients while 77.1% (84/109) remained unchanged. Out of the 25 changed results, 
20 changed from either negative (4) or positive (16) to indeterminate. The remaining 5 results 
changed as follows: positive to negative (4) and indeterminate to positive (1) (Fisher’s exact, p 
<0.001). 
Patients whose results changed were similar in age, sex (Fisher’s exact, p = 0.63) and HIV status 
(Fisher’s exact, p =1.0) to those whose results remained unchanged. There was no evidence that 
HIV status (OR= 1.04; 95%CI 0.65-1.65, p=0.87) or CD4 count levels (OR=1.00, 95% CI 0.99-1.00 
p= 0.99) was associated with delayed incubation using standard incubation 1. A further 
comparison with standard incubation 2 showed similar results (OR 0.92, 95%CI 0.57-1.50, p= 
0.75).  
4.3 The effect of power outages on IFN-γ responses (Study 2) 
 
Introduction 
Power outages are common in resource limited settings, affecting mostly rural communities and 
high density urban and peri-urban areas. A new diagnostic test designed to be used in such 
settings requires a consideration of whether the test is dependent on uninterrupted electric 
power supply and whether results are grossly affected by power outages. Some tests require a 
stable electric power supply, and even short term interruption of power may cause 
indeterminate or incorrect results. 
 
This study stemmed from frequent power outages that occurred in Zambia during the period 
2008-2010. At this time the main study under discussion in this thesis was enrolling and 
following up study participants. During this period, the country experienced power outages due 
to increased demand for power due to high consumption; increased output in the mining sector 
as well as economic growth i.e. the demand outstripped the supply. Although the power 
outages which mostly affected the remote study sites subsequently improved over the study 
period, we initiated a study to examine to what extent QFT-GIT results were affected by power 
outages. We therefore aimed to determine the effect of power outages on IFN-γ responses 
during incubation.  
4.3.1 Methods 
 
a) Study subjects 
9 people volunteered to take part in the study. These volunteers were healthy adults, most of 
whom were members of staff at ZAMBART project Head Office. The median age was 46 years 
(IQR: 31-54) and 6/9 were male. No other personal details were captured from the volunteers. 
b) Ethical approval 
This study was laboratory based and did not need ethical approval 
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c) Laboratory methods 
To explore the effect of power outages during incubation of blood samples on IFN-γ response, 
simulated laboratory experiments were performed. Information on the pattern of power 
outages experienced in the different study sites was collected by a Quality Assurance team 
during routine monitoring visits. The patterns of power outages during incubation reported 
from the study sites were summarized into four categories as follows:  
1) No power outage (standard incubation)  
2) Early power outage  
3) Late power outage 
4) Early power outage with extension. 
Four sets of QFT-GIT blood collection tubes were obtained from each of 9 volunteers and 
incubated according to the four power outage categories. The first set was incubated for 24 
hours with no power interruption (standard incubation). The second set was incubated for 2 
hours; power was turned off for 5 hours, and then switched back on for 17 hours (early power 
outage). The third set was incubated for 16 hours, power was switched off for 5 hours, and then 
power was turned back on for an additional 3 hours (late power outage). The fourth set was 
incubated for 2 hours, power was switched off for 5 hours, turned back on for 17 hours, and 
incubation extended by 5 hours to compensate for the time lost during the power outage (early 
power outage with extension).  
The total incubation time for each experiment was 24 hours for standard incubation and early 
power outage with extension. However, the total incubation time for early and late power 
outages experiments was 19 hours each (excluding the 5 hours of power outage). After 
incubation, the rest of the samples were processed as per standard manufacturer 
recommendations. All concentrations greater than 10 IU/mL were reported as “10” in line with 
manufacturer recommendations. 
4.3.2 Results 
9 people volunteered to take part in the study. Power outages during incubation decreased IFN-
γ responses to TB antigens and the effect was greatest during late power outages (Figure 4.8).  
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Figure 4.8:  Effect of power outages on IFN-γ responses during incubation 
 
Median IFN-γ responses to TB antigens obtained during the different power outages patterns 
were as follows: standard incubation 1.4 IU/ml (IQR 0.01-12.69); early power outage with 
extension 1.44 IU/ml (IQR 0.02-4.58); early power outage 0.57 IU/ml (IQR 0.005-3.8) and late 
power outage 0.6 IU/ml (IQR -0.03-2.52) IFN-γ responses. When compared to standard 
incubation, these differences in median IFN-γ responses were significant apart for the early 
power outage with extension group (Wilcoxon signed-rank test: early power outage, p=0.02; 
late power outage, p=0.02; early power outage with extension, p=0.08). 
6 out of the 9 (66.67%) volunteers had positive QFT-GIT results and 3 (33.33%) were negative. Of 
the 6 with positive results, 5 (volunteers 1-5 in figure 4.8) remained positive in all the power 
outage experiments whilst 1 (volunteer 6) became negative (0.12 IU/ml) during the late power 
outage experiment .The 3 volunteers whose results remained negative during the different 
power outage experiments had median IFN-γ responses of zero. 
4.4 Effect of storage temperature on IFN-γ response (Study 3) 
 
Introduction 
Conditions of storage of any test are important as there are defined storage temperatures for 
most tests. In hot or humid conditions, the selection of tests that are heat-stable is a priority. 
For most tests designed for use in resource limited tropical settings, the manufacturers’ 
recommended room operating temperature is limited to a maximum of 30°C, not different from 
operating temperatures recommended for a wide range of other laboratory equipment. In 
settings where room temperature regularly exceeds 30˚C, air conditioning of the room where 
the assay is performed may be recommended.  
According to the manufacturer, the unused tubes of QFT-GIT should be stored at room 
temperature i.e. 4-25°C. However, it is widely known that in some tropical settings like Zambia, 
the room temperature exceeds 25˚C and may even reach a maximum of 40˚C in certain areas. In 
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these places, laboratories at most primary health centers in such sites do not have air 
conditioning facilities. In this study we therefore aimed to determine the effect of increased 
storage temperature of unused blood collection tubes on IFN-γ responses. 
4.4.1 Method 
 
a) Study subjects 
14 people volunteered to take part in the study. These volunteers were healthy adults, most of 
whom were members of staff at ZAMBART project Head Office. The median age was 46 years 
(IQR: 34-51) and 9/14 were male. No other personal details were captured from the volunteers. 
 
A simulated laboratory experiment was done to determine the effect of increased storage 
temperature of unused blood collection tubes on IFN-γ response. From each of 14 volunteers, 
blood was collected in two sets of blood collection tubes. One set had been stored at 37°C for 3 
months before blood was drawn and the other set had been stored in an air conditioned storage 
area where the temperature was maintained at less than 25 °C.  
b) Ethical approval 
This study was laboratory based and did not need ethical approval. 
4.4.2 Results 
 
There was no difference in IFN-γ responses between blood collected in tubes stored at <25°C 
and blood collected in tubes stored at 37°C for three months. 
4.5 The financial cost of using QFT-GIT for the diagnosis of TB infection (Study 4) 
 
Introduction 
The evaluation of new diagnostic tools in any given setting should not only examine 
performance, feasibility and sustainability but should also consider costs and cost-effectiveness. 
This is because for resource-limited setting, cost can be a major barrier for the introduction of a 
test even if other performance factors are favourable.  
Currently, a limited number of studies have been done looking at the cost or cost-effectiveness 
of QFT-GIT in resource-limited settings. We therefore conducted a small financial costing study. 
The aim of the study was to determine the financial cost of diagnosing TB infection using QFT-
GIT in a field setting in Zambia. 
4.5.1 Methods 
 
We performed a study to look at the financial cost of diagnosing TB infection using QFT-GIT from 
the provider’s perspective. Financial cost was defined as the accounting cost where costs were 
the monetary value of expenditures. Costs which patients incurred for seeking care for TB 
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infection were not included. The study was performed in six ZAMSTAR sites in Zambia; two sites 
from Kabwe and four from Lusaka. We collected costs using the ingredients approach (243).  
We first identified all the ingredients required to perform QFT-GIT testing. In each site the 
health economist independently observed the entire process of performing QFT-GIT. This 
included all steps from sample collection to reading the results and final disposable of the 
waste. We recorded all processes, equipment and consumables used and time applied for a 
specific task. Time of staff spent on individual procedures and tasks was observed in detail for 
two weeks for all procedural steps separately. The amount of consumables used over time was 
observed and estimated with the help of laboratory staff. Other information was also collected 
through interviews with laboratory staff, project administrative staff and myself, as head of the 
QFT-GIT study. 
We ascertained costs by reviewing expenditures, quotations and equipment and by consulting 
with laboratory staff, project administrative staff and me. I provided detailed information on the 
consumables needed to perform a QFT-GIT test i.e. where they were obtained from, at what 
price and the role of the funders. Laboratory staff provided information on the running costs of 
central laboratory including construction/maintenance of buildings, utilities (water, electricity, 
phone and internet), security and cleaning costs. 
All costs were collected in June 2009 and compared to the average number of QFT-GIT tests 
done during the 1st follow-up visit of the main study under discussion in this thesis. The costs of 
transportation of samples from the point of collection to the central laboratory at Head office 
were included. All samples, regardless of test result were included. 
Overhead costs were established by means of expenditure records in addition to staff costs. 
Overheads were apportioned according to the time proportion of personnel dedicated to QFT-
GIT testing. Capital costs were depreciated and annualized over the estimated lifetime at a 
discount rate of 3% as applied in similar studies (244). The lifetime of equipment was estimated 
with the help of staff of the laboratory with consultation from staff from finance department. 
Shared costs (for equipment and consumables) that were not only used for QFT-GIT procedures 
but also for other applications in the laboratory were apportioned by dividing the cost of each 
item by number of tasks. In order to obtain cost per QFT-GIT test, cost-per-step was then 
multiplied by the number of steps in which the item was used during the QFT-GIT procedure. All 
costs in local currency (Zambian kwacha) were converted into US Dollars (USD) at the official 
annual exchange rate for 2008.  
4.5.2 Results 
 
Our calculations were based on the average throughput of 2,942 individuals tested per year 
during SOCs visit 2 follow up. We differentiated between study-specific costs and overhead 
costs. The total cost per QFT-GIT test was estimated at US$ 22.29 (Table 4.4).  
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Table 4.4:  Financial cost of performing one QFT-GIT test 
 Consumables                                                                 (US$)       % of total cost 
Medical supplies 2.24 10% 
3 QFT-GIT test tubes  3.50 16% 
QFT-GIT  ELISA kit   5.09 23% 
Other (non-medical supplies & supervision) 2.74 12% 
Subtotal 13.58 61% 
Equipment (US$) 
 Medical equipment 2.32 10% 
Washer machine 0.74 3% 
Elisa 0.74 3% 
Other (non-medical equipment) 0.02 0% 
Subtotal 3.81 16% 
Personnel (study-specific) (US$) 
 Nurses 1.327 6% 
Laboratory Personnel 0.98 4% 
Data personnel 0.90 4% 
Study Manager 0.15 1% 
Subtotal 3.37 15% 
Overheads (US$) 
 Recurrent 0.56 3% 
Capital 0.41 2% 
Personnel ( support staff)  0.57 3% 
Subtotal 1.53 8% 
Total cost (US$) 22.29 100% 
 
Under the current average rate of throughput, roughly two thirds (US$ 13.58; 61%) of the total 
cost per QFT-GIT test are made up of recurrent costs. This was followed by equipment costs at 
US$ 3.81 (17%) of the total cost per test. The study-specific costs comprised equipment costs 
(US$ 3.81), consumables costs (US$ 13.58) and staff costs (US$ 3.37) forming US$ 20.75/22.29 
(93%) of the total costs. The overhead costs were estimated at US$ 1.53 forming 7% of the total 
cost per QFT-GIT test. 
The most costly line items that drove the cost per QFT-GIT test high were consumables and 
medical equipment. QFT-GIT testing tubes and the QFT-GIT ELISA kit are proportional to the 
number of samples tested. All other line items are shared costs, and thus are subject to 
economies of scale. 
4.5.3 Conclusion 
The total cost of performing a QFT-GIT test was estimated at US$ 22.29 in our setting. 
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Summary 
In this chapter I have illustrated the practical feasibility of using QFT-GIT in a poor resource 
setting like Zambia.  I have shown that the sensitivity of QFT-GIT is greater than that of TST 
overall, at all the standard TST cut-offs and when stratified by HIV status. The sensitivity of QFT-
GIT was 74.1% (95%CI: 65.0-81.9) (indeterminate results included) compared to that of TST at 
51.6% (95% CI: 40.9-62.2) at a cut-off of ≥ 10 mm. I have showed that the test-retest 
reproducibility of QFT-GIT was high at 91.74% for both dichotomous (kappa=0.81 (95% CI: 0.78-
0.85)) and continuous (ICC: 0.90; 95% CI 0.82- 0.97) data, even in a resource limited setting. 
However, the studies I have presented here have demonstrated that there are some biological 
and operational factors that affect the performance of this test in this setting. HIV positivity, low 
CD4+ T-lymphocytes, delayed incubation of blood samples and power outages all affect test 
performance. With falling CD4 count, there was a trend towards an increase in both 
indeterminate and negative results overall (test for trend, p<0.001) and in HIV positive patients 
(test for trend, p=0.03). A 24-hour delay in incubation of blood samples decreased IFN-γ 
responses by 3.34 IU/ml and changed the results for 22.9% patients. Power outages, especially 
those that occurred during late incubation decreased IFN-γ responses to TB antigens by 0.8 
IU/ml. Storage of blood collection tubes at 37°C had no effect on IFN-γ responses. 
These studies emphasize the need for stringent sample collection and processing techniques to 
ensure the accuracy of QFT-GIT results. These factors may need to be taken into account in 
determining whether this test is appropriate for resource limited settings. While most of these 
factors can be controlled, the effect of HIV infection like TST may be a major limiting factor for 
the role of this test. Our financial costing study showed that the total cost of performing a QFT-
GIT test was US$ 22.29 in our setting. 
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5.0 Baseline results  
 
Introduction 
 In this chapter I will present the baseline results of the QFT-GIT cohort study which was nested 
within the SOCS study. After a descriptive analysis of the socio-demographic and clinical 
characteristics of the study population, I will explore the baseline quantitative QFT-GIT and TST 
results that will be linked to disease progression in the subsequent chapters. Due to the absence 
of a gold standard for the diagnosis of TB infection, I will evaluate the diagnostic performance of 
QFT-GIT and TST by examining the association between test positive results and risk factors for 
TBI. In addition I will determine concordance between the two tests. 
This chapter focuses on a population of household contacts (HHCs) of newly notified TB cases in 
whom QFT-GIT was performed at baseline. The specific objectives of this chapter are: 
1) To describe the socio-demographic and clinical characteristics of household contacts (HHCs) 
in the baseline population. 
2) To describe the baseline quantitative QFT-GIT and TST results.  
3) To determine the prevalence of TB infection as measured by QFT-GIT and TST.  
4) To determine risk factors associated with positive QFT-GIT and TST results. 
5) To determine the level of agreement or concordance between QFT-GIT and TST results. 
5.1 Study enrollment  
 
 For every household, once permission to enroll household members was given and the study 
fully explained; all members were then enumerated. Although all household members were 
enumerated, this study focuses on adult’s ≥ 15 years invited to participate in the SOCS study. 
The SOCS study enumerated 16, 872 adults from 5,062 households. The total household size for 
adults, (as enumerated regardless of eligibility to the QFT-GIT cohort) varied from 1 to 25 with 
11% having 1 adult household member (index case only), 32.4% having 2 adult household 
members, 19.1% having 3 adult household members and 37.5% having 4 or more adult 
household members. Of those enumerated, 9,582 (56.8%) agreed to take part in the SOCS study 
and were enrolled while 7,242 (42.9%) were not enrolled. Reasons for not enrolling into the 
study were refusal (4,537; 62.6%), absenteeism (2,118; 29.2%), exclusion (400; 5.5%) and 
missing data (187; 2.6%) (Figure 5.1).  
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Figure 5.1:  Flow diagram of study participants at baseline 
 
The SOCS study enrolled 9,582 adults from 4,948 households. The total household size, (adults 
enrolled in the SOCS study) varied from 1 to 14 with 46.3% having 1 household member (index 
case only), 31.6% having 2 household members, 12.1% having 3 household members and 10% 
having 4 or more household members. Out of 9,582 adults who accepted to take part in the 
SOCS study, 4,858 (50.7%) were HHCs and 4,682 (48.9%) were TB patients (index cases). TB 
patients and 42 individuals whose contact status (index or contact) was unspecified were 
excluded from the study. 
Out of 4,858 HHCs enrolled in the SOCS study, 2,342 (48.2%) were excluded because they were 
enrolled before the QFT study began, hence QFT-GIT testing could not be offered to them. The 
2,342 HHCs were determined by excluding all those enrolled into the SOCS study prior to the 
date of the first QFT-GIT test in each community. Most QFT-GIT tests were performed on the 
same day HHCs were enrolled into the SOCS study. 
 After HHCs were enrolled into the SOCS study, they were introduced to the QFT study. Of the 
4,858 HHCs enrolled in the SOCS study, 2,288 accepted to be enrolled in the QFT study, resulting 
in an acceptance rate of 90.9 % (2,288/2,516), (2,342 HHCs not offered QFT-GIT were excluded 
from denominator). Those who accepted to take part in the QFT study had blood drawn for QFT-
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GIT testing and a risk factor questionnaire administered to them. For 228 HHCs, QFT-GIT tests 
were not done and data on why these tests were not done was not collected.  
A total of 2,200 (96.1%; 2,200/2,288) HHCs had valid QFT-GIT results. Reasons for invalid QFT-
GIT result were (i) insufficient blood samples (1.2%; 28/2,288) , (ii) spoilt blood samples (2.6%; 
60/2,288) defined as samples that had hemolysed or had been subjected to power outages 
during incubation, and (iii) indeterminate QFT-GIT results (9.6%; 220/2,288 ). All the invalid QFT-
GIT results were excluded from analysis. Of the 2,200 HHCs with valid QFT-GIT results, 1,789 
(90.0%) also had an interpretable TST result. Reasons for excluding TST results were (i) refusal 
(4.9%; 98/1,980), (ii) not returning for reading, (4.0%; 80/1,980) and (iii) missing data (0.7%; 
13/1,980).  
Therefore 1,789 HHCs with interpretable results for both QFT-GIT and TST form the baseline 
population of the QFT cohort study described in this chapter.  
5.2 Socio-demographic and clinical characteristics of HHCs 
 
 The study population was predominantly women (71%) and the median age was 28 years 
(interquartile range [IQR], 21-43). Overall, there was approximately an equal number of single 
(45.4%) and married (44.8%) HHCs in this study population. However, when results were 
stratified by country, there were more single (58.2%; 438/752) and less widowed (3.6%; 27/752) 
or separated (2.8%; 21/752) HHCs in SA than Zambian communities (Table 5.1).  
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Table 5.1:  Individual level demographic and clinical characteristics of HHCs at baseline 
  HHCs  (column %) 
 Zambia SA Total 
Total 1037 752 1789 
Sex    
 Male 318 (30.7) 199 (26.7) 517 (29.0) 
Female 719 (69.3) 547 (73.3) 1266 (71.0) 
Missing 0 6 6 
Age group (years)    
15-24 413 (39.8) 278 (37.0) 691 (38.6) 
25-34 277 (26.7) 178 (23.7) 455 (25.4) 
35-44 132 (12.7) 105 (14.0) 237 (13.3) 
45-54 97 (9.3) 110 (14.6) 207 (11.6) 
55-64 59 (5.7) 55 (7.3) 114 (6.4) 
>65 59 (5.7) 25 (3.3) 84 (4.7) 
Missing   1 
Marital status    
Single 373 (36.0) 438 (58.2) 811 (45.4) 
Married 534 (51.6) 266 (35.4) 800 (44.8) 
Widow 82 (7.9) 27 (3.6) 109 (6.1) 
Separated 46 (4.4) 21 (2.8) 67 (3.7) 
Missing 2 0 2 
Highest level of education    
Not attended school 74 (7.3) 42 (5.7) 116 (6.6) 
Primary school 365 (36.2) 190 (25.6) 555 (31.7) 
Secondary school 465 (46.1) 449 (60.5) 914 (52.2) 
College or University 105 (10.4) 61 (8.2) 166 (9.5) 
Missing 28 10 38 
Economic activity    
Dependant 117 (11.4) 40 (5.3) 157 (8.8) 
Unemployed -Not looking for 
employment 
499 (48.5) 130 (17.4) 629 (35.4) 
Unemployed-actively looking 
for employment 
146 (14.2) 430 (57.5) 576 (32.4) 
Employed 266 (25.9) 148 (19.8) 414 (23.3) 
Missing 9 4 13 
Smoking habits    
Never smoked 910 (88.0) 551 (73.3) 1461 (81.8) 
Ex-smoker 47 (4.5) 29 (3.9) 76 (4.3) 
Occasional smoker 28 (2.7) 32 (4.3) 60 (3.3) 
Daily smoker 49 (4.7) 140 (18.6) 189 (10.6 ) 
Missing 3 0 3 
1Alcohol consumption    
No 782 (75.8) 555 (74.3) 1337 (75.2) 
Yes 249 (24.1) 192 (25.7) 441 (24.8) 
Missing 6 5 11 
HIV status (laboratory 
reported)  
   
Negative 716 (69.8) 549 (75.4) 1265 (72.1) 
Positive 310 (30.2) 179 (24.6) 489 (27.9) 
Missing 11 24 35 
Household level variables 
Smear status of the index    
Smear negative 355 (57.0) 325 (42.8) 680 (49.2) 
Smear positive 268 (43.0) 435 (57.2) 703 (50.8) 
Missing 144 88 232 
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Sleeping proximity to index    
Different  house 102 (10.1) 22 (7.3) 124 (9.4) 
Same house 403 (39.9) 150 (49.5) 553 (42.1) 
Same room 58 (5.7) 5 (1.6) 63 (4.8) 
Same bed 197 (19.5) 31 (10.2) 228 (17.3) 
Unknown  251 (24.8) 95 (31.3) 346 (26.3) 
Missing 26 449 475 
1Defined as alcohol consumption four weeks prior to the interview. 
 
 Overall, most HHCs had attended secondary education (52.2%; 914/1,751), had no history of 
smoking (81.8%; 1461/1,786) or alcohol consumption (75.2%; 1,337/1,778). In addition, a 
greater proportion of them were unemployed (67.8%; 1,205/1,776) although only 32.4% 
(576/1,776) were actively looking for employment.  
 As expected in this setting, overall, the prevalence of HIV infection in HHCs was high at 27.9% 
(489/1,754). When stratified by country, a higher prevalence of HIV infection was observed in 
HHCs residing in Zambian communities (30.2 %; 310/1,026) compared to those residing in South 
African ones (24.6%; 179/728) (chi2; p=0.01). 
HIV prevalence was also explored by sex and age group for each country. Overall HIV prevalence 
was higher among females, 31.7% (395/1,244) compared to males, 18.6% (94/505) (p<0.001) 
and the results were similar when stratified by country (chi2; p<0.001). When HIV prevalence 
was explored by age, it remained higher in the Zambian communities in all age groups apart 
from the 15-24 age group. In this age group, HIV prevalence was 20% (54/270) for HHCs residing 
in the SA communities compared to 18.6% (76/408) for those in the Zambian communities.  
There were 43.8% (777/1,773) HHCs who self reported to have had an HIV test, of these 19.8% 
(148/746) were HIV positive and 80.2% (598/746) were HIV negative. Of the HHCs who self-
reported to be HIV positive, 35.1% (52/148) were on antiretroviral therapy (ART) at baseline. 
The median time between ART initiation and study enrolment was 1.15 years (IQR: 0.53-1.82).   
The uptake of IPT in this study population was low at 4.7% (7/148) among those who self-
reported to be HIV positive. Data on the presence of a BCG scar was only available for 974 HHCs 
residing in Zambia. Of these, 26% (253) had a BCG scar whereas 74% (721) did not have a scar. 
Overall, 50.8% (703/1,383) of HHCs lived with a smear positive TB index case. A greater 
proportion of HHCs who lived with smear positive TB index cases resided in SA (57.2%) than in 
Zambian (43.0%) communities. Index cases were mostly men (50.2%), with a median age of 33 
years (IQR: 27, 40). 
Out of 1,789 HHCs, 1,037 (58%) resided in Zambian communities and 752 (42%) in SA 
communities. The number of HHCs varied across the 24 communities from 18 to 140, with a 
mean of 74 HHCs per community. When the communities were stratified by urban and rural, 
there were only two rural communities, all of which were in Zambia. Therefore, overall the 
majority, 97.3% (1,740/1,789) of HHCs resided in urban communities in both countries. For the 
Zambian communities, 4.7% (49/1,037) of HHCs resided in rural areas while 95.3% (988/1,037) 
were in urban areas.  
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5.3 Quantitative QFT-GIT and TST responses  
Overall, the median IFN-γ responses to TB antigens at baseline was 1.1 IU/ml (IQR; 0.1-5.7). 
Figure 5.2 shows the distribution of TB antigen stimulated IFN-γ response at baseline. As shown 
in Figure 5.2, the majority of HHCs; 646 (36.1%) had IFN-γ responses below 0.35 IU/ml while 459 
(25.7%) had IFN-γ levels between 5.5-10 IU/ml. There was a difference in IFN-y response to TB 
antigens by country, with HHCs in SA having a larger response (median 1.5 IU/ml (IQR: 0.3-6.0)) 
than HHCs in Zambia (median 0.8 IU/ml (IQR: 0.02-5.4) (rank-sum; p<0.001). For both TB antigen 
and mitogen minus nil values, results ≥ 10 IU/ml are shown as 10 IU/ml as recommended by the 
manufacturer. 
Figure 5.2:  TB Antigen stimulated interferon-gamma responses at baseline 
 
Overall, the median IFN-γ response to mitogen at baseline was 8.9 IU/ml (IQR: 2.55-10) (Figure 
5.3). As shown in Figure 5.3, the majority of HHC, 1,109 (62%) had IFN-γ responses between 5.5-
10 IU/ml. 
Figure 5.3:  Mitogen stimulated interferon-gamma responses at baseline 
 
TB antigen stimulated IFN-γ responses were also stratified by HIV status (Figure 5.4) and 
responses were lower in HIV positive (median 0.4 IU/ml (IQR: 0.02-3.0)) compared to HIV 
negative HHCs (median 1.5 IU/ml (IQR: 0.13-7.0)) (rank-sum; p <0.001). Similar results were 
found when mitogen stimulated IFN-γ responses were stratified by HIV status (rank-sum; 
p=0.005) (Figure 5.4). 
 124
Figure 5.4:  Box plots showing IFN-γ responses by HIV status at baseline 
 
Figure 5.4: IFN-γ responses to Mtb antigens and mitogen. Box plots illustrate the median and 
distribution of log transformed IFN-γ results by HIV status. 
Quantitative TST results at baseline showed that the mode of the TST distribution for non-zero 
indurations was 10 mm while the mean TST response was 7.1 mm (range 0-45). There was 
strong evidence that TST indurations differed by HIV status; mean induration in HIV positive was 
6.3 mm (range 0-45) compared to 7.3 mm (range 0-35) in HIV negative HHCs (rank-sum; 
p=0.0005) (Figure 5.5). In addition, a greater proportion of HIV positives, 50.7% (248/489) had 
zero indurations compared to HIV negatives, 39.3% (497/1,265). 
Figure 5.5:  TST responses by HIV status at baseline 
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5.3.1 Effect of age on quantitative IFN-γ responses and TST reactivity 
 
 The median IFN-γ response to TB antigens ranged from 0.96 (IQR: 0.04-6.2)IU/ml in the 
youngest age group (15-24 years) to 1.28 (IQR: 0.12-7.5) IU/ml in the oldest age group (over 65 
years).  
There was a tendency of the TB antigen stimulated IFN-γ responses to peak between 55-64 
years (median IFN-γ response: 2.08 (IQR: 0.35-7.6) and decline after 65 years of age (Figure 5.6). 
When this pattern was formally tested, there was a trend of increasing IFN-γ responses with 
increasing age group (test for trend; p =0.001). In all age groups the median IFN-γ responses 
were above the manufacturer’s cut-off point of ≥ 0.35 IU/ml. 
The mean TST reactions ranged from 6.6 mm (range 0-44) in the youngest age group (15-24 
years) to 5.2 mm (range 0-22) in the oldest age group (over 65 years). Both quantitative QFT-GIT 
and TST responses were associated with increasing age (aOR for each 10 year increase for QFT-
GIT 1.21; 95% CI: 1.08-1.36; p=0.02 for linear trend, and for TST aOR: 1.03; 95% CI: 0.95-1.12; p = 
0.001 for linear trend). 
Figure 5.6:  Age-specific interferon-gamma responses to TB antigens 
 
Figure 5.6: Box plots show the range, median (red diamonds), 25th and 75th percentiles of  
IFN-γ-responses to TB antigens in different age groups  
5.4 Prevalence of tuberculous infection (TBI) 
 
The prevalence of TBI was 63.7% (1,140/1,789) using QFT-GIT at the manufacturer’s cut-off 
point of ≥ 0.35 IU/ml and 39.6% (709/1,789) using TST at ≥10 mm cut-off. 31.6% (565/1,789) 
HHCs were positive on both QFT-GIT and TST (10 mm) while 40.2% (719/1,789) were positive on 
either QFT-GIT or TST. Overall, the prevalence of infection was higher in SA than in Zambian 
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communities using both QFT-GIT (SA: 71.1% vs. Zambia 58.3%; p<0.001) and TST (SA: 47.2.1% vs. 
Zambia 34.1%; p<0.001).  
The prevalence of TBI was also explored by age group. For QFT-GIT, prevalence increased with 
age, peaked between 55-64 years and declined after 65 years of age. However, for TST 
prevalence, a trend with age was less clear (Figure 5.7). 
Figure 5.7:  Prevalence of QFT-GIT and TST by age group 
 
The prevalence of TBI stratified by HIV status showed a lower proportion of test positive results 
in HIV positive HHCs compared with HIV negative HHCs for both tests and regardless of TST cut-
off. Using QFT-GIT, the prevalence of TBI was 52.8% (258/489) in HIV positive compared to 
67.8% (857/1265) in HIV negatives HHCs (p<0.001). Using TST at ≥10 mm cut-off, the prevalence 
of TBI was 34.6% (169/489) in HIV positives compared to 41.5% (525/1265) in HIV negatives 
HHCs (p=0.008) (Figure 5.8).  
Literature suggests that a lower TST cut-off point of 5 mm should be used in HIV positive 
individuals because of cutaneous anergy associated with progressive HIV immunosuppression 
resulting in high rates of test unresponsiveness (245). Using TST at ≥ 5mm cut-off, the 
prevalence of TBI was 47.0% (230/489) in HIV positives compared to 56.6% (716/1275) in HIV 
negatives HHCs (p<0.0003).  
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Figure 5.8:  Proportion positive by each test stratified by HIV status 
 
5.5  Risk factors associated with positive QFT-GIT and TST results 
 
 In unadjusted analysis, HIV (OR: 0.53; 95% CI: 0.43–0.66; p<0.001) and being an ex-smoker 
(OR:0.66; 95% CI:0.41-1.04)  were negatively associated with  QFT-GIT positivity, whereas daily 
smoking (OR: 1.56; 95% CI: 1.11-2.18; p=0.007), smear status of index (OR: 1.34; 95% CI: 1.06-
1.69; p=0.01), residing in an urban area (OR: 2.03; 95% CI: 1.15–3.58; p<0.01) and country (OR: 
1.76; 95% CI: 1.44–2.15; p<0.001) were positively associated with QFT-GIT positivity.  
QFT-GIT positivity was also associated with increasing age (aOR for each 10 year increase for 
QFT-GIT 1.15; 95% CI: 1.06–1.25; p<0.001 for linear trend). In further analysis to test the null 
hypothesis that the effect of age group on QFT-GIT positivity was linear, there was no evidence 
of departure from linearity in this relationship (LR chi2 (1)1.52; p=0.22).  
In multivariable analysis (adjusted for sex, age  and community) results were similar as for the 
unadjusted analysis apart from smear status of the index case. In multivariable analysis, HIV 
(aOR: 0.48; 95% CI: 0.37-0.63; p<0.001) and being an ex-smoker (OR: 0.56; 95%CI: 0.32-1.00) 
were negatively associated with QFT-GIT positivity whereas, residing in an urban area (aOR: 
2.37; 95% CI: 1.10-5.13; p<0.03) and country (aOR: 1.93; 95% CI: 1.48-2.51; p<0.001) were 
positively associated with QFT-GIT positivity. In unadjusted and multivariable analyses, data 
were consistent with no association of education, socioeconomic status, alcohol consumption 
and sleeping proximity to the index case with QFT-GIT positivity (Table 5.2). In addition, there 
was weak evidence of an association between presence of a BCG scar and QFT-GIT positivity 
(aOR: 0.71 (0.47-1.05; p=0.09).  
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Table 5.2:  Univariable and multivariable odds ratios showing risk factors associated with 
positive QFT-GIT results 
(nmax =1789). 
 QFT-GIT positive 
n (row %) 
Crude OR  
 (95% CI) 
2P 
value 
Adjusted OR1 
 (95% CI)  
2P value 
Sex      
Female  808 (63.8) 1  1 1 
 Male  329 (63.6) 0.99 (0.80-1.23) 0.94 1.08 (0.83-1.39) 0.57 
Age group (years)      
15-24 417(60.3) 1 P<0.001 1 p<0.001 
25-34 282(62.0) 1.07 (0.84-1.36)  1.04 (0.77-1.39)  
35-44 155(65.4) 1.24 (0.91-1.69)  1.27 (0.88-1.83)  
45-54 145 (70.0) 1.54 (1.10-2.15)  1.62 (1.09-2.42)  
55-64 85 (74.6) 1.93 (1.23-3.01)  2.34 (1.36-4.04)  
>65 55 (65.5) 1.25 (0.77-2.00)  1.78 (1.00-3.19)  
Highest level of education      
Not attended school 75 (64.7) 1 0.06 1 p<0.001 
Primary school 374 (67.4) 1.13 (0.74-1.72)  1.41 (0.83-2.38)  
Secondary school 557(60.9) 0.85 (0.57-1.28)  1.03 (0.60-1.79)  
College or University 112 (67.5) 1.13 (0.69-1.87)  1.45 (0.76-2.77)  
Socioeconomic status      
Dependant 102 (65.0) 1 0.91 1 p<0.001 
3Unemployed  768 (63.7) 1.03 (0.82-1.30)  1.11 (0.83-1.50)  
Employed 261 (63.0) 1.09 (0.74-1.59)  1.30 (0.80-2.11)  
Smoking habits      
Never smoked 918 (62.8) 1 0.007 1 p<0.001 
Ex-smoker 40(52.6) 0.66 (0.41-1.04)  0.56 (0.32-1.00)  
Occasional smoker 42 (70.0) 1.38 (0.79-2.42)  1.10 (0.55-2.18)  
Daily smoker 137 (72.5) 1.56 (1.11-2.18)  1.10 (0.71-1.71)  
Alcohol consumption      
No 841 (62.9) 1  1  
Yes 289 (65.5) 1.12 (0.89-1.40) 0.32 1.06 (0.80-1.41) 0.67 
HIV status       
Negative 857(67.7) 1    
Positive 258 (52.8) 0.53 (0.43-0.66) p<0.001 0.48 (0.37-0.63) p<0.001 
Smear status of the index      
Smear negative 373 (61.0) 1  1  
Smear positive 424(67.7) 1.34 (1.06-1.69) 0.01 1.26(0.91-1.76) 0.15 
Sleeping proximity to index      
Different  house 71 (57.3) 1 0.63 1 0.0009 
Same house 352 (63.6)  1.31 (0.88-1.94)  1.09 (0.62-1.89)  
Same room 36 (57.1) 0.99 (0.54-1.84)  1.20 (0.52-2.73)  
Same bed 142 (62.3) 1.23 (0.79-1.92)  1.15(0.62-2.14)  
Unknown  219 (63.3) 1.29 (0.85-1.95)  1.07 (0.60-1.93)  
Residence      
Rural  23 (46.9) 1  1  
Urban  1117 (64.2) 2.03 (1.15-3.58) 0.01 2.37 (1.10-5.13) 0.03 
Country      
Zambia 605 (58.3) 1  1  
South Africa 535 (71.1) 1.76 (1.44-2.15) p<0.001 1.93 (1.48-2.51) p<0.001 
1Odds ratios-adjusted for sex, age and community using random effects logistic regression. Missing: sex-6; age-1; education-38; 
socioeconomic-13; smoking habits-3; taken alcohol-11; HIV status-35; sleeping proximity to index-475. 2P value from likelihood 
ratio test. 3 Total actively looking for employment and not looking for employment. 
As a comparison to QFT-GIT, risk factors associated with TST positivity were determined. In 
unadjusted analysis, HIV (OR: 0.74; 95% CI: 0.60–0.92; p=0.008) was negatively associated with 
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TST positivity  whereas  having post-secondary education (OR: 1.76; 95% CI: 1.07-2.89; p=0.10), 
smear status of index (OR: 1.73; 95% CI: 1.21-2.48; p=0.003), residing in an urban area (OR: 2.62; 
95% CI: 1.30-5.28; p=0.007) and country (OR: 1.72; 95% CI: 1.42-2.09; p<0.001) were positively 
associated with TST positivity. TST positivity was also associated with increasing age (aOR for 
each 10 year increase: 1.10; 95% CI 1.02-1.21; p <0.001 for linear trend).  
In multivariable analysis, HIV (aOR: 0.65; 95% CI: 48-0.87; p=0.004) was negatively associated 
with TST positivity whereas smear status of index (OR: 1.44; 95% CI: 1.01-2.05; p=0.04), residing 
in an urban area (aOR: 3.17; 95% CI: 1.14-8.80; p=0.03) and country (aOR: 2.35; 95% CI: 1.71-
3.24; p<0.001) were positively associated with TST positivity. In both unadjusted and 
multivariable analyses, data were consistent with no association of socioeconomic status, 
smoking, alcohol consumption and sleeping proximity to the index case with TST positivity 
(Table 5.3). In addition, there was weak evidence of an association between presence of a BCG 
scar and TST positivity (aOR: 0.83 (0.54-1.27; p=0.38). 
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Table 5.3:  Univariable and multivariable odds ratios showing risk factors associated with 
positive TST results (nmax =1789). 
 TST positive n 
(row %) 
Crude OR  
 (95% CI) 
2P 
value 
Adjusted OR1 
 (95% CI)  
2P value 
Sex      
Female  510(40.3) 1  1  
 Male  198 (38.3) 0.92 (0.74-1.13) 0.44 0.86 (0.65-1.13) 0.27 
Age group (years)      
15-24 253 (36.6) 1 0.10 1 p<0.001 
25-34 184 (40.4) 1.17 (0.92-1.50)  1.25 (0.91-1.72)  
35-44 102 (43.0) 1.31 (0.97-1.76)  1.66(1.12-2.46)  
45-54 87(42.0) 1.25 (0.91-1.72)  1.39(0.92-2.11)  
55-64 55 (48.2) 1.61(1.08-2.40)  2.01(1.18-3.40)  
>65 28 (33.3) 0.86 (0.53-1.40)  1.29(0.70-2.38)  
Highest level of education      
Not attended school 37 (31.9) 1 0.10 1 p<0.001 
Primary school 232 (41.8) 1.53 (1.00-2.35)  1.67 (0.95-2.91)  
Secondary school 357(39.1) 1.37 (0.90-2.07)  1.34 (0.75-2.39)  
College or University 75(45.2) 1.76 (1.07-2.89)  1.28 (0.65-2.54)  
Socioeconomic status      
Dependant 155 (37.4) 1 0.18 1 p<0.001 
3Unemployed  474 (39.3) 1.08( 0.86-1.36)  1.01(0.73-1.39)  
Employed 72 (45.9) 1.41 (0.98-2.05)  1.41(0.86-2.32)  
Smoking habits      
Never smoked 563 (38.5) 1 0.13 1 p<0.001 
Ex-smoker 31(40.8) 1.10 (0.69-1.76)  1.22 (0.66-2.27)  
Occasional smoker 30 (50) 1.59 (0.95-2.67)  1.27 (0.63-2.55)  
Daily smoker 85 (45.0) 1.30 (0.96-1.77)  1.16 (0.75-1.82)  
Alcohol consumption      
No 531(39.7) 1  1  
Yes 174 (39.5) 0.99 (0.79-1.23) 0.92 0.98( 0.72-1.33) 0.88 
HIV status       
Negative 525 (41.5) 1  1  
Positive 169(34.6) 0.74 (0.60-0.92) 0.008 0.65 ( 0.48-0.87) 0.004 
Smear status of the index      
Smear negative 223 (36.5) 1  1  
Smear positive 286 (45.7) 1.73 (1.21-2.48) 0.003 1.44 (1.01-2.05) 0.04 
Sleeping proximity to index      
Different  house 42 (33.9) 1 0.67 1 p<0.001 
Same house 196 (35.4) 1.07 (0.71-1.62)  0.78 (0.45-1.35)  
Same room 20 (31.7) 0.91 (0.47-1.73)  0.96 (0.42-2.21)  
Same bed 91 (39.9) 1.30 (0.82-2.05)  0.81 (0.44-1.49)  
Unknown  127 (36.7) 1.13 (0.73-1.74)  0.74 (0.41-1.34)  
Residence      
Rural  10 (20.4) 1  1  
Urban  699 (40.2) 2.62 (1.30-5.28) 0.007 3.17 (1.14-8.80) 0.03 
Country      
Zambia 354 (34.1) 1    
South Africa 355 (47.2) 1.72 (1.42-2.09) P<0.001 2.35 (1.71-3.24) P<0.001 
1Odds ratios-adjusted for sex, age and community using random effects logistic regression. Missing: sex-6; age-1; education-38; 
socioeconomic-13; smoking habits-3; taken alcohol-11; HIV status-35; sleeping proximity to index-475. 2P value from likelihood 
ratio test. 3Total actively looking for employment and not looking for employment.  
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5.6 Concordance between QFT-GIT and TST results 
To determine the level of agreement or concordance between QFT-GIT and TST results, 1,789 
individuals with valid results for both tests were examined (figure 5.1). Of these, 505 (28.2%) 
were concordantly negative, 565 (31.6%) were concordantly positive, while 719 (40.2%) were 
discordant (p<0.001) at TST ≥ 10 mm. Among TST positive HHCs, 20.3% (144/709) had a negative 
and 79.7% (565/709) a positive QFT-GIT result; whereas among the 1,080 TST negative HHCs, 
46.8% (505/1080) had a negative and 53.2% (575/1080) a positive QFT-GIT result (TST ≥ 10 mm).  
When stratified by HIV status, negative concordance was more common in HIV positives, 39.9% 
(195/489) compared to HIV negatives, 23.9% (303/1,265); positive concordance was more 
common in HIV negatives, 33.2% (420/1,265) compared to HIV positive, 27.2% (133/489); and 
discordance was more common in HIV negative, 42.8% (542/1,265) compared to HIV positive 
HHCs, 32.9% (161/489) (chi2; p<0.001). 
 Overall, there was a low level of agreement (% agreement=59.7%; kappa=0.24) between TST (≥ 
10 mm) and QFT-GIT. Using different cut-off values for the TST did not improve overall test 
agreement (kappa: 0.26, 0.24 and 0.13 for TST cutoffs of 5, 10 and 15 mm respectively). 
However, overall agreement between the two tests was best (64.0%) with a TST cut-off of ≥ 5 
mm and least good (49.2%) with a TST cut-off of ≥ 15 mm. When results were stratified by HIV 
status, agreement appeared slightly better in HIV positive (% agreement =67.1%; kappa 0.35) 
compared to HIV negative (%agreement= 57.1%; kappa 0.19) HHCs at a TST cut-off of ≥ 10 mm 
(Table 5.4).  
Table 5.4: Agreement between QFT-GIT and TST at different cut off levels, stratified by HIV 
status 
 Overall HIV negative HIV positive 
 Agreement 
% 
1Kappa  
(95% CI) 
p- 
value 
Agreement 
 % 
Kappa 
( 95% CI) 
p-
value 
Agreement 
% 
1Kappa  
( 95% CI) 
p-
value 
QFT vs. TST  
5 mm 
64.0 0.26 
(0.22-0.31) 
<0.001 62.9 0.22  
(0.17-0.27) 
<0.001 67.3 0.35  
(0.26-0.43) 
<0.001 
QFT vs. TST 
10 mm 
59.8 0.24 
(0.2-0.28) 
<0.001 57.1 0.19  
(0.15-0.24) 
<0.001 67.1 0.35  
(0.28-0.43) 
<0.001 
QFT vs. TST 
15 mm 
49.2 0.13 
(0.11-0.16) 
<0.001 45.6 0.11  
(0.08-0.14) 
<0.001 58.7 0.20  
(0.14-0.26) 
<0.001 
1Cohen’s k coefficient 
Agreement between QFT-GIT and TST was further analyzed using quantitative QFT-GIT and TST 
results. Overall, there was a weak positive correlation between TB antigen stimulated IFN-γ 
responses and TST indurations (Person’s correlation coefficient=0.30; p<0.001). As the diameter 
of the TST induration increased there was an increase in the total amount of IFN-γ released 
(Figure 5.9). Similarly, there was an increase in the proportion of QFT-GIT positive results with 
increasing TST indurations ranging from 48.5% (369/760) at TST 0 mm, to 84.5% at TST ≥ 15 mm. 
In contrast, there was a decrease in the proportion of  QFT-GIT negative results with increasing 
TST cut-offs ranging from  51.4% (391/760) at TST 0 mm to 15.5% (52/335) at TST ≥ 15 mm. 
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Figure 5.9: IFN-gamma responses at different TST cut offs 
 
There were 719 HHCs with discordant results between the TST and QFT-GIT tests using TST at ≥ 
10 mm. At this cut-off,  QFT+/TST- discordance was found in 80% (575/719) of HHCs while 20% 
(144/719) had QFT-/TST+ discordance (chi2; p<0.001). QFT+/TST- discordance was more 
frequent than QFT-/TST+ discordance regardless of TST cut-off. Using TST at ≥ 5 mm, QFT+/TST- 
discordance was found in 63.5% (409/644) of HHCs while 36.5% (235/644) had QFT-/TST+ 
discordance (chi2; p<0.001). Using TST at ≥15 mm, QFT+/TST- discordance was found in 94.3% 
(857/909) of HHCs while 5.7% (52/909) had QFT-/TST+ discordance (chi2; p<0.001). Therefore as 
shown, QFT+/TST- discordance increased whereas QFT-/TST+ discordance decreased with 
increasing TST cut off points. 
In order to account for key factors that could be responsible for discordant QFT/TST results 
multivariable analysis was performed adjusted for age, sex and household clustering. The 
discordant groups (TST+/IGRA-; TST-/IGRA+) were each compared with a concordant negative 
reference group (TST-/IGRA-). Compared to concordant negative results, QFT+/TST- discordance 
was positively associated with age group 55-64 years (aOR:3.09 (95% CI:1.45-6.61, p=0.003)), 
smear status of the index (aOR:1.45 (95% CI:1.18-1.78, p<0.001) and  country (aOR:2.02 (95% 
CI:1.40-2.92, p<0.001). These results were similar for QFT-/TST+ discordance. However, while 
QFT+/TST- discordance was associated with increasing age (aOR for each 10 year increase: 1.18; 
95% CI: 1.06-1.31; p <0.003 for linear trend) there was weak evidence for QFT-/TST+ 
discordance (aOR for each 10 year increase: 1.14; 95% CI: 0.95-1.37; p=0.15 for linear trend). 
Both types of discordance were negatively associated with HIV status (aOR for QFT+/TST-: 0.38; 
95% CI: 0.26-0.56; p<0.001); aOR for QFT-/TST+: 0.41; 95% CI: 0.22-0.76; p=0.005). For each type 
of discordance, there was no evidence of an association with BCG scar (aOR for QFT+/TST-: 0.81; 
95% CI: 0.49-1.35; p=0.43); aOR for QFT-/TST+: 0.98; 95% CI: 0.45-2.15; p=0.97).  
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Summary 
In Chapter 5 of this thesis, I have presented the baseline results of the QFT study which forms 
the foundation of the survival analysis I will present in the subsequent two chapters. The study 
population at baseline consisted of 1,789 HHCs who were predominantly women (71%) and had 
a median age of 28 years (IQR: 21-43). Overall, the median IFN-γ responses to TB antigens was 
1.1 IU/ml (IQR; 0.1-5.7). The majority of HHCs, 36.1% (646/1789) had IFN-γ responses below 
0.35 IU/ml while 25.7% (459/1789) had IFN-γ responses between 5.5-10 IU/ml. 
 I have shown that as expected in this setting, overall, the prevalence of HIV infection was high 
at 27.9% and that of TBI was 63.7% as detected by QFT-GIT and 39.6% when TST was used. In 
addition, both tests showed that TBI prevalence was higher in SA communities (QFT-GIT: 71.7% 
and TST: 47.2%; p<0.001) compared to the Zambian ones (QFT-GIT: 58.3% and TST: 34.1%; 
p<0.001). 
Both QFT-GIT and TST showed a significantly lower proportion of test positive results in HIV 
positive HHCs (QFT-GIT: 52.8%; TST: 34.6%; p<0.001) compared with HIV negative ones (QFT-
GIT: 67.8% %; TST: 41.5%; p=0.008) regardless of TST cut-off. Similar results were obtained when 
TB antigen stimulated IFN-γ responses were stratified by HIV status (rank-sum; p <0.001). 
 In multivariable analysis adjusted for age, sex and community, HIV positivity (aOR: 0.48; 95% CI: 
0.37–0.63; p<0.001) and being an ex-smoker (aOR:0.56; 95%CI:0.32-1.00; p<0.001) were 
negatively associated with QFT-GIT positivity while residing in an urban area (aOR: 2.37; 95% CI: 
1.10–5.13; p<0.03), smear status of index (OR: 1.34; 95% CI: 1.06-1.69; p=0.01) and country 
(aOR: 1.93; 95% CI: 1.48–2.51; p<0.001) were negatively associated with QFT-GIT positivity. 
Similar results were obtained for TST. As expected, exploration of QFT-GIT (aOR:1.15; 95% CI: 
1.06–1.25; p<0.001) and TST (aOR: 1.10; 95% CI 1.02-1.21; p <0.001) results by age revealed a 
trend to increased responses with increasing age suggesting cumulative exposure to Mtb and an 
increased likelihood of TB infection with age. 
 An assessment of agreement showed that out of 1,789 HHCs, 28.2% were concordantly 
negative, 31.6% were concordantly positive, while 40.2% were discordant (p<0.001) at TST ≥ 10 
mm. There was a low level of agreement between the tests regardless of TST cut-off point (% 
agreement=59.7%; kappa=0.24). QFT+/TST- discordance (575/719; 80%) was more frequent 
than QFT-/TST+ discordance (144/719; 20%) at TST ≥10 mm and this was true of other TST cut-
offs  and regardless of HIV status.  
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6.0 Are IGRAs better than the TST at predicting HHCs at highest risk of 
progression to active TB?  
 
Introduction 
 The aim of this chapter is to assess whether QFT-GIT can predict the development of active TB 
and whether its predictive ability is better than that of the TST in HIV positive and negative 
household contacts. I also report incidence rates of TB in these HHCs for both QFT-GIT and TST, 
stratified by HIV status.  I define QFT-GIT results as a dichotomous exposure using the 
manufacturer definition (TB antigen response ≥0.35 IU/ml above the negative control). While 
incident TB is defined as self-reported TB confirmed in the patient treatment card, in a 
sensitivity analysis I explore other definitions of TB which include smear and culture results. 
 The specific objectives of this chapter are as follows: 
1. To determine the incidence rates of TB in HHCs with positive and negative QFT-GIT and 
TST results, stratified by country and HIV status.   
2. To determine positive and negative predictive values for QFT-GIT and TST 
3. To determine the association between QFT-GIT and TST positivity and the subsequent   
development of TB.  
4. To determine risk factors associated with incident TB. 
5. To conduct a sensitivity analysis exploring three other definitions of TB. 
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6.1 Participants’ Characteristics and Follow-up 
 
A total of 1,789 HHCs were recruited of whom 676 (37.8%) were excluded because they had no 
follow-up data leaving 1,113 (62.2%) HHCs available for this analysis. There were 1,113 HHCs 
available at the second follow-up visit, 18 months from enrolment. At Visit 2 (1st follow-up visit) 
of the study, 84.5% (941/1,113) agreed to continue with study, 7.4% (83/1,113) were absent, 
1.6% (18/1,113) had moved out of the community, 1.7% (19/1,113) refused and 4.7% (52/1,113) 
had missing results. Apart from those who refused, all HHCs remained in the cohort and were 
followed up until visit 3; 36 months from enrolment.  
At visit 3 (2nd follow-up visit), 729 (65.5%) HHCs were still in the cohort while 94 (24.5%) refused 
to continue with the study; 150 (39.1%) had moved out of the community; 112 (29.2%) were 
absent; 22 (5.7%) had died and 6 (1.5%) had missing results. Follow-up of HHCs at the scheduled 
visits is summarized in Figure 6.1. HHCs lost to follow-up were defined as those who were 
absent, had moved out of the community or had died by the time of the final follow-up visit, 
visit 3.  Although 22 HHCs had date of deaths recorded, further analysis was not conducted 
among this group since it was not an outcome. 
Figure 6.1:  Study cohort from enrollment to completion   
 
*At visit 2, HHCs recorded as absent, moved, or those with missing results were followed up. 
Visit 2=1st follow-up visit; Visit 3=2nd follow-up visit 
 
The demographic and clinical characteristics of those who completed the study were compared 
to those who refused, were lost to follow-up and had missing data (Table 6.1). Generally these 
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groups did not differ with respect to demographic and clinical characteristics apart except for 
country (p<0.001).  
Table 6.1: Comparison of HHCs lost to follow up with those completing the study, row % 
(N=1113) 
 Completed study 
(n, row %)  
Refused (n, 
row %)  
Lost to follow up at 
final visit (n, row %)  
Missing results  
(n, row%) 
 p value (chi-square) 
Total 729  94  284  6   
Sex      
 Male  193 (63.5) 28 ( 9.2) 81 (26.6) 2 (0.6)  
Female  534 (66.2) 66 (8.2) 203 (25.1) 4 (0.5) 0.84 
Missing 2     
Age group (years)      
15-25 306 (62.2) 42 (8.5) 142 (28.9) 2 (0.4) 0.29 
26-39 165 (67.6) 17 (7.0) 60 (24.6) 2 (0.8)  
40-87 258 (68.4) 35 (9.3) 82 (21.8) 2( 0.5)  
Highest level of 
education 
     
Not attended school 47 (64.4) 12 (16.4) 13  (17.8) 1 (1.4) 0.14 
Primary school 238 (67.8) 32 (9.1) 81  (23.1) 0 (0)  
Secondary school 356 (64.7) 42 (7.6) 148 (26.9) 4 ( 0.7)  
College or University 73 (64.0) 8 (7.0) 32 (28.1) 1 (0.9)  
Missing 15 (60.0) 0 10  (40.0) 0  
Socioeconomic status      
Dependant 158  (62.4) 24 ( 9.5) 70 (27.7) 1 (0.4) 0.59 
 Unemployed  483 (64.5) 65 (8.7) 196 (26.2) 4 (0.5)  
Employed 82 (79.6) 4  (3.9) 17 (16.5) 0  
Missing 6 (66.7) 1 (11.1) 1 ( 11.1) 1 (11.1)  
Smoking habits      
Never smoked 617 (66.5) 79 (8.5) 227 (24.5) 5 (0.5) 0.39 
Ex-smoker 28  (63.6) 2 (4.5) 14. (31.8) 0  
Occasional smoker 19  (55.9) 2 (5.9) 13 (38.2) 0  
Daily smoker 63 (60.6) 10 ( 9.6) 30 (28.8) 1 (1.0)  
Missing 2 (100)     
Alcohol consumption      
No 549 (66.3) 69 (8.3) 206 (24.9) 4 (0.5)  
Yes 175 (62.9) 25 (9.0) 76 (27.3) 2 (0.7) 0.76 
Missing 5 (71.4) 0 2 (28.6)   
HIV status       
Negative 506 (63.3) 69 (8.6) 219 ( 27.4) 5 (0.6)  
Positive 212 (71.4) 25 (8.4) 59 (19.9) 1 (0.3) 0.06 
Missing 11 (64.7) 0 6 (35.3) 0  
Smear status of the 
index 
     
Smear negative 260 (67.5) 33 (8.6) 90 ( 23.4) 2 (0.5)  
Smear positive 253 (65.2) 28  (7.2) 105 (27.1) 2 (0.5) 0.65 
Missing 216 (63.5) 33 (9.7) 89 (26.2) 2 (0.6)  
TST measured at 
enrolment 
     
<10mm 439 (63.9) 65 ( 9.5)     181 (26.3) 2 (0.3)  
≥10mm 290 (68.1) 29  (6.8) 103  (24.2) 4 (0.9) 0.14 
QFT results measured at 
enrolment 
     
Negative 263 (64.6) 36 (8.8) 105 (25.8) 3 (0.7)  
Positive 466 (66.0) 58 (8.2) 179 (25.3) 3 (0.4) 0.88 
Residence      
Urban 626 (65.7) 80  (8.4) 242 (25.4) 5 (0.5)  
Rural 103 (64.4) 14 (8.7) 42 (26.2) 1 (0.6) 0.99 
Country      
Zambia 501 ( 68.8) 72 (9.9) 155 (21.3) 0  
South Africa 228 (59.2) 22 (5.7) 129 (33.5) 6 (1.6) P<0.001 
Lost to follow-up at final visit; 284=150 moved + 112 absent + 22 died 
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6.2 Summary of incident cases 
 
Out of 1,113 HHCs who entered follow up, there were 51 incident cases. 44.0% (22/51) of 
incident cases were in the age range 26-39 years, 64% (32/51) were HIV positive, 42.5% (17/40; 
11 had missing results) had a history of sleeping in the same bed as the index case, and 52.9% 
(27/51) resided in Zambia.  
 
The total household size (as enumerated regardless of eligibility to the QFT cohort) of the 
incident cases varied from 1-9.  Out of the 51 incident cases, 25 of them had records indicating 
disease site. The majority of incident cases, 88% (22/25) had pulmonary TB, while 12% (3/25) 
had extra-pulmonary disease. Out of those with pulmonary TB, 54.5% (12/22) were smear 
positive, 31.8% (7/22) smear negative and 13.6% (3/22) had missing data. 
The median follow up period for incident cases was 0.99 years (IQR: 0.42-1.65). A description of 
incident cases by socio-demographic and clinical characteristics is shown in Table 6.2.   
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Table 6.2:  Description of incident cases by socio-demographic and clinical characteristics  
 Incident cases (col %) 
Total N=51 
Sex  
 Male  14 (27.4) 
Female  37 (72.5) 
Age group (years)  
15-25 14 (28.0) 
26-39 22 (44.0) 
40-87 14 (28.0) 
Median age (years 29.5 (IQR:25-40) 
Missing 1 
Highest level of education  
Not attended school 3 ( 5.9) 
Primary school 22 (43.1) 
Secondary school 23 (45.1) 
College or University 3 (5.9) 
Socioeconomic status  
Dependant 15 (29.4)  
 Unemployed  32 (62.8) 
Employed 4 (7.8) 
Smoking habits  
Never smoked 37 (72.6) 
Ex-smoker 2 (3.9) 
Occasional smoker 4 (7.8) 
Daily smoker 8 (15.7) 
Alcohol consumption  
No 35 ( 68.6) 
Yes 16 (31.4) 
HIV status   
Negative 18 (36.0 ) 
Positive 32 (64.0) 
Missing 1 
Smear status of the index  
Smear negative 15 (36.6) 
Smear positive 26 (63.4) 
Missing 10 
Sleeping proximity to index  
Different  house 4 (10.0) 
Same house 13 (32.5) 
Same room 2 (5.0) 
Same bed 17 (42.5) 
Unknown  4 (10.0) 
Missing 11 
Residence  
Urban  47 (92.2) 
Rural  4 (7.8) 
Country  
Zambia 27 ( 52.9) 
South Africa 24 (47.1) 
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6.3 TB incidence rates stratified by baseline QFT-GIT and TST results 
 
 Out of the 1,113 HHC s that entered follow-up, 51 (4.6%) HHCs developed active TB (incident 
cases) over 2,433 person-years (pyrs) of follow-up, giving an incidence rate of 20.96/1000 pyrs.  
The median follow-up time was 2.43 years (IQR: 1.53-2.79).  
Of the incident cases, approximately half, 52.9% (27/51) developed TB within a year of being 
enrolled into the study, 29.4% (15/51) between 1-1.9 years, 13.7% (7/51) between 2-2.9 years 
and 3.9% (2/51) between 3-4 years. 
 
Out of 707 HHCs with QFT-GIT positive results at baseline, 38 developed active TB over 1555.3 
pyrs of follow-up (incidence rate, 24.43 per 1000 pyrs). Out of 406 HHCs with QFT-GIT negative 
results at baseline, 13 developed active TB over 877.9 pyrs of follow-up (incidence rate, 14.81 
per 1000 pyrs).  Therefore, 74.5% (38/51) and 25.5% (13/51) of incident cases were QFT-GIT 
positive and negative at baseline respectively.  
The (Incidence rate ratio (IRR) among incident cases with positive QFT-GIT results was 1.65 (95% 
CI 0.86-3.37; p=0.06) compared to those with negative results (Table 6.3). 
Table 6.3:  Overall incidence rate ratios (nmax=1113). All TB cases (n=51). 
Variable n (col %) 
 
 TB cases/1pyrs Incidence rate/ 
1000 pyrs (95% CI) 
Incidence rate ratio 
(95% CI) 
P value 
Overall N=1113 51/2433 20.96 (15.93-27.58)    
QFT-GIT  (>=0.35 IU/ml)      
Negative 406 13/877.9 14.81 (8.60-25.50) 1  
Positive 707 38/1555.3  24.43 (17.78-33.58) 1.65 (0.86-3.37) 0.06 
TST ( >=10 mm)      
Negative 687 23/1476.0 15.58 (10.35-23.45) 1  
Positive 426 28/957.2 29.25 (20.20-42.36) 1.88 (1.04-3.41) 0.01 
TST (mm) responses      
< 5  529 19/1128.7 16.83 (10.74-26.39) 1  0.03 
5-9 158 4/347.3 11.52 (4.32-30.69) 0.68 (0.17-2.06)  
10-14 231 12/507.7 23.63 (13.42-41.62) 1.40 (0.62-3.05)  
≥ 15 195 16/449.5 35.59 (21.80-58.10) 2.11 (1.02-4.34)  
Concordance in TST and 
QFT-GIT results 
(N=1113) 
     
 QFT -/TST - 323 10/693.2 14.42 (7.76-26.81) 1 0.04 
 QFT -/ TST+ 84 3/184.7 16.24 (5.24-50.36) 1.13 (0.20-4.37)  
QFT +/ TST - 364 13/782.8 16.61 (9.64-28.60) 1.15 (0.47-2.93)  
QFT +/ TST + 342 25/772.5 32.36 (21.87-47.89) 2.24 (1.04-5.23)  
1pyrs =person-years; 2TST (10 mm).   
 Out of 426 HHCs with TST positive results at baseline, 28 developed active TB over 957.2 pyrs of 
follow-up (incidence rate, 29.25 per 1000 pyrs). Out of 687 HHCs with TST negative results at 
baseline, 23 developed active TB over 1476 pyrs of follow-up (incidence rate, 15.58 per 1000 
pyrs). Therefore, 54.90% (28/51) and 45.01% (23/51) of incident cases were TST positive and 
negative at baseline respectively. 
The IRR among incident cases with TST positive results was 1.88 (95% CI 1.04-3.41; p=0.01) 
compared to those with negative results (table 6.3). 
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 For TST, IRRs were  2.11  (95% CI: 1.02-4.34 ), 1.40 ( 95%CI: 0.62-3.05) and 0.68 (0.17-2.06) in 
HHCs with responses greater or equal to 15 mm, 10-14 mm,  and 5-9 mm respectively compared 
to those less than 5 mm (table 6.3).  
The incidence rate was highest among HHCs with concordant positive results compared to those 
with concordant negative results (IRR: 2.24, 95% CI: 1.04-5.23) (table 6.3). The incident rates 
among discordant pairs were comparable to each other (table 6.3).   
6.4 Descriptive survival analysis 
Kaplan-Meier was used to estimate TB-free survival probability as a function of time from entry 
into the study. Overall, the 4-year TB-free survival proportion (HHCs who did not develop TB at a 
given time) rate was 0.92 (95% CI: 87.5-94.8).TB-free survival proportion was lower in QFT-GIT 
positives, 0.90 (95%CI: 0.83-0.94) compared to QFT-GIT negatives, 0.95 (95%CI: 0.92-0.97). All 
incident cases developed TB before the median survival time (time with probability of survival 
equal to 0.5). 
Kaplan Meier curves showing TB-free survival probabilities according to baseline QFT-GIT and 
TST results are shown in Figure 6.2. 
Figure 6.2:  Kaplan Meier curves showing probability of remaining TB-free according to 
baseline QFT and TST results  
 
For both QFT-GIT and TST, the TB-free survival probability was lower among test-positive 
individuals compared test- negative ones. There was some evidence that survival curves differed 
between those who were tested positive and negative for TST (log-rank test, p=0.02) but not for 
QFT-GIT (log-rank test, p=0.11).  
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6.5 The Proportional Hazard Assumption (PHA) in the Cox model 
 
 The Kaplan-Meier curves presented in Figure 6.3 showed that the proportional hazard 
assumption was met for both tests since there was an increasing difference between the two 
curves and the two curves did not cross. Furthermore, using log-minus-log survival plot (plots of 
Schoenfeld residuals) to test the proportional hazard assumption showed that the assumption 
was largely met since the curves for both tests were approximately linear.  
 Figure 6.3:  Assessing the proportional hazards assumption: "log-log" plots 
 
The proportional-hazards assumption is not violated when the curves are parallel. 
Testing PHA by using the interaction test suggested no evidence against proportionality (LRT: 
p=0.70). The likelihood ratio test also showed no evidence that the effects of QFT-GIT (LRT: 
p=0.29) and TST (LRT: p=0.74) within time bands was not constant (time an effect modifier).  
6.6 Risk factors for the development of TB  
 
Incidence rates, unadjusted and adjusted analysis of the relationship between risk factors and 
TB incidence is shown in Table 6.4. 
 In unadjusted analysis , there was evidence that being  between  26-39 years of age (HR:2.31; 
95%CI: 1.18-4.52; p=0.04) HIV positivity (HR: 4.68; 95%CI: 2.62-8.35, p<0.001); smear status of 
the index  (HR: 1.74; 95%CI: 0.92-3.28; p=0.09); sleeping in the same room and same bed as 
index (HR:1.88 ; 95%CI:0.64-5.53; p=0.02) and country ( HR: 1.55; 95%CI:0.90-2.67; p=0.04) were 
associated with an increased risk of TB (table 6.4).  
In multivariable analyses, adjusted for age, sex , HIV status and country there was evidence that  
occasional smoking, (HR: 4.07; 95%CI:1.31-12.63), HIV positivity (HR: 4.60; 95%CI:2.48-8.56), 
smear  positivity of the index (HR: 2.00 ; 95%CI:1.04-3.87)  and country (HR: 1.79 ; 95%1.02-3.15; 
p=0.04) ) were associated with incidence of TB.  
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 Data were consistent with no association of sex, education, socioeconomic status, residence, 
and sleeping proximity with increased risk of TB (Table 6.4).  
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Table 6.4:  TB incidence rates and hazard ratios stratified by baseline socio-demographic and 
clinical characteristics  
 N (col %) 
N=1113 
 TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR (95% 
CI) 
P value  aHR (95% CI) P value  
Sex         
Male 304 (27.4%) 14/653.3 21.43 (12.69-36.18) 1  1  
Female 807 (72.6%) 37/1773.7 20.86 (15.11-28.79) 0.97 (0.53-1.80) 0.93 0.71 (0.38-1.34) 0.29 
Age group (years)        
15-25 492 (44.2) 14/983.4 14.23 (8.43-24.04 1 0.04 1 p<0.001 
26-39 244 (21.9) 22/665.4 33.06 (21.77-50.21 2.31 (1.18-4.52)  1.46 (0.72-2.93)  
40-87 377 (33.9) 14/770.9 18.16 (10.76-30.66 1.29 (0.61-2.70)  1.35 (0.64-2.85)  
Highest level of education        
Not attended school 73 (6.7) 3/155.3 19.31 (6.23-59.88) 1 0.41 1 p<0.001 
Primary school 351 (32.3) 22/778.1 28.27 (18.62-42.94) 1.46 ( 0.44-4.89)  1.66 (0.39-7.13)  
Secondary school 550 (50.5) 23/1202.1 19.13 (12.71-28.79) 1.00 (0.30-3.33)  1.20 (0.27-5.34)  
College or University 114 (10.5) 3/246.1 12.19 (3.93-37.80) 0.64 ( 0.13-3.16)  0.74 (0.12-4.53)  
Socioeconomic status        
Dependant 253 (22.9) 15/538.4 27.86 (16.79-46.21) 1 0.48 1 p<0.001 
Unemployed  748 (67.7) 32/1638.4 19.53 (13.81-27.62) 0.70 (0.38-1.30)  0.76 (0.39-1.49)  
Employed 103 (9.3) 4/236.4 16.92 (6.35-45.09) 0.62 (0.20-1.87)  0.83 (0.23-3.00)  
Smoking habits        
Never smoked 928 (83.4) 37/2039.2 18.14 (13.15-25.04) 1 0.11 1 p<0.001 
Ex-smoker 44 (4.0) 2/99.4 20.12 (5.03-80.47) 1.10 (0.26-4.57)  0.79 (0.17-3.55)  
Occasional smoker 34 (3.1) 4/63.4 63.11 (23.69-
168.15) 
3.41 (1.22-9.59)  4.07 (1.31-12.63)  
Daily smoker 104 (9.4) 8/224.5 35.63 (17.82-71.25) 1.93 (0.90-4.16)  1.87 (0.77-4.56)  
Alcohol consumption        
No 828 (74.9) 35/1823.3 19.20 (13.78-26.74) 1  1  
Yes 278 (25.1) 16/594.5 26.91 (16.49-43.93) 1.39 (0.77-2.52) 0.27 1.31 (0.69-2.46) 0.41 
HIV status         
Negative 799 (72.9) 18/1741.4 10.34 (6.51-16.40) 1  1  
Positive 297 (27.1) 32/655.0 48.86 (34.55-69.09) 4.68 (2.62-8.35) P<0.001 4.60 (2.48-8.56) p<0.001 
Smear status of the index        
Smear negative 385 (49.8) 15/846.1 17.73 (10.69-29.41) 1  1  
Smear positive 388 (50.2) 26/836.9 31.07 (21.15-45.63) 1.74 (0.92-3.28) 0.09 2.00 (1.04-3.87) 0.04 
Sleeping proximity to index        
Different  house 98 (12.10) 4/202.4 19.76 (7.42-52.65) 1 0.02 1 P<0.001 
Same house 470 (58.02) 13/987.3 13.17 (7.64-22.68) 0.68 (0.22-2.08)  0.52 (0.16-1.68)  
Same room and same bed  242 (29.88) 19/520.6 36.49 (23.28-57.21) 1.88 (0.64-5.53)  1.10 (0.36-3.35)  
Residence        
Rural  160 (14.4) 4/327.7 12.20 (4.58-32.52) 1  1  
Urban  953 (85.6) 47/2105.5 22.32 (16.77-29.71) 1.81 (0.65-5.03) 0.26  1.78 (0.63-5.04) 0.28 
Country        
Zambia 728 (65.4) 27/1550.0 17.42 (11.95-25.40) 1  1  
South Africa 385 (34.6) 24/883.2 27.17 (18.21-40.54) 1.55 (0.90-2.67) 0.11 1.79 (1.02-3.15) 0.04 
P value from likelihood test if > 2 sub-groups.  Missing: sex-2; age-1; education-25; socioeconomic-9; smoking habits-3; taken alcohol-7; HIV status-17; 
index smear-340; sleeping proximity to index-152. 1aHR: adjusted for age, sex, HIV and country  
HIV was an important risk factor for the development of TB. Figure 6.4 shows the Nelson-Aalen 
cumulative hazard estimate of TB incidence, by HIV status.  
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Figure 6.4:  Nelson-Aalen cumulative hazard estimate of TB incidence, by HIV status.  
 
 
Confounders and effect modifiers for the association between QFT-GIT positivity and TB 
incidence 
Identification of confounders 
HIV was an important confounder in the association between QFT-GIT positivity and TB 
incidence while age and sex were considered as priori confounders. There was no evidence that 
socioeconomic status, smoking habits, smear status of the index and sleeping proximity to the 
index were important confounders. 
 
Identification of effect modifiers using likelihood ratio test 
There was weak evidence that educational status (p=0.08 for interaction), smear status of the 
index (p=0.10) and HIV status (p=0.40) were effect modifiers. Country was considered as an 
important effect modifier (p=0.001). The rest of the risk factors showed no evidence of effect 
modification with the QFT-GIT positivity. 
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6.7 Overall univariable and multivariable analysis of the association between test positivity 
and TB incidence. 
 
Four regression models were used in the univariable and multivariable analysis and results for 
each model are shown in Table 6.5 as follows: 
Table 6.5:  Overall univariable and multivariable analysis of the association between test 
results, and TB incidence. 
 QFT-GIT results TST results 
Test result 
 
Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value 
Model 1     
Negative 1 0.11 1  
Positive 1.66 (0.88-3.11)  1.89 (1.09-3.28) 0.02 
Model 2     
Negative 1  1  
Positive 1.60 (0.85-3.02) 0.15 1.82 (1.04-3.17) 0.03 
Model 3     
Negative 1  1  
Positive 2.20 (1.14-4.25) 0.02 2.19 (1.24-3.86) 0.007 
Model 4     
Negative 1  1  
Positive 6.38 (1.90-21.30) 0.003 2.32 (1.07-5.04) 0.03 
Model 1: Unadjusted analysis 
Model 2: Adjusted for age and sex as priori confounders. 
Model 3: Adjusted for age and sex and HIV 
Model 4: as in model 3 plus country as an effect modifier (adjusting for household clustering not included because it does not 
change results) (see results presented by country in next section). 
 
In univariable analysis, the HR showing the association between QFT-GIT positivity and risk of TB 
was 1.66 (95%CI: 0.88-3.11; P=0.01). When results were adjusted for age and sex as priori 
confounders, HR was similar to the unadjusted one (table 6.5). In multivariable analysis, 
adjusted for sex, age and HIV (model 3), the adjusted HR was 2.20 (1.14-4.25; p=0.02). In model 
4, the adjusted HR was 6.38 (95%CI: 1.90-21.30; p=0.003) after results were adjusted for sex, 
age, HIV plus an interaction between QFT-GIT positivity and country (p for interaction=0.001).   
For TST, the HR remained similar across all models. In all models, there was strong evidence that 
TST positive HHCs had a two-fold increased risk of developing TB (table 6.5). 
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6.8 Analysis by Country 
 
Incidence rates by country 
 
Because there was interaction between country and QFT-GIT positivity (table 6.5), results were 
also reported separately by country. 
6.8.1 Incidence rates in Zambia 
 
 Overall, 27 HHCs developed active TB over 1550 pyrs of follow-up, giving an incidence rate of 
17.42/1000 pyrs (95%CI: 11.95- 25.40) for HHCs residing in Zambia. The median follow-up time 
was 2.44 years (IQR: 1.26-2.76).   
 Out of 412 HHCs with QFT-GIT positive results, 24 developed active TB over 936.2 pyrs of 
follow-up (incidence rate, 25.64 per 1000 pyrs). Out of 289 HHCs with QFT-GIT negative results, 
3 developed active TB over 613.8 pyrs of follow-up (incidence rate, 4.89 per 1000 pyrs).  
Therefore, 88.89% (24/27) and 11.11% (3/27) of incident cases were QFT-GIT positive and 
negative at baseline respectively.   
The IRR among QFT-GIT positive HHCs was 5.24; (95% CI: 1.59-27.21; p=0.0007) compared to 
QFT-GIT negative ones (table 6.6).  
Table 6.6:  Zambia: Incidence rates and incidence rate ratios stratified by test (nmax=728). All 
TB cases (n=27) 
Variable n (col %) 
 
 TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Incidence rate  
ratio (95% CI) 
P value 
Overall N=728 27/1550 17.42 ( 11.95- 25.40)   
QFT  (>=0.35 IU/ml)      
Negative 289 3/613.8 4.89 (1.58-15.15) 1  
Positive 412 24/936.2 25.64 (17.18-38.25) 5.24 (1.59-27.21) 0.0007 
TST (10 mm)      
Negative 459 12/979.3 12.25 (6.96-21.58 1 0.02 
Positive 242 15/570.7 26.28 (15.84-43.60 2.14 (0.94-5.02)  
TST (mm) responses      
< 5  360 11/737.2 14.92 (8.26-26.94) 1  0.02 
5-9 111 1/242.1 4.13 (0.58-29.33) 0.28 (0.006-1.90)  
10-14 152 6/327.0 18.35 (8.24-40.84) 1.23 (0.37-3.63)  
≥ 15 105 9/243.7 36.93 (19.21-70.97) 2.47 (0.91-6.57)  
2Concordant results 
(N=728) 
     
 QFT -/TST - 239 3/503.3 5.96 (1.92-18.48) 1 0.08 
 QFT -/ TST+ 50 0/110.6 0 0 (0-11.01)  
QFT +/ TST - 220 9/476.0  18.91 (9.84-36.34) 3.17 (0.79-18.22)  
QFT +/ TST + 192 15/460.2 32.60 (19.65-54.07) 5.47 (1.55-29.47)  
  2TST (10 mm) and QFT-GIT results.   
For TST, 55.55% (15/27) and 44.44% (12/27) of incident cases were TST positive and negative at 
baseline respectively. At the standard TST cut off (10 mm), the IRR among TST positive HHCs was 
2.14 (95% CI: 0.94-5.02). For other  TST cut-offs in Zambia, IRRs were  0.28  (95% CI: 0.15-0.59 ), 
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1.23 ( 95%CI: 0.82-1.82) and 2.47 (1.80-3.26) (p=0.02) in HHCs  for  5-9 mm, 10-14mm, greater 
or equal to 15 mm respectively compared to those less than 5 mm (table 6.6).   
6.8.2 Incidence rates in SA 
 
24 HHCs developed active TB over 883.2 pyrs of follow-up, giving an incidence rate of 
27.17/1000 pyrs (95%CI: 18.21-40.54) for HHCs residing in SA. The median follow-up time was 
2.41 years (IQR: 1.76-2.87).   
 Out of 256 HHCs with QFT-GIT positive results, 14 developed active TB over 619.1 pyrs of 
follow-up (incidence rate, 22.61 per 1000 pyrs).  Of 105 HHCs with QFT negative results, 10 
developed active TB over 264.1 pyrs of follow-up (incidence rate, 37.86 per 1000 pyrs). The IRR 
among HHCs with QFT-GIT positive results was 0.60; (95% CI: 0.25-1.50; p=0.11) compared to 
those with negative results (Table 6.7). 
Table 6.7:  South Africa: Incidence rates and incidence rate ratios stratified by test 
(nmax=358). All TB cases (n=24). 
Variable n (col %) 
N=361 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
Incidence rate ratio 
(95% CI) 
P value 
Overall N=361 24/883.2 27.17 (18.21-40.54)   
QFT  (>=0.35 IU/ml)      
Negative 105 10/264.1 37.86 (20.37-70.37) 1  
Positive 256 14/619.1 22.61 (13.39-38.18) 0.60 (0.25-1.50) 0.11 
TST (10 mm)      
Negative 205 11/496.7 22.14 (12.26-39.99) 1  
Positive 156 13/386.5 33.63 (19.53-57.92) 1.52 (0.63-3.74) 0.15 
TST (mm) responses      
< 5  169 8/391.5 20.43 (10.21-40.86) 1  0.74 
5-9 47 3/105.2 28.51 (9.20-88.41) 1.39 (0.24-5.81)  
10-14 79 6/180.7  33.20 (14.91-73.90) 1.62 (0.46-5.34)  
≥ 15 90 7/205.8  34.01 (16.22-71.35) 1.66 (0.51-5.25)  
2Concordant results 
(N=385) 
     
 QFT -/TST - 74 7/190.0 36.85 (17.57-77.30 1 0.38 
QFT +/ TST + 125 10/312.4 32.01 (17.23-59.50 0.87 (0.30-2.69)  
 QFT -/ TST+ 31 3/74.1 40.46 (13.05-125.44) 1.10 (0.18-4.81)  
QFT +/ TST - 131 4/306.8 13.04 (4.89-34.74) 0.35 (0.07-1.39)  
 
For TST, the IRR among TST positive HHCs was 1.52 (95% CI: 0.63-3.74) in comparison to those 
who were negative (Table 6.7). Furthermore, IRRs were  1.39  (95% CI: 0.99-1.92 ), 1.62 ( 95%CI: 
1.19-2.21) and 1.66 (1.23-2.27) (p=0.74) in HHCs  for 5-9 mm, 10-14mm, greater or equal to 15 
mm respectively compared to those less than 5 mm (table 6.7). 
6.8.2. Zambia: Univariable and multivariable analysis of the association between test 
positivity and TB incidence 
Three regression models were used in the univariable and multivariable analysis and results for 
each model are shown in table 6.8: 
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Table 6.8:  Zambia: Univariable and multivariable analysis of the association between test 
results, and TB incidence. 
 QFT-GIT results TST results 
 Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value 
Model 1     
Negative 1  1  
Positive 5.29 (1.59-17.56) 0.007 2.15 (1.00-4.60) 0.05 
Model 2     
Negative 1  1  
Positive 5.07 (1.52-16.94) 0.008 2.00 (0.92-4.33) 0.08 
Model 3     
Negative 1  1  
Positive 6.57 (1.96-22.06) 0.002 2.37 (1.08-5.19) 0.03 
Model 1: Unadjusted analysis 
Model 2: Adjusted for age and sex as priori confounders. 
Model 3: Adjusted for age and sex and HIV 
 
In univariable analysis, the HR showing the association between QFT-GIT positivity and risk of TB 
was 5.29 (95%CI: 1.59-17.56; P=0.007). When results were adjusted for age and sex as priori 
confounders, HR was similar to the unadjusted one (table 6.8). In multivariable analysis, 
adjusted for sex, age and HIV (model 3), the adjusted HR was 6.57 (95%CI: 1.96-22.06; P=0.002).  
For TST, the HR remained similar across all models; as in the overall results (table 6.8). In all 
models, there was some evidence that TST positive HHCs had a two-fold increased risk of 
developing TB, similar to the overall findings. 
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6.8.3 South Africa: Univariable and multivariable analysis of the association between test 
positivity and TB incidence 
 
Three regression models were used in the univariable and multivariable analysis and results for 
each model are shown in table 6.9 as follows: 
Table 6.9:  South Africa: Univariable and multivariable analysis of the association between test 
results, and TB incidence. 
 QFT-GIT results TST results 
 Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value 
Model 1     
Negative 1  1  
Positive 0.60 (0.26-1.34) 0.21 1.57 (0.70-3.50) 0.27 
Model 2     
Negative 1  1  
Positive 0.58 (0.25-1.30) 0.19 1.52 (0.68-3.39) 0.31 
Model 3     
Negative 1  1  
Positive 0.84 (0.36-1.99) 0.70 1.98 (0.86-4.53) 0.10 
Model 1: Unadjusted analysis 
Model 2: Adjusted for age and sex as priori confounders. 
Model 3: Adjusted for age and sex and HIV 
 
The crude HR showing the association between QFT-GIT positivity and risk of TB for HHCs 
residing in SA was 0.60 (95% CI: 0.26-1.34; p=0.21). When results were adjusted for age and sex 
as priori confounders, HR was similar to the unadjusted one (table 6.9). In multivariable analysis, 
adjusted for sex, age and HIV (model 3), the adjusted HR was 0.84 (95%CI: 0.36-1.99; P=0.70) 
(table 6.9).  
For TST results in SA, the HR remained similar across all models, similar to the overall results and 
results for Zambia. In all models, there was strong evidence that TST positive HHCs had a two-
fold increased risk of developing TB, although results were not statistically significant. 
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6.9 Analysis by HIV Status 
 
Effect of test results on TB incidence, stratified by HIV status 
 
Kaplan Meier curves stratified by test results and HIV status are shown in figure 6.5. For HIV 
negative HHCs, there was strong evidence that the Kaplan-Meier survival curves differed 
between QFT-GIT positive and negatives (log rank test, p=0.05) but not for TST (log rank test, 
p=0.09) (Figure 6.5). For HIV positive HHCs, there was strong evidence that the survival curves 
differed for TST (log rank test, p=0.01) but evidence was modest for QFT-GIT (log rank test, 
p=0.08). 
 
Overall, the 4-year TB-free survival proportion was lower in HIV positive HHCs, 0.86 (95%CI: 
81.05-90.37) compared to HIV negatives, 0.94 (95%CI: 0.86-0.97) ones. 
 
 In both HIV negatives and positives TB-free survival proportion was lower in test positives HHCs 
compared to negative ones. In HIV negatives, TB-free survival proportion was 0.91 (95% CI: 0. 
80-0.96) in QFT-GIT positives while it was 0.99 (95%CI: 0.96-0.99) in QFT-GIT negatives. Among 
HIV positive HHCs, TB-free survival proportion was 0.84 (95%CI: 0.76-0.89) in QFT-GIT positives 
while it was 0.90 (95%CI: 0.81-0.94) in QFT-GIT negatives. Results were similar for TST (Figure 
6.5) 
Figure 6.5:  Kaplan Meier curves of TB-free survival probability according to baseline test 
results and stratified by HIV  
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The overall incidence rate among HIV negatives was 10.34 (18 cases/1741.4 pyrs) while for HIV 
positives it was 48.86 (32 cases/655 pyrs) per 1000 pyrs. Overall for QFT-GIT, the IRR was higher 
among HIV negative HHCs (IRR: 3.85; 95%CI: 0.90-34.51; p=0.07) compared to HIV positives (IRR; 
1.93; 95%CI: 0.88-4.57; p=0.04). Overall for TST, the IRR for HIV negatives (IRR: 2.21; 95%CI: 
0.78-6.72; p=0.05) was similar to that among HIV positives (IRR: 2.32; 95%CI: 1.09-5.00; 
p=0.009).  
Table 6.10:  Overall incidence rates, univariable and multivariable analysis of time to TB 
episode, stratified by HIV status (nmax=1113) All TB cases (n=51). 
 Total  TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR (95% 
CI) 
P value 1Adjusted  
HR (95% CI) 
P value 
HIV negatives 
Overall 799 18/1741.4 10.34 (6.13-16.34)     
QFT        
Negative 265 2/565.7 3.53 (0.88-14.14) 1  1  
Positive 534 16/1175.7 13.61 (8.34-22.21) 3.88 (0.89-6.92) 0.07 2N/A P<0.001 
TST (10 
mm) 
       
Negative 480 7/ 1017.3 6.88 (3.28- 14.43 1  1  
Positive 319 11/ 724.1 15.19 (8.41-27.43) 2.21 (0.86-5.72) 0.10 3.02 (0.75-12.10) 0.12 
HIV  positives 
Overall 297 32/655.0 48.86 (33.42-68.97)     
QFT          
Negative 138 10/306.2 32.66 (17.57-60.70) 1  1  
Positive 159 22/348.8 63.08 (41.53-95.80) 1.93 (0.91-4.07) 0.08 4.72 (1.35-16.46) 0.01 
TST (10 
mm) 
       
Negative 198 15/440.2 34.07 (20.54-56.52) 1  1  
Positive 99 17/214.7 79.17 (49.22-127.36) 2.32 (1.16-4.65) 0.02 2.13 (0.81-5.60) 0.12 
1Adjusted for age, sex, and country as effect modifier (p value for interaction=0.5) 2HR very large because all HIV negative QFT-GIT 
negative cases in SA.  
In multivariable analysis adjusted for age, sex and country as an effect modifier, the HR for 
developing TB in HIV negative QFT-GIT positive was very large and  clinically insignificant  (all 
incident cases in this group were from SA) while in HIV positives QFT-GIT positives, the HR was 
4.72 (95%CI: 1.35-16.46; p=0.01). There was therefore strong evidence of a five-fold increased 
risk of TB in HIV positive QFT-GIT positive HHCs compared to HIV positive QFT-GIT negative ones 
(table 6.10).  
 For TST, in multivariable analysis adjusted for age, sex and country as an effect modifier, the HR 
in HIV negative TST positive HHCs was 3.02 (95% CI: 0.75-12.10; p=0.12) while it was 2.13 
(95%CI: 0.81-5.60; p=0.12) in HIV positives TST positive. 
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Effect of test results on TB incidence by country, stratified by HIV status  
Zambia 
For HHCs residing in Zambia, the IRR was 5.12 (95%CI: 1.45-27.57; p=0.002) in HIV positives 
while it was 0 among HIV negative for QFT-GIT (no one developed TB among the HIV negative 
QFT-GIT negative group). For TST, the IRR among HIV negatives was higher (IRR: 3.03; 95%CI: 
0.65-18.72; p=0.06) than that of HIV positives (IRR: 2.36; 95%CI: 0.83-6.71; p=0.04).  
 For QFT-GIT, in multivariable analysis adjusted for age and sex, there was strong evidence of a 
five-fold increased risk of TB in HIV positives (aHR: 4.77; 95%CI: 1.36-16.66; p=0.01), as in the 
overall analyses (table 6.10).  
 For TST, in multivariable analysis adjusted for age and sex, the HR in HIV negative HHCs was 
3.02 (95% CI: 0.75-12.09; p=0.12) while it was 2.21 (95%CI: 0.84-5.85; p=0.11) in HIV positives 
(table 6.11). 
Table 6.11:  Zambia: Univariable and multivariable analysis of time to TB episode; stratified by 
HIV status (nmax=728) All TB cases (n=27). 
Variable Total  TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR  
(95% CI) 
P value 2Adjusted  
HR (95% CI) 
P 
value 
HIV 
negatives 
       
QFT        
Negative 187 0/383.6 0 1  1  
Positive 327 9/696.5 12.92 (6.72-24.83) 0 (0-0.92)   2 N/A  
TST (10 mm)        
Negative 321 3/650.6 4.61 (1.49-14.30) 1  1  
Positive 193 6/429.5 13.97 (6.27-31.09) 3.06 (0.76-12.27) 0.11 3.02 (0.75-12.09) 0.12 
HIV  positives        
QFT          
Negative 103 3/226.8 13.23 (4.27-41.01) 1  1  
Positive 102 15/221.6 67.69 (40.80-112.27) 5.03  (1.46-17.38) 0.01 4.77 (1.36-16.66) 0.01 
TST (10 mm)        
Negative 144 9/314.9 28.58 (14.87-54.92) 1  1  
Positive 61 9/133.5 67.43 (35.08-129.60) 2.36 (0.94-5.95) 0.07 2.21 (0.84-5.85) 0.11 
2 No one developed TB in the HIV negative QFT negative group. 2HR very large as all HIV negative QFT-GIT negative cases in SA.   
South Africa 
For test positive HHCs residing in SA, the IRR was 0.62 (95%CI: 0.19-2.09; p=0.19) in HIV positives 
while it was 1.33 (95%CI: 0.25-13.12; p=0.39) among HIV negative for QFT-GIT. For TST, the IRR 
was 1.55 (0.33-7.84; p=0.26) among HIV negatives compared to 2.06 (0.62-7.19; p=0.09) among 
HIV positives. Crude HRs were similar to the IRR (Table 6.12). 
For QFT-GIT, in multivariable analysis adjusted for age and sex, there was no evidence of an 
increased risk of TB in HIV negatives (aHR: 1.09; 95%CI: 0.22-5.38; p=0.91), while in HIV positives 
adjusted HR was 0.67 (95%CI: 0.23-1.96; P=0.47). 
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 For TST, in multivariable analysis adjusted for age and sex, the HR in HIV negative HHCs was 
1.46 (95% CI: 0.39-5.52; p=0.57) while it was 2.16 (95%CI: 0.74-6.32; p=0.16) in HIV positives 
(Table 6.12). 
Table 6.12:  South Africa: Univariable and multivariable analysis of time to TB episode; 
stratified by HIV status (nmax=385) All TB cases (n=24). 
Variable Total  TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR 
 (95% CI) 
P 
value 
1Adjusted  
HR (95% CI) 
P 
value 
HIV negatives 
QFT        
Negative 78 2/182.1 10.99 (2.75-43.93) 1  1  
Positive 207 7/479.2 14.61 (6.96-30.64) 1.35 (0.28-6.50) 0.71 1.09(0.22-5.38) 0.91 
TST (10 
mm) 
       
Negative 159 4/366.7 10.91 (4.09-29.06) 1  1  
Positive 126 5/294.6 16.97(7.06-40.78) 1.63 (0.44-6.09) 0.47 1.46 (0.39-5.52) 0.57 
HIV  
positives 
       
QFT          
Negative 35 7/79.4 88.14 (42.02-184.88) 1  1  
Positive 57 7/127.1 55.05 (26.25-115-48) 0.64 (0.22-1.83) 0.41 0.67 (0.23-1.96) 0.47 
TST (10 
mm) 
       
Negative 54 6/125.3 47.88 (21.51-106.57) 1  1  
Positive 38 8/81.2 98.46 (49.24-196.89) 2.06 (0.71-5.94) 0.18 2.16 (0.74-6.32) 0.16 
1Adjusted for sex and age  
6.10 Positive and Negative Predictive Values 
 
Overall, the PPV for QFT-GIT was 5.38% (95%CI: 3.84-7.31), this was slightly lower than that of 
TST, 6.57% (95% CI: 4.41- 9.36) even when results were stratified by country (Table 6.13) 
especially for SA. In addition, overall both tests had comparable NPV estimated at 97% (Table 
6.13). Overall PPV and NPV by country are shown in table 6.13.   
 Table 6.13:  Negative and Positive values by test and country 
 Overall Zambia SA 
QFT-GIT    
PPV % (95%CI) 5.38  (3.84-7.31) 5.50 (3.56-8.08) 5.19 (2.86-8.55) 
NPV % (95%CI) 96.81 (94.60-98.29)  98.97 (97.03 -99.79) 91.30 (84.59-95.75) 
TST    
PPV % (95%CI) 6.57 (4.41- 9.36) 5.84 (3.30-9.44) 7.69 (4.16-12.79) 
NPV% (95%CI) 96.65 (95.02-97.87) 97.40 (95.59-98.68) 94.91 (91.07- 97.43) 
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Positive and negative predictive values, stratified by HIV status 
Overall, among HIV negatives, the PPV and NPV of QFT-GIT was comparable to that of TST (Table 
6.14).  
Overall, in HIV positives, while the NPV of both tests remained comparable (but lower than that 
in HIV negatives), the PPV for QFT-GIT lower at 13.8% (95% CI: 8.88-29.22) compared to that of 
TST at 17.2% (95% CI: 10.33-26.06)(table 6.15). Results by country are shown in Tables 6.14 and 
6.15. 
Table 6.14: Negative and positive predictive values by test in HIV negative HHCs, overall and 
by country 
 Overall Zambia SA 
QFT-GIT    
PPV % (95%CI) 3.00 (1.72-4.82) 2.75 (1.27-5.16) 3.38 (1.37-6.84) 
NPV % (95%CI) 99.25 (97.30-99.9) 100 (98.05-100.0) 97.44 (91.04-99.69) 
TST    
PPV % (95%CI) 3.45 (1.73-6.09) 3.11(1.15-6.64) 3.97 (1.30- 9.02) 
NPV% (95%CI) 98.54 (97.02-99.41) 99.07 ( 97.29- 99.81) 97.48 ( 93.68-99.31) 
 
Table 6.15: Negative and Positive predictive values by test in HIV positive HHCs, overall and by 
country 
 Overall Zambia SA 
QFT-GIT    
PPV % (95%CI) 13.84 (8.88-20.22) 14.71 (8.47-23.09) 12.3 (5.08-23.68) 
NPV % (95%CI) 92.75 (87.08-96.47) 97.1 (91.72-99.40) 80.0 (63.06-91.56) 
TST    
PPV % (95%CI) 17.17 (10.33-26.06) 14.75 (6.98-26.17) 21.05 (9.55-37.32) 
NPV% (95%CI) 92.42 (87.81- 95.70) 93.75( 88.47-97.10) 88.89 (77.37- 95.81) 
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6.11 Sensitivity Analysis for Incident TB 
 
Previously in this chapter, incident TB was defined as self-reported TB confirmed in the clinic TB 
register.  In this section a sensitivity analysis aimed at exploring other definitions of incident TB 
is presented. The sensitivity analysis is for overall estimates. Three definitions were used to 
define incident TB as follows: 
• Self-reported TB confirmed in the TB treatment register but excluding co-prevalent TB 
cases.  
• Bacteriologically confirmed TB (presence of one or more sputum smears positive for 
acid fast bacilli). 
• Bacteriologically confirmed TB plus one or more positive cultures for M.tuberculosis plus 
positive on MPB64 antigen test. 
6.11.1 Self-reported TB confirmed in the TB treatment register but excluding co-prevalent TB 
cases 
 
 Out of a total of 51 incident cases, 6 were defined as co-prevalent TB cases, leaving 45 incident 
cases. Some selected characteristics of the 6 co-prevalent cases were as follows:  4/6 (66.7%) 
were female; 4/6 (66.7%) were HIV positive; 3/5 (60.0%) were smear positive and all 6 lived in 
urban areas in Zambia. There were no differences between co-prevalent cases and incident 
cases with regard to the following characteristics: sex (p=0.66); age (p=0.35); socioeconomic 
status (p=0.62); education (p=0.65); smoking (p=0.46); Alcohol (p=0.65); HIV (p=0.63); smear 
status (p=0.61) and residence (p=0.44).  
Excluding co-prevalent cases, the overall incidence rate was 18.50 (95%CI: 13.81-24.77) per 
1000 pyrs. For both tests, TB IR was higher among test positive HHCs compared to test negative 
ones (IRR for QFT-GIT 1.55; 95% CI: 0.78-3.30; p=0.09 and for TST: 1.76; 95%CI: 0.94-3.33, 
p=0.03).  
Overall for QFT-GIT, the IRR was higher among HIV negative HHCs (IRR: 3.37; 95%CI: 0.77-30.53; 
p=0.04) compared to HIV positives (IRR; 1.85; 95%CI: 0.80-4.65; p=0.06). These results were 
similar as for the main analysis.  For TST, the IRR for HIV negatives (IRR: 1.81; 95%CI: 0.60-5.71; 
p=0.12) was similar as for HIV positives (IRR: 2.37; 95%CI: 1.05-5.41; p=0.01).  
Crude analysis showed similar HRs for developing TB for QFT-GIT (HR: 1.56; 95% CI: 0.80-3.02; 
p=0.19) and TST (HR: 1.72; 95%CI: 0.95-3.12; p=0.07) as for the main analysis.  In multivariable 
analysis adjusted for sex, age, HIV status, and country as effect modifier (p for interaction=0.09), 
adjusted HR for QFT-GIT was 7.79 (95%CI: 1.81-33.55; p=0.006) while that for TST was 2.13 
(95%CI: 0.90-5.05, p=0.08) (table 6.16).        
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Table 6.16:  Univariable and multivariable analysis; TB defined excluding co-prevalent TB 
(nmax=45) All TB cases (n=45). 
Variable n (col 
%) 
 
 TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR (95% 
CI) 
P value 2Adjusted  
HR (95% CI) 
P 
value 
Overall N=1107 45/2433 18.50 (13.81-24.77)     
QFT          
Negative 406 12/877.9 13.67 (7.76-24.07) 1  1  
Positive 701 33/1554.9 21.22 (15.09-29.85) 1.56 (0.80-3.02) 0.19 7.79 (1.81-33.55) 0.006 
TST (10 mm)        
Negative 685 21/1476 14.23 (9.28-21.82) 1  1  
Positive 422 24/956.9 25.08 (16.81-37.42) 1.77 (0.98-3.17) 0.06 2.13 (0.90-5.05) 0.08 
2Adjusted for sex, age, HIV status, and country as effect modifier (p=0.09) 
6.11.2  Bacteriologically confirmed TB (presence of one or more sputum smears positive for 
acid fast bacilli). 
 
Out of the 51 incident cases, 34 (66.67%) had smear status recorded and 17 (33.33%) had 
missing results. Of the 34 incident cases with smear status recorded, 52.94 (18/34) were smear 
positive while 47.06% (16/34) were smear negative. 
 TB incidence rates were higher among test positive HHCs compared to those with negative 
results for both QFT (IRR: 1.97; 95% CI 0.62-8.24; p=0.11) and TST (IRR: 2.42; 95% CI: 0.86-7.37; 
p=0.03) (table 6.17).  
For QFT-GIT, the IRR was higher among HIV negative HHCs (IRR: 4.33; 95%CI: 0.60-189.79; 
p=0.07) compared to HIV positives (IRR: 2.19; 95%CI: 0.36-23.05; p=0.18). These results were 
similar as for the main analysis. For TST, the IRR among HIV negatives was 5.62 (95%CI: 1.12-
54.32; p=0.009) compared to HIV positives at 1.54 (95%CI: 0.22-9.09; p=0.29).  
Crude analysis showed slightly lower HR for developing TB for QFT-GIT (HR: 2.00; 95% CI: 0.66-
6.09; p=0.22) than for TST (HR: 2.49; 95%CI: 0.96-6.42; p=0.06). In multivariable analysis 
adjusted for sex, age, HIV status, and country as effect modifier, adjusted  HR for QFT-GIT was 
7.69 (95%CI: 0.98-60.43; p=0.05) while that for TST it was  3.40 (95%CI: 0.99-11.70; p=0.05) 
(table 6.17). 
Table 6.17:  Univariable and multivariable analysis; TB defined by smear (nmax=34) All TB 
cases (n=18). 
Variable n (col 
%) 
 
 TB 
cases/pyrs 
Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR (95% 
CI) 
P  
value 
1Adjusted  
HR (95% CI) 
P  
value 
Overall N=34 18/2433 7.40 (4.66-11.74)      
QFT          
Negative 9 4/877.9 4.56 (1.71-12.14 1  1  
Positive 25 14/1555.3 9.00 (5.33-15.20 2.00 (0.66-6.09) 0.22 7.69 (0.98-60.43) 0.05 
TST (10 mm)        
Negative 15 7/1476.0 4.74 (2.26-9.95) 1  1  
Positive 19 11/957.2 11.49 ( 6.36-20.75) 2.49 (0.96-6.42) 0.06 3.40 (0.99-11.70) 0.05 
1Adjusted for sex, age, HIV status and country as effect modifier (p=0.59) 
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6.11.3 Bacteriologically confirmed TB plus one or more positive cultures for M.tuberculosis 
plus positive on MPB64 antigen test. 
 Using this strict criterion, overall there were 8 incident cases of TB that occurred over 1653.4 
pyrs, giving an IR of 4.84 (95%CI: 2.42-9.67) per 1000 pyrs. Due to the small number of incident 
cases these results were unreliable and further analysis was not possible. However briefly, TB 
incidence rate was 3.23 (95%CI: 0.81-12.92) (2 cases/618.9 pyrs) and 5.80 (95%CI: 2.60-12.91) (6 
cases/1034.6 pyrs) per 1000 pyrs among those with negative and positive QFT-GIT results 
respectively. For QFT-GIT the IRR was 1.79 (95%CI: 0.32-18.18; p=0.25). For TST, TB incidence 
rate was 4.87 (95%CI: 2.02-11.69) (5 cases/1027.4 pyrs) and 4.79 (95%CI: 1.54-14.86) (3 
cases/626 pyrs) per 1000 pyrs among those with negative and positive results respectively. For 
TST the IRR was 0.98 (95%CI: 0.15-5.06; p=0.5). 
6.12 Summary of incidence rate ratios and adjusted HR for the main and sensitivity analyses 
stratified by country 
 
IRRs are summarized in Table 6.18. Overall for QFT-GIT, the IRR ranged from 1.55 to 1.97 with 
TB defined using smear having the highest estimates. Overall for TST, the IRR ranged from 0.98 
to 2.42 with TB defined using smear having the highest estimates. However, for all definitions 
for both tests, confidence intervals were overlapping. For HHCs residing in Zambia, there was 
strong evidence when QFT-GIT was used that the IRR ranged from 5.24 to 6.56 for all definitions. 
Similarly for TST, there was some moderate to strong evidence that IRR ranged from 1.89 to 
3.00 for all definitions. For HHCs residing in SA, IRR were similar across all definitions for both 
tests. 
 A summary of adjusted HR for overall estimates and stratified by country is also presented in 
table 6.19.  
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Table 6.18:  Summary of incidence rate ratios and 95% CI for the main and sensitivity analyses, overall and stratified by country 
Variable Main analysis  
 
P value Exclude Co-prevalent TB1 P value Smear P value  
Overall       
QFT  (>=0.35 IU/ml)       
Negative 1  1  1  
Positive 1.65 (0.86-3.37) 0.06 1.55 ( 0.78-3.30) 0.09 1.97 (0.62-8.24) 0.11 
TST (10 mm)       
Negative 1  1    
Positive 1.88 (1.04-3.41) 0.01 1.76 (0.94-3.33) 0.03 2.42 (0.86-7.37) 0.03 
Zambia       
QFT  (>=0.35 IU/ml)       
Negative 1  1  1  
Positive 5.24 (1.59-27.21) 0.0007 6.23 (1.50-55.17) <0.001 6.56 (0.93-284.56) 0.02 
TST (10 mm)       
Negative 1  1  1  
Positive 2.14 (0.94-5.02) 0.02 1.89 (0.73-4.96) 0.08 3.00 (0.76-14.00) 0.04 
South Africa       
QFT  (>=0.35 IU/ml)       
Negative 1  1  1  
Positive 0.60 (0.25-1.50) 0.11 0.60 (0.25-1.50) 0.11 0.57 (0.10-3.88) 0.24 
TST (10 mm)       
Negative 1  1  1  
Positive 1.52 (0.63-3.74) 0.15 1.52 (0.63-3.74) 0.15 1.71 (0.29-11.70) 0.25 
 1In the main analysis, TB is defined as self-reported TB confirmed in the clinic register. 2All co-prevalent cases were residents in Zambia so results remained unchanged for SA.   
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Table 6.19:  Summary of adjusted HR and 95% CI for the main and sensitivity analyses  
 1Main analysis  P value Exclude Co-prevalent TB1 P value Smear P value  
Overall       
QFT  (>=0.35 IU/ml)       
Negative 1  1  1  
Positive 6.38 (1.90-21.30) 0.003 7.79 (1.81-33.55) 0.006 7.69 (0.98-60.43) 0.05 
TST (10 mm)       
Negative 1  1  1  
Positive 2.32 (1.07-5.04) 0.03 2.13 (0.90-5.05) 0.08 3.40 (0.99-11.70) 0.05 
1In the main analysis, TB is defined as self-reported TB confirmed in the patient treatment card.; adjusted for sex, age, HIV status and country as an effect modifier 
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Summary  
From a total of 1,789 HHCs seen at baseline, 1,113 (62.2%) HHCs entered follow-up and were 
included in the main analysis.  Overall, the demographic and clinical characteristics of those who 
completed the study did not differ significantly to those who refused, were lost to follow-up or 
had missing data.  
The overall incidence rate of TB was 20.96 cases (95% CI: 15.93-27.58) per 1000 pyrs. TB 
incidence rate was higher among test positive HHCs compared to those who were negative (IRR 
for QFT: 1.65; 95% CI: 0.86-3.37; p=0.06) and for TST (IRR: 1.88; 95%CI: 1.04-3.41; p=0.01). 
The IR was highest among HHCs with concordant positive results compared to those with 
concordant negative results (IRR: 2.24, 95% CI: 1.04-5.23; p=0.01) (table 6.3).  As expected IRR 
was highest when both tests were positive, 2.24 (95%CI: 1.04-5.23) compared to discordant or 
concordant negative results.  
HIV was an important confounder in the association between QFT-GIT positivity and TB 
incidence while age and sex were considered as priori confounders. Country was considered as 
an important effect modifier (p=0.001). In univariable analysis, the HR showing the association 
between QFT-GIT positivity and risk of TB was 1.66 (95%CI: 0.88-3.11; P=0.01). In multivariable 
analysis adjusted for sex, age, HIV plus country as an effect modifier the HR for QFT-GIT was 
6.38 (95%CI: 1.90-21.30; p=0.003) while that for TST was 2.32 (1.07-5.04; p=0.03). 
For Zambia for QFT-GIT, the IRR among QFT-GIT positive HHCs was 5.24; (95% CI: 1.59-27.21; 
p=0.0007) compared to 2.14 (95% CI: 0.94-5.02) among TST positive HHCs. In SA the IRR among 
HHCs with QFT-GIT positive results was 0.60; (95% CI: 0.25-1.50; p=0.11) compared to 1.52 (95% 
CI: 0.63-3.74) among TST positive HHCs.  
Overall for QFT-GIT, the IRR was higher among HIV negative HHCs (IRR: 3.85; 95%CI: 0.90-34.51; 
p=0.07) compared to HIV positives (IRR; 1.93; 95%CI: 0.88-4.57; p=0.04). Overall for TST, the IRR 
for HIV negatives (IRR: 2.21; 95%CI: 0.78-6.72; p=0.05) was similar to that among HIV positives 
(IRR: 2.32; 95%CI: 1.09-5.00; p=0.009). In multivariable analysis, there was therefore strong 
evidence of a five-fold increased risk of TB in HIV positive QFT-GIT positive HHCs compared to 
HIV positive QFT-GIT negative ones (HR : 4.72; 95%CI: 1.35-16.46; P=0.01). For TST, in 
multivariable analysis adjusted for age, sex and country as an effect modifier, the HR in HIV 
negative TST positive HHCs was 3.02 (95% CI: 0.75-12.10; p=0.12) while it was 2.13 (95%CI: 0.81-
5.60; p=0.12) in HIV positives TST positive. 
Overall, among HIV negatives, the PPV and NPV of QFT-GIT was comparable to that of TST (NPV 
range 98.5%-99.2% and PPV of approximately 3.00% for both tests) although the confidence 
intervals for PPV were overlapping. Overall, in HIV positives, the NPV of both tests remained 
comparable but the PPV for QFT-GIT was slightly lower at 13.8% (95% CI: 8.88-29.22) compared 
to that of TST at 17.2% (95% CI: 10.33-26.06). 
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In a sensitivity analysis, for QFT-GIT, there was strong evidence that the adjusted HR was as 
reported for the main analysis (aHR: 6.38; 95%CI: 1.90-21.30; p=0.003). HRs were similar when 
TB was defined excluding co-prevalent cases and smear although the confidence interval was 
overlapping for smear. Overall for TST, all definitions provided some evidence that the adjusted 
HR ranged from 2.32 in the main analysis to 3.40 when defined by smear. Sensitivity analysis 
results where TB was defined as the presence of one or more positive cultures for Mtb that 
were also positive on ZN staining and MPB64 antigen test were unreliable due to the small 
number of incident cases. 
Risk factors for TB were also explored. In unadjusted analysis , there was strong evidence that 
26-39 years (HR:2.31; 95%CI: 1.18-4.52; p=0.04); HIV positivity (HR: 4.68; 95%CI: 2.62-8.35, 
p<0.001); smear status of the index  (HR: 1.74; 95%CI: 0.92-3.28; p=0.09); sleeping in the same 
room and same bed as index (HR:1.88 ; 95%CI:0.64-5.53; p=0.02) and country ( HR: 1.55; 
95%CI:0.90-2.67; p=0.04)  were associated with an increased risk of TB.  
In multivariable analyses, adjusted for age, sex , HIV status and country there was strong 
evidence that  occasional smoking, (HR: 4.07; 95%CI:1.31-12.63), HIV positivity (HR: 4.60; 
95%CI:2.48-8.56), smear  positivity of the index (HR: 2.00 ; 95%CI:1.04-3.87)  and country (HR: 
1.79 ; 95%1.02-3.15; p=0.04) ) were associated with incidence of TB.   
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7.0 Are household contacts with high levels of IFN-γ in response to Mtb 
specific antigen in the QFT-GIT assay at higher risk of developing TB? 
 
Introduction 
In this chapter I will answer the main research question of the thesis:  Are HHCs with high levels 
(≥10 IU/ml) of IFN-γ in response to Mtb specific antigens (ESAT-6, CFP-10 or TB 7.7) in the QFT-
GIT assay at higher risk of developing TB compared to those with low levels (≥ 0.35 <10 IU/ml)?  
Specific objectives of this chapter are:  
1. To determine the incidence rates of TB in HHCs with low and high IFN-γ levels in the QFT-GIT 
assay, also stratified by country and HIV status. 
2. To determine the association between high IFN-γ levels in the QFT-GIT assay and the risk of 
developing TB? 
7.1 The cohort for this analysis 
 
Out of the 1,113 HHCs who entered follow-up, 406 HHCs had IFN-γ levels <0.35 IU/ml at 
baseline and were therefore excluded from analysis. Therefore 707 HHCs were present for 
analysis in this chapter. Out of these 536 (75.8%) had IFN-gamma levels ≥ 0.35 and <10 IU/ml 
(low IFN-γ levels) while 171 (24.2%) HHCs had ≥ 10 IU/ml (high IFN-γ levels). 
7.2 Socio-demographic and clinical characteristics of HHCs with low versus high IFN-γ levels  
 
Of the 171 HHCs, 74.8% were female, median age was 28 years (IQR:21-45), 58.8% had attended 
secondary school or higher education, 88.9% had no history of smoking and  54.7% had lived 
with a smear positive index case (Table 7.1.).  
There was no difference between HHCs with low and high IFN-γ levels with regard to the 
following characteristics: sex (p=0.55), age (p=0.37), level of education (p=0.93), socioeconomic 
status (p=0.99), smoking habits (p=0.20), alcohol consumption (p=0.90), smear status of the 
index (p=0.73), proximity to the index case (p=0.28). 
However, there were differences between HHCs with low and high IFN-γ levels with respect to 
the following characteristics: HIV status (p=0.04), TST results at the 10 mm cut-off (p=0.02) and 
country (p=0.01) (table 7.1). 
17.1% of HHCs with high IFN-γ levels were HIV positive compared to 24.8% with low levels.  A 
greater proportion of HHCs with high levels (70.2%) resided in Zambia than with low levels 
(59.0%) (Table 7.1).  
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Table 7.1:  Socio-demographic and clinical characteristics of HHCs with low versus high IFN-γ 
levels  
 Low IFN-γ levels High IFN-γ levels  p value  (chi-square)* 
Total 536 (column %) 171 (column %)  
Sex    
 Male  147 (27.5) 43 (25.1) 0.55 
Female  388 (72.5) 128 (74.8)  
Missing 1 0  
Age group (years)    
15-25 198 (37.1) 73 (43.2) 0.37 
26-39 149 (27.9) 42 (24.8)  
40-86 186 (34.9) 54 (31.9)  
Median age (IQR) 31 (22; 47) 28 (21; 45)  
Highest level of education    
Primary school  and below 217  (41.6) 70 (41.2) 0.93 
Secondary school and above 305 (58.4) 100 (58.8)  
Missing 14 1  
Socioeconomic status    
 Unemployed & dependent 478 (90) 154 (90.1)  
 Employed  53 (10.0) 17 (9.9) 0.99 
Missing 5 0  
Smoking habits    
Never smoked or ex-smoker 453(85.0) 152 (88.9)  
Smoker (occasional or daily) 80 (15.0) 19 (11.1) 0.20 
Missing 3 0  
Alcohol consumption    
No 393 (74.1) 126 (73.7) 0.90 
Yes 137 (25.8) 45 (26.3)  
Missing 6 0  
HIV status     
Negative 394 (75.2) 141 (82.9) 0.04 
Positive 130 (24.8) 29 (17.1)  
Missing 12 1  
TST results (10 mm)    
Negative 290 (54.1) 75 (43.9) 0.02 
Positive 246 (45.9) 96 (56.1)  
Smear status of the index    
Smear negative 180  (47.1) 53 (45.3) 0.73 
Smear positive 202 (52.9) 64 (54.7)  
Missing  54  
Sleeping proximity to index    
Different house 38 (9.9) 19 (14.7) 0.28 
Same house 232 (60.7) 71 (55.0)  
Same room and same bed 112 (29.3) 39 (30.2)  
Missing 154 42  
Residence    
Rural  75 (14.0) 26 (15.2)  
Urban  461 (86.0) 145 (84.4) 0.69 
Country    
Zambia 316 (59.0) 120 (70.2) 0.01 
South Africa 220 (41.0) 51 (29.8)  
*Fisher’s exact used when the expected numbers were less than 5. 
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Using TST at the 10 mm cut-off, 56.1% (96/171) of HHCs with high IFN-γ levels and 246 (45.9%) 
of those with low levels were TST positive (table 7.1).  
TST responses (TST>0 mm) were higher in HHCs with high IFN-γ levels (mean: 9.9 mm; standard 
deviation (SD): 7.9 mm) compared to those with low IFN-γ levels (mean: 6.2 mm; SD: 7.1 mm) 
(figure 7.1). In addition, 26.31% (45/171) of HHCs with high IFN-γ levels had TST indurations of 0 
mm compared to 34.14 % (183/536) with low IFN-γ levels. 
Figure 7.1:  Distribution of TST responses in low and high IFN-γ levels 
 
7.3 Overall TB incidence rates  
 
Out of the 707 HHCs that entered follow-up, 38 (5.4%) HHCs developed active TB over 1558.0 
person-years (pyrs) of follow-up, giving an incidence rate of 24.39 (95%CI: 17.75-33.52) per 1000 
pyrs.  The median follow-up time was 2.44 years (IQR: 1.59-2.82).  
TB incidence rates were 24.51/1000 pyrs (9 cases/367.2 pyrs) in HHCs with high levels and 24.35 
(29 cases/1190.7 pyrs) among those with low levels of IFN-γ, giving an IRR of 1.0 (95% CI: 0.42-
2.18). (p=0.48).  
7.4 Kaplan Meier TB-free survival probability for low and high levels  
 
Kaplan Meier curves showing TB-free survival probabilities in HHCs with high and low IFN-γ 
levels are shown in Figure 7.2. Overall, the two-year (actual last observed exit was at 3.8 years) 
TB-free survival probability at 0.96 (95%CI: 0.91-0.98) among HHCs with high IFN-γ levels was 
0
1
0 
2
0 
3
0 
4
0 
0 10 20 30 40 0 10 20 30 40 
HHCs with low IFN-γ levels  HHCs with high IFN-γ levels 
Pe
rc
e
n
t 
TST indurations
  
 165
similar to those with low IFN-γ levels at 0.95 (95% CI: 0.92-0.96) (figure 7.2). There was no 
evidence that survival curves differed between those with low and high IFN-γ levels for 
unadjusted analysis (log rank test, p=0.96) (figure 7.2). 
Figure 7.2:  Kaplan Meier survival curves for high and low IFN-γ levels 
 
 
7.5 The Proportional Hazard Assumption in the Cox model 
 
Figure 7.3 shows the cumulative hazard against time since study enrolment for HHCs with low 
and high levels. It suggests that there that the proportional hazard assumption was violated 
since the lines appear not to be reasonably parallel. Mathematically, this assumption was tested 
by adding interaction terms to the proportional hazards model, the result of the interaction test 
suggested no evidence against proportionality (LRT: p=0.60).  
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Figure 7.3:  Nelson-Aalen Cumulative hazard against time for HHCs with low and high levels, in 
order to check for the proportional hazards assumption 
 
7.6 Risk factors for the development of TB  
 
Incidence rates, unadjusted and adjusted HRs of risk factors for incident TB for the primary 
objective is shown in Table 7.2. 
In unadjusted analysis, age group 26-39 years (HR: 1.83; 95%CI: 0.83-4.03; P=0.30); smoking (HR: 
1.93; 95%CI: 0.91-4.08; p=0.09), HIV positivity (HR: 4.55; 95%CI: 2.38-8.68, p<0.001);  sleeping in 
the same room and same bed as index (HR:2.01 ; 95%CI:0.58-6.97; p=0.05) and being in an 
urban area (HR:2.76; 95%CI:0.66-11.47; p=0.16) were positively associated with an increased 
risk of TB  (table 7.2).  
 Higher education was negatively associated with risk for TB (HR: 0.52; 95%CI: 0.27-0.99; p=0.05) 
(table 7.2). 
 
 
 
 
 
 
0.10 
0.20 
0.30
0 1 2 3 4
Time since study enrolment (years)
High IFN-g levels 
 Low IFN-g levels
Cu
m
u
la
tiv
e 
ha
za
rd
 
 167 
 
Table 7.2:  TB incidence rates and hazard ratios stratified by baseline socio-demographic and clinical 
characteristics  
 N (col %) 
N=707 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
Crude HR (95% 
CI) 
P value  aHR (95% CI) P value  
Sex         
Male 190 (26.91%) 10/414.6 24.11 (12.98-44.83 1  1  
Female 516 (73.06%) 28/1140.3 24.55 (16.95-35.56 1.03 (0.50-2.12) 0.94 0.84 (0.40-1.76) 0.64 
Age group (years)        
15-25 271 (38.60 11/589.7 18.65 (10.33-33.68 1  1  
26-39 191 (27.21 14/410.4 34.11 (20.20-57.59 1.83 (0.83-4.03)  1.19 (0.53-2.67) 0.007 
40-87 240 (34.19 12/544.3 22.05 (12.52-38.82 1.19 (0.52-2.69) 0.30 1.29 (0.57-2.93)  
Highest level of education        
Primary school  and below 287 (41.47 22/633.0 34.75 (22.88-52.78 1  1  
Secondary school and above 405 (58.53 16/891.0 17.96 (11.00-29.31 0.52 (0.27-0.99) 0.05 0.54  (0.28-1.03) 0.06 
Socioeconomic status        
 Unemployed & dependent 632 (90.03 34/1387.8 24.50 (17.50-34.29 1  1  
 Employed  70 (9.97 4/156.8 25.50 (9.57-67.95 1.07 (0.38-3.02) 0.89 0.94 (0.28-3.13) 0.92 
Smoking habits        
Never smoked or ex-smoker 605 (85.94) 29/1341.2 21.62 (15.02-31.11 1  1  
Smoker (occasional or daily) 99 (14.06) 9/210 42.86 (22.30-82.37 1.93 (0.91-4.08) 0.09 2.27 (1.04-4.94) 0.04 
Alcohol consumption        
No 519 (74.04) 26/1152.6 22.56 (15.36-33.13 1  1  
Yes 182 (25.96 12/392.4 30.59 (17.37-53.85 1.35 (0.68-2.68) 0.39 1.28 (0.64-2.56) 0.49 
HIV status         
Negative 535 (77.09) 16/1178.4 13.58 (8.32-22.16 1  1  
Positive 159 (22.91 22/348.8 63.09 (41.53-95.80 4.55 (2.38-8.68) P<0.001 4.30 (2.15-8.60) P<0.001 
Smear status of the index        
Smear negative 233 (46.69 13/513.1 25.33 (14.71-43.63 1  1  
Smear positive 266 (53.31 18/570.5 31.55 (19.88-50.08 1.23 (0.60-2.51) 0.57 1.38 (0.66-2.90) 0.39 
Sleeping proximity to index        
Different  house 57 (11.15 3/128.3 23.38 (7.54-72.49 1  1  
Same house 303 (59.30 12/645.6 18.59 (10.55-32.73 0.80 (0.22-2.83)  0.61 (0.16-2.27)  
Same room and same bed  151 (29.55 15/318.6 47.08 (28.38-78.10 2.01 (0.58-6.97) 0.05 1.13 (0.31-4.07) 0.0007 
Residence        
Rural  101 (14.29 2/206.6 9.68 (2.42-38.71 1  1  
Urban  606 (85.71 36/1351.4 26.64 (19.21-36.93 2.76 (0.66-11.47) 0.16 2.22 (0.52-9.38) 0.28 
Country        
Zambia 436 (61.67 24/936.2 25.64 (17.18-38.25 1  1  
South Africa 271 (38.33 14/621.8 22.52 (13.33-38.02 0.87 (0.45-1.68) 0.68 0.98 (0.50-1.90) 0.95 
P value from likelihood test if > 2 sub-groups.  Missing: sex-1; age-5; education-15; socioeconomic-5; smoking habits-1; taken alcohol-6; HIV 
status-13; index smear-208; sleeping proximity to index-196. 1Adjusted HR: adjusted for age, HIV and country . 
 In multivariable analyses, adjusted for age, HIV status and country there was strong evidence that 
smoking, (HR: 2.27; 95%CI: 1.04-4.94; p=0.04) and HIV positivity (HR: 4.30; 95%CI: 2.15-8.60; p<0.001), 
were associated with increased risk of TB (table 7.2).   
Data were consistent with no association of sex, education, socioeconomic status, alcohol use, and 
smear status with increased risk of TB in both univariable and multivariable analysis (table 7.2).  
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7.7 Incidence rates, stratified by country 
 
 In Zambia, out of the 436 HHCs that entered follow-up, 24 (5.5%) HHCs developed active TB over 936.16 
pyrs of follow-up, giving an incidence rate of 25.64/1000 pyrs (table 7.3).  The median follow-up time 
was 2.46 years (IQR: 1.32-2.77).  
Table 7.3:  Incidence rates for Zambia; All TB cases (N=24). 
Variable  N (col %) 
 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
Incidence rate ratio 
(95%CI) 
P value 
Overall N=436 24/936.16 25.64 (17.18-38.24)   
Low IFN-γ levels 316 18/688.5 26.14 (16.47-41.49) 1  
High IFN-γ levels 120 6/247.6 24.23 (10.88-53.93) 0.93 (0.30-2.44) 0.45 
 
In SA, out of the 271 HHCs that entered follow-up, 14 (5.2%) HHCs developed active TB over 621.79 pyrs 
of follow-up, giving an incidence rate of 22.52/1000 pyrs (Table 7.4).  The median follow-up time was 
2.39 years (IQR: 1.76-2.91). 
Table 7.4:  Incidence rates for South Africa; All TB cases (N=14). 
Variable  N (col %) 
 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
Incidence rate ratio 
(95%CI) 
P value 
Overall N=271 14/621.79 22.52 (13.33-38.02)   
Low IFN-γ levels 220 11/502.2 21.90 (12.13-39.55) 1  
High IFN-γ levels 51 3/119.6 25.08 (8.09-77.78) 1.14 (0.20-4.33) 0.40 
 
By country, the IRR for those residing in Zambia was 0.93 (95%CI: 0.30-2.44; p=0.45) and it was 1.14 
(95%CI: 0.20-4.33; p=0.40) for those residing in SA.  Hence there was no difference in incidence rates 
between those with low and high levels, overall and by country. 
7.8 Incidence rates, stratified by HIV status 
 
HIV Negatives 
Out of the 535 HIV negative HHCs that entered follow-up, 16 (3.0%) HHCs developed active TB over 
1178 pyrs of follow-up, giving an overall incidence rate of 13.58/1000 pyrs.  The median follow-up time 
was 2.44 years (IQR: 1.59-2.81).  
TB incidence rates were 19.56/1000 pyrs (6 cases/306.7 pyrs) in HHCs with high levels and 11.47 (10 
cases/871.7 pyrs) among those with low levels of IFN-γ, giving an IRR of 1.70 (95%CI: 0.51-5.18) (Table 
7.5). However, results were not statistically significant. 
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Table 7.5: Overall incidence rates, stratified by HIV status; All TB cases (N=38). 
Variable  N (col %) 
 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
Incidence rate ratio 
(95%CI) 
P value 
HIV negatives N=535 16/1178 13.58 (8.32-22.16)   
Low IFN-γ levels 394 (73.6) 10/871.7 11.47 (6.17-21.32) 1  
High IFN-γ levels 141 (26.3) 6/306.7 19.56 (8.79-43.54) 1.70 (0.51-5.18) 0.16 
      
HIV positives N=159 22/348.8 63.08 (41.54-95.80)   
Low IFN-γ levels 130 (81.8) 19/291.0 65.29 ( 41.65-102.36) 1  
High IFN-γ levels 29 (18.2) 3/57.8 51.94 (16.75-161.04) 0.79 (0.15-2.70) 0.38 
*13 HHCs with missing HIV test results; col=column 
 
 HIV positives 
 
Out of the 159 HIV positive HHCs that entered follow-up, 22 (13.8%) HHCs developed active TB over 
348.8 pyrs of follow-up, giving an overall incidence rate of 63.08/1000 pyrs. The median follow-up time 
was 2.43 years (IQR: 1.56-2.87).  
TB incidence rates in HIV positives was 51.94/1000 pyrs (3 cases/57.8 pyrs) in HHCs with high levels and 
65.29/1000 pyrs (19 cases/291.0 pyrs) among those with low levels of IFN-γ, giving an IRR of 0.79 
(95%CI: 0.15-2.70; p=0.38) (table 7.3). However, results were not statistically significant.  
7.9 TB-free survival probability for low and high levels, stratified by HIV status  
 
Kaplan Meier curves showing TB-free survival probabilities according to low/high levels and stratified by 
HIV are shown in Figure 7.4. In HIV negatives, the 2-year (actual last observed exit was at 3.6 years) TB-
free survival probability was 0.98 (95%CI: 0.93-0.99) in those with high IFN-γ levels and similar to those 
with low IFN-γ levels at 0.97 (95%CI: 0.95-0.99). In HIV positives, the 2-year (actual last observed exit 
was at 3.8 years) TB-free survival probability was 0.88 (95%CI: 0.67-0.96) in those with high IFN-γ levels 
compared to those with low levels at 0.86 (95%CI: 0.78-0.91) (Figure 7.4). 
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Figure 7.4:  Kaplan Meier curves of TB-free survival probability according to IFN-γ levels and stratified 
by HIV 
 
 
In HIV negatives, there was no evidence (log-rank test; p=0.28) that the survival curves differed between 
HHCs with low and high IFN-γ levels (figure 7.4). Similarly, in HIV positives, there was no evidence that 
survival curves differed between HHCs with low and high IFN-γ levels (log-rank test; p=0.65)(Figure 7.4).  
7.10 Confounders and effect modifiers for the association between high IFN-γ levels and TB incidence 
 
Identification of confounders 
Age and sex were considered as priori confounders in the association between high levels and risk of 
developing TB. Country was identified as important confounder since it was associated with both 
incidence of TB and high levels and was not in the causal pathway.  
 Identification of effect modifiers using likelihood ratio test 
HIV was identified as important effect modifier priori even if the statistical evidence was weak (LRT, 
p=0.36). There was no evidence for interaction for the rest of the risk factors that age (p=0.65), sex 
(p=0.50), socioeconomic status (p=0.34), smoking habits (p=0.82), smear status of the index (p=0.54), 
sleeping proximity to the index (p=0.95) and country (p=0.80) (table 7.4). However, there was weak 
evidence that education was an effect modifier (p=0.13).  
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7.11 Overall univariable and multivariable analysis  
 
Four regression models were used in the univariable and multivariable analysis and results for each 
model are shown in table 7.6 as follows: 
Table 7.6:  Overall univariable and multivariable analyses  
  Adjusted Hazard Ratio (95% CI) P value 
Model 1   
Low IFN-γ levels 1  
High IFN-γ levels 1.02 (0.48-2.15) 0.96 
 Model 2   
Low  IFN-γ levels 1  
High IFN-γ levels 1.06 (0.50-2.26) 0.87 
Model 3    
Low IFN-γ levels 1  
High IFN-γ levels 1.73 (0.63-4.78) 0.29 
Model 4   
Low IFN-γ levels 1  
High IFN-γ levels 1.74 (0.63-4.79) 0.29 
Model 1: Unadjusted analysis 
Model 2: Adjusted for age and sex as priori confounders. 
Model 3: Adjusted for age and sex plus interaction between high IFN-γ levels and HIV (separate results for HIV are shown in table 7.8) 
Model 4: as in model 3 plus adjusted for country 
 
In univariable analysis, there was no evidence that high IFN-γ levels were associated with an increased 
risk of TB (HR: 1.02 (95% CI: 0.48-2.15; p=0.96). When results were adjusted for age and sex as priori 
confounders, HR was similar to the unadjusted one (Table 7.6). In multivariable analysis, adjusted for 
sex, age with interaction between HIV and high levels (model 3), the adjusted HR was 1.73 (95% CI: 0.63-
4.78; p=0.29) (p value for interaction for HIV, p=0.36). Adjusting for the effect of country (model 4), gave 
similar results as in model 3. However, for all models the results were not statistically significant (table 
7.6). 
7.12 Univariable and multivariable analysis by country 
 
Three regression models were used in the univariable and multivariable analysis that was stratified by 
country and results for each model are shown in Table 7.7. 
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Table 7.7:  Univariable and multivariable analysis, stratified by country. 
 Zambia SA 
High/low IFN-γ levels 
 
Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value 
Model 1     
Low IFN-γ levels 1  1  
High IFN-γ levels 0.94 (0.37-2.37) 0.90 1.13 (0.32-4.07) 0.85 
Model 2     
Low  IFN-γ levels 1  1  
High IFN-γ levels 0.98 (0.38-2.50) 0.97 1.09 (0.30-3.92) 0.89 
Model 3     
Low IFN-γ levels 1  1  
High IFN-γ levels 1.91 (0.51-7.15) 0.33 1.37 (0.27-7.09) 0.70 
Model 1: Unadjusted analysis 
Model 2: Adjusted for age and sex as priori confounders. 
Model 3: Adjusted for age and sex plus interaction between high IFN-γ levels and HIV ( p value for interaction with HIV, p=0.6) 
 
In univariable analysis, there was no evidence that high IFN-γ levels were associated with an increased 
risk of TB for both Zambia (HR: 0.94 (95% CI: 0.37-2.37; p=0.90) and SA (HR:  1.13 (95% CI: 0.32-4.07; 
p=0.85). When results were adjusted for age and sex as priori confounders, results were similar to the 
unadjusted analysis for both countries (table 7.7).  
In multivariable analysis, adjusted for sex, age with interaction between HIV and high levels (model 3), 
the adjusted HR was 1.91 (95% CI: 0.51-7.15; p=0.33) for Zambia and 1.37 (95%CI: 0.27-7.09; p=0.70) for 
SA (table 7.7). For all models results were not statistically significant (table 7.7). 
7.13 Univariable and multivariable analysis stratified by HIV status 
 
Three regression models were used in the analysis exploring the association between high IFN-γ levels 
and TB incidence stratified by HIV status.  For both HIV positives and negatives, HRs were similar from 
model 1 to model 3 within the group (Table 7.8.) In HIV negatives, there was some evidence from these 
three models that high IFN-γ levels were associated with an almost two-fold increased risk of developing 
TB although results were not statistically significant (Table 7.8).  
Table 7.8: Overall univariable and multivariable analysis, stratified by HIV status. 
Models HR in HIV negatives  
(95% CI) 
P value HR in HIV positives  
  (95% CI) 
P value 
Model 1     
Low IFN-γ levels 1  1  
High IFN-γ levels 1.73 (0.63-4.77) 0.29 0.75 (0.22-2.55) 0.65 
Model 2     
Low  IFN-γ levels 1  1  
High IFN-γ levels 1.74 (0.63-4.80) 0.28 0.81 (0.24-2.77) 0.74 
Model 3     
Low IFN-γ levels 1  1  
High IFN-γ levels 1.75 (0.63-4.84) 0.28 0.79 (0.23-2.74) 0.72 
 Model 1: Unadjusted analysis 
Model 2: Adjusted for age and sex as priori confounders. 
Model 3: as in model 2 plus adjusted for country  
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In HIV positives evidence from models 1-3 suggested a protective effect of high levels; there was an 
almost twenty percent reduction in the risk of TB among HHCs with high IFN levels although results were 
not statistically significant (table 7.8).  
Summary 
Out of the 1,113 HHCs who entered follow-up, 406 HHCs had IFN-γ levels <0.35 IU/ml and were 
therefore excluded from analysis. Therefore 707 HHCs were present for analysis in this chapter. Out of 
these 536 (75.8%) had IFN-gamma levels ≥ 0.35 and <10 IU/ml (low IFN-γ levels) while 171 (24.2%) HHCs 
had high IFN-γ levels (≥ 10 IU/ml). 
 
Out of the 707 HHCs available for analysis, 38 (5.4%) HHCs developed active TB over 1558.0 person-
years (pyrs) of follow-up, giving an incidence rate of 24.39/1000 pyrs. The median follow-up time was 
2.44 years (IQR: 1.59-2.82).  There was no difference in incidence rates between HHCs with low and high 
levels, by country and overall (overall IRR: 1.0 (95% CI: 0.42-2.18)). 
In HIV negatives, out of the 535 HHCs that entered follow-up, 16 (3.0%) HHCs developed active TB over 
1178 pyrs of follow-up, giving an overall incidence rate of 13.58/1000 pyrs.  The IRR in HIV negatives was 
1.70 (95%CI: 0.51-5.18; p=0.16). In HIV positives, out of the 159 HHCs that entered follow-up, 22 (13.8%) 
HHCs developed active TB over 348.8 pyrs of follow-up, giving an overall incidence rate of 63.08/1000 
pyrs. The IRR in HIV positives was 0.79 (95%CI: 0.15-2.70; p=0.38).  
Therefore in HIV negatives, incidence rates were higher in HHCs with high levels compared to those with 
low IFN-γ levels, although statistical evidence was weak (IRR: 1.70; 95%CI: 0.51-5.18; p=0.16). In HIV 
positives, incidence rates were lower in HHCs with high levels compared to those with low IFN-γ levels 
(IRR: 0.79), although statistical evidence was equally weak (IRR: 0.79; 95%CI: 0.15-2.70; p=0.38). 
Country was an important confounder in the association between high IFN-γ levels and TB incidence 
while age and sex were considered as priori confounders. HIV positivity was an effect modifier (p for 
interaction=0.36).  
Overall, unadjusted HR in HHCs with high IFN-γ levels was 1.02 (95%CI: 0.48-2.15; p=0.96) Hence there 
was equally no evidence of an association between high IFN-γ levels and TB incidence overall. Results 
were consistent when stratified by country. 
Overall, in multivariable analysis adjusted for age, sex, country and HIV as an effect modifier, HR was 
1.74 (95%CI: 0.63-4.79; p=0.29). Unadjusted HR among HIV negative HHCs was 1.73 (95%CI: 0.63-4.77; 
p=0.29) and 0.75 (95%0.22-2.55; p=0.65) among HIV positives ones respectively. In a multivariable 
analysis adjusted for age, sex and country, the HR remained similar as unadjusted analysis for both HIV 
negatives and positives. 
 Overall, there was no evidence to suggest that HHCs with high levels of IFN-γ in response to Mtb 
specific antigens in the QFT-GIT assay were at a higher risk of developing TB than those with low levels.  
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8.0 Exploring quantitative QFT-GIT cut-offs  
 
Introduction 
In this chapter I aim to explore other quantitative QFT-GIT cut-offs to determine whether there is an 
association between high IFN-γ levels and risk of progression to active TB.  In answering the main 
question (presented in chapter 7) I restricted the analysis to a binary exposure (high IFN-γ levels versus 
low levels). However, in this chapter I will answer the main question by using three to six QFT-GIT 
subgroups defined by different methods.  
Specific objectives of this chapter are to conduct a sensitivity analysis with the following aims: 
1. To explore other quantitative QFT-GIT cut-offs as a comparison to the ones used to answer the main 
research question (high IFN-γ levels versus low levels). 
2. To determine incidence rates and incidence rate ratios for each group, stratified by HIV status.  
3. For each  exploratory group, to determine whether HHCs with high levels of IFN-γ in response to 
Mtb specific antigens in the QFT-GIT assay are at higher risk of developing TB compared to those 
with low levels. 
8.1 Exploratory analysis results to define QFT-GIT and TST groups used in sensitivity analysis  
The cohort for this analysis includes all the 1,113 HHCs who entered follow-up. 
Three QFT-GIT groups and one TST group were defined after exploratory analysis (Table 8.1). These 
groups were used for sensitivity analysis.  
Table 8.1:  QFT-GIT and TST definitions used for sensitivity analysis (n=1113)  
 Group definition by IFN-γ (IU/ml)  and 
TST cut-offs (mm)  
N=1113 for each 
group 
Median IFN-γ response for each sub-
group (95% CI) 
Method used 
Group 3 group (IU/ml)    
<0.27 377 0.01 (0-0.07) Data divided into 3 equal groups. 
0.28 to 3.12 365 1.03 (0.54-1.94) 
3.13 to 10 371 9.19 (5.55-10) 
 Group 4 (IU/ml)    
<0.35 406 0.02 (0-0.1) Choice based on  distribution of baseline IFN- 
γ responses of this data and literature review 
(246) 
0.35 to <1.0 147 0.6 (0.43-0.83) 
1.0 to 5.0 261 2.4 (1.57-3.25) 
>5.0 to 10 299 10 (7.58-10) 
Group 6 (IU/ml)    
<0.35 406 0.02 (0-0.1)   Based on literature review but modified by 
author (166)  0.35 to 0.49 53 0.42 (0.39-0.45) 
0.5 to 0.99 94 0.77 (0.62-0.89) 
1.0 to 3.99 228 2.13 (1.52-2.86) 
4.0 to 9.99 161 6.76 (5.21-8.02) 
10  171 10 (10-10) 
TST group ( mm)    
<5  529 0.3 (0.01-2.49) Literature review-commonly used 
approaches(169, 246)   5 to 9  158 1.5 (0.15-6.19) 
10 to 14 231 2.18 (0.42-7.89) 
>15  195 3.88 (0.93-10) 
Kwallis test for median, p-value=0.0001 for all groups. Overall median is 1.01 (95% CI: 0.07-5.55).  
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8.2 Overall TB incidence rates and incidence rate ratios  
 
Incidence rate and incidence rate ratios (IRRs) by group and sub-group are shown in table 8.2.  
For all the groups, HHCs in sub-groups with the highest IFN-γ levels had increased IRRs ranging from 1.5 
to 2-fold compared to the reference sub-group (Table 8.2).  The IRRs of HHCs in sub-groups with the 
highest IFN-γ levels were 1.85 (95%CI: 0.90-3.83), 1.46 (95%CI: 0.69-3.10), 1.65 (95%CI:  and 2.11 
(95%CI: 1.10-4.05) for groups 3, 4, 6 and the TST group respectively (table 8.2). 
For group 3 and the TST group, HHCs in sub-groups with the highest IFN-γ levels had the highest IRRs 
compared to the reference sub-group. For group 4 and 6, IRRs were highest in HHCs with IFN-γ levels 
between 1.0-5.0 IU/ml (IRR: 2.08; 95%CI: 1.02-4.24) and 1.0-3.99 IU/ml (IRR: 1.83; 95%CI: 0.86-3.90) 
respectively (Table 8.2).  
Table 8.2:  Overall incidence rates and incidence rate ratios by group. All TB cases (n=51). 
Group (IU/Ml) N (col %) 
N=1113 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
IRR  (95% CI) P value 
 
Group 3       
<0.27 377 11/812 13.55 (7.50-24.46) 1 0.05 
0.28 to 3.12 365 20/823.8 24.28 (15.66-37.63) 1.79 (0.87-3.70)  
3.13 to 10 371 20/797.4 25.08 (16.18-38.88) 1.85 (0.90-3.82)  
*Test for trend, p=0.10 
 Group 4      
<0.35 406 13/875.3 14.85 (8.62-25.58) 1 0.17 
0.35 to <1.0 147 6/330.8 18.14 (8.15-40.37) 1.22 (0.46-3.21)  
1.0 to 5.0 261 18/583.8 30.83 (19.43-48.94) 2.07 (1.03-4.17)  
>5.0 to 10 299 14/643.4 21.76 (12.89-36.74) 1.46 (0.69-3.10)  
*Test for trend, p=0.15 
Group 6       
<0.35 406 13/875.3 14.85 (8.62-25.58) 1 0.16 
0.35 to 0.49 53 1/120.7 8.29 (1.17-58.84) 0.56 (0.07-4.14)  
0.5 to 0.99 94 5/210.2 23.79 (9.90-57.16) 1.60 (0.58-4.45)  
1.0 to 3.99 228 14/514.1 27.23 (16.13-45.98) 1.83 (0.87-3.86)  
4.0 to 9.99 161 9/345.8 26.03 (13.54-50.02) 1.75 (0.76-4.05)  
10  171 9/367.2 24.51 (12.75-47.10) 1.65 (0.71-3.83)  
*Test for trend, p=0.08 
TST group (mm)      
<5  529 19/1128.7 16.83 (10.74-26.39) 1 0.15 
5 to 9 158 4/347.3 11.52 (4.32-30.69) 0.68 (0.23-2.00)  
10 to 14  231 12/507.7 23.63 (13.42-41.62) 1.40 (0.68-2.88)  
>15  195 16/449.5 35.59 (21.80-58.10) 2.11 (1.10-4.05)  
*Test for trend, p=0.01 
* Score test for trend of odds, chi2 (1) 
A test for trend for each group showed no evidence of a trend for groups 3, 4 and 6 while there was 
strong evidence that there was a trend for the TST group (test for trend, p=0.01) (Table 8.2).  
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8.2.1 TB incidence rates and incidence rate ratios by country 
  
 Zambia 
For group 3, although the IRR was highest in HHCs with IFN-γ levels between 0.28-3.12 IU/ml (IRR: 4.98; 
95%CI: 1.60-15.57) (Table 8.3). For groups 4 and 6, IRRs were highest in those with IFN-γ levels between 
1.0-5.10 IU/ml (IRR: 8.05; 95%CI: 2.81-23.10) and 1.0-3.99 IU/ml (IRR: 6.93; 95%CI: 2.28-20.99) 
respectively. These results for group 4 and 6 were similar to those in the overall analysis (table 8.2). For 
the TST group, IRR was highest in HHCs with the largest TST indurations (IRR: 2.50; 95%CI: 1.03-6.04) 
(Table 8.3). 
Table 8.3:  Zambia: incidence rates of TB and incidence rate ratios, by group (nmax=728). All TB cases 
(n=27). 
Group (IU/Ml) N (col %) 
N=728 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
IRR (95% CI) P value 
 
Group 3       
<0.27 278 3/582.5 5.15 (1.66-15.97) 1 0.004 
0.28 to 3.12 211 12/467.4 25.67 (14.58-45.20) 4.98 (1.60-15.57)  
3.13 to 10 239 12/500 24.00 (13.63-42.26) 4.66 (1.48-14.69)  
*Test for trend, p=0.41 
 Group 4      
<0.35 292 3/613.8 4.89 (1.57-15.15) 1 0.04 
0.35 to <1.0 84 3/189.1 15.86 (5.11-49.19) 3.24(0.71- 14.71)  
1.0 to 5.0 153 13/330.2 39.37 (22.86-67.81) 8.05(2.81-23.10)  
>5.0 to 10 199 8/416.9 19.19 (9.60-38.37) 3.93 (1.15-13.42)  
*Test for trend, p=0.01 
Group 6       
<0.35 292 3/613.8 4.89 (1.58-15.15) 1 0.07 
0.35 to 0.49 28 1/65.3 15.31 (2.16-108.69) 3.13 (0.37-26.76)  
0.5 to 0.99 56 2/123.8 16.16 (4.04-64.60) 3.30 (0.61-17.86)  
1.0 to 3.99 135 10/295.4 33.86 (18.22-62.92) 6.93 (2.28-20.99)  
4.0 to 9.99 97 5/204 24.50 (10.20-58.87) 5.01 (1.38-18.17)  
10  120 6/247.6 24.23(10.88-53.93) 4.96(1.42-17.27)  
*Test for trend, p=0.005 
TST  group (mm)      
<5 mm 360 11/737.2 14.92 (8.26-26.94 1 0.16 
5 to 9 mm 111 1/242.1 4.13  (0.58-29.33 0.28 (0.04-1.87)  
10 to 14 mm 152 6/327 18.35 (8.24-40.84 1.23 (0.45-3.32)  
>15 mm 105 9/243.7 36.93 (19.21-70.97 2.47 (1.06-5.80)  
*Test for trend, p=0.03 
* Score test for trend of odds, chi2 (1) 
A test for trend in Zambia showed evidence of a trend for all groups apart from group 3 (p=0.41) (table 
8.3) 
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South Africa  
For HHCs residing in SA, all QFT-GIT groups showed that highest levels had a protective effect when 
compared to the reference sub-group although results were not statistically significant. The IRRs of 
HHCs in sub-groups with the highest IFN-γ levels were 0.77 (95%CI: 0.29-2.05), 0.69 (95%CI: 0.25-1.89) 
and 0.65 (95%CI: 0.18-2.36) for groups 3, 4 and 6 respectively (Table 8.4).  
Table 8.4:  South Africa: Incidence rates of TB and incidence rate ratios, by group (nmax=385). All TB 
cases (n=24). 
Group (IU/Ml) N (col %) 
N=385 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
IRR (95% CI) P value 
Group 3       
<0.27 99 8/229.4 34.86 (17.44-69.72) 1 0.24 
0.28 to 3.12 154 8/356.4 22.45 (11.22-44.88) 0.64 (0.24-1.70)  
3.13 to 10 132 8/297.4 26.90 (13.45-53.80) 0.77 (0.29-2.05)  
*Test for trend, p=0.61 
 Group 4      
<0.35 114 10/261.4 38.25 (20.58-71.09) 1 0.18 
0.35 to <1.0 63 3/141.7 21.17 (6.83-65.64) 0.55 (0.15-1.97)  
1.0 to 5.0 108 5/253.6 19.72 (8.21-47.37) 0.51 (0.18-1.48)  
>5.0 to 10 100 6/226.5 26.49 (11.90-58.96) 0.69 (0.25-1.89)  
*Test for trend, p=0.38 
Group 6       
<0.35 114 10/261.4 38.25 (20.58-71.09) 1 0.29 
0.35 to 0.49 25 0/55.3 0 n/a  
0.5 to 0.99 38 3/86.4 34.74 (11.20-107.70) 0.91 (0.25-3.29)  
1.0 to 3.99 93 4/218.8 18.28 (6.86-48.72) 0.48 (0.15-1.48)  
4.0 to 9.99 64 4/141.7 28.22 (10.59-75.20) 0.74 (0.23-2.34)  
10  51 3/119.6 25.08 (8.09-77.78) 0.65 (0.18-2.36)  
*Test for trend, p=0.47 
TST  group (mm)      
<5 mm 169 8/391.5 20.43 (10.22-40.86) 1 0.34 
5 to 9 mm 47 3/105.2 28.51 (9.20-88.41) 1.39 (0.37-5.23)  
10 to 14 mm 79 6/180.7 33.20 (14.91-73.90) 1.62 (0.57-4.63)  
>15 mm 90 7/205.8 34.01 (16.22-71.35) 1.66 (0.61-4.54)  
*Test for trend, p=0.26 
* Score test for trend of odds, chi2 (1) 
TST results showed that IRRs were highest in HHCs with the highest IFN-γ levels (IRR: 1.66; 95%CI: 0.61-
4.54; p=0.17) although results were not statistically significant. A test for trend in SA showed no 
evidence of a trend for all the groups (table 8.4).  
8.2.2 TB incidence rates, stratified by HIV status  
 
For HIV negatives, HHCs with the highest IFN-γ levels had the highest incidence rates in all groups apart 
from group 6 (table 8.5). The IRRs of HHCs with the highest IFN-γ levels were 4.02 (95%CI: 0.99-16.34), 
4.38 (95%CI: 1.06-18.06), and 5.51 (95%CI: 1.33-22.82) for groups 3, 4 and 6 respectively. For the TST 
group, the IRR of HHCs with the highest IFN-γ levels was 2.76 (95%CI: 0.88-8.61) (Table 8.5). 
There was a tendency of increasing IRRs with increasing IFN-γ production levels. A test for trend in HIV 
negatives showed strong evidence of a trend across all groups (table 8.5). For all the QFT-GIT groups, 
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HIV negative HHCs with the highest IFN-γ levels had increased IRRs ranging from 4 to 5-fold compared to 
the reference sub-group (table 8.5). For the TST group, there was an almost 3-fold increase in IRR in 
HHCs with the highest IFN-γ level compared to the reference sub-group although results were not 
statistically significant. 
Table 8.5:  Overall incidence rates of TB and incidence rate ratios in HIV negatives, by group 
(nmax=799). All TB cases (n=18). 
Group (IU/Ml) N (col %) 
N=799 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
IRR  (95% CI) P value 
 
Group 3       
<0.27 244 2/517.49 3.86 (0.97-15.45) 1 0.07 
0.28 to 3.12 260 6/580.26 10.34  (4.65-23.02) 2.67 (0.57-12.45)  
3.13 to 10 295 10/643.67 15.54 (8.36-28.87) 4.02 (0.99-16.34)  
*Test for trend, p=0.05      
 Group 4      
<0.35 264 2/563.02 3.55 (0.89-14.20) 1 0.10 
0.35 to <1.0 105 3/229.66 13.06 (4.21-40.50) 3.68 (0.69-19.51)  
1.0 to 5.0 194 5/434.42 11.51 (4.79-27.65) 3.24 (0.69-15.25)  
>5.0 to 10 236 8/514.32 15.55 (7.78-31.10) 4.38 (1.06-18.06)  
*Test for trend, p=0.05      
Group 6       
<0.35 264 2/563.0 3.55 (0.89-14.20) 1 0.18 
0.35 to 0.49 39 0/85.0 0 0  
0.5 to 0.99 66 3/144.6 20.74 (6.69-64.31) 5.84 (1.21-28.25)  
1.0 to 3.99 168 4/377.1 10.60 (3.98-28.26) 2.99  (0.59-15.02)  
4.0 to 9.99 121 3/264.9 11.33 (3.65-35.12) 3.19 (0.59-17.32)  
10  141 6/306.7 19.56 (8.79-43.54) 5.51 (1.33-22.82)  
*Test for trend, p=0.02 
TST  group (mm)      
<5 mm 362 5/760.1 6.58 (2.74-15.80) 1 0.20 
5 to 9 mm 118 2/257.2 7.78 (1.94-31.10) 1.18 (0.23-6.08)  
10 to 14 mm 178 5/393.8 12.70(5.28-30.50) 1.93 (0.57-6.52)  
>15 mm 141 6/330.3 18.16 (8.16-40.43) 2.76 (0.88-8.61)  
*Test for trend, p=0.05 
* Score test for trend of odds, chi2 (1) 
In HIV positives, IRs were highest in HHCs with the highest IFN-γ levels for group 3 and the TST group  
but this was less obvious for groups 4 and 6 (Table 8.6). There was also a clear tendency of increasing 
IRRs with increasing IFN-γ levels in groups 3 and the TST group. A test for trend in HIV positives showed 
strong evidence of a trend in these groups while for other groups it was less obvious (Table 8.6). 
For all the QFT-GIT groups, HIV positive HHCs with the highest IFN-γ levels had increased IRRs ranging 
from   1.6 to 2.6 compared to the reference sub-group (table 8.6). For the TST group, results were 
similar as in HIV negatives with an almost 3-fold increase in IRR in HHCs with the highest IFN-γ level 
compared to the reference sub-group. 
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Table 8.6:  Overall incidence rates of TB and incidence rate ratios in HIV positives, by group 
(nmax=297) All TB cases (n=32). 
Variable N (col %) 
N=297 
 TB cases/pyrs Incidence rate/ 
1000 pyrs (95% CI) 
IRR (95% CI) P value 
Group 3       
<0.27 130 8/291 27.49 (13.75-54.98 1 0.02 
0.28 to 3.12 98 14/225.9 61.99 (36.71-104.66 2.26 (0.97-5.27)  
3.13 to 10 69 10/138.1 72.39 (38.95-134-53 2.63 (1.08-6.44)  
*Test for trend, p=0.04 
 Group 4      
<0.35 138 10/306.2 32.66 (17.57-60.70 1 0.23 
0.35 to <1.0 39 3/93.3 32.15(10.37-99.70 0.98 (0.27-3.57)  
1.0 to 5.0 63 13/139.6 93.10(54.06-160-33 2.85 (1.29-6.26)  
>5.0 to 10 57 6/115.8 51.81(23.27-115.31) 1.58 (0.58-4.32)  
*Test for trend, p=0.09 
Group 6       
<0.35 138 10/306.2 32.66 (17.57-60.70 1 0.25 
0.35 to 0.49 14 1/35.6 28.07(3.95-199.29 0.86 (0.11-6.70)  
0.5 to 0.99 25 2/57.7 34.67(8.67-138.65 1.06 (0.23-4.84)  
1.0 to 3.99 56 10/127.3 78.56(42.27-146.00 2.40 (1.03-5.62)  
4.0 to 9.99 35 6/70.40 85.22(38.29-189.69 2.61 (0.98-6.91)  
10  29 3/57.8 51.94(16.75-161.04 1.59 (0.44-5.70)  
*Test for trend, p=0.06 
TST  group (mm)      
<5 mm 161 13/356.3 36.48 (21.18-62.83 1 0.10 
5 to 9 mm 37 2/83.9 23.82 (5.96-95.27 0.65 (0.15-2.86)  
10 to 14 mm 51 7/110.1 63.58 (30.31-133.37 1.74 (0.70-4.32)  
>15 mm 48 10/104.6 95.58(51.43-177.64 2.62 (1.18-5.79)  
*Test for trend, p=0.01 
* Score test for trend of odds, chi2 (1) 
In both HIV positives and negatives, there was a clear trend of a tendency of increasing IRRs with 
increasing IFN-g levels for groups 3 and the TST group while this was less clear for groups 4 and 6  
(Figure 8.1 and 8.2). 
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Figure 8.1: Incidence rates in groups 3 and 6 stratified by HIV status 
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Figure 8.2: Incidence rates in the TST Group  
 
 
8.2.3 Examining linear effects between magnitude of IFN-γ response and TB incidence by group 
 
Assessing departure from linearity using LRT showed that overall there was no evidence that the 
relationship between IFN-γ levels and log odds of disease was not linear for all the groups i.e. a linear 
trend adequately described the relationship (Table 8.7) The linear trend was observed for both HIV 
negatives and positives and for all groups in SA and half the groups in Zambia (table 8.7).  
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Table 8.7: Testing for departure from linearity  
 LRT chi(2) p-value 
Overall   
Group 3 0.83 0.36 
Group 4 2.21 0.33 
Group 6 1.59 0.81 
TST group 1.71 0.42 
Overall HIV negative   
Group 3 0.18 0.67 
Group 4 0.89 0.64 
Group 6 2.93 0.40 
TST group 0.05 0.97 
 Overall HIV positives   
Group 3 0.99 0.32 
Group 4 4.05 0.13 
Group 6 2.37 0.67 
TST group 1.26 0.53 
Zambia   
Group 3 3.77 0.05 
Group 4 7.99 0.02 
Group 6 4.45 0.35 
TST group 4.17 0.12 
SA   
Group 3 0.53 0.47 
Group 4 1.07 0.58 
Group 6 4.41 0.35 
TST group 0.13 0.94 
 
8.3 TB-free survival probability using Kaplan Meier estimates  
Figure 8.3 shows Kaplan Meier survival curves for groups 3 and 4. For both groups, HHCs with the 
highest IFN-γ categories had the lowest TB-free survival probability. For group 3, the two-year TB-free 
survival probability was at 0.95 (95%CI: 0.92-0.97) among HHCs with the highest IFN-γ levels compared 
to 0.97 (95% CI: 0.95-0.99) among those in the reference group (figure 8.3).  For group 4, the TB-free 
survival probability was lower at 0.96 (95%CI: 0.93-0.98) among HHCs with the highest IFN-γ levels 
compared to 0.97 (95% CI: 0.95-0.98) among those in the reference group (figure 8.3).  
 
However, overall there was no evidence that survival curves differed for these groups (log rank test: 
group 3, p=0.19 and group 4, p=0.22) (figure 8.3). 
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Figure 8.3: Kaplan Meier survival curves for groups 3 and 4   
 
    Note: Kaplan-Meier curves:  survival curves ends in a plateau; represents some HHC without disease after the study’s maximum follow-up time  
A Kaplan-Meier curve for the TST group is shown in figure 8.4. Overall, the two-year TB-free survival 
probability was 0.97 (95%CI: 0.94-0.98) in HHCs with TST indurations <5 mm while those with TST 
indurations > 15 mm it was at 0.92 (95%CI: 0.87-0.95) (figure 8.4). There was some evidence that 
survival curves differed for the TST group (log rank test, p=0.06).   
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Figure 8.4: Kaplan Meier survival curves by TST group 
 
TB-free survival probability stratified by HIV status. 
When TB-free survival probabilities were stratified by HIV, results were similar to the overall results for 
all groups; see examples in Figure 8.5 and Figure 8.6.  
Figure 8.5: Kaplan Meier curves for group 3 stratified by HIV  
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Figure 8.6: Kaplan Meier curves for the TST group stratified by HIV 
  
8.4 Overall univariable and multivariable analyses  
 
The results for the overall univariable and multivariable analyses are presented in table 8.8. 
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p=0.01) while there was no evidence for the rest of the groups (test for trend:  p=0.10 for group 3; 
p=0.15 for group 4; p=0.08 for group 6) (Table 8.8). 
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Table 8.8: Overall univariable and multivariable analysis of time to TB episode; hazard ratios; 95% CI and P-values 
 Model 1 Model 2 Model 3 Model 4 
 
Variable 
Crude 
HR (95% CI) 
P value Adjusted HR (95% CI) P value Adjusted HR (95% CI) P value Adjusted HR (95% CI) P value 
Group 3          
<0.27 1 0.17 1 0.44 1 P<0.001 1 P<0.001 
0.28 to 3.12 1.79 (0.86-3.74)  1.68 (0.80-3.55)  2.65 (0.53-13.18)  2.42 (0.48-12.08)  
3.13 to 10 1.88 (0.90-3.93)  1.86 (0.89-3.90)  4.07(0.89-18.62)  3.83(0.83-17.58)  
1Test for trend, p value LRT 0.36  0.48      
 Group 4         
<0.35 1 0.23 1 0.57 1 P<0.001 1 P<0.001 
0.35 to <1.0 1.22 (0.46-3.20)  1.23 (0.47-3.24)  3.70 (0.62-22.22  3.40 (0.56-20.46  
1.0 to 5.0 2.08 (1.02-4.24)  1.92 (0.93-3.96  3.15 (0.61-16.31  2.93 (0.56-15.22  
>5.0 to 10 1.49 (0.70-3.17)  1.48 (0.70-3.16)  4.45 (0.94-21.01  4.35 (0.92-20.51  
Test for trend, p value 0.33  0.48      
Group 6          
<0.35 1 0.47 1 0.71 1 P<0.001 1 P<0.001 
0.35 to 0.49 0.56 (0.07-4.28)  0.55 (0.72-4.24  2n/a  n/a  
0.5 to 0.99 1.59 (0.57-4.46)  1.62 (0.58-4.55)  6.08 (1.01-36.49  5.68 (0.94-34.18  
1.0 to 3.99 1.83(0.86-3.90)  1.65 (0.76-3.59)  2.89 (0.53-15.84  2.70 (0.49-14.84  
4.0 to 9.99 1.79 (0.76-4.19)  1.77 (0.76-4.16)  3.26 (0.54-19.54  3.09 (0.51-18.55  
10  1.67 (0.71-3.91)  1.67 (0.71-3.91)  5.60 (1.12-27.79  5.48 (1.10-27.19  
Test for trend, p value 0.81  0.87      
TST  group (mm)         
<5 mm 1 0.08 1 0.21 1 P<0.001 1 P<0.001 
5 to 9 mm 0.68 (0.23-2.01)  0.68 (0.23-2.01)  1.16 (0.22-6.00  1.20 (0.23-6.21  
10  to 14 mm 1.42 (0.69-2.92)  1.30 (0.62-2.74)  1.97 (0.57-6.81  2.02 (0.58-6.97  
>15 mm 2.12 (1.09-4.13)  2.11 (1.08-4.11)  2.77 (0.85-9.10  2.58 (0.78-8.49  
Test for trend, p value 0.42  0.39      
Model 1: Unadjusted analysis 
Model 2: Model 1 adjusted by a priori confounding factors: age, sex  
Model 3: as in model 2 plus HIV as an effect modifier 
Model 4: as in model 3 plus controlled for country 
1Test for trend in the unadjusted model 
2HR: 1.5x10-9(1.9X10-10)
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Summary 
Three QFT-GIT groups and one TST group were used for sensitivity analysis after exploratory 
analysis (table 8.1). Overall for all the groups, HHCs with the highest IFN-γ levels had increased 
IRRs ranging from 1.5 to 2 compared to the reference sub-group (table 8.2). The IRRs of HHCs 
with the highest IFN-γ levels were 1.85 (95%CI: 0.90-3.83), 1.46 (95%CI: 0.69-3.10), 1.65 (95%CI:  
and 2.11 (95%CI: 1.10-4.05) for groups 3, 4, 6 and the TST group respectively (table 8.2). A test 
for trend for each group showed no evidence of a trend for groups 3, 4 and 6 while there was 
strong evidence for the TST group (test for trend, p=0.01) (table 8.2).  
For group 3 and the TST group, HHCs with the highest IFN-γ levels had the highest IRRs 
compared to the reference sub-group. For group 4 and 6, IRRs were highest in HHCs with IFN-γ 
levels between 1.0-5.0 IU/ml (IRR: 2.08; 95%CI: 1.02-4.24) and 1.0-3.99 IU/ml (IRR: 1.83; 95%CI: 
0.86-3.90) respectively (table 8.2).  
Overall, HIV negative HHCs with the highest IFN-γ levels had increased IRRs ranging from 4 to 5-
fold compared to the reference sub-group (table 8.5). For the TST group, there was an almost 3-
fold increase in IRR in HHCs in the highest IFN-γ levels compared to the reference sub-group. 
Overall for the QF-GIT groups, HIV positive HHCs with the highest IFN-γ levels had increased IRRs 
ranging from 1.6 to 2.6 compared to the reference sub-group (table 8.6). For the TST group, 
results were similar as in HIV negatives with an almost 3-fold increase in IRR in HHCs with the 
highest IFN-γ level compared to the reference sub-group. In HIV positives, IRRs were highest in 
HHCs with the highest IFN-γ levels for group 3 and the TST group  but this was less obvious for 
groups 4 and 6 (table 8.6). There was a tendency of increasing IRRs with increasing IFN-γ levels 
in groups 3 and the TST group (test for trend: group 3 p=0.04; group 4, p=0.09; group 6, p=0.06; 
TST group p=0.01) (table 8.6). 
 Therefore in both HIV positives and negatives, there was a trend towards increasing IRRs with 
increasing IFN-g levels for groups 3 and the TST group while this was less clear for groups 4 and 
6.   
In crude analyses there was some evidence in all groups that HHCs with the highest IFN-γ levels 
had 1.5-2 increased risk of developing TB although results were not statistically significant ( 
table 7.13, model 1). In multivariable analysis adjusted for sex, age and HIV as an effect 
modifier, there was strong evidence across all QFT-GIT groups that HHCs with the highest IFN-γ 
levels had approximately 4-5-fold increased risk of developing TB in follow-up (table 8.8, model 
3). For the TST group the HR in those with TST indurations > 15 mm was 2.77 (95%CI: 0.85-9.10). 
Apart from group 6, HHCs with the highest IFN-γ levels had the highest HRs (table 8.8, model 3). 
  
  189
9.0 Discussion 
 
Introduction 
In this chapter, I will discuss the results of this research project. Although the results of each 
chapter will be discussed separately, these discussions are not independent of each other. The 
objectives of the discussion are as follows:  
1. To give an overview of the key study findings for each objective. 
2. To describe what each finding adds to our understanding of the main research question. 
3. To discuss results in light of previous research in this area. 
4. To discuss the strengths and limitations of the research. 
5. To highlight study implications in terms of TB control policies and future research agenda. 
9.1 The performance and operational characteristics of QFT-GIT in Zambia 
 
At the onset of this research project we carried out a number of feasibility studies that looked at 
performance and operational characteristics of QFT-GIT in Zambia.  At that time there were very 
few feasibility studies looking at factors that may affect QFT-GIT performance in a resource poor 
setting like Zambia (242). These studies were therefore key in guiding the implementation of the 
study especially in Zambia where QFT-GIT was not centrally processed during the cohort study. 
We were able to explain and understand some of the teething problems that we had with the 
QFT-GIT assay and identify context specific solutions. 
Four small studies were used to examine performance and operational characteristics of QFT-
GIT in Zambia. The first feasibility study addressed four objectives namely; the sensitivity and 
test-retest reproducibility of QFT-GIT as well as the effect of CD4+ T-lymphocyte counts and 
delayed incubation of blood samples on IFN-γ responses. 
Sensitivity of QFT-GIT and TST 
We found that the sensitivity of QFT-GIT was 85.6% (95% CI: 77.0-91.9) compared to that of TST 
at the 10 mm cut-off of 51.6% (95% CI: 40.9-62.2). Like TST, we also found that the sensitivity 
was reduced by severe immunosuppression.  In a subgroup analysis of patients with known HIV 
status, sensitivity was lower in HIV positives, 62.9% (95%CI: 49.7-74.8) compared to HIV 
negatives, 85.3% (95%CI: 68.9-95.0) (chi2: p=0.03).  However, most systematic reviews have 
shown that QFT-GIT has higher or equal sensitivity to TST in these settings (131).  In a recent 
systematic review evaluating 37 studies that included 5,736 HIV-infected individuals, pooled 
sensitivity for QFT-GIT was  61%,( 95% CI: 41–75%) and  neither  QFT-GIT  nor  TSPOT was 
consistently more sensitive than the TST in head-to-head comparisons (131). 
QFT-GIT sensitivity is affected by several biological and operational factors. Sensitivity may be 
influenced by factors that alter the immune response (247) such as BCG vaccination, HIV, 
malnutrition, tropical infections and widespread exposure to NTM. Most of these conditions 
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which are thought to affect QFT-GIT sensitivity are prevalent in Zambia and may have been 
present in many individuals used in these feasibility studies even though we did not specifically 
measure them. For example, we found that 46.2% of the TB patients used  for  sensitivity 
analysis  were underweight and some literature suggested that they may be a relationship 
between malnutrition and QFT-GIT indeterminate results (248). It is now well recognized that 
IGRAs perform differently in low vs. high TB burden settings with lower sensitivity in high-
incidence countries  due to some of these factors (188).  
Another significant finding was that with falling CD4 count, there was a trend towards an 
increase in both indeterminate and negative results overall (test for trend, p<0.001) and in HIV 
positive patients (test for trend, p=0.03)(222).  The majority of HIV positive patients in this study 
were severely immune-suppressed (CD4/CD8 ratio was 0.45). There is evidence now from many 
studies that a low CD4+ count (<200 cells/all) is associated with increases in indeterminate 
results (131, 217, 222, 223). 
Test-retest reproducibility 
Test-retest reproducibility may not be relevant in routine practice but becomes very important 
when contemplating serial screening for high risk groups like health workers (181); also useful in 
cohort studies like this one.  We reported a high test-retest reproducibility of QFT-GIT assay of 
91.74%. Our study  confirmed that QFT-GIT has excellent reproducibility although the 
percentage was lower than that of the manufacturer (a diagnostic reproducibility of 97.2% 
(95%CI 94.1%-98.7%) (249). Despite the substantial body of literature on IGRAs over the recent 
years, few studies have data on test-retest reliability and reproducibility of IGRAs (157, 191, 230, 
250), especially under field conditions (251). Some studies have focused on within-person 
variability of QFT (250, 252).  
Effect of delayed incubation on IFN-γ response  
 Another objective of the feasibility studies was to determine the effect of a 24-hour delay in 
incubation of blood samples on IFN-γ  responses. We showed that a 24-hour delay in incubation 
decreased IFN-γ responses by 3.34 IU/ml and changed the results for 22.9% patients.(251). Most 
results changed from either positive or negative to indeterminate. In both the reproducibility 
and delayed incubation studies, the reason for the indeterminate results for approximately 95% 
of results was due to low TB Antigen minus Nil and low Mitogen minus Nil responses, suggesting  
either a poor immune response(251) or degradation of cells in the process. 
Indeterminate results such as a high background detected in the negative control tube, or low 
responses in the positive-control tube,  may be explained by technical factors or an impaired 
immune system (175). A low response to Mitogen (<0.5 IU/mL) indicates an indeterminate 
result when a blood sample also has a negative response to the TB antigens (249). This pattern 
may occur with insufficient lymphocytes, reduced lymphocyte activity due to prolonged 
specimen transport or improper specimen handling, including filling/mixing of blood tubes, or 
inability of the patient’s lymphocytes to generate IFN-γ (249). Elevated levels of IFN-γ in the Nil 
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sample may occur with the presence of heterophile antibodies, or to intrinsic IFN-γ secretion 
(249). 
One of the duplicate samples (standard incubation 1) was used as a comparison to the set of 
samples that was delayed (delayed incubation). Either set of duplicate samples could have been 
used as a comparison to the one that was delayed as the agreement between the duplicate 
samples was high and the discordance was not significant. The decrease in IFN-γ responses due 
to delayed incubation has implications for resource limited settings especially in our settings 
where samples may not be incubated within the recommended time due to operational 
problems. 
The effect of power outages on IFN-γ responses (Study 2) 
 Our second feasibility study aimed to determine the effect of power outages on IFN-γ responses 
during incubation. This study was conceived as a result of serious power outages that the 
country (Zambia) was experiencing which affected the study sites as well. We found that power 
outages, especially those that occurred during late incubation decreased IFN-γ responses to TB 
antigens by 0.8 IU/ml. The processing of QFT-GIT is dependent on a stable power supply needed 
for, particularly, incubation, centrifugation and freezing of samples (if ELISA is performed in 
batches from a central point). However, incubation remains a critical part of the process as it 
requires a constant power supply for at least 20-24 hours (manufacturers’ recommendation). In 
certain cases , it is recommended that an uninterruptable power source, for instance, a UPS 
system or generator be installed in case of power outages in settings where this is a problem. 
Some equipment may even malfunction owing to frequent power supply interruptions.  
Power outages are a potential problem in many developing countries and this may affect 
processing (especially incubation) and storage of QFT-GIT samples. The decreased IFN-γ 
response due to power outages during incubation  led to minor modification of the QFT-GIT 
protocol in our sites (251). The incubation time was extended following power outages with the 
aim of achieving an overall incubation period of 16-24 hours. It remains unknown whether this 
benefit could have been sustained during long periods of power outages. 
 Although it could have been possible to counteract the effect of power outages in our sites by 
using generators, solar energy or better-insulated incubators, this unplanned cost was  difficult 
to implement (251). Since no such measures were in place during the course of the study, 
management forms were used to capture data on samples that experienced power outages. 
Effect of storage temperature on IFN-γ response  
 Our third feasibility study aimed to determine the effect of increased storage temperature of 
unused blood collection tubes on IFN-γ responses. This study demonstrated that storage of 
unused blood collection tubes at 37°C for three months had no effect on IFN-γ responses. In this 
setting, storage space with the recommended temperature of 4-25°C (air conditioned room or 
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refrigerator) is limited.  Therefore this was reassuring for the study staff especially those who 
were in the remote areas in Zambia. 
General comment on studies above 
These studies demonstrated that there are some biological and operational factors that affect 
the performance of this test in this setting. HIV positivity, low CD4+ T-lymphocytes, delayed 
incubation of blood samples and power outages all affect test performance. While most of these 
factors can be controlled, the effect of HIV infection like TST may be a major limiting factor for 
the role of this test. These feasibility studies emphasize the need for stringent sample collection 
and processing techniques to ensure the accuracy of QFT-GIT results.  
Role of Quality Assurance 
A multi-disciplinary Quality Assurance (QA) team was constituted during the course of the QFT 
cohort study due to the decentralized nature of sample collection, incubation, separation and 
storage.  The aim of the QA team was to ensure that sample processing was done accurately as 
well as identify and correct gaps and weaknesses. A similar team was not formed in SA because 
samples are processed centrally and the laboratory already had existing QA systems. The QA 
visits were done once a year in all the sites although the QA team also conducted other support 
supervision visits in sites experiencing difficulties. 
A QA monitoring tool was designed to help with this process. There were also other routine 
laboratory checks each time samples arrived at the central laboratories and these included: 
checking for leakages during transportation, quality of the sample, correct use of barcodes, type 
of specimen bottles and packaging used.  
The financial cost of using QFT-GIT for the diagnosis of TB infection  
 In the fourth feasibility study, we aimed to determine the financial costing of diagnosing TB 
infection using QFT-GIT from the provider’s perspective. Cost can be a major barrier for the 
introduction of a test even if other performance factors are favourable. In this study we found 
that the total cost of performing a QFT-GIT test was estimated at US$ 22.29 in our setting. 
In this study, we collected costs using the ingredients approach (243). The ingredients approach 
to cost estimation entails three distinct phases: identification of ingredients; determination of 
the value or cost of the ingredients and the overall costs of an intervention; and an analysis of 
the costs in an appropriate decision-oriented framework. This approach was used for all 
procedural steps that are required for performing QFT-GIT testing. 
In public health interventions, cost analysis should be based on economic costing rather than 
financial (253).  Ideally, a better designed study could have been a cost effective analysis 
comparing QFT-GIT and TST as tools for diagnosing tuberculous infection. The goal of cost-
effectiveness analysis is to identify interventions that provide the greatest health impact with 
  193
the lowest cost per unit of output. However, this did not come to fruition during the course of 
this study because it was not one of the objectives of the study.   
There are many guidelines on the use of QFT-GIT for diagnosing TB infection, some of which are 
based on cost effective studies. The perspective of our study was that of a provider and thus did 
not take other costs into consideration such as those to the patients. By using the financial 
approach of costing we did not include indirect costs and thus did not put the opportunity cost 
into consideration. 
Our analysis has some limitations in that the costs did not include the cost of maintenance and 
servicing of equipment. This is because records on expenditure specific to this study were 
sometimes difficult to triangulate. The costs of ZAMBART administration were not included in 
the overhead cost because it was difficult to estimate the percentage of their contribution to 
the study. However, this would not have a significant effect on the final cost because QFT study 
expenditures were embedded in the ZAMBART’s main expenditures.  
9.2 Baseline results  
 
Study population at enrolment 
This study is among the first studies in HHCs in SSA to conduct both TST and QFT-GIT tests using 
a large sample size which illustrates the realistic implementation of QFT-GIT in a setting with a 
high burden of TB and HIV. It is one of the largest cohort studies evaluating the predictive value 
of QFT-GIT among HIV positive and negative HHCs in SSA. 
The QFT-GIT cohort was nested within ZAMSTAR, which was a big study involving approximately 
1.2 million individuals. Although the aim of this section is to discuss baseline results of the QFT-
GIT cohort study, a brief discussion of the ZAMSTAR SOCS numbers at enrolment is necessary 
due to the nested design of the study under discussion. In addition, some of the findings or 
limitations of this study arise from the design of the main study.  
Out of the 16,824 adults enumerated in the ZAMSTAR SOCS study 9,582 (56.8%) agreed to take 
part in the SOCS study. Reasons for not enrolling into the study show that refusal rate was high 
(62.6%) as well as absenteeism (29.2%). High refusal rate was probably because ZAMSTAR was 
the first time most of these communities were exposed to a trial of this magnitude and the 
concept of research especially the idea of signing for one’s consent. Many individuals in these 
communities had been exposed to routine home based TB/HIV services that didn’t require 
consent. Other reasons for refusal could have been due to lack of community trust, poor 
explanation of the study by study staff especially in households where individuals had already 
consented to taking part in one component of the study; both the household intervention and 
SOCS teams visited the same households. Also some people may have refused because they had 
to answer three long questionnaires during each visit. While some of these reasons were 
addressed and improved during the course of the study, for SOCS it was not possible to recruit 
new individuals in subsequent follow-ups as this was a cohort. It was not possible to 
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differentiate at this stage the refusals that were specific to the QFT-GIT cohort study as this data 
was not being collected. Like every study, ZAMSTAR was designed to meet certain objectives 
with little flexibility making it difficult to collect many additional data specific for this study 
without making the entire process complex for the study participant.  
High rate of absenteeism was due to the fact that most of the individuals in these households 
were out trying to earn a living through socio-economic activities. Additionally, at the beginning 
of the study no prior formal appointments were made to visit some of these households; once 
the index TB patient gave the study team permission to visit the house, household members 
were visited on the same day although thereafter appointments were made for those who were 
absent. An individual was described as absent only after three failed visit attempts. Similarly as 
for refusal, it was not possible to determine which absenteeism was specific for QFT-GIT as this 
data was not being collected.  
 We were not able to determine reasons why some 228 HHCs did not have QFT-GIT tests done. 
However, since QFT-GIT was offered to everyone, it can be assumed that QFT-GIT tests were not 
done for the same reasons explaining why HHCs were not enrolled into SOCS at the different 
follow-up times. Such reasons were due to refusal, absenteeism, moved or died. This is why we 
restricted the analysis to adults enrolled in SOCS and in whom QFT-GIT test was performed.  
In this study 88 samples were excluded either because the blood samples were spoilt or 
insufficient. Usually samples were considered spoilt if blood had hemolyzed in the mitogen tube 
(if any other tube the sample was run), incubation had been severely affected by disrupted 
power supply or if not well stored prior to being processed.  
The study population at baseline consisted of 1,789 HHCs who were predominantly women 
(71%) and had a median age of 28 years (IQR: 21-43). This study enrolled few men at enrolment 
(>70 % of HHCs at enrolment were women) because it was difficult to find men at home as they 
were out involved in socio-economic activities, some of which included income generating 
activities. This finding is not unfamiliar for most African settings. Men may also have been 
absent from home because of social activities such as beer drinking as well. Some of the 
qualitative work in these communities before the start of the study showed high levels of 
unemployment in these communities and that men spent a lot of time away from home in 
taverns and beer halls (ZAMSTAR BBS findings, unpublished). In this study, only 23% of HHCs 
were employed. Although a majority of HHCs in these communities reported that they did not 
take alcohol (75.5%) or smoke (82%) this could have been due to reporting or response bias.   
As expected in this setting, overall, the prevalence of HIV infection in HHCs was high at 27.9%, a 
reflection of the burden of disease in the sub-Sahara region. The prevalence of HIV was higher, 
overall in Zambian communities compared to SA ones probably because Zambia had double the 
number of communities in SA, hence more HHCs. It is well known that SA has one of the highest 
prevalence of HIV in the sub-Sahara region (89, 91, 92). In 2009, HIV prevalence in antenatal 
women was 16.4% in  Zambia (93) and 29.4% in South Africa (89, 91, 92). 
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HIV prevalence was highest in the youngest age group, 15-24 years. Young people, ages 15–24, 
account for 41% of new HIV infections (among those 15 and over)(254). As expected and widely 
accepted, HIV prevalence was higher in women compared to men overall and when stratified by 
country. Women represent slightly more than half of all people living with HIV worldwide, and 
60% in sub-Saharan Africa. Gender inequalities, differential access to services, and sexual 
violence increase women’s vulnerability to HIV, and women, especially younger women, are 
biologically more susceptible to HIV. In sub-Saharan Africa, the HIV prevalence rate among 
young women is more than double that of their male counterparts (254). 
Uptake of IPT among self-reported HIV positive HHCs was low at 4.7% (7/148). This is because 
IPT is not routinely offered by the Ministry of Health in Zambia and in SA its uptake has been 
problematic even after the policy was revised in 2010 to remove TST as a requirement to start 
therapy (255). Nevertheless, at the time of this study a pilot project to demonstrate the 
operational feasibility of providing IPT through the primary health care system was done in the 
16 ZAMSTAR sites by ZAMBART project and the MoH in Zambia.  However, in this study because 
of the few numbers, further baseline or survival analysis with IPT data was not possible to do.  
Prevalence of Tuberculous infection  
Findings in this study suggest a high prevalence of TBI among this population, 63.7% as 
determined by QFT-GIT (0.35 IU/ml cut off) and 39.7% using TST (10 mm). These findings are 
consistent with results observed elsewhere (166, 182). In a community based cross sectional 
study in Ethiopia among 652 healthy pastoralists, the prevalence of TBI was 63.7% using QFT-GIT 
and 31.2% using TST (10 mm)(182).  In another prospective study enrolling 5244 adolescents 
aged 12-18 years from high schools in Cape Town, SA, 50.9% had a positive QFT-GIT while 42.2%   
had a TST ≥10 mm (166). In a recent systematic review by Fox and colleagues looking at 203 
published studies of which 95 studies were from middle and low income countries to determine 
prevalence of TBI  and incidence of TB in HHCs, the prevalence of LTBI (defined as TST ≥10 mm 
or definition applied in paper if not available) was 51.5% (256). 
 In a cross sectional study done in Zambia by Talati and others to assess the prevalence of and 
risk factors for a positive test for TBI, among 596 (298 HIV-discordant couples) individuals, the 
overall prevalence of TBI was  55.5%, 47% and 44.5% using TST, QFT-GIT and TSPOT respectively. 
In contrast to this study, in the study by Talati and others, a positive TST was defined as ≥5 mm 
of indurations in HIV-infected persons and ≥10 mm in HIV-seronegative persons and HIV 
prevalence was  very high since half of the participants were HIV positive (257). In another study 
done in India among 719 health workers, the prevalence of TBI was 40.1% using QFT-GIT and 
41.4% using TST (258).  
 In this study, TBI prevalence was lower by 24 % when defined by TST compared to QFT-GIT (i.e. 
difference in % positive). Despite our teams being trained and the reading standardized, TBI 
prevalence as defined by TST (10 mm cut off) was lower than expected probably due to the 
effect of HIV and the well recognized limitations in its operating characteristics. In Zambia, 
because of the geographical position of the communities most of the study procedures for both 
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SOCS and QFT-GIT were decentralized while in SA where possible a central team was 
maintained. Therefore overall, TST testing in both countries was done by different teams (one 
team consisted of two nurses and one research assistant) although as much as possible the 
same injectors and readers were used for a specific community. Use of different teams may 
have contributed to inter-reader variability. In addition, it is not widely appreciated that a 
substantial proportion (perhaps up to 50%) of close contacts of microbiologically confirmed 
index cases, even in many  high burden settings, have no immunodiagnostic (positive TST) 
evidence of LTBI (10). 
TBI prevalence in HIV positive HHCs was lower than that in HIV negatives for both  QFT-GIT (HIV 
positives 52.8% Vs. HIV negatives 67.8%) and TST (HIV positives 34.6% Vs. HIV negatives 41.5 %), 
as shown elsewhere (131, 173). QFT-GIT just like TST is prone to false negatives in HIV positive 
populations. 
In line with recommendations of using a 5 mm cut-off for HIV positives (259), TBI prevalence in 
this study was 47.03%. In settings with high TB prevalence, use of TST at the 5 mm cut-off even 
in HIV positives may result in increased false positives; hence others still recommend use of a 10 
mm in  this group (260). Current evidence suggests that IGRAs perform similarly to the TST at 
identifying HIV-infected individuals with TBI (131, 173). In the study done in Zambia by Talati 
and others, HIV positive persons were significantly less likely to have a positive TST, QFT or 
TSPOT result (differences in % among HIV positive and negatives ranged from 16-26%) (257). In 
a study done in Western Cape Province in SA, among 43 HIV infected adults and children, 
prevalence among the different tests was 28% QFT; 61% TSPOT and 41% TST (147). The QFT 
results are lower than ours due to the small sample size and a different study population (almost 
half were children). In a study conducted in a SA community a large proportion (58%) of the HIV 
positive patients had cutaneous anergy to PPD (261). 
TBI prevalence was higher in SA communities compared to the Zambian ones, using both QFT-
GIT (SA: 71.1% vs. Zambia 58.3%) and TST (SA: 47.2.1% vs. Zambia 34.1%) as in previous findings 
(95). This is because overall, the burden of infection and disease is higher in the SA compared to 
Zambia.  A large TST survey done in 2005 as a  baseline study  and for randomization purposes of 
the ZAMSTAR study  found that the ARTI in the Zambia was between 0.8%-2.8% and 2.5% -4.2% 
in SA, depending on the method used (95). These results confirmed that TB transmission is high 
in these communities, irrespective of the method used to define it. In the 2012 WHO Global TB 
report, incidence rate of TB was 444/100,000 for Zambia and 993/100,000 for South Africa 
thereby confirming findings in this study (85). 
Risk factors associated with positive QFT-GIT and TST results 
Although neither IGRAs nor TST are gold standards for TBI, an analysis of risk factors associated 
with test positivity are used as a proxy of the risk factors for Mtb infection. In this study, 
important risk factors associated with QFT-GIT positivity were HIV positivity (aOR: 0.48; 
p<0.001), residing in an urban area (aOR: 2.37; p<0.03), smear status of index (OR: 1.34; p=0.01) 
and country (aOR: 1.93; p<0.001) in multivariable analysis adjusted for age, sex, country and 
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household clustering. Similar results were obtained for TST. QFT-GIT may not be more sensitive 
than the TST to detect risk factors associated with TBI.  
As expected, exploration of QFT-GIT and TST results by age revealed a trend to increased 
responses with increasing age. Studies (61, 166, 262) have shown that QFT-GIT positivity 
correlates with increasing age as a result of a higher prevalence of TBI in the older age groups 
(due to cumulative exposure in settings with a high burden of TB) or suboptimum sensitivity in 
younger individuals. In two studies done in Columbia and Uganda, exploration of IFN-gamma 
variations by age revealed a trend to increased responses up to adulthood with CFP, but not 
with CFP-10 (35, 263). However, children were included in both of these studies. 
HIV positivity was less common among those with positive results on QFT-GIT and TST. Some 
studies have shown that IGRA sensitivity is lower in individuals with HIV and severe 
immunosuppression (185, 222). Current evidence suggests that IGRAs perform similarly to the 
TST at identifying HIV infected individuals with TBI (131). 
For both QFT-GIT and TST, prevalence of infection was higher in contacts exposed to smear 
positive index cases compared to smear negative ones, consistent with findings of other studies 
(264). It  is widely accepted that infection is more likely to occur from close contact with a 
sputum smear positive case (58). The rates of infection in HHCs with a sputum positive index 
case are 30-50% above community controls (58). In sputum negative culture positive cases, 
transmission occurs to a lesser extent of 5% above community controls. Sleeping proximity of 
the contact to the index case was not associated with either QFT-GIT or TST results although this 
relationship has been well established in other studies that predominantly have HIV negative 
populations (211, 214). There is growing evidence suggesting a stronger and better defined 
association between surrogate markers for TB exposure and QFT-GIT results in low TB incidence 
settings compared to high-TB incidence settings (149).  
It is now well accepted that transmission of TB in high incidence settings occurs not only within 
households but in the community as well (57) and among various social locations (265).  A study 
in Zimbabwe found that the proportion of ELISpot positive contacts was not different from 
community controls (264) while in another study done in two communities in Zambia, almost 
50% of community controls were QFT-GIT positive (63).  The mix of intra- and extra- household 
transmission varies according to the degree of TB endemicity in the general population. In a high 
TB prevalence setting in Capetown, South Africa, isolates matched on molecular subtyping in 
less than half (46%) of households with two TB patients and it was estimated that only 19% of 
Mtb transmission occurred within households (57). However, an existing problem is the 
occurrence of multiple (mixed) infections in high prevalence settings. In such places, 
transmission routes are less clear. It has been argued that, in settings of high endemicity where 
a mixture of recent and old infections are commonly found, long term assays are more sensitive 
than those with shorter culture times (35).  
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Concordance between QFT-GIT and TST 
 An assessment of agreement between QFT-GIT and TST tests in this study showed that  28.2% 
were concordantly negative, 31.6% were concordantly positive, while 40.2% were discordant 
(p<0.001) at TST ≥ 10 mm. There was a low level of agreement between the tests regardless of 
TST cut-off point (% agreement=59.7%; kappa=0.24) consistent with findings of studies done in 
high-TB burden settings (183, 211, 264). As IGRAs are designed to be more specific than TST, 
perfect agreement is not expected (266). However, better agreement has been shown when the 
comparison is done within specific risk groups like HIV positives (218).  
In this study, QFT+/TST- discordance (575/719; 80%) was more frequent than QFT-/TST+ 
discordance (144/719; 20%) at TST ≥10 mm and this was true of other TST cut-offs  and 
regardless of HIV status. Particularly high number of QFT+/TST- discordant results have been 
found in studies from poor-resource settings (212). In contrast, studies done in settings with low 
TB incidence (202, 267) have shown that TST+/QFT- discordance is more common.  
In this study, 20% of HHCs were positive by TST but negative by QFT-GIT. The reason for 
TST+/QFT- discordance has been generally explained by a false positive TST, reflecting former 
sensitization by either BCG or environmental mycobacteria/NTM or diminished sensitivity of 
QFT-GIT compared with TST. A study from South Africa found that among those with large TST 
reaction (>=15 mm), approximately one-third had negative QFT tests (183). In a study from 
India, 11% of individuals with positive TST (at least 15 mm) were negative by QFT (112). 
TST+/QFT- discordance could also indicate a genuine difference between TST and IGRAs in their 
ability to detect remote and probably cleared infection versus recent, persisting TB infection 
(52).  It has been suggested that TST and IGRAs may not be equivalent in what they measure. T-
cells responding to the RD antigens after 24 hours stimulation are predominantly CD4 T-cells of 
an effector memory phenotype, consistent with having recently encountered antigens in vivo.  
TST reflects the mobilization of a wider spectrum of memory T-cells that are long-lived and may 
even persist after clearance of live mycobacteria (5). 
TST-/QFT+ discordance has been explained by a past history of TB infection, poor TST sensitivity 
or false positive QFT-GIT (197). However, TST+/QFT- discordance may indicate a diminished 
sensitivity of QFT-GIT compared with TST in low TB incidence settings rather than high TB 
incidence settings where it is increasingly being accepted that sensitivities of the two tests are 
most likely comparable (149). Another reason for TST-/QFT+ response discordance could be 
related to variations around the respective thresholds, since both tests are continuous measures 
(52).  In a study in Cape Town among 43 HIV positive adults and children (147), in 42% of 
subjects with discordant results, IGRA values were close to the manufacturers’ recommended 
cut-offs. Low cut-off points may be a possible cause of lower specificity and higher rates of false 
positives.  
In clinical practice, discordance between QFT-GIT and TST follows different guidelines. For 
instance in the case of an individual with a history of BCG vaccination and a positive TST and 
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negative IGRA results, if risk for TBI is otherwise low, it is reasonable to assume that the TST 
result is false positive and to withhold further evaluations (149). In the case of a negative TST 
and positive IGRA results, if the individual is considered to be at a high risk for TBI the negative 
TST result alone should not prevent further examination (149). Another consideration when 
interpreting discordant TST and IGRA results is the observation that TST preceding IGRA testing 
could boost IGRAs (268). This effect appears more pronounced on the days after the TST and 
could wane with time. However, this study did not explore reasons for discordance between the 
two tests as it was outside the scope of this thesis. 
9.3 Are IGRAs better than the TST at predicting HHCs at highest risk of progression to active 
TB? 
 
 In 2010, WHO identified the prognostic ability of IGRAs compared to the TST, to accurately 
identify people living with HIV at a higher risk for progression from latent to active TB as a 
priority research question in resource limited setting (269). This research gap has not yet been 
adequately addressed. In this study, I aimed to address this. 
The aim of this thesis was to report overall results for Zambia and SA due to the expected small 
number of TB incident cases (the primary outcome). However, exploratory analyses by country 
revealed that there were important differences between the countries that could affect or 
explain the overall results. Therefore in some sections of this thesis, results were presented by 
country to emphasise these important differences. Some of these differences could be 
explained by differences in the burden of TB infection and disease and some variation in the 
implementation of the study between the two countries. Country was also identified as an 
effect modifier in the association between QFT/TST positivity and TB incidence.  
In this study, I report a high incidence rate of TB in HHCs, compared to the general population. 
Out of the 1,113 HHCs that entered follow-up, 51 (4.6%) developed active TB over 2,433 pyrs, 
giving an IR of 20.96/1000 pyrs. This represents TB rates that are more than that of the general 
population in Zambia and SA respectively. TB  rates were 993 for SA and 444 for Zambia per 100, 
000 population in 2011 according to WHO’s global TB report (85). It is well known that close 
contacts of infectious TB cases such as HHCs are at a higher risk of becoming infected with Mtb 
and development of active TB (256). Studies have shown that individuals with recent infection 
such as HHCs rapidly progress to disease (64, 66, 270) and that recent infection is ten times 
more likely to produce a case than a long standing infection (271). 
The overall TB incidence rates in this study were also higher than those found elsewhere. In a 
study in Senegal, among 2,679 HHCs,TB was diagnosed in 52 contacts; IR was 9.27/1000 pyrs  
(159).  Among 2,348 HHCs in Gambia, 26 were diagnosed with definite TB; IR was 6/1000 pyrs 
(164). Out of 908 children and adolescents HHCs in Turkey, 15 developed TB; IR was 12.5/1000 
pyrs (158). In one of the largest prospective studies conducted among 5,244 high school 
adolescents in Cape Town, SA (166), 67 cases of bacteriologically confirmed TB were detected 
giving an overall incidence of 4.5/1000 pyrs. 
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The proportion of HHCs with incident TB reported in this study is consistent with previous 
findings in contact investigation studies in similar settings (272). HHCs studies among TB 
patients and large epidemiological surveys have established this effect (273). Morrison and 
colleagues performed a systematic review to determine the yield of TB in  HHCs (273). In this 
review which included 41 studies the overall yield for all TB (bacteriologically confirmed and 
clinically diagnosed) was 4.5% (95%CI: 4.3-4.8) of contacts investigated; for cases with 
bacteriological confirmation the yield was 2.3% (95%CI:2.1-2.5)(273). In this study, the yield of 
TB was 4.6%.  
There was some evidence that QFT-GIT positive (IRR: 1.65; 95%CI: 0.86-3.37; p=0.06) and TST 
positive (IRR was 1.88 ; 95%CI: 1.04-3.41; p=0.01) HHCs had a two-fold increased risk for 
developing TB compared to test negative ones, although for QFT-GIT the results were not 
statistically significant. These results are consistent with results shown elsewhere in similar 
settings (108). 
In this study, IR was highest among HHCs positive by both tests, 32.4 (95%CI: 21.87-47.89) per 
1000 pyrs. This IR is much higher than that of longitudinal studies reporting IRs for both TST and 
IGRA done in Gambia, Turkey, Senegal and India (158, 159, 164, 274).  In these studies, the IRs 
ranged from 3.9 to 22.2 per 1000 pyrs in individuals with positive concordant results; however 
the study populations were different (children, HHCs, HCWs). In the study in Senegal, HHCs with 
both TST and ELISPOT positive responses had an IR of TB of 14.74/1000 pyrs (159). In the study 
in India, HCWs with concordant positive test results had an IR of  3.90 (95%CI:1.62-9.38) per 
1000 pyrs although results were not statistically significant (274). In the studies in Turkey and 
Gambia, the IR among ELISpot-positive and TST-positive were 22.2 (95% CI: 10.6–40.8) and 8.86 
(95%CI: 2.4-15.4) per 1000 pyrs respectively. 
 The IR among discordant pairs in this study were comparable to each other. There was little 
difference in IRs between the discordant pairs for the three studies done in Gambia, Senegal and 
India (IRR ranged from 1.1 to 1.3)(159, 164, 274) while the study in Turkey (158) showed an IRR 
of 1.58 (95%CI: 0.03-30.38)(275). IR was lowest among HHCs with negative concordant results, 
14.42 (95%CI: 7.76-26.81), as shown elsewhere (158, 164). 
A key finding in this study was the strong evidence supporting the association between QFT-GIT 
positivity results and development to subsequent TB in both unadjusted and adjusted analyses. 
Compared with test-negative results, QFT-GIT-positive (aHR: 2.20; 95%CI: 1.14-4.25; p=0.02) and 
TST-positive (aHR: 2.19; 95%CI: 1.24-3.86; p=0.007) results had similar risks of progression to TB 
in multivariable analysis adjusted for sex, age and HIV. These findings are consistent with IRR 
reported in this study for both tests. This is the first time these results are being reported in 
HHCs in a high TB/HIV burden settings like Zambia and SA although previous studies done in 
Colombia, Gambia and Senegal have shown similar results (35, 159, 164).  
The studies done in Colombia, Gambia and Senegal found that HHCs with positive ELISPOT or 
TST results at baseline were associated with  a two-fold increased risk of developing active TB 
compared to those who were ELISPOT or TST negative (35, 159, 164). Although all three studies 
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involved HHCs followed up for 2-3 years, important differences with this study were the use of 
different assays and the lack of a HIV infected population (2% were HIV positive in the study in 
Gambia). All three studies used in house ELISPOT or whole blood assays in contrast to the 
commercial types of IGRAs, like QFT-GIT (35, 159, 164). Despite this, all these studies including a 
recent systematic review by Rangaka and others (275) confirm similar findings as of this study. 
 In the systematic review by Rangaka and others (275), 15 studies with a combined sample size 
of 26,680 participants were evaluated. Compared with test-negative results, IGRA-positive and 
TST-positive results were much the same with regard to the risk of TB; pooled IRR in the five 
studies that used both was 2.11 (95% CI: 1.29–3.46) for IGRA vs. 1.60 (0.94–2.72) for TST at the 
10 mm cutoff(275). However, heterogeneity was high.  In addition, the relative risks differed 
between studies with possible incorporation or work-up biases (IGRA considered in the 
diagnosis of TB mainly from high income countries; RR 8.35; 95%CI: 3.19-21.87) and studies 
without this bias (from low-income or middle in-come countries; RR 2.22; 95%CI: 1.54-
3.19)(275). 
In the review by Rangaka and others, there was only one study done in SA; the study in high-
school adolescents in SA (166, 275). Furthermore, apart from the study done in Kenya among 
HIV positive pregnant women,  no other study had a “reasonable” at risk population of HIV 
negative and positive  individuals (in one study in Gambia, 2% of individuals were HIV 
positive)(167, 275). Most of the studies done in inpatient or outpatient clinics consisted of HIV 
positive individuals only (167, 172). 
A study in Turkey that looked at children and adolescents (0-16 years) HHCs, 76% whom were 
given IPT  found  a  3- to 4-fold increased risk for progression to TB in ELISpot positive HHCs 
relative to ELISpot-negative ones (158). Among silicosis outpatients (33% were given IPT) in 
China, Leung and others found that a positive T-Spot.TB test significantly predicted the 
subsequent development of active TB (relative risk: 4.50, 95% CI: 1.03-19.68) and culture/ 
histology-confirmed TB (relative risk: 7.80, 95%CI: 1.02-59.63)(168). The details of these studies 
have been well summarized in two systematic reviews (275, 276).  
Results by country showed that there was strong evidence that QFT-GIT positive HHCs residing 
in Zambia had a five-fold increase in  IRR compared to  QFT-GIT negative ones (IRR: 5.24; 95%CI: 
1.59-27.21; p=0.0007).  This is the first time this finding is being reported.  
For HHCs residing in SA there was weak evidence that QFT-GIT-positive results (IRR: 0.60; 95%CI: 
0.25-1.50; p= 0.11) could predict subsequent development of active TB in HHCs. This evidence 
remained the same in both unadjusted and adjusted analyses. Interestingly, there was some 
evidence in both unadjusted and adjusted analyses that positive TST results could predict who 
develops active TB, although numbers were small. For the TST, HR remained similar across all 
models, as in the overall results and the ones for Zambia. In all models, there was some 
evidence that TST positive HHCs had a two-fold increased risk of developing TB, although results 
were not statistically significant due to the small numbers. Hence whilst results may reflect that 
QFT-GIT was not predictive of who develops TB in SA, TST consistently showed this evidence. 
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The QFT-GIT results from SA reported in this study are different from a recent study (166) done 
in the same setting. In the  study in Cape Town SA, among 5,244 adolescents (166), IRR  was 2.9 
(95%CI: 1.55-5.41) in QFT-GIT and 2.7 (95% CI: 1.4–5.0) in TST positives compared to negatives. 
However, the difference in results with this study could be differences in target population, age 
groups and inclusion of a HIV positive individuals (166). 
Some reasons can be explored to explain the differences in QFT-GIT results between Zambia and 
SA. Some obvious reasons have been discussed in detail in the introduction and these include 
differences in the following areas: climatic conditions; urbanization and stage of TB/HIV 
epidemic (see details in introduction). It is plausible also that because SA has a higher 
prevalence of infection (also confirmed by this study) and disease the force of infection in SA is 
very high i.e. that most people had converted by the time TB was being diagnosed. In addition it 
is also plausible that the QFT-GIT test did not work well due to technical reasons or a reduced 
sensitivity which was as a result of an advanced HIV epidemic. This study did not have evidence 
that HHCs residing in SA were more severely immuno-suppressed than those in Zambia but this 
study showed consistent results in SA in both IRR and HR. It is plausible that the HIV positive 
HHCs in SA were more severely immuno-suppresed which led to less QFT-GIT positivity and 
caused interaction. 
Predictive value of QFT-GIT versus TST 
Overall, the PPV for QFT-GIT was 5.4% while that of TST was 6.6%. These observations mean 
that the majority of HHCs (more than 95% for QFT-GIT and 93% for TST) would not progress to 
disease during the observed follow-up time. The overall PPVs reported in this study were not 
consistent with those reported in a systematic review consisting of studies done mainly from 
low TB incidence settings (142). In the review by Diel et al, the PPV for  QFT-GIT and the T-
SPOT.TB both showed a similar PPV for progression;(2.8-14.3% for QFT-GIT; 3.3-10% for 
TSPOT.TB and 2.3–3.3% for TST)(142). However, limitations of this review were the low number 
of individuals included in the studies, the short durations of follow-up and absence of studies 
from high burden settings.  
Overall both tests had comparable NPV estimated at 97%. High NPVs were found for five studies 
performed in low-incidence for both the QFT-G-IT and the T-SPOT.TB (pooled NPV of 97.8% for 
TSPOT.TB and 99.8% for QFT-G-IT). This indicates that an individual testing negative will most 
likely not develop TB in the future. Similar conclusions can be drawn for PPV and NPV when 
results were stratified by country.  
Based on a systematic review (275) and international expert opinion, WHO recommended in 
2011 that neither IGRAs nor the TST should be used in low- and middle-income countries for the 
identification of individuals at risk of developing active TB (strong recommendation)(111). At the 
time of issuing this policy on IGRAs, the quality of evidence for the predictive value of IGRAs was 
very low. The recommendation by WHO was based on three studies with heterogeneous 
populations (older males with confirmed silicosis, school-going adolescents, and adult TB 
contacts including HIV-infected individuals (111). The three studies included  one published 
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study  from China (168)  and  two unpublished (Zambia and South Africa) (Zambia: one 
presented in this thesis and South Africa now published by Mahomed and others (166)).  
Much of the evidence from which the WHO policy was based on  showed an association with 
subsequent incident TB in test-positive individuals compared to test negatives appeared higher 
for IGRA than for TST; however, this was not statistically significant (IGRA:  IRR=3.24; 95% CI 
0.62-5.85; p=0.90; TST: IRR=2.28; 95% CI 0.83-3.73). Furthermore, the vast majority of 
individuals (>95%) with a positive IGRA result did not progress to disease during follow-up.  
 Therefore as previously reported by others (108, 111) both IGRAs and the TST appear to have 
modest predictive value and may not help identify those who are at highest risk of progression 
to disease. Several reasons could be put forward as to why the predictive value of QFT-GIT is 
likely to be modest. One of the reasons suggested for lack of prognostic value of IGRAs in high 
burden settings is the endemicity of TB; community transmission may dilute prognostic 
usefulness (167). In a setting where TB is endemic and households are large and likely to contain 
co-prevalent TB cases, it is extremely difficult to determine the exact time of TB exposure 
(where an IGRA assay is likely to perform the best). IFN-γ alone might not be sufficiently 
predictive of progression (or correlate of protection). A single TST or IGRA result cannot tell us 
about the underlying phenotype of when infection occurred and how the host immune system 
responded (159).  
Overall incidence rates and risk of progression to active TB in HIV infected HHCs 
Even though the evidence so far seems to show that IGRAs have modest predictive ability (108) 
and may be by themselves only unlikely to be sufficient enough to act as predictive markers for 
disease, longitudinal data especially in HIV infected populations is still lacking. Currently there 
are only two published systematic reviews specifically evaluating the predictive value of IGRAs in 
this area (108, 276).  
In this study, overall, the IRR was higher among HIV negative HHCs (IRR: 3.85; 95%CI: 0.90-
34.51; p=0.02) compared to HIV positives (IRR; 1.93; 95%CI: 0.88-4.57; p=0.04) for QFT-GIT. 
Unadjusted analysis showed similar results. Overall, for TST, the IRR among HIV negatives (IRR: 
2.21; 95%CI: 0.78-6.72; p=0.05) was similar to that among HIV positives (IRR: 2.32; 95%CI: 1.09-
5.00; p=0.009). 
Another principal finding was that there was strong evidence of a five-fold increased risk of TB in 
HIV positive QFT-GIT positive HHCs compared to HIV positive QFT-GIT negative ones (aHR : 4.72; 
95%CI: 1.35-16.46; P=0.01) while that of TST remained modest (aHR: 2.37; 95%CI: 0.94-6.02; 
p=0.07) in the same group. 
Overall, among HIV negatives, the PPV and NPV of QFT-GIT was comparable to that of TST (NPV 
range 98.5%-99.2% and PPV of approximately 3.00% for both tests). These results contribute to 
the already existing evidence indicating that NPV for QFT-GIT is very high especially for HIV 
negative populations. In HIV positives, the NPV of both tests remained comparable but lower 
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than that in HIV negatives (NPV approximately 92.0% for both tests), the PPV for QFT-GIT was 
lower at 13.8% (95% CI: 8.88-29.22) compared to that of TST at 17.2% (95% CI: 10.33-26.06).  
There are at least two systematic reviews examining the role of IGRAs for the diagnosis of LTBI 
in HIV infected adults (131, 173). Of the 38 studies assessed in the review by Santin and others 
(173), only three studies conducted in low TB incidence settings (UK, Austria, and Spain) were 
reported. In the systematic review by Cattamanchi and others (131), these same three studies 
are used to evaluate the predictive value of IGRAs in HIV infected individuals with an additional 
one (277).  
The systematic review by Cattamanchi and others  identified 37 studies that included 5,736 HIV 
infected individuals (131). In three longitudinal studies, the risk of active TB was higher in HIV-
infected individuals with positive versus negative IGRA results. Each study showed that IGRAs 
had poor positive predictive value but high negative predictive value for active TB. However, the 
studies had limitations, including small sample sizes with short duration of follow-up (131, 174, 
277) and differential evaluation and/or follow-up of persons with positive and negative IGRA 
results (131, 172, 174, 277). Only one study (172) had an adequate duration of follow-up (1 year 
or greater) and no study performed adequate outcome assessment (ie, ruled out active TB at 
baseline and evaluated all participants for active TB  during follow-up). In addition, all studies 
had few (less than 12) incident cases of active TB (131) and the review had limited evidence 
especially from resource constrained settings. 
Incidence rates and risk of progression to active TB in HIV infected HHCs by country 
Results were different when the effect of HIV was factored in by country. Generally the adjusted 
HRs in Zambia were similar to the overall results for both tests while in SA results were different 
for QFT-GIT. For HHCs residing in Zambia, the IRR was 5.12 (95%CI: 1.45-27.57; p=0.002) in HIV 
positives while it was 0 among HIV negative for QFT-GIT (no one developed TB among the HIV 
negative QFT-GIT negative group). This is higher than IRRs reported in some studies that have 
HIV positive populations (167, 174), apart from the one done in Austria (172). The only 
comparable study is the one done in China in silicosis patients which is a different population 
(168). Similar to IRR in Zambia, in multivariable analysis adjusted for age and  sex, there was 
strong evidence of a five-fold increased risk of TB in HIV positives (aHR: 4.77; 95%CI:1.36-16.66; 
p=0.01) for QFT-GIT. TST results for Zambia for both HIV positives and negatives were similar to 
the overall ones (table 6.10 and 6.11). 
 In both Zambia and SA, results suggest that there was no difference between QFT-GIT positive 
and negatives in HIV negatives HHCs (tables 6.11 and 6.12). These results are unreliable and 
should be interpreted with caution due to the small number of incident cases in the sub-groups.   
In HIV positives in SA, there was weak evidence to suggest that QFT-GIT positivity was protective 
because the results were not statistically significant in both unadjusted and adjusted analyses 
(table 6.12).  
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Other few studies have looked at the risk for progression to TB in HIV infected populations (167, 
172-174). Three of these studies (167, 172, 174) showed a higher risk in IGRA-positive compared 
to IGRA-negative subjects, but one study could not confirm this hypothesis because no cases of 
TB occurred (173). In this study done in Spain assessing 135 HIV-infected individuals, none of the 
103 patients who had a negative or indeterminate QFT-GIT result and negative TST at baseline 
developed TB after a median follow-up of 20 months. All  the 15 patients who were QFT-GIT 
positive at baseline accepted IPT apart from one (173). 
Studies that showed a higher risk in IGRA-positive compared to IGRA-negative subjects in HIV 
infected populations were done in Austria, United Kingdom and Kenya (167, 172, 174). In the 
study done in Austria (172) among 822 HIV positive out-patients, active TB occurred  among 
8.1% (3/37) of QFT-GIT positive; 0% of QFT-GIT negatives (0/738) and 0% (0/47) QFT-GIT 
indeterminates at baseline during the 19 months of follow-up. The risk ratio for positive vs. 
negative IGRA  for this study was reported as 136.13 (95%CI:7.16-2588.46) (108)  but was 
grossly limited by incorporation or work-up bias. In this study, individuals with a positive QFT-
GIT assay result were extensively investigated for active TB (including cultures and PCR) while 
those with negative results were not; making it likely to miss active TB  in the group. 
 In the UK study with 201 HIV-seropositive individuals, two out of 20 infected patients with 
positive T-SPOT.TB who did not receive IPT developed active TB during the 12 months follow-up 
(174). Furthermore, none of the 114 patients who were T-SPOT.TB negative developed TB. In 
the Kenya study done among 333 HIV positive pregnant mothers, risk ratio  for QFT-GIT 
positivity was 2.69 compared to test-negative mothers (108). 
Currently there is no meta-analysis that primarily focuses on the predictive value of IGRAs in HIV 
infected population. Yet this should be the focus of most predictive value studies so that these 
people can benefit from IPT. The risk of developing active TB in TST-positive HIV infected 
individuals is well documented.  
Limitations of longitudinal studies evaluating risk of progression to disease 
In reviewing these results and other studies looking at the predictability of IGRAs one needs to   
keep in mind the limitations of these tests and that they detect host immune response, rather 
than the activity of the pathogen itself (278). Nor can they overcome the diagnostics difficulties 
posed by remote infection and ongoing transmission after testing (278). In high income low TB 
incidence countries where re-infection and ongoing transmission is low, IGRAs have been 
reported to work better (149). Many low TB incidence high-resource countries have 
incorporated IGRAs in their guidelines with considerable diversity in their approaches (134, 135).  
PPV and NPV are dependent on prevalence of disease in the population as well as the sensitivity 
and specificity of the procedure used. Therefore comparisons should be done with caution 
across regions with different burdens of disease. Otherwise, positive and negative likelihood 
ratios are more accurate than NPV and PPV, because likelihood ratios do not depend on 
prevalence but these were outside the objective of this study. While a positive test may be 
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helpful in predicting disease, a negative test suggests that risk of progression to disease is low 
although it does not rule out the possibility entirely (166). High prevalence of disease will 
increase the PPV but decrease the NPV.  
The studies comparing the predictive value of TST and IGRAs for active TB have limitations. 
There are important differences amongst the studies -different products are compared, 
different cutoffs are used for TST and different populations have been studied. The designs, 
measurement differences; quality of study with regard to comparability (adjustments made to 
effect measures) and outcome (ascertainment of incident TB, losses to follow-up, and reporting 
of incidence rates vs. cumulative incidence), leading to possible verification bias (108) and lack 
of adjustment of all confounders may also explain some of the different results obtained (108).  
This limits the degree to which these studies are comparable. The challenge of most studies 
done in high and middle income countries is that ethically they were done in individuals who 
had refused IPT, as it is the standard of care for LTBI. 
Risk factors for the development of TB  
Note: some of the evidence for this section has already been reviewed (see discussion on risk 
factors associated with QFT-GIT positivity section). 
Most risk factors for infection will apply to disease as well. In this study, there was no difference 
in the risk of TB by sex. This is inconsistent with what has been known about sex differential in 
TB from the past although currently there is no consensus.   
In most settings, TB incidence and prevalence are higher for males at all ages except in 
childhood, when they are higher in females (279). The reasons for the higher male prevalence 
and incidence are poorly understood. Whether, and the extent to which, identifying fewer 
women with TB globally is due to sex (as a biological determinant) or gender (as a socio-cultural 
determinant influencing access to TB care) have been issues for discussion and debate (279). 
While some attribute it to barriers women may face in accessing TB care, risk of exposure to 
infection, in health seeking behaviour and health systems response and  economic 
consequences, others ascribe it to the natural epidemiology of the disease (279). Some studies 
have also shown that progression from TB infection to disease is likely to be faster for women 
compared with men in their reproductive years, and faster for men after 40 years of age (73). 
There was some evidence in this study that the age group 26-39 years was associated with TB 
(HR: 1.95; 95%CI: 0.89-4.27; p<0.001). A prevalence survey conducted in two districts in Lusaka, 
Zambia found that the prevalence of TB  was highest in the 35-44 years age group (aOR 3.31) 
but there was no difference seen between the prevalence in men and women (68).  
In this study, there was no association between socioeconomic status and active TB. 
Employment was used as a proxy to socioeconomic status. It has been reported that people with 
low socioeconomic status have a higher risk of being infected and a higher incidence of TB but 
evidence is not conclusive (280). Part of the limitations of studies looking at the association 
between socioeconomic factors and TB are due to unclear measurements/definitions of 
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socioeconomic position at household and/or individual level (74, 280). Some of the recent 
evidence of the association between socioeconomic status and TB comes from a case-control 
study nested within a population-based TB and HIV prevalence survey conducted in 2005–2006 
in two Zambian communities. Prevalent TB was significantly associated with lower household 
SEP (aOR = 6.2, 95%CI: 2.0–19.2 and aOR = 3.4, 95%CI: 1.8–7.6 respectively for low and medium 
household SEP compared to high)(74).  
 There was some evidence to suggest that a higher level of education was protective against TB 
(aHR for university/college: 0.74; 95%CI: 0.12-4.53) compared to low education levels (aHR for 
primary education: 1.66; 95%CI: 0.39-7.13) although results were not statistically significant. A 
case-control  study to evaluate risk factors for TB in South India found that a higher level of 
education was significantly protective against TB (OR:0.30; 95%CI: 0.11-0.82) (281). Both 
employment and education can be considered as proxies of a socioeconomic status. 
As expected, there was strong evidence that smear positivity of the index (HR: 2.00; 95%CI: 
1.04-3.87) was associated with TB. Epidemiological studies conducted during mid-20th century 
have shown that smear positive cases are more infectious than the others (55, 273).  
There was some evidence that sleeping in the same room and bed as the index case was 
associated with a higher risk of TB (HR:1.88;95%CI:0.64-5.53) although this evidence was not 
sustained in adjusted analysis. The influence of the proximity to an infectious case was shown in 
outbreak investigation studies. In one study, passengers seated within two rows of the index TB 
patient were more likely to have positive  TST compared to those in the rest of the section 
(30.8% versus 3.6%, RR = 8.5, CI = 1.7–41.3)(273).  
 
Although we found weak evidence of an association between incident TB and alcohol (HR: 1.64; 
95%CI: 0.86-3.15; p=0.13); incidence rates were higher in those who self-reported to have haven 
taken alcohol. The association between alcohol use and TB could also be explained  by both 
increased risk of infection related to specific social mixing patterns associated with alcohol use, 
as well as influence on the immune system of alcohol itself and of alcohol related conditions 
(282).  
In this study, there was strong evidence that occasional smoking, (HR: 4.07; 95%CI: 1.31-12.63; 
p<0.0001) was associated with TB compared to non-smokers. Studies have shown that smokers 
are approximately twice as likely to be infected with TB and are more than twice as likely to 
develop active TB, compared to  non-smokers (283).  Smoking increases the risks of becoming 
infected with TB, of developing the active form of disease, and of dying from it (76, 283). 
 In this study univariable and multivariable analyses for risk factors for incident TB may have 
been limited by the small number of incident cases. For most risk factors confidence intervals 
were overlapping even if HRs were suggestive of an effect. 
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9.4 Are household contacts with high levels of IFN-γ in response to Mtb specific antigen in 
the QFT-GIT assay at higher risk of developing TB? 
 
In the 2010 updated guidelines on the use of IGRAs, CDC recommended that both the 
qualitative results and the quantitative assay measurements for IGRAs should be reported (132). 
Reporting IFN-y measurements does provide useful information in individuals undergoing serial 
IGRA testing [51]. However, in the absence of interpretive guidelines, this practice could lead to 
false assumptions and misinterpretation of the results. There are limited data on the 
significance of changing IFN-gamma levels [52]. It is not clear whether higher IFN- γ responses 
correlate with greater risk of progression to active TB. The manufacturer for QFT-GIT, Cellestis, 
also warns that  the magnitude of the measured IFN-gamma level cannot be correlated to stage 
or degree of infection, level of immune responsiveness, or likelihood for progression to active 
disease (237). In a review published in 2011, Herrera and others (284) recommended that 
quantitative results should not be used for prognostic or therapeutic monitoring purposes 
because evidence is lacking or non-supportive. 
Therefore the main reason behind addressing the main question in this thesis is because of  
limited data on the significance of IFN-γ levels (268) in relation to disease progression. It is not 
clear whether high IFN-γ responses correlate with greater risk of progression to active TB. It has 
been postulated that individuals with strong and/or rising IFN-γ responses to QFT-GIT may be at 
greater risk for progressing to active disease (22, 28, 33, 50, 141). It is thought that among 
recently exposed individuals are those with strong ESAT-6/CFP-10 responses or high levels of 
IFN-γ in response to Mtb specific antigens that offer a vigorous T-cell response as a result of 
active bacterial replication (39).  
Overall, out of the 707 HHCs, 38 (5.4%) HHCs developed active TB over 1558.0 person-years 
(pyrs) of follow-up, giving an incidence rate of 24.39/1000 pyrs. The median follow-up time was 
2.44 years (IQR: 1.59-2.82).  
As expected, overall incidence rates were highest in HIV positives, at 63.08 (95% CI: 41.54-95.80) 
compared to HIV negatives, 13.58 (95%CI: 8.32-22.16). HIV positive individuals have been shown 
to be at highest risk of progression to disease (131). The principal finding in this study is that 
there was no difference in incidence rates between HHCs with low and high levels, by country 
and overall (overall IRR: 1.0 (95% CI: 0.42-2.18)). However, IRRs were different by HIV status. 
The IRR in HIV negatives was 1.70 (95%CI: 0.51-5.18; p=0.16) while in HIV positives it was 0.79 
(95%CI: 0.15-2.70; p=0.38).   
The overall findings in this study are similar to those found in another study in Turkey among 
children (158). Within ELISpot-positive contacts, the size of the baseline IFN-γ response to 
peptides did not signiﬁcantly differ between contacts who developed TB and those who 
remained well (median SFCs per million peripheral blood mononuclear (PBM) cells, 176 (IQR: 88 
to 1332) vs. 182 (IQR: 70 to 534); p= 0.27). This was also true for responses to recombinant 
antigen (median SFCs per million PBM cells, 246 (IQR: 200 to 918) vs. 264 (IQR: 124 to 526); 
p=0.183)(158). 
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 Another study of 631 HIV infected Ugandan adults found that active TB was not associated with 
IFN-γ responses to PPD or CFP (285). Unadjusted IRR for PPD was 1.36 while for CFP it was 1.09.  
When the RR was adjusted for CD4 count, there was still no difference in IFN-γ response to CFP 
(adjusted IRR: 1.33; 95%CI: 0.60-2.97; p=0.50) while IFN-γ responses to PPD increased to almost 
two-fold (adjusted IRR; 1.77; 95%CI: 0.85-3.66; p=0.14). 
In unadjusted analysis in this study, there was no evidence of an association between high IFN-γ 
levels and TB incidence overall (unadjusted HR: 1.02; 95%CI: 0.48-2.15; p=0.96). Results were 
similar when stratified by country. These findings are consistent with evidence from IRRs. 
 A prospective cohort study of 109 healthy HHCs in Pakistan assessed the patterns of cytokines 
at 0, 6, 12, and 24 months after exposure to TB (13). In this study,  IFN-γ/IL-10 ratio was used 
which is thought to be a critical determinant of disease severity across the TB spectrum (13). 
The most significant findings were the exponential increases (approximately 1,000-fold) in both 
the CFP and the mitogen-induced IFN-γ/IL-10 ratio in healthy HHCs (n=26), which peaked at 12 
months, compared to the levels in HHCs who developed disease (n=7), in whom relatively flat 
responses were observed during the 24-month period.  
 The study in Pakistan had the advantage that cytokine testing was done at four time points. 
However, in this study like many studies that have looked at the prognostic ability of IGRAs a 
single test showing a high level of IFN-γ response was used which does not provide information 
on when the response became elevated (whether this was recently or in the past) or whether it 
has stayed elevated for a long time (whether it has been persistently elevated or not). This has 
been recognized by others as  a limitation of such studies (135). 
 Although there was no difference between HHCs with low and high IFN-γ levels, other studies 
have found contrasting findings. Some of the hypotheses behind these studies stem from 
studying TST longitudinal data. Since it is well documented that individuals with recent TST 
conversions have a high probability to develop active TB, it is plausible that strong increases in 
interferon-γ responses after recent exposure might predict progression towards active disease 
(28, 33, 50). These high levels of IFN-γ production in response to Mtb-specific antigens may 
imply a risk factor for developing active TB (28, 107, 161). 
In multivariable analysis adjusted for age and sex, results were similar as to the unadjusted 
analysis. Although there is substantial evidence indicating age and sex as risk factors for the 
development of TB in individuals infected with Mtb, no specific evidence exists indicating them 
as important risk factors in the relationship between high IFN-g levels and TB.   
Despite the weak evidence from the interaction test (p=0.36), HIV was considered as an effect 
modifier. HIV was an effect modifier in the relationship between high IFN-γ levels and TB 
incidence as results were clearly different in HIV negative and positive HHCs. This is because it is 
likely that power to provide evidence for interaction in this study was reduced due to the small 
number of incident cases.  
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Unadjusted HR among HIV negative HHCs was 1.73 (95%CI: 0.63-4.77; p=0.29) and 0.75 
(95%0.22-2.55; p=0.65) among HIV positives ones respectively. In a multivariable analysis 
adjusted for age, sex and country, the HR in remained similar as unadjusted analysis for both 
HIV negatives and positives. 
 Several hypotheses can be put forward as to how HIV modifies the relationship between high 
IFN-γ levels and disease. The answer is based on the well known interaction between TB and HIV 
and the mechanism is immunological. Mtb, interacts with HIV through a number of mechanisms 
that support disease progression to active TB. 
It is well established that HIV impairs the ability to control Mtb infection (286). Clinical studies 
provide compelling evidence that HIV leads to an increased risk of developing TB shortly after 
HIV infection (286). It is widely accepted that HIV causes a depletion of CD4 T-cells, which is 
likely to contribute to the susceptibility of co-infected persons to TB, as this T cell subset is 
important in the control of TB. However, HIV has effects on other cells, including macrophages, 
and influences cytokine production, which may also prevent a host from containing an initial or 
latent Mtb infection (286). 
In a mini-review looking at how HIV-1 exacerbates TB by Flynn and others,  a number of 
hypotheses from indirect evidence have been put forward (286).  One area of focus includes 
changes in Mtb-specific T-cell responses. In their review they postulate that HIV increases TB risk 
through changes in Mtb specific T-cell responses in the following hypotheses: 
HIV impairs the function of Mtb specific T-cells within involved tissue;  decreases peripheral 
Mtb-specific T cell responses;  reduces Mtb-specific T-cell responses in the airways;  changes the 
cytokine profile within granulomas (286). Two hypotheses important for this research are the 
following:  
 
1. HIV impairs the function of Mtb specific T cells within involved tissue(286).  
T-cells release cytokines, including IFN-γ TNF, and IL-2, as well as a variety of cytolytic 
molecules that are important in controlling both Mtb and HIV. HIV can exhaust HIV-specific 
and nonspecific T-cells, which has led to the hypothesis that HIV reduces the number and 
functionality of Mtb specific T-cells in co-infected individuals. 
 
2. HIV decreases peripheral Mtb-specific T cell responses (286).  
Numerous studies have examined Mtb T cell responses in individuals infected with Mtb by 
stimulating PBMC, BAL fluid, or pleural fluid cells with PPD or CFP, killed Mtb, or peptide 
pools from immunogenic Mtb-specific proteins ESAT-6, CFP10. Most of the data support, the 
idea that HIV impairs the ability of T cells to respond to Mtb. The reduction in the 
observable number of peripheral Mtb-specific CD4 T cells may result from their direct 
infection by HIV in co-infected individuals. 
 
In this study, for all the groups used for sensitivity analyses of the main question, HHCs with the 
highest IFN-γ levels had increased IRRs ranging from 1.5 to 2 compared to the reference sub-
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group. For HIV negatives, HHCs with the highest IFN-γ levels had the highest IRRs in all groups 
apart from one group. HIV negative HHCs with the highest IFN-γ levels had increased IRRs 
ranging from 4 to 5-fold compared to the reference sub-group. In comparison, HIV positive HHCs 
with the highest IFN-γ levels had increased IRRs ranging from 1.6 to 2.6 compared to the 
reference sub-group. 
Two studies in Senegal and Columbia, supported the main hypothesis of this research study, 
since the magnitude of the ELISPOT response was 5-fold higher in contacts who developed TB 
compared to those who did not develop TB, and the significant difference in performance of the 
QFT compared to the TST was only seen in definite TB cases (35, 159).  In the study in Columbia, 
the rate of development of TB was highest in HHCs with high IFN-γ response to CFP-10 at 
baseline (35) 
9.5 Study Limitations and Biases 
 
Selection bias 
Selection bias is a systematic error which occurs from the process used to identify the study 
participants. It leads to preferential selection or participation of subjects according to their 
exposure status or outcome status. Selection bias in this study may have been due to diagnostic 
bias, non-response bias and loss to follow up. Loss to follow up was mainly due to mortality, 
moving out of the study community, withdrawal or being absent. 
Selection bias in the study was minimized in the following ways: 
1.  This study was nested in the ZAMSTAR study which was randomized as described in the 
methods. Stratification and restriction was used to randomize 24 clusters into intervention 
arms to avoid enrolment imbalances for its primary outcome. 
2. The study population was clearly defined. 
3. At least three attempts were made at each of the follow up visits to trace individuals who 
were absent or had moved. In addition, at enrolment all household HHCs were invited to 
participate in the study.  
4. All individuals recorded as lost to follow up during the first follow up visit were revisited 
during the second follow up visit to minimize loss to follow ups. 
5. Those who completed the study did not have a different disease risk than individuals lost to 
follow up. 
Information Bias  
When the information obtained from study participants is systematically inaccurate regarding 
the disease or exposure under study, information bias may occur. In this study information bias 
may have been due to errors in measurement introduced by the observer (interviewer bias, 
biased follow -up), by the study participants (recall bias, prevarication), or by measurements 
tools such as questionnaires or instruments such as weighing scales. 
 In this study, information bias was minimized in the following ways: 
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1. The exposure and the outcome were clearly defined using standard criteria. 
2. Standardized measurement instruments were used as described below: 
a) The questionnaire 
1) The questionnaire was field tested/piloted in order to improve and refine it. 
2) The questionnaire used closed precise questions and avoided open-ended questions. 
3) Different questions were used to test the same hypothesis. 
4) Interviewers’ techniques were standardized through training so that questions could be 
asked in the same way using the exact translation. 
(b) QFT and TST tests 
The exposure was defined using internationally recommended validated commercial tests 
for tuberculous infection. 
3. Data on outcome was collected without prior knowledge of exposure status of a participant 
i.e. sputa from HHCs were collected without prior knowledge of enrolment QFT-GIT results.  
Although the research assistants and nurses were not formally blinded to exposure status of 
the HHCs at enrolment, the results for QFT-GIT test were only returned to the HHCs ( and 
hence known by the research assistants)  after 1-2 months of being recruited into the study. 
This is because QFT-GIT was processed in batches from the central laboratories. This 
minimized interviewer bias. 
4. Written protocols were used to standardize procedures on data collection. 
5. Information provided by the participant through the questionnaire on outcome was 
validated against other records (clinic TB register records and study laboratory results).  
6. Multiple sources of information were used e.g. questionnaire, direct measurements. 
Response Bias 
 Response bias occurs when study participants are more likely to suppress information that they 
feel would incriminate them as the cause of their own illness. This could have occurred when 
HHCs when questioned about risk behavior like smoking and drinking alcohol.  
 
Prevalent-cohort Bias (287) 
This study may have been subjected to some degree of prevalent-cohort bias. This has been 
described as bias arising from recruiting participants assumed to be disease free at enrolment 
when they are actually not(287). This may be due to the difficulty in identifying when 
transmission occurred, the period of latency and other risk factors. This creates a cohort that is 
rife with incidence-prevalence bias. In this study the true disease status of HHCs at enrolment 
was not known and whether the disease process had already begun. Due to this difficulty and to 
avoid overestimation the true number of incident cases, HHCs who developed active disease 
within two months of being in the study were excluded from analysis. These were assumed to 
be co-prevalent cases. Exclusion from analysis of individuals assumed to have co-prevalent TB 
has been done in studies with high prevalence of TB and HIV(159). However, there seems to be 
no consensus on how these time points (2 or 3 months) are selected or whether they are 
dependent on individual studies. 
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 The inability to screen individuals for TB at enrolment was because the ZAMSTAR study design 
allowed little flexibility. 
Confounding 
Unlike selection and information bias, confounding is one type of bias that can be, to some 
extent, adjusted in the analysis. 
Confounding occurs when the causal effect of the factor we are interested in is “mixed up” with 
the causal effects of other factors. Confounding is concerned with “alternative” explanations for 
the effect seen between the exposure of interest and the outcome. Randomisation, matching 
and restriction can be tried at the time of designing a study to reduce the risk of confounding. 
Confounding can be controlled at the analysis stage by stratification and multivariable (adjusted) 
analysis. 
 In the ZAMSTAR trial, control of confounding at the design stage was done through 
randomization and restriction. Randomisation was an attempt to evenly distribute potential 
confounders in study groups.  It reduced potential for confounding by generating groups that 
are fairly comparable with respect to known and unknown confounding variables. However, it 
did not guarantee control of confounding and is useful only for intervention studies. Restriction 
eliminated variation in the confounder but caused loss of statistical power.  
 All relevant variables other than the exposure were taken into account to explain the results. 
Important imbalances on risk factors associated with active TB that were not taken into 
consideration in the ZAMSTAR randomization could arise. For this reason, clustering at 
household level was adjusted for and possible confounders were identified.  
The possible confounders were 
1. age  
2. sex  
3. socio-economic status 
4. alcohol consumption 
5. smoking 
6. educational level 
 
Non measurable confounders  
Another source of bias could have been non-measurable confounders. 
 
Individuals lost to follow up 
A limitation of this study was the number of individuals lost to follow up. 25.5% of HHCs were 
lost to follow-up between the different time points. While we did not find any significant 
differences in the basic characteristics of those followed versus those lost to follow-up, the 
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study was vulnerable to unknown sources of bias. Furthermore, because no verbal autopsies 
were conducted many of those who died could have been as a result of TB. 
 
Bias from missing results  
 We had missing data on individuals that had refused to have skin tests or did not return for the 
reading as well as on a number of risk factors. A study of this magnitude done across diverse 
communities and countries made data collection over the study period a challenge.  Although 
some missing data (see data analysis) were excluded from analysis, bias was not expected to 
result from this elimination since the data was not systematically missing. Missing data generally 
leads to misclassification if the data are estimated, imputed or otherwise placed in the analysis 
in the absence of certainty about the exposure and disease category. 
 
Our results may have been severely compromised by missing data on some risk factors. This was 
difficult for survival analysis; as the number of TB cases reduced depending on the definition, 
some risk factors had to be grouped. Therefore although the baseline chapter presents more 
groups for individual risk factors, these were later grouped due to the few outcomes. 
 
Diagnostic or Work-up (verification) bias 
Differential evaluations and/or follow up of individuals with positive and negative IGRA results 
can underestimate active TB in those with negative results. Incorporation or work-up bias was 
unlikely to have influenced results since those who were QFT-GIT or TST positive at baseline 
were not investigated for TB.  
 
Other Study Limitations 
a) HHCs at enrolment had mixed infections (acute, latent, and previously infected) and in 
an environment with ongoing, intensive nosocomial exposure, persistence of infection 
and/or re-infection might occur.  All these influenced the outcome differently. 
b) Incident cases may have been underestimated due to HIV positive individuals on IPT 
and ART. This effect was minimal since few HHCs were on ART and IPT (4.7% of HHCs 
were on IPT).  
c) The true number of secondary cases in this study may have been underestimated. 
Some of those that had died or were lost to follow up may have had TB. 
d) Both TST and QFT-GIT assay cannot distinguish between infection and disease and 
there is no standard for the diagnosis of TBI. Infection prevalence estimates were 
affected by test limitations discussed in the introduction and literature review. Due to 
the limitations of the TST, testing done across sites and countries could have affected 
results. However, SOPS were standardized across countries and training included 
exchange visits between Zambia and SA so that the trainers were using the same 
methods throughout. 
e) Underlying ZAMSTAR Interventions (Enhanced case finding and household TB/HIV 
intervention) may have increased TB cases found and introduced bias.  
  215
f) TB diagnosis using register:  It is possible that we did not capture everyone with TB 
within the community since some TB patients may access treatment from other places 
(clinics not within the ZAMSTAR community, private clinics, traditional healers) or are 
not recorded in the register. Therefore patient treatment cards were also used in such 
instances. 
g) There were also difficulties to recruit HHCs into the study in cases where the index has 
died. Staff were trained in how to improve information giving in such instances. 
Conclusions 
The principal finding in this study is that there was no difference in incidence rates between 
HHCs with low and high levels (overall IRR: 1.0 (95% CI: 0.42-2.18)).  
Another principal finding was that there was strong evidence of a five-fold increased risk of TB in 
HIV positive QFT-GIT positive HHCs compared to HIV positive QFT-GIT negative ones (aHR : 4.72; 
95%CI: 1.35-16.46; P=0.01). For all the groups used in the sensitivity analysis of the primary 
question, HHCs with the highest IFN-γ levels had increased IRRs ranging from 1.5 to 2 compared 
to the reference sub-group. The feasibility studies emphasized the need for stringent sample 
collection and processing techniques to ensure the accuracy of QFT-GIT results. 
 
 
  
  216
10.0 The Role of IGRAs as diagnostic tests in high TB/HIV endemic 
resource settings and the evolving future research 
 
In this chapter I will highlight the role of IGRAs as diagnostic tests in high TB/HIV endemic 
resource settings and some evolving IGRA and TST research in the context of this thesis. 
10.1 IGRAs as diagnostic tests in high TB/HIV endemic resource constrained settings. 
 
The utility of IGRAs in high-burden settings remains unclear. In contrast, in low TB burden 
settings with high BCG vaccination programs, IGRAs are used as screening tests for TB infection. 
Many countries in such settings have published guidelines on IGRAs although some are not 
evidence based. 
There is evidence that IGRAs performance varies across high TB burden vs. low TB burden 
settings (149). 
In high-burden settings, many factors may influence the results of IGRAs. These may be 
influenced by factors that modulate the immune response (7) such as HIV co-infection, BCG 
vaccination, poverty related malnutrition, tropical infections and widespread exposure to non-
tuberculous mycobacteria. 
IGRA performance depends on intact cellular immune responses; however, malnutrition and 
infection with helminths are known to alter such responses. The effects of malnutrition and 
helminth infection on cell mediated immunity include reduced IFN-γ production and altered 
balance between Th1-type and Th2-type responses, respectively. In the severely malnourished 
host, the absolute number and function of T lymphocytes are compromised, which corresponds 
to reduced IFN-γ production in human and experimental animal studies (288). A recent study in 
Bangladesh showed that malnutrition and helminth infections were associated with 
indeterminate QFT-GIT results in children (288). 
Although the specific antigens encoded within the RD-1 of Mtb are absent in many NTM, their 
presence in other species like in M. leprae and M. kansasii can pose challenges if prevalent. 
Theoretically, the presence in the host of some NTM could cause a false-positive IGRA result. 
The presence of environmental mycobacteria in Zambia communities was evident in a recent 
TST survey (95). A study in Malawi (152)  found a high rate of  IFN-γ  responses to PPD of atypical 
mycobacteria, especially to those of MAIS complex (M.avium, M.intracellulare, M. scrofulaceum 
and  M. marinum)which was strongly associated with positive TST response to human PPD. Only 
M. kansasii can cause disease similar to tuberculosis and it does so only infrequently (113).  
To be useful in settings with high prevalence of TB and HIV, IGRAs should not only detect recent 
infection but should be of better sensitivity for HIV positive populations than the TST. This is 
because HIV is the strongest risk factor for developing TB in those with latent or new Mtb 
infection (111). HIV-positive individuals have a 5-10% annual risk (119, 289) of active disease 
while HIV negatives have a lifetime risk of 5-10%. There is now sufficient evidence to show IGRA 
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sensitivity varies across populations and tends to be lower in high-endemic countries and in HIV-
infected individuals (131). 
Studies from low-burden countries indicate that the IGRAs correlate better, along a gradient of 
exposure, than the TST. Nevertheless, in high-burden settings, the TST performs reasonably well 
and correlates as well, or better, with proxy measures of exposure (149). Studies from Uganda, 
India and the Gambia showed that the TST correlated well with proximity to an index case and 
performed better than the IGRA along an Mtb gradient of exposure. 
According to WHO, novel technologies successfully introduced into developed countries require 
adaptation to match the needs of developing countries (71), which includes feasibility and cost 
effectiveness considerations. In developing countries, potential drawbacks may include the cost, 
the need for highly skilled staff and a good laboratory infrastructure (with capacity to run ELISA 
or ELISPOT), the high HIV prevalence as well as logistical issues (e.g. power shortages) peculiar 
to these settings. In addition, strict assay techniques have to be followed for accurate results. 
For example,  QFT-GIT indeterminate results can  occur due to improper assay techniques (e.g. 
time delays that lead to loss of viable T cells in the specimens)(112). Our own experience of 
using QFT-GIT on a large scale identified some of these operational factors that affected the 
robustness of this test in Zambia (251). 
Given the current grey areas in the use of IGRAs especially in poor resource settings and their 
sub-optimal sensitivity, the decision to use either IGRAs or TST should be based on country 
guidelines and resource and logistical considerations (131).  
10.2 Evolving IGRAs research  
 
Technical modifications of IFN-γ-based tests are being explored (290). The attempts to improve 
IFN-γ-based tests include:  
1 Incorporation of additional antigens of high specificity. 
2 Use of alternative Mtb specific antigens/peptides. 
3 Use of different marker from IFN-γ, for example IP-10, IL-2, MCP-2. 
4 Alternative readouts to measure IFN-γ release, which are different from ELISA or ELISPOT. 
5 Simultaneous measurement of chemokines and interleukins (130, 290, 291).  
6 Applicability of IGRAs with extrasanguinous samples i.e. biological sample different from 
blood (BAL, pleural fluid, CNS). 
Novel test formats that include other antigens, additional markers, the comparative use of 
various patient specimens and advanced techniques, have been suggested as a replacement for  
today’s commercially available IGRAs for a better diagnosis of true TBI. Novel concepts have 
been investigated that include the use of different epitopes of RD antigens, readout different 
from IFN-γ such as chemokines or cytokines, new antigens different from the RD genomic 
region, such as those defined as Rv1733c, Rv2029c, additional cytokines  or characteristic 
phenotypic markers (5). 
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Diagnostic sensitivity of IGRA can also be enhanced by incorporation of a novel RD1-encoded 
antigen, Rv3879c, without compromising diagnostic specificity (5). In a large prospective study 
of patients with suspected TB, incorporation of a novel RD-1-encoded antigen, RV3879c, 
alongside ESAT-6and CFP-10, significantly improved diagnostic sensitivity over the standard 
ELISpot test (5). Similarly, the addition of Rv2645 in QFT-GIT significantly improved sensitivity of 
this assay in diagnosing active TB over QFT-G without compromising specificity (290).Alternative 
readouts to measure IFN-γ release by Mtb-specific T-cells have also been explored, for example, 
using flow cytometry (290). 
Other biomarkers, alone or in combination, could enhance the diagnostic performance of IGRAs. 
Downstream chemokines induced by IFN-γ,  such as  IP-10 or CXCL10, monocyte 
chemoattractant protein (MCP)-2 may serve as a more amplified readout than IFN- γ itself, 
thereby yielding higher sensitivity (290).It has been shown that IFN-γ-inducible IP-10 and IL-2 
could be alternative or adjunct biomarkers to IFN-γ (292). A study conducted in Nigeria among 
59 children showed that IP-10  was expressed in high amounts in response to Mtb specific 
antigens and performed with excellent concordance with the QFT-IT test and the agreement 
between the IP-10 and QFT-IT was stronger than with the TST (292).The combined readout of 
IFN-g/IP-10 has been suggested  as a potentially more sensitive marker of Mtb infection than 
current IGRAs (290). 
IGRAs were developed and licensed for use on blood. However, it is known that Mtb-specific T-
cells are recruited at the site of infection, where their frequency is increased compared to 
peripheral blood. As a result, there is increased research activity on the applicability of IGRAs 
with extrasanguinous samples (e.g. pleural fluids, materials from bronchoalveolar lavage, ascitis, 
or liquor cerebrospinalis)(175). 
Other biomarkers for disease progression 
There is need for further research to enhance our understanding of the biology of Mtb and 
interactions with the human host. Such knowledge gaps impede the development of biomarkers 
that can distinguish between latent and active TB, especially in HIV-infected adults and children. 
Research regarding predictive biomarkers for disease progression in susceptible individuals for 
early intervention is still ongoing (Table 10.1). Despite these diagnostic advancements, there are 
currently no reliable surrogate markers for disease progression. Some studies have suggested 
that relative mRNA concentrations of interferon γ, interleukin 4,and interleukin 4δ2 (a splice 
variant of interleukin 4) might be better predictors than interferon γ alone, since ratios of 
interferon γ or interleukins 4 and 4δ2 fall as healthy contacts develop tuberculosis, and increase 
as patients with tuberculosis are cured (104). The ratio of interleukin 4 to 4δ2 is also increased 
in longstanding latent tuberculosis infection, presumably suggesting low risk of reactivation (22). 
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Table 10.1: Biomarkers associated with disease progression (11) 
Cytokines & chemokines Diagnosis Correlate of risk  or of protection References 
IFN-γ Latent or active TB Vaccine efficacy or disease progression 70-73 
CXCL10,IL-10 Active TB Increased after BCG 74-77 
IL4↑  Active TB Progression 78,79 
IL-4δ2/ IL-4 ratio Extent of disease Not determined 54,82 
IFN-γ/IL-4 ratio Latent or active TB Not determined 54 
IL-17 and TNF Latent or active TB Increased after BCG 81 
*Correlates of risk of tuberculosis are markers that are associated with low risk of disease development or the absence of 
markers associated with high risk of disease, whereas correlates of protection against tuberculosis reliably predict the level of 
protective efficacy induced by a vaccine on the basis of differences in the immunological measurements of vaccinated and 
unvaccinated groups. ‡ 
Evolving TST research 
An attempt to improve the skin test was recently made using a recombinant dimer of ESAT-6 
(rdESAT-6), a protein encoded by the region of difference 1 (RD1) of the Mtb chromosome 
(293). This region, and thus the proteins and their epitopes, is not present on BCG and on most 
NTMs, making it a perfect candidate for a more specific skin test. Inoculation of rdESAT-6 in the 
skin of subjects with TBI or previous TB was proven to induce local responses similarly to TST, 
but no skin reaction was observed in BCG-vaccinated individuals (294).  
Recently, results of a phase I trial of a skin test that uses rdESAT-6 instead of tuberculin have 
demonstrated safety and tolerability of such a test (293). In combination CFP-10 antigen to 
increase diagnostic sensitivity, such a skin test could overcome some of the obstacles currently 
related to the use of the TST. If clinical trials show superiority to the TST this test could be made 
widely available for the diagnosis of TBI in resource-limited settings where the use of IGRA is 
prohibited by their costs and demands for an established laboratory infrastructure. 
Vaccines 
Current TB vaccine development efforts aim at preventing primary Mtb infection through 
preinfection vaccination, or at interrupting the transition from TBI to active disease through 
post-BCG booster vaccination approaches. The number of promising tuberculous vaccine 
candidates has increased in the last decade. Currently there are eight vaccine candidates in 
human phase I and phase IIa trials (10). The identification of those in need of vaccine-induced 
protection and preventive chemotherapy is of major importance not only for the individual but 
also for disease control.   
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Future research needs  
Future research needs in line with identifying predictive biomarkers for TB infection include the 
following: 
• Larger prospective studies assessing the positive and negative predictive values of IGRAs for 
the diagnosis of LTBI especially in children and other high-risk groups such as 
immunocompromised populations. 
• Prospective studies on the efficacy of preventive therapy based on IGRA results.  
• Research to develop IGRAs that incorporate new Mtb-specific antigens and alternative 
cytokines that would enhance sensitivity, allowing TBI to be distinguished from active TB. 
• Future studies will also need to better illuminate the kinetics of Mtb–specific immune 
responses in relation to actual tuberculosis risk (107). 
• Studies to evaluate the feasibility and cost of IGRAs in the diagnosis of TBI and active TB in 
different settings and for different purposes (e.g. contact screening, serial testing of 
healthcare workers). 
Randomized controlled trials 
In the absence of a gold standard for diagnosing LTBI, the best way to assess the predictive value 
of the test for subsequent development of TB, in theory, could be to compare IGRAs with TST in 
a controlled trial of treatment for test-positive individuals, thereby circumventing the ethical 
hurdle of withholding interventions from individuals at risk of TB (173, 278). However, a very 
large sample size would be needed and with suboptimum acceptance, adherence and 
effectiveness of available treatment regimes, the number of TB cases averted might be few for 
the efficient assessment of simple diagnostic devices (278). Randomized controlled trials alone 
are unlikely to improve existing technology but more basic research is needed to identify a 
suitable biomarker for progression to active disease (278).  
TB Biomarker Signatures (Gene expression profiling). 
Comprehensive analysis of gene expression patterns associated with different Mtb infectious 
status have important implications for developing novel diagnostic biomarkers to differentiate 
active disease from LTBI. Gene expression profiles provide valuable clues for better 
understanding of progression from latent infection to active disease and pave the way for 
defining predictive correlates of protection in TB (295, 296).  
 
Many studies have been done to clarify the cytokine and chemokine responses to Mtb-specific 
antigens that are involved in the progression from latent infection to active disease (19,20,21 
from Chanyi). However, these studies revealed only limited insight into human resistance or 
susceptibility to Mtb infection. More recently, genome-wide transcriptome analyses have been 
widely used to explore the complex interaction between human and bacteria (295, 297, 298). 
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Using blood transcriptional profiling, several signature gene sets have been identified in adult 
cohorts from South Africa, The Gambia and The United Kingdom (295, 297). Although peripheral 
blood transcriptional signatures discriminating between TB, LTBI and HC subjects have been 
identified in adult studies, concerns about the specificity of these signature sets have been 
raised (295, 297, 299). More recently, single candidate biomarkers were combined into 
multicomponent signatures to increase power and specificity. Such signatures appear to be 
more powerful biomarkers than individual genes or proteins (295, 298, 300).                                              
 
Berry and others (297) provided one of the first complete descriptions of the human blood 
transcriptional signature of TB in a study done in more than 400 participants with active TB, LTBI 
and healthy controls from London and Cape Town, South Africa. This study suggested that the 
signature of active TB, observed in 10–20% of patients with latent TB, may identify individuals 
who will develop active disease but longitudinal studies are needed to confirm this (297). 
 
In another study, Chanyi and others performed genome-wide transcription analysis of PPD-
stimulated PBMCs from subjects with TB, LTBI and HC, and identified unique transcript profiles 
in individuals with tuberculous infection and active disease (296). In this study, they found that 
the combination of CXCL10, ATP10A and TLR6 could be used as novel biomarkers to 
differentiate TB from LTBI. Transcriptional profiling is becoming more and more frequent as an 
additional immunological approach in clinical trials of new TB vaccines, where gene expression 
signatures are compared in samples from various time points (301). 
An ideal test for diagnosing TB infection 
An ideal test for LTBI diagnosis should meet the following criteria: High sensitivity in all 
populations at risk; high specificity regardless of BCG vaccination and infection with NTM; 
reliability and stability over time; objective criteria for positive result, affordability and easy 
administration and ability to distinguish recently infected individuals with increased risk of 
progression to active TB. Such a test, if widely implemented and accompanied by successful 
treatment, could revolutionize TB control (109). 
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Appendix 1. : Ethics approval for the ZAMSTAR study 
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Appendix 2. : Ethics approval for the Quantiferon-TB Gold Study 
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Appendix 3. : SOCS enumeration form at baseline 
 
VISIT:  
 
HOH QUESTIONNAIRE DONE:  
TOTAL NUMBER OF PAGES:  
                 
GPS-X S -   o   ,    ‘   Address:  
GPS-Y E 0   o   ,    ‘     
Compound: 
 
 
 
 
DATE CODE SIGN 
Number of Study Cards Issued for this Address:: 
   
SIGNED OFF: D D M M Y Y Y Y 
    
CODES for Enumeration Form 
Consent: N=no consent Y=consent M=Moved Out D=Died A=absent/not found 
Shared … with 
Index/Other TB 
B=same Bed R=same Room H=same House O=Other house  U= Unknown/Don’t remember 
 
  SIGN OFF :  FIELD    SIGN-OFF : DATA CENTRE 
RESEARCH ASSISTANT (RA): 
 
DATE SENT TO DC: D D M M Y Y Y Y DC1:   
 
Note: For visit 3, this form was amended to include sputum 
                                                        ADDRESS 
BARCODE: 
 
 
N
o
.
 
Adult / Child 
Barcode 
First name Surname Sex 
 
 
Age 
 
Consent  
On 
 
Shared with 
Index / 
Other 
Consent Q –done 
 
 
Y      N 
Blood 
 
 
Y       N 
QFT 
 
 
Y       N 
TST 
 
 
Y      N 
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Appendix 4. : SOCS Information Sheet  
 
You are invited to take part in a study called Zamstar (Zambia South Africa TB and AIDS Reduction 
Study) looking at ways to reduce TB and HIV in your community………………………………………………….. (Fill 
in community name). Three hundred-and-fifty (350) adults and three hundred (300) to four hundred 
(400) children <5 years of age from 150-200 households from your community will take part. 
Information about the study is supplied in this document. Project staff will be on hand to explain the 
contents and answer all your questions. Please make sure that you understand everything described 
in this document. If you decide to participate, you will be asked to give written consent before you 
take part. 
Who is doing the study? 
This study is being performed by ZAMBART Project from the University of Zambia and London School 
of Hygiene and Tropical medicine  
Dr/Mr./Mrs.……………………………………………………is responsible for the day to day running of the study. 
The study has been approved by the Medical Ethics Committees of the University of Zambia and the 
London School of Hygiene and Tropical Medicine.  
In your area we are working with the health centre committee (Community advisory board). 
What is the purpose of the study? 
In spite of a good TB tracing and treatment programme in your community, the number of TB cases 
remains high. The purpose of this study is to determine the most effective way of reducing TB and 
HIV in the community. ZAMSTAR as a study is not meant to provide health care that you would 
ordinarily get from your local health centre, but to assist with this care.   
What is TB? 
Tuberculosis (TB) is an infectious disease caused by bacteria (germs), which are spread through 
droplets (coughing). TB infection affects mainly the lungs, but can also affect other parts of the body. 
Many people with TB are not diagnosed quickly, and go on infecting other people without knowing it. 
It is however possible to diagnose TB quickly through examining sputum.  TB can be cured once 
diagnosed. 
TB is sometimes associated with HIV, the virus that can cause AIDS. We would like to find out 
whether this is the case here and so will be asking you to provide a blood sample that we will test for 
HIV. We will be testing these samples in groups labeled only with a barcode or number and so we will 
not be able to provide you with the results immediately.  
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If you would like to find out your HIV status, please tell the nurse who is taking the blood and he/she 
will ensure that a small sample is tested for HIV here at the clinic laboratory. We would encourage 
you to find out your HIV status by visiting the voluntary counseling and testing centre at 
………………………………….. (Fill in name of local VCT). To ensure that you get the results of your blood 
test you will need to take your study card and number along with you. 
Why diagnose TB infection?  
A person who gets TB first becomes infected and then may develop the disease after some years. 
People infected with tuberculosis are well. 
We would like to find out how many people are infected with tuberculosis in order to consider 
medical treatment to protect them from becoming unwell with tuberculosis disease and to provide 
them with all the information required on what to do if they start to become unwell. 
Until recently the tuberculin skin test (TST) was the only way to diagnose infection with TB. 
Nowadays, there is a new test – the QuantiFERON®-TB Gold In-Tube (QFT-Gold IT). This test is 
considered to be more reliable than TST. Differently from TST, this test is performed on blood. 
It is important for you to know the following: 
1. If you give blood for testing for tuberculosis infection, we will use your blood only for TB 
testing and no further test for any other disease will be performed on it. 
2. Blood samples will be labeled with barcodes and results will be reported to you only. 
3. If your result is positive, this DOES NOT mean you have TB, but only that you have been 
infected with TB. 
4. If your result is positive, we will come back to you and we will give you more information 
about what to do next. 
 
What is required of you? 
1. You will be asked to complete a questionnaire about your health at the local health centre.  
2. You will be asked to provide a blood sample for examination for HIV (For adults aged above ≥ 
15 years). Just more than a teaspoon of blood (6mls) will be taken from you on 3 occasions; 
now, 18 months from now and 36 months from now (total volume of blood = less than a 
tablespoon [18mls]). 
3. You will be asked to provide a blood sample for examination for Tuberculosis infection (For 
adults aged above ≥ 15 years). As for HIV testing, this will require not more than a teaspoon of 
blood (3mls, approximately 1 ml for each blood tube). Blood samples will be taken from you on 
3 occasions; now, 18 months from now and 36 months from now (total volume of blood = less 
than a tablespoon [9mls]). 
4. Each time we take blood we will use a separate sterile needle.  
5. We will test all children under 5 years and all adults for tuberculosis infection by doing a skin 
test. This test involves giving an injection into the skin with a small needle and then reading the 
reaction to the injection 3 days later. Each individual will be injected with a separate sterile 
needle. We will not take any blood from the children. 
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Are there any risks for people who take part in this survey? 
The main risk from participating in the study is that we will take 3 blood samples from you. This may 
cause some transient discomfort and you may develop a bruise at the site of the blood draw.  
The tuberculin skin test is done by injection into the skin using a small needle. We will not be taking 
any blood from the children in the study. We will look at the injection site after 3 days to see if there 
is any reaction on the skin. The main risk from this procedure is that there may be some discomfort 
at the time of injecting and the skin may become red and swollen. If this happens we will give you 
some cream to apply to the area which will make the swelling go down quickly.  
 Benefits 
 
The main benefit is for your community where we are finding out whether we can reduce TB and HIV 
by providing certain interventions.  
For the children in the study, any child who has a positive skin test will be referred to the clinic to be 
examined to rule out tuberculosis. Children who do not have tuberculosis but have evidence of 
exposure to tuberculosis will be referred for preventive treatment for TB. 
You may wish to find out your HIV status, and by participating in this study that will be possible. You 
will receive standard counseling and testing and your blood will be tested using a rapid HIV test using 
the same procedures as are in current usage at this clinic. You must sign an additional consent form 
for this to be done and for you to receive the result. If you are HIV positive we will refer you for 
further treatment, care and support, including preventive treatment for TB if you are also found to 
have TB infection.  
Participation on this study is completely on a voluntary basis. You are free to withdraw from the 
study at any stage, without any consequences for you or your family. No financial reward will be 
given to any persons taking part in this study.  
Alternatives to the study 
 
Access to health services (TB and VCT) for you or your family will not be influenced if you choose not 
to participate on the study.  
Confidentiality of information and privacy of the participant 
 
All personal information obtained from individuals or households during this study will remain strictly 
confidential. The answers will be transferred to a computer, but your name will not be included, and 
you will be identified by a coded number only. No information about individuals will be released to 
any other parties but the research team, without your further consent. Completed questionnaires 
will be stored in a safe place. No information regarding personal details which could identify 
individuals or individual households will be disclosed. 
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The data collected from this study will be published in scientific journals, but without names being 
available to anyone. 
Thank you for reading this information sheet. If you have any questions, please feel free to ask them 
now. The interviewer will be pleased to answer them. If you wish to take part, please read and sign 
the consent form. If you wish children less than 5 years in your household to take part, please read 
and sign a separate consent form on their behalf. Please keep this information sheet in a safe place. 
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Appendix 5. : SOCS Informed consent form 
 
 
 
 
1. I confirm that I have read the information sheet, and that the information and 
procedures involved in my taking part in the survey have been explained to me. 
2. I confirm that I have had the opportunity to ask questions about the study and that I am 
satisfied with the answers and explanations that have been provided. 
3. I have been given time and opportunity to read the information carefully, to discuss it 
with others and to decide whether or not to take part in this survey. 
4. I understand that I can withdraw any time from the study. 
5. I understand that I will provide a blood sample for HIV testing. I further understand my 
HIV results will be strictly confidential. I understand that I can receive my HIV results on 
my request following counseling. 
6. I understand that I will provide a blood sample and undergo a skin test for TB infection 
testing. I further understand my TB results will be strictly confidential. I understand that 
if these results are positive, I will receive information about what to do in case of 
symptoms occurrence.  
7. I understand that study staff will visit me after 18 and 36 months to conduct similar 
tests.  
8. I agree to take part in the study. 
 
Participant’s information: 
Signature (or fingerprint): ____________________ 
Surname: ___________________________ Name: _________________________ (please print) 
Date ______________________________________ 
The person who conducts the informed consent discussion must sign and date this form. 
 
Signature: _______________________________________date ___________________ 
Surname:__________________________ Name: ______________________(please print) 
Signature of witness, if applicable. 
Witnessed by: (print name): _________________________________________________ 
Signature of Witness: _____________________________ date _____________________
Adult Barcode:  
  6:9
Appendix 6. : Individuals adult Questionnaire (visit 1)  
 
ADDRESS BARCODE ADULT BARCODE 
  
 
SECTION A – GENERAL INFORMATION 
 
  Diagnosis 
   M18 
(Visit 2) 
   M36 
(Visit 3) 
Q01_VIS VISIT 1 2 3 
Q02_COD INTERVIEW’S CODE     
   
 D D M M Y Y Y Y 
Q03_DAT DATE OF INTERVIEW          
        M F 
Q04_SEX SEX       1 2 
 D D M M Y Y Y Y 
Q05_DOB DATE OF BIRTH (01/01/1800 IF UNKNOWN)         
Q05_1DOB If not known, what was your age in years on your last birthday? (999 IF UNKNOWN)    
    
Q06_ETH To which ethnic group do you belong? 
 Black Zambian 1   Black SA 2 
 Black Other 3   White 4 
 Coloured 5   Asian 6 
 Other 7 Specify:  
    
Q07_REL What is your religion? 
 Catholic 0   Protestant 1 
 Muslim 2   Hindu 3 
 SDA 4   JW 5 
 Pentecostal/Evangelical 6   No Religion 7 
 Other 8 Specify:  
    
 No Yes Unknown 
Q08_AS Have you ever attended a school? 0 1 9 
 (IF YES CONTINUE.IF NO OR UNKNOWN GO TO Q9) 
Q08_1_HG What is the highest grade attended?   
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 No Yes Unknown 
Q08_2_AC Have you attended College or Higher Institution? 0 1 9 
 
 No Yes Unknown 
Q09_IH 
In the past 6 months have you made any contribution in cash or kind to 
the household? 
0 1 9 
Q10_NAH In the last month, how many nights have you spent away from home?   
 
(WRITE NUMBER IN BOX) 
 
I would now like to ask you some questions about your current drinking and smoking habits 
 
 
 
No 
 
 
Yes 
 
 
Unknown 
Q11_DA During the last 4 weeks have you taken any drinks containing alcohol? 0 1 9 
Q12_DD 
During the last year have you ever drunk so much that you were 
unable to remember what you were doing? 
0 1 9 
 
Q13_SH 
 
How would you classify your smoking habits? 
 Daily Smoker 1  Occasional Smoker 2 
 Ex-smoker 3  Never Smoked 4 
 
(IF SMOKER OR EX-SMOKER CONTINUE, IF NEVER-SMOKER SKIP TO Q14) 
 
Q13_1 SD How long have you/did you smoke for? (years)    
Q13_2 SA How many cigarettes per day do/did you smoke?    
 
 
 
 
No 
 
Yes 
 
Unknown 
Q14_SM Do you ever smoke marijuana/dagga etc? 0 1 9 
Q15_RD Do you take any other recreational drugs? 0 1 9 
 
I would now like to ask you some questions about your sexual relationships 
 
Q16_MS 
 
What is your marital status now? 
 Single 1  Married/living as married 2 
 Widowed 3  Divorced/separated 4 
 No Yes Unknown 
Q17_SX In the last 6 months have you had sex? 0 1 9 
 
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO NEXT SECTION B, Q18) 
 
 
 No Yes Unknown 
Q17_1_OP 
In the last 6 months at any stage, have you had more than one sexual 
relationship at the same time? 
0 1 9 
                               (IF YES CONTINUE. IF NO OR UNKOWN GO TO Q17_2) 
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Q17_1_1_CM Did you use condoms with these partners? 
 Never 1  Always 2 
 Sometimes 3  Unknown/ no answer 9 
 
 
No 
 
Yes 
 
Unknown 
Q17_2_POP 
In the last 6 months do you think that your main partner has had 
other partners apart from you? 
0 1 9 
 
 
 
SECTION B – TB AND HIV QUESTIONS – ASK ALL RESPONDENTS 
 
I would now like to ask you some questions about your health, specifically about TB and HIV 
 
 
 
No 
 
 
Yes 
 
 
Unknown 
Q18_TBT Are you currently on TB Treatment? 0 1 9 
 (IF YES CONTINUE.  IF NO OR UNKNOWN GO TO Q19 ) 
Q18_1_TBT What is your TB registration number?           
 
 No Yes Unknown 
Q19_HIV Have you ever been tested for HIV? 0 1 9 
 
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO SECTION C, Q22) 
 
 Negative Positive Unknown 
Q19_1_HIV Would you mind telling me what the result was? 0 1 9 
 
(IF POSITIVE CONTINUE.  IF NEGATIVE OR UNKNOWN GO TO SECTION C, Q22) 
 
 No Yes Unknown 
Q20_ARV Have you ever taken ARV treatment? 0 1 9 
 
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO Q21) 
 
 No Yes Unknown 
Q20_1_CARV Are you currently taking ARV treatment? 0 1 9 
 (IF YES CONTINUE.  IF NO OR UNKNOWN GO TO Q21) 
 D D M M Y Y Y Y 
Q20_1_2_SARV When did you start ARV treatment?         
Q20_1_3_WARV Which health center do you receive treatment from?  
  (NAME OF CLINIC/HEALTH CENTER)  
 
 
 No Yes Unknown 
Q21_IPT Have you ever been on preventive therapy for TB (IPT)?   0 1 9 
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SECTION C – STIGMA QUESTIONS – FOR ALL RESPONDENTS 
 
Tuberculosis Stigma Indicators: For all Respondents. Read Out the Statements Slowly, One at a Time and Record 
Response. 
 
I am going to read to you some statements that have been heard in relation to TB and HIV. I would like you to tell 
me whether you agree or disagree with these statements. 
 
 
 
 
Agree 
 
Disagree 
Q22_TSCT 
You can catch tuberculosis if you touch a patient who is diagnosed as 
having TB 
  
 
You can catch tuberculosis by sharing eating utensils with someone 
who has TB 
  
 You can catch tuberculosis from having sex with someone who has TB   
 TB Patients should be isolated from others in the community   
    
Q23_TSBJ It is women who spread TB in our communities   
 It is men who spread TB in our communities   
 It is outsiders who spread TB in our communities   
 TB is a punishment for bad behaviour   
 TB patients are careless   
 TB patients are disgusting   
 TB patients are promiscuous   
Q24_TES 
 
Do you personally know anyone with TB who has experienced any of 
the following: (YES/NO ANSWERS) 
 
 
Yes 
 
 
No 
 Been excluded from a social gathering   
 Abandoned by spouse/partner   
 Isolated by their household   
 Lost housing/denied housing for rent   
 Lost respect or standing in the community   
 Been teased, insulted or sworn at   
 Been gossiped about   
 Whose children or family have been isolated/shunned   
 Been treated worse than patients with other diseases by health staff   
Q_25_TD 
Do you personally know of anyone who has tried to hide their TB 
diagnosis?  
  
 
Q_26_THIV 
 
Do you agree or disagree with the following statements 
 
Agree 
 
Disagree 
 TB is curable in those living with HIV   
 All TB patients have HIV/AIDS   
 
                      N.B. ASK TB PATIENTS ONLY.  SKIP TO Q32 IF NOT A TB PATIENT. 
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Q27_TPES Since you fell sick with TB have you experienced any of the following: 
 
Yes 
 
No 
 Been excluded from a social gathering   
 Abandoned by spouse/partner   
 Isolated by your household   
 Lost housing/denied housing for rent   
 Lost respect or standing in the community   
 Been teased, insulted or sworn at   
 Been gossiped about   
 Your children or family have been isolated/shunned   
 Been treated worse than patients with other diseases by health staff   
 
 
(IF YES TO ANY OF THE ABOVE CONTINUE, IF NO TO ALL OF ABOVE SKIP TO Q29) 
  
 
Yes 
 
No 
Q28_TIS Do you think it was reasonable for you to be treated in this way?   
    
Q29_TIS2 Since you were diagnosed with TB have you felt:   
 Less of yourself because of your TB   
 Guilty about having TB   
 Unclean or dirty because of your TB   
 Careless to have got TB   
 Afraid of being seen at the TB corner / clinic   
 
 
 
 
Yes 
 
No 
Q30_TBD Have you tried to hide your TB diagnosis from anyone?   
Q31_OTD 
Have you told anyone outside of your household about your TB 
diagnosis 
  
 
 
  
HIV Stigma Indicators: For all Respondents. Read Out the Statements Slowly, One at a Time and Record 
Response. 
 
I am now going to read to you some statements that have been heard in relation to HIV. I would like you to tell me 
whether you agree or disagree with these statements. 
 
 
 
 
Agree 
 
Disagree 
Q32_HSCT 
You can become infected with HIV if you are exposed to the saliva of 
someone who is HIV positive 
  
 
Children can become infected with HIV if they play with children who are 
HIV positive 
  
 
You can become infected with HIV by caring for/looking after someone 
who has HIV 
  
Q33_HSBJ It is women who spread HIV in our communities   
 It is men who spread HIV in our communities   
  6:14
 It is outsiders who spread HIV in our communities   
 HIV is a punishment for bad behaviour   
 HIV is a punishment from God   
 People with HIV are promiscuous   
    
Q34_HES 
Do you personally know anyone who is HIV positive who has experienced 
any of the following: 
 
Yes 
 
No 
 Been excluded from a social gathering   
 Abandoned by spouse/partner   
 Isolated by their household   
 Lost housing/denied housing for rent   
 Lost respect or standing in the community   
 Been teased, insulted or sworn at   
 Been gossiped about   
 Whose children or family have been isolated/shunned   
 Been treated worse than patients with other diseases by health staff   
    
Q35_HD 
Do you personally know anyone who has disclosed their HIV status 
directly to you or publicly in the last 12 months? 
 
  
 
IF THE RESPONDENT HAS NOT BEEN TESTED FOR HIV, OR IS HIV NEGATIVE OR UNWILLING TO DISCLOSE 
THEIR HIV STATUS THE INTERVIEW WILL END HERE. THANK THEM FOR THEIR TIME AND ASSISTANCE 
IF THE RESPONDENT HAS TOLD YOU THAT THEY ARE HIV POSITIVE CONTINUE WITH THESE QUESTIONS FOR 
PEOPLE LIVING WITH HIV ONLY. 
  
 
Yes 
 
No 
Q36_HPD 
Have you disclosed your HIV status to anyone (except to me for the 
purpose of this study) 
  
 (IF YES CONTINUE, IF NO SKIP TO Q36)  
Q36_1 Have you disclosed your HIV status to your main sexual partner?   
Q36_2 Have you disclosed your HIV status to other household members?   
Q36_3 Have you disclosed your HIV status to anyone outside of the household?   
    
Q37_HES 
In the last year have you experienced any of the following due to your HIV 
status: 
 
Yes 
 
No 
 Been excluded from a social gathering   
 Abandoned by spouse/partner   
 Isolated by their household   
 Lost housing/denied housing for rent   
 Lost respect or standing in the community   
 Been teased, insulted or sworn at   
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 Been gossiped about   
 Whose children or family have been isolated/shunned   
 Been treated worse than other patients by health staff   
 (IF YES TO ANY OF THE ABOVE CONTINUE, IF NO TO ALL OF ABOVE SKIP TO Q39) 
  Yes No 
Q38_HIS Do you think it was reasonable for you to be treated in this way?   
Q39_HIS2 
In the last year have you ever avoided or withdrawn from any of the 
following due to your HIV status 
 
Yes 
 
No 
 Applying for school, further training or a scholarship   
 Promotion or job opportunity   
 Travel   
 Seeking health care   
 Relationship with friends or family   
 Having a sexual relationship, getting married or having a child   
Q40_HIS2 In the last year, because of your HIV status, have you felt: Yes No 
 Less of yourself because of your HIV   
 Guilty about having HIV   
 Unclean or dirty because of your HIV   
 
That you deserved to get HIV 
 
  
 
 
 
THANK THE RESPONDENT FOR THEIR PARTICIPATION 
 
 
 
  Interviewer’s 
Code 
Date 
Signature 
  d d m m y y y y 
 Interviewer           
 Field Manager           
 1
st data entry           
 2
nd data entry           
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Appendix 7. : HIV Testing Algorithm 
 
1. The first line testing is AxSYM HIV test although there are slight differences in the generation of 
assays used between the two countries. Samples processed in South Africa are first tested on a 4th 
generation assay, AxSYM HIV Ag/Ab Combo Assay (Abbott). Samples processed in Zambia are first 
tested on a 3rd generation assay, AxSYM HIV 1/2gO (Abbott). Interpretation of results for AxSYM 
HIV Ag/Ab Combo Assay are as defined by the manufacturer: Specimens with S/CO (sample 
rate/cutoff rate) < 0.90 are considered negative; ≥ 1.00 as reactive (positive); 0.90 - < 1.00 as gray 
zone. 
2. For both countries, the second line testing is done on the VironostikaUni-form11 Ag/Ab assay 
(Manual ELISA test). Interpretation of results for Vironostika Uniform tests are as described by the 
manufacturers (manual ELISA test). A cut-off value = Mean negative control (NCx) + 0.100 is used. 
Samples are positive if sample absorbance is ≥ cut-off value. Samples are negative if sample 
absorbance is ≤ cut-off value. 
3. Discrepant samples i.e. those positive on the first line testing, and negative on second line testing 
are tested with the Determine HIV ½ Ag/Ab Combo rapid test. 
4. Interpretation of Determine rapid HIV test is as described by the manufacturers. 
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Appendix 8. : SOP for QuantiFERON® – TB Gold IT 
 
Summary and Explanation of the Test. 
 The QuantiFERON® – TB Gold IT test is a test for Cell Mediated Immune (CMI) responses to peptide 
antigens that simulate mycobacterial proteins. These proteins, ESAT-6, CFP-10 and TB7.7 (p4), are 
absent from all BCG strains and from most non-tuberculosis mycobacteria with the exception of M. 
kansasii, M. szulgai, and M. marinum. Individuals infected with M. tuberculosis complex organism 
usually have lymphocytes in their blood that recognise these and other mycobacterial antigens. This 
recognition involves the generation and secretion of the cytokine, IFN-γ. The detection and subsequent 
quantification of IFN-γ forms the basis of the test. 
 Numerous studies have demonstrated that peptides antigens used in this test stimulate IFN-γ 
responses in T-cells from individuals infected with M. tuberculosis, but generally not from uninfected or 
BCG vaccinated people without disease or risk for LTBI. However, medical treatments or conditions that 
impair immune functionality can potentially reduce IFN-γ responses.  
 QuantiFERON® – TB Gold IT test is both a test for LTBI and may be useful in diagnosing M. tuberculosis 
complex in sick people. A positive result supports the diagnosis of tuberculosis disease: however 
infection by other mycobacteria (e.g. M. kansasii) could also lead to a positive result. Other medical and 
diagnostic evaluations (i.e. risk assessment, radiography) are necessary to confirm or exclude 
tuberculosis disease. 
 The QuantiFERON® – TB Gold IT test is performed in two stages:  
i. Blood is collected into each of the QuantiFERON® – TB Gold IT tubes which include: 
- Nil control (Grey cap) 
- TB Antigen (Red Cap) 
- Mitogen control (Purple Cap) 
ii. Following a 20 to 24 hour incubation period, the tubes are centrifuged, the plasma is removed, and 
the amount of IFN-γ measured by ELISA. 
Sample Collection and Incubation 
Samples will be collected at either household or clinic level as part of the SOCS procedure. 
1. Before sample collection make sure: 
- The phlebotomy equipment is ready 
- Each blood collection tube is correctly labeled with the individual’s barcode ID 
- Each record form is labeled with the individual’s barcode ID 
2. For each subject collect 1 ml of blood by venepuncture directly into each of the QuantiFERON-TB Gold 
blood collection tubes (three tubes per patient). 
- As 1 ml tubes draw blood relatively slowly, keep the tube on the needle for 2-3 seconds once 
the tube appears to have completed filling, to ensure that the correct volume is drawn. 
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The black mark on the side of the tubes indicates the 1ml fill volume. QuantiFERON TB Gold blood 
collection tubes have been validated for volumes ranging from 0.8 to 1.2 ml. If the level of blood in 
any tube is not close to the indicator line, it is recommended to obtain another blood sample. If 
this happens, remember to put the individual’s ID bar code on the tube. 
3. Mix the contents of the tube with the blood thoroughly by turning the tube end-over 8 to 10 times or 
shaking the tube for 5 seconds ensuring that the entire inner surface of the tube has been coated with 
blood.  
4. Keep the samples at room temperature in an UPRIGHT position and transfer to a 370C incubator within 
30 minutes of collection, either a portable incubator in the vehicle, or a small incubator in the clinic 
lab. 
5. Report the date and time of blood collection on the record form. 
Important notes: 
- Do not refrigerate or Freeze the blood sample before incubation! 
- Before incubation of the samples, make sure they have been properly mixed as described 
above. 
 
6. Incubate the samples for 20-24 hours maximum: 
• All samples MUST be incubated for the same time period (make sure you record the time of 
start of the incubation period and respect the agreed 20-24 hours of incubation). 
• Samples must NOT exceed 24 hours of incubation. 
7. Report the time of incubation’s start on the record form. 
Laboratory Procedures 
South Africa and Lusaka Sites in Zambia:  
- Portable incubators will be used: 
- Make sure that you plug in the portable incubator at the start of the day to allow it to 
equilibrate its temperature. 
- Ensure that all switches are in the correct position and that the temperature is 37oC (+/-1 oC) 
when putting blood tubes in. 
- Record any problems on the sample form e.g. power supply failures, failure to maintain 
correct temp etc. 
- Samples must be taken to the research laboratory using the portable incubators the same day of 
collection and then transferred to laboratory incubator until the end of the incubation period. 
- The laboratory staff member receiving the specimens must sign on the record form as 
appropriate. 
- Once the samples are delivered to the laboratory, make sure the portable incubators are 
brought back and are available for the field work. 
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Zambia except for Lusaka sites: 
- Blood samples will be incubated in small incubators in the ZAMSTAR clinics. They will remain in 
the incubators for the full incubation period. 
- If blood is to be taken in the household in a site where this will take more than 30 minutes to 
get back to the clinic, a portable incubator should be used in the field (in the car) and then the 
blood transferred into the incubator at the clinic as soon as possible. 
- Samples will be processed in the laboratories in the clinics. 
In the central laboratory in South Africa and Zambia and in the peripheral laboratories in Zambia (all sites 
EXCEPT for Lusaka) the following procedures will be conducted: 
STAGE 1: Bar-coding and harvesting of plasma. 
1. At the end of the incubation period the samples must be removed from the incubator and the date and 
time recorded on the sample form. 
2. Samples should be centrifuged as soon as possible after the end of the 20-24 hours of incubation.  
3. If samples cannot be processed immediately after this period of time (e.g. due to unforeseen 
circumstances such as power failure or weekends), the blood collection tubes may be held in the fridge 
between 2°C and 27°C for up to 3 days prior to centrifugation. 
4. Centrifuge the blood collection tubes for 10 min at 1500 to 2200 RCF (g). The gel plug will separate the 
cells from the plasma, if this does not occur, the tubes should be re-centrifuged at higher speed. 
5. Report the date and time of plasma extraction on the record form. 
6. After centrifugation, arrange centrifuged tubes in the blood stand making sure each triplet of tubes 
refer to the same patient. Check that the barcodes on the 3 tubes are all the same and that the record 
form matches the barcode. 
7. For each triplet of blood collection tubes do the following: 
A. RED CAP Blood collection tube  
- Take one of the red-topped (or pink) 1.5 ml eppendorf provided, labeled with a unique 
random number.  
- Harvest 150µl plasma from red cap blood collection tube into the 1.5 ml red topped (pink) 
eppendorf tube. 
- Report the barcode number of the eppendorf on the record form. 
B. GREY CAP Blood collection tube  
- Take one of the grey topped (or grey) 1.5 ml eppendorf provided, labeled with a unique 
random number.  
- Harvest 150µl plasma from the grey cap blood collection tube into the 1.5 ml grey topped 
(grey) eppendorf tube. 
- Report the barcode number of the eppendorf on the record form. 
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C. PURPLE CAP Blood collection tube  
- Take one of the purple topped (purple) 1.5 ml eppendorf provided, labeled with a unique 
random number.  
- Harvest 150µl plasma from the purple cap blood collection tube into the 1.5 ml purple 
topped (purple) eppendorf tube.  
- Report the barcode number of the eppendorf on the record form. 
8. Place the 3 eppendorfs (1 red topped (pink), 1 grey topped (grey) and 1 purple topped (purple)) in a 
plastic bag and seal. 
9. Store the plasma at +2-8oC (in the fridge) for 4 to 8 weeks.  
10. Store the record form in the proper folder or in the envelope in the specimen bag. 
Zambia sites except Lusaka: 
All specimens will be transported to Lusaka on the agreed day of the month in a cooler box. The specimens 
with completed laboratory forms (and matching SOCS envelopes) will be carried by the data person to 
Lusaka and handed over and signed for by the laboratory staff. 
STAGE 2: Freezing Samples 
To be performed at the central laboratories in both Zambia and South Africa. 
Note: In Lusaka Sites and in South Africa transport of samples will not be needed as samples are already 
stored in the Central lab. At the end of the 4-8 weeks, take the samples stored at 2-8°C and follow the 
procedures as described below. 
 After 4-8 weeks at +2-8°C, or whenever the samples from Zambian sites (except Lusaka) arrive at the 
central laboratory, plasma will be stored at -70°C until ELISA is performed. 
 
 For each specimen bag, do the following: 
 
1. Complete the information on the record form detailing the date of delivery at the central lab and 
the receiving technician (if applicable). 
2. Scan the barcode from each quantiferon recording form and the corresponding eppendorfs (with 
the unique random number). 
3. Allocate the eppendorfs to specified storage boxes/racks/freezers.  
4. Take the eppendorfs out of the plastic bags and store them in the specified freezer space at -70°C. 
5. Record the date of freezing on the record form. 
6. Enter the data on the record forms in the database. 
 
STAGE 3. Human IFN-γ ELISA  
This will be done in batches when enough samples are ready to be tested. It is best for samples to be tested 
in batches of 28 subjects (i.e. 28 sets of the 3 tubes) 
1. Bring all plasma samples and reagents, except for Conjugate 100X Concentrate, to room 
temperature (22°C ± 5°C) before use. Allow at least for 60 minutes for equilibration. 
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2. Remove strips that are not required from the frame, reseal in the foil pouch, and return to the 
refrigerator for storage until required. 
Allow at least one strip for the QuantiFERON® – TB Gold standards and sufficient strips for the 
number of subjects being tested. After use retain frame, and lid for use with the remaining strips. 
3. Reconstitute the freeze dried Kit Standard with the volume of deionised or distilled water 
indicated on the label of the Standard vial. Mix gently to minimise frothing and ensure complete 
solubilisation. Reconstitution of the Standard to the stated volume will produce a solution with a 
concentration of 8.0 IU/ml. 
 
Note: the reconstitution volume of the Kit Standard will differ between batches. 
Use the reconstituted Kit Standard to produce a 1 in 4 dilution series of IFN-γ Green Diluent (GD). 
S1 (Standard 1) contains 4IU/ml, S2 (Standard 2) contains 1IU/ml, S3 (Standard 3) contains 0.25IU/ml, and 
Standard 4 contains 0 IU/ml (GD alone). The standard should be assayed at least in duplicate.  
 
Recommended procedure for duplicate 
standards 
 Recommended procedures for triplicate 
standards 
a. Label 4 tubes “S1”, “S2”, “S3”, “S4”  a. Label 4 tubes “S1”, “S2”, “S3”, “S4” 
b. Add 150 µl of GD to S1, S2, S3, S4  b. Add 150 µl of GD to S1, S2, S3, S4 
c. Add 150 µl of the Kit Standard to S1 and 
mix thoroughly. 
 c. Add 210 µl of GD to S2, S3, S4 
d. Transfer 50 µl from S1 to S2 and mix 
thoroughly. 
 d. Add 150 µl of the Kit Standard to S1 and 
mix thoroughly. 
e. Transfer 50 µl from S2 to S3 and mix 
thoroughly. 
 e. Transfer 70 µl from S1 to S2 and mix 
thoroughly. 
f. GD alone serves as zero standard.  f. Transfer 70 µl from S2 to S3 and mix 
thoroughly. 
  g. GD alone serves as zero standard. 
 
Note: prepare fresh dilutions of the Kit Standard for each ELISA session. 
4. Reconstitute freeze dried Conjugate 100X Concentrate with 0.3 mL of deionised or distilled water. 
Mix gently to minimise frothing and ensure complete solubilisation of the Conjugate. 
 
Prepare working Strength conjugate by diluting the required amount of reconstituted Conjugate 
100X Concentrate in Green Diluent as set out in Table 8.1 – Conjugate Preparation. 
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Table 8.1: Conjugate preparation 
Number of strips Volume of Conjugate 100X 
Concentrate 
Volume of Green Diluent 
2 10 µL 1.0 mL 
3 15 µL 1.5 mL 
4 20 µL 2.0 mL 
5 25 µL 2.5 mL 
6 30 µL 3.0 mL 
7 35 µL 3.5 mL 
8 40 µL 4.0 mL 
9 45 µL 4.5 mL 
10 50 µL 5.0 mL 
11 55 µL 5.5 mL 
12 60 µL 6.0 mL 
 
• Mix thoroughly, but gently to avoid frothing. 
• Return any unused Conjugate 100X Concentrate to 2°C to 8°C immediately after use. 
• Use only Green Diluent. 
 
5. Prior to assay, mix the plasma to ensure that IFN-γ is evenly distributed throughout the sample. 
 
6. Add 50 µL of freshly prepared Working Strength conjugate to the required ELISA wells using a 
multi-channeled pipette. 
 
7. Add 50 µL of the test plasma samples to appropriate wells using a multichannel pipette (see figure 
J. 1). 
 
8. Finally, add 50 µL each of the Standard 1 to 4. 
 
9. Mix the conjugate and plasma samples/standards thoroughly using a microplate shaker for 1 
minute. 
 
10. Cover each plate with a lid and incubate at room temperature (22°C ± 5°C) for 120 ± 5 minutes. 
 
• plates should not be exposed to direct sunlight during incubation 
 
 
 
 
  8:23
Figure J.1: Recommended sample layout for the Nil, TB Antigen and Mitogen tubes (28 tests per plate) 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 1N 1A 1M S1 S1 S1 13N 13A 13M 21N 21A 21M 
B 2N 2A 2M S2 S2 S2 14N 14A 14M 22N 22A 22M 
C 3N 3A 3M S3 S3 S3 15N 15A 15M 23N 23A 23M 
D 4N 4A 4M S4 S4 S4 16N 16A 16M 24N 24A 24M 
E 5N 5A 5M 9N 9A 9M 17N 17A 17M 25N 25A 25M 
F 6N 6A 6M 10N 10A 10M 18N 18A 18M 26N 26A 26M 
G 7N 7A 7M 11N 11A 11M 19N 19A 19M 27N 27A 27M 
H 8N 8A 8M 12N 12A 12M 20N 20A 20M 28N 28A 28M 
 
• S1 (Standard 1), S2 (Standard 2), S3 (Standard3) 
• 1N (Sample 1. Nil Control plasma) 
• 1A (Sample 1. TB Antigen plasma) 
• 1M (Sample 1. Mitogen Control plasma) 
 
11. During the incubation, dilute one part Wash Buffer 20X Concentrate with 19 parts deionised or 
distilled water and mix thoroughly. Sufficient Wash Buffer 20X Concentrate has been provided to 
prepare 2L of working Strength wash buffer. 
 
Wash wells with 400 µL of Working Strength wash buffer for at least 6 cycles. An automated plate 
washer is recommended. 
• Thorough washing is very important to the performance of the assay. Ensure each well is 
completely filled with wash buffer to the top of the well for each wash cycle. A soak period of 
at least 5 seconds between each cycle is recommended.  
• Standard laboratory disinfectant should be added to the effluent reservoir, and established 
procedures followed for the decontamination of potentially infectious material. 
 
12. Tap plates face down on absorbent towel to remove residual wash buffer. Add 100 µL of Enzyme 
Substrate Solutions to each well and mix thoroughly using a microplate shaker. 
 
13. Cover each plate with a lid and incubate at room temperature (22°C ± 5°C) for 30 minutes. 
 
- Plates should never be exposed to direct sunlight during incubation. 
 
14. Following the 30 minutes incubation, add 50 µL of Enzyme Stopping Solutions to each well and mix. 
 
- Enzyme stopping solution should be added to wells in the same order and approximately the 
same speed as the substrate in step 13. 
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15. Measure the Optical Density (OD) of each well within 5 minutes of stopping the reaction using a 
microplate reader fitted with a 450 nm filter and with a 650 reference filter. OD values are used to 
calculate results. 
 
Quality Control of the Test 
For the ELISA to be valid: 
• The mean OD value for Standard 1 must be ≥ 0.600. 
• The %CV for Standard 1 and Standard 2 replicate OD values must be ≤ 15%. 
• Replicate OD values for Standard 3 and Standard 4 must not vary by more than 0.040 OD units from 
their mean. 
• The correlation coefficient (r) calculated from the mean absorbance values of the standard must be ≥ 
0.98. 
The QuantiFERON® – TB Gold IT Analysis Software calculates and reports these quality control 
parameters. 
Note: If the above criteria are not met, the run is invalid and must be repeated. 
• The mean OD value for the Zero Standard (Green Diluent) should be ≤ 0.150. If the mean OD value is > 
0.150 the plate washing procedure should be investigated. 
 
Interpretation of the Results 
Nil (IU/mL) TB Antigen minus 
Nil (IU/mL) 
Mitogen minus 
Nil (IU/mL)1 
QuantiFERON® – 
TB Gold IT Result 
Report/Interpretation 
≤ 8.0 
< 0.35 ≥ 0.5 
Negative 
M. tuberculosis 
infection NOT likely 
≥ 0.35 and <25% 
of Nil value 
≥ 0.5 
≥ 0.35 and ≥ 25% 
of Nil value 
Any Positive2 M. tuberculosis 
infection likely 
< 0.35 < 0.5 
Indeterminate3 
Results are 
indeterminate for TB-
Antigen 
responsiveness 
≥ 0.35 and <25% 
of Nil value 
< 0.5 
> 8.04 Any Any 
 
Key: 
1. Responses to the Mitogen positive control (and occasionally TB Antigen) can be commonly outside the 
range of the microplate reader. This has no impact on test results. 
 
2. Where M. tuberculosis infection is not suspected, initially positive results can be confirmed by retesting 
the original plasma samples in duplicate in the QuantiFERON® – TB Gold ELISA. If repeat testing of one, 
or both replicates, is positive, then the individual should be considered test positive. 
 
3. Indeterminate results should be uncommon and may be due to the immune status of the individual 
being tested, but many also be related to a number of technical factors: 
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- Longer than 16 hours from blood draw to incubation at 37°C. 
- Storage of blood outside the recommended temperature range (22°C±5°C). 
- Insufficient mixing of blood collection tubes. 
- Incomplete washing of the ELISA plate. 
 
4. In clinical studies, less than 0.25% of subjects had IFN-γ levels of > 8.0 IU/mL for the Nil Control. 
 
Note: the magnitude of the measured IFN-γ level cannot be correlated to stage or degree of infection, 
level of immune responsiveness, or likelihood of progression to active disease. 
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Appendix 9. : QuantiFERON® – TB Gold IT Recording Form 
 
ADULT BARCODE 
 
 
   
QGIT01_ Visit No   
   QGIT02a_ Nurse Code     
    D D M M Y Y Y Y 
QGIT03_Date of sample collection         
  h h m m 
QGIT03a_Time of sample collection      
 D D M M Y Y Y Y 
QGIT04_Date of incubation’s start         
  h h m m 
QGIT05_Time of incubation’s start      
      QGIT05a_Temp of incubation’s start (0C)    
 D D M M Y Y Y Y 
QGIT06_Date of Incubation’s end         
  h h m m 
QGIT07_ Time of incubation’s end      
      QGIT07a_Temp of incubation’s end (0C)    
 D D M M Y Y Y Y 
QGIT08_Date of plasma extraction         
  
QGIT09_ Eppendorf barcodes GREY CAP TUBE         
          
 RED CAP TUBE         
          
 PURPLE CAP TUBE         
 D D M M Y Y Y Y 
QGIT10_Date of storage at –20 Celsius         
 D D M M Y Y Y Y 
QGIT11_Date of delivery at central lab         
 D D M M Y Y Y Y 
QGIT12_Date of storage at – 800C         
    
QGIT13a_ Signature                                                      
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Appendix 10. :  Standardized QuantiFERON –TB Gold IT responses to participants 
 
Quantiferon results: response to participants 
QGIT is a new blood test, still under research and not yet fully understood by researchers 
throughout the world. 
If a participant has TB symptoms, regardless of the QGIT results they should be referred to the 
clinic for further screening. Below are suggested guidelines of how these results can be 
explained to participants. 
1. Positive Quantiferon test results. This means that the participant has been exposed to TB or 
is infected with TB. This does not mean that they have TB disease, as many people in the 
community are exposed to TB and get infected without getting the disease. The participant does 
not need to be referred to the clinic for further investigations due to a positive result unless they 
are unwell.   
2. Negative Quantiferon test result. This means that the participant has not been exposed to TB 
or is not infected with TB.  
3. Indeterminate Quantiferon test result: The test is neither positive nor negative. This means 
that the test has failed to work. The TB infection status of the participant could not be 
determined although it may be able to do so at a later stage when the test is repeated (Note: 
Indeterminate results will not be routinely repeated). Failure of the test to work can be a result 
of many factors related to the participant (low immune response), process (blood collection and 
sample management) or laboratory technical errors.   
4. Discordant QGIT and TST results: Discordant results are when the two tests do not agree 
(QGIT +ve and TST –ve or QGIT -ve / TST +ve). The two tests are different and measuring 
different aspects of the immune system and may not necessarily agree. When results are 
discordant, the TST (which has been used for a long time and better understood) result should 
take preference over the QGIT result. 
5. No test result available due to errors: In some cases the participant had given blood for QGIT, 
but no test could be done in the ZAMBART laboratory. Possible technical and logistical errors are 
for example: (1) the volume of the blood sample was insufficient (2) the tube broke during 
transport (3) the tube was not well closed and blood leaked out (4) the blood had clotted. 
  
  11:28
Appendix 11. : QuantiFERON® –TB Gold IT Monitoring Tool  
 
Name of site: _______________________  Date: _______________ Quarter under review: _________________________ 
 
 
 
 
 
 
 
Functional 
area 
Question Indicator 
 
Specific indicator 
 
Source 
Of data 
Method Field Evaluation 
General work 
place and sop 
observation 
Is all the necessary equipment for 
sample processing in stock? 
Blood collection bottles (red, 
grey, purple) 
butterflies/vacutainer, 
Needles   and holder, mobile 
and laboratory incubator 
centrifuge 
 
 
 
 
Evaluator Observation See table 1 
Do staff know the QGIT SOP (select 
one staff responsible for 
centrifugation and incubation 
randomly)? 
Staff accurately narrates how 
samples are processed 
according to SOP 
 
 
 
Nurse or 
Microscopist 
 
Interview  See table 2 ( A and B) 
Do all the three bottles for one person 
(grey , red, purple) have the same 
barcode? 
Barcodes on the three bottles 
(red, grey, purple) 
Check specimens collected 
on evaluation day and 
check the barcode  
label 
Evaluator Observation Yes Table 4 
 
Is blood properly mixed before 
incubation as per SOP? 
Observe them mix samples 
collected on evaluation day 
 Evaluator Observation Yes 
No 
 After blood collection how long does 
it take before samples are put   
in the incubator? 
Time 
 
Take note of the time 
between collection and   
incubation 
Nurse or 
 
Microscopist 
Interview Time: 
  
 
Are the management forms properly 
and accurately filled in? 
Management form Pick ten forms randomly 
and check if their 
accurately and properly 
filled 
Microscopist 
or nurse 
Interview See table 3 
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 After centrifugation how long does it take 
before the plasma is extracted? 
  Microscopist 
or nurse 
 
Interview  
 Are the eppendorfs kept in the freezer after 
plasma extraction? 
Serum eppendorfs in 
the freezer 
 Evaluator Observation Yes  
No  
 What is the approximate temperature of the 
freezer used? 
Temperature  Check   whether they use a 
deep freezer (-20) or an 
ordinary freezer (4) degrees 
Evaluator  Observation  Temperature  
 
-------------- 
 How often do power cuts occur? 
(during which time night or day) 
 Interview the person in 
charge of sample incubation 
Microscopist  
or nurse 
 
 
Interview Hours per week 
 
-------------------- 
 
 The Following section evaluates equipment used in the processing, knowledge of QuantiFERON SOP and completeness of recorded forms. 
Equipment 
 
Field Evaluation Number in Stock Comment 
Collection bottles (grey, red, purple) Yes / No   
Vacutainer needles and holder/butterflies Yes / No   
Mobile incubator (where applicable) Yes / No   
Working Laboratory incubator(where applicable) Yes / No   
Working Centrifuge Yes / No   
 
Functional area Question Indicator 
 
Specific indicator 
 
Source 
Of data 
Method Field 
Evaluation 
Laboratory 
procedure after 
incubation 
After sample incubation how long does it take 
before samples are centrifuged? 
 Time  Microscopist 
or nurse 
 
Interview Time  
Are the samples properly centrifuged   before 
separation? 
 Blood cells should be 
at the bottom, gel in 
the middle and serum 
on top  
Check   samples centrifuged 
on evaluation day 
Evaluator Observation  Yes 
No 
 
Is centrifuged serum transferred to their 
corresponding colour eppendorfs (grey to 
grey, red to red, purple to purple)? 
 Observe them transfer the 
serum into eppendorfs  
Evaluator  Observation Yes 
No 
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Accuracy  =  Number of forms checked            x  100                                                 Accuracy =  Number of bottle sets checked      x     100 
                    Number of forms correctly filled                                                                                Number of bottle sets with same barcodes 
SOP Content for Sample Incubation (for 
responsible person) 
 
Field Evaluation Comment 
Know the maximum time before sample incubation Yes / No  
Know what temperature samples should be incubated Yes / No  
 Know how long samples should be incubated Yes / No  
SOP Content for Sample Centrifugation (for 
responsible person) 
 
Field Evaluation Comment 
Know what is meant by fully centrifuged Yes / No  
Know the temperature  at which serum is stored Yes / No  
Check for completeness of management Form  
 
Field Evaluation Comment 
Nurse name Yes / No  
Nurse code Yes / No  
Date of sample collection Yes / No  
Time sample collection Yes / No  
Date of start incubation Yes / No  
Time of incubation start Yes / No  
Date of incubation end Yes / No  
Time of incubation end Yes / No  
Date of serum separation Yes / No  
Barcodes label properly and accurately filled Yes / No  
Is the same barcode on all three specimen 
 
Field evaluation Comment 
Study participant 1 Yes / No  
Study participant 2 Yes / No  
Study participant 3 Yes / No  
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Comments on Sample collection, storage and processing 
__________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________
__________________________________________________________________________________________________________________________________
_______________________________________________________________________________________ 
 
In general comment on what happens to the samples in case of power outage  
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________
_______________________________________________________________________________
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Appendix 12. : TST recording form 
 
ADDRESS BARCODE ADULT BARCODE 
  
PPD batch 
used 
                                   Dose 0.1ml (2TU)  
  Baseline M18 (Visit 2) M36 (Visit 3) 
Q01_VIS Visit  1 2 3 
 
 D D M M Y Y Y Y 
Q03_DAT Today’s date          
 
 
 
Q09_ASSINJ SOCS nurse code injecting PPD     
Q10_ASSREAD SOCS nurse code reading TST     
 D D M M Y Y Y Y 
Q11_TSTDONE Date TST done          
 D D M M Y Y Y Y 
Q12_TSTREAD Date TST read          
 
Q13_TSTIND Induration (mm)     
 
 
 
 
 
  
Code 
Date 
Signature 
  d d m m y y y y 
 Field Manager           
 1
st data entry           
 2
nd data entry           
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Appendix 13. : Sputa transportation form for SOCS Visit 3 
 
ZAMSTAR Transportation Form Date Samples collected: Page 
 
Site Date sent to Zambart 
House/Post courier 
Total No. of samples sent: 
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Delivered By ITL/Post Courier:                                 Received By:     
Date Received at CTL: 
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Appendix 14. : Algorithm for sputum processing and decision on whom to follow-up 
 
 
 
 
 
 
 
 
 
Reminder stored at 
-20 ºC 
Sputum sample 
Leaked out, no barcode 
or no matches of 
barcodes discarded 
Log into Computer 
Digestion/decontamination 
Inoculation 2 manual 
MGIT and incubate 
Read once a week 
Aurumine staining if 
MPB64 positive 
Archive culture  
-20 C (-80C).  
Make slide from 
MGIT culture 
Growth No growth after 
6 week 
Discard tube  
Contaminated 
Log as growth “negative” 
ZN negative 
MPB64 1. If ZN cording and 
strong positive MPB64 
= TB send PI report 
and refer patient 
2. If few AFB, no 
cording/unsure or 
faint positive MPB64= 
pending and await 
further test results 
(MTBDRplus or second 
MPB64 test, or 
auramine result). If 
additional information 
confirms then refer 
patient 
? NTM 
Log as growth “positive” 
ZN positive  
Generate ZN stain worksheet 
Negative 
Positive 
Generate MPB64 worksheet 
Generate 
Auramine 
worksheet 
(SA only) 
 Smear Auramine positive 
MTBDR plus 
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Appendix 15. : Culture positive follow up form for Visit 3 
 
Q01_SURNAME 
 
 
Q02_FIRST NAME 
 
 
Q03_SEX  Q04_AGE  
Q05_ADDRESS 
 
 
Q06_LATITUDE  Q07_LONGITUDE  
 
Section B – Availability of Individual 
Q08_IND_AVAILABLE FOR FOLLOW-
UP 
Yes No  
Q09_REASON_NOT_ AVAILABLE Died Moved Absent Refused Unknown 
 
Section C – Clinical Review Symptoms (More Options are Possible) 
Q10_SYMPTOMS Cough Chest Pains Cough Up Blood Fever 
 Weight Loss Night Sweats Difficulty Breathing  
 
Section D – FU SPUTUM Smear Results – Fill Follow-Up Smear Results from Local Clinic Lab 
Q11_SPOT Negative Scanty (1-9) 1+ 2+ 3+ Not Done 
Q12_MORNING Negative Scanty (1-9) 1+ 2+ 3+ Not Done 
 
Section E – Chest X-Ray 
Q13_XRAY Abnormal TB Abnormal Not TB Normal Not Done 
 
Section F – FU CULTURE Results – Complete when Follow_Up Results are Available from CTL 
Q14_CULTURE TB Isolated TB Not Isolated 
Q15_DST Q15_INH Q15_SM Q15_RIF Q15_EMB 
 S R S R S R S R 
 
Section H – Decision 
Q16_DECISION TB No TB 
Q17_CLINICAL_DECISION Yes No 
Q18_TREATMENT_STARTED Yes No 
Q19_DATE_TREATMENT_STARTED  
Q20_TB TREATMENT_NUMBER  
Q21_TB TREATMENT_OUTCOME  
Q22_REMARK 
 
 
 
 
SIGNATURE DATE SIGNED OFF D D M M Y Y Y Y 
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Appendix 16.  : Adult Questionnairre for Visit 3   
 
        M36  (Visit 3) 
Q01_VIS Visit  3 
Q02_COD Interviewer’s code     
 D D M M Y Y Y Y 
Q03_DAT Date of Interview          
I would now like to ask you some questions about your current drinking habits 
 No Yes Unknown 
Q11_DA During the last 4 weeks have you taken any drinks 
containing alcohol? 
Pamasabatainaiyapita, munamwapo moba uliwonse? 
Bushe pa milunguine (4) iyapita ,mwalinwapo 
ubwalwa? 
0 1 9 
    
Q12_DD During the last year have you ever drunk so much 
that you were unable to remember what you were 
doing? 
Mu chaka chathaichi munamwapo moba 
ndikulezelakwambirikufikilakutisimunakumbukilechi
menemunalikuchita? 
Muliumwakawapwilemwaliikolwapoicakutimwalaban
efyomwalecita? 
0 1 9 
    
I would now like to ask you some questions about your sexual relationships 
Q16_MS What is your marital status now? 
Kodi ndinuokwatilakapenaosakwatilapaliinonthawi? 
Bushe: 
 Single 
Osakwatila 
Tamwaupa/tamwaupwa? 
1 Married/living as married 
Okwatila / kukhalamongaOkwatila 
Mwalyupa/mwalyupwa/mwikapamonga
baupana 
2 
   
 Widowed 
Ofedwamwamunakapenamufelek
azi 
Abena mwenu balifwa? 
3 Divorced/separated 
Chikwatichinathaolokupatukanachabe 
Mwalilekana/tamwikalapamo? 
4 
   
 No Yes Unknown 
Q17_SX In the last 6 months have you had sex? 0 1 9 
 
Pa mweziisanundiumodziyapitapomunagonapondimkazi/mwamuna 
Mu myeshimutanda (6) iyapita, mwalilalapo no mwanakashi/umwaume? 
 
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO NEXT SECTION B, Q18) 
 
 
 
 
SECTION A – GENERAL INFORMATION 
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 No Yes Unknown 
Q17_1_OP In the last 6 months at any stage, have you 
had more than one sexual relationship at the 
same time? 
Kodi pa mweziisanundiumodzi (6) yapitapoiyi, 
munagonanapokapenakukumanandimwamun
akapenamkaziwinakuchoselakoamenemumak
umananayenthawizonse? 
Mu myeshimutanda (6) iyapitamwalilalapo no 
mwanakashi/umwaumeumbiukucilipabomula
lanabosana? 
0 1 9 
    
   (IF YES CONTINUE.  IF NO OR UNKNOWN GO TO Q17_2_POP) 
 
Q17_1_1_CM 
Did you use condoms with these partners? 
Kodimunasebenzesamupilawakondomupali abo munagonananao? 
Bushemwalibomfesheumupilanaba bantu mwalelenabo? 
 Never 
Simunasebenzese 
Awe 
1 Always 
Nthawi zones 
Lyonse 
2 
   
 Sometimes 
Nthawizina 
Limolimo 
3 Unknown/ no answer 
Siniziwa 
Nshishibe 
9 
   
 No Yes Unknown 
Q17_2_POP 
 
In the last 6 months do you think that your main 
partner has had other partners apart from you? 
Pa mweziisanundiumodziyapita, 
muganizakutiabwenzianuanagonapondimunthuwina? 
Mu myeshimutanda (6) iyapita, 
bushemuletontonkanyaukutiabatemwikabenu abo 
mulalanabosanabalikwatabambi abo 
balelalanaboukucilapaliimwe? 
0 1 9 
    
 
SECTION B – TB AND HIV QUESTIONS – ASK ALL RESPONDENTS 
I would now like to ask you some questions about your health, specifically about TB and HIV 
Ndifunakufunsamafunso a khanizaumoyowanumakamaka pa TB na HIV 
Ndefwayanombaukumwipushakoamepusho pa bumiwenumakamakapali TB na HIV 
 No Yes 
Q18_TBT Since 2006, have you been on TB treatment? 
Kucokera mu choka cha 2006, 
kodimunakhalakopamankhwala a chifuwa cha TB? 
Ukufumamumwakawa 2006, 
bushemwalibapopamutiwa TB? 
0 1 
   
 
 
(IF YES CONTINUE.  IF NO GO TO Q19) 
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Q18_3_TBT How many times have you been on TB treatment since 
2006? 
Kodi munakhalapo kangati pa mankhwala a chifuwa cha TB 
kucokera mu chaka cha 2006? 
Miku inga iyo mwalipo pamuti wa TB ukufuma mumwaka 
wa 2006? 
 
1 2 3 
 
  No Yes 
Q18_4_TBT 
Can I see your TB card(s)? 
Nipempakuona TB (ma TB) card yano? 
Ndelombaukumona TB (nangulaama TB) card yenu? 
0 1 
 
Q18_5_TBT 
If yes, using TB card (s). Research assistant to check and  
complete the following 
 TB 
Regnum 
Date TB treatment 
started  
Clinic where 
TB treatment 
was given 
Type of TB 
 on card1 
Type 
Of 
Patient2 
D D M M Y Y Y Y 
1           1 2 3 9 1 2      9 
2           1 2 3 9 1 2      9 
3           1 2 3 9 1 2      9 
1Type of TB on card 1 = Pulmonary Smear positive, 2 = Pulmonary Smear negative, 
 3 = Extra pulmonary, 9 = Unknown 
2Type of Patient 1 = New, 2 = Retreatment, 9 = Unknown 
 
 
Q18_6_TBT If no TB card (s) available, Research assistant to ask the following:   
Which month and year(s) did you start TB treatment? 
Kodindimweziutindichaka(Zaka) pamenemunayambakulandirathandizo la 
mankhwalaachifuwa cha TB? 
Ni mumweshinshikabilimwakanshimwatendekeukubapamutiwa TB?  
Where did you receive your TB treatment? 
Kodindikutikomwemunalandilirathandizo la mankhwala a chifuwa cha TB? 
Nikwisamwalesendelaumutiwenuwa TB? 
Was it sputum positive? 
Kodizinkholodwa (Zikolala) zanuzinalimatenda a TB? 
Busheubulwelebwa TB babusangilemufikolala? 
 Month 
started 
(eg February) 
Year started Which TB treatment 
Centre did you receive 
your treatment from? 
Was it Sputum Positive? 
No Yes Unknown 
1    0 1 9 
2    0 1 9 
3    0 1 9 
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 No Yes Unknown 
Q19_HIV 
 
Have you ever been tested for HIV? 
Kodimunapimitsakomagazi? 
Bushemwalipimwapopalwakashishi ka HIV? 
0 1 9 
    
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO SECTION C, Q22_TSCT) 
 Negative Positive Unknown 
Q19_1_HIV Would you mind telling me what the result 
was? 
Kodi mungakondwele kuniuza zimene 
anapezamo? 
Bushekutimwanjebakofyatumbwikemo? 
0 1 9 
    
(IF POSITIVE, CONTINUE.  IF NEGATIVE OR UNKNOWN GO TO END) 
 No Yes Unknown 
Q20_ARV Have you ever taken ARV treatment? 
KodimunamwapomankhwalayamaARVs? 
BushemwalitalaamunwapoamaARVs? 
0 1 9 
    
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO Q21_IPT)   
   
Yes Unknown       No 
Q20_1_CARV Are you currently taking ARV treatment? 
Kodimukumwamankhwalaya ARVs palipano? 
Bushemulenwaama ARVs paliinonshita? 
0 1 9 
    
(IF YES CONTINUE.  IF NO OR UNKNOWN GO TO Q21_IPT) 
 D D M M Y Y Y Y 
Q20_1_2_SAR
V 
When did you start ARV treatment? 
(01/01/1800 if unknown) 
Kodimunayambalitikumwamankhwalaya 
ARVs? 
Nilisamwayambileukunwaama ARVs? 
        
        
 
No Yes 
 
Unknown 
Q21_IPT 
 
Have you ever been on TB Preventive Therapy 
(IPT)? 
Kodimunamwapomankhwalayochingiliza TB (IPT)? 
Bushemwalitalaamunwapoumutiwakucingililwakub
ulwelebwa TB (IPT)? 
0 1 9 
    
Thank the Respondent for their Participation 
 
 
Interviewer’s 
code 
Date 
Signature 
 d d m m y y y y 
Interviewer           
Field Manager           
1st data entry           
2nd data entry           
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Appendix 17. :Information sheet for QuantiFERON-TB Gold sensitivity and         
reproducibility studies.  
 
An Investigation into the Sensitivity and Reproducibility of the QuantiFERON-TB Gold In-
Tube Assay in Zambian Adults with Smear-Positive Tuberculosis. 
Information about this Research Study 
 
This study is being conducted by Dr Edward Raby, a student from the London School of Hygiene 
and Tropical Medicine as part of his Masters’ degree. He is working with a Zambian doctor, Dr 
Joseph Banda. 
We would like to invite you to take part in a research study. Before you make a decision, you 
need to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like more information. 
What is the purpose of the study?  
A new blood test for tuberculosis (TB) has recently been developed and is used in routine 
practice in the United States of America and the United Kingdom. However, the blood test has 
not yet been widely used or tested in Zambia. In order to better understand how useful this test 
will be here, we need to see how well it works in people who have TB. 
Why have I been invited?  
The clinic staff have identified you as having tuberculosis. 
Do I have to take part? 
It is up to you to decide. We will describe the study and go through this information sheet, 
which we will then give to you. We will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving a reason. This would 
not affect the standard of care you receive. 
What will happen to me if I take part?  
There are three parts to the study: (1) a blood test, (2) a skin test and (3) a short questionnaire 
about your health. This will take no more than thirty minutes today and five minutes next week 
to get the result of the skin test. If you have not begun your TB treatment yet, we will also ask 
you to give a second blood sample in 2 weeks time.  
What will happen to the blood? 
We will take the blood to the laboratory in Lusaka and use the blood sample to study the new 
TB blood test. With the same blood sample we will also do a special test called a CD4 count that 
tests the way your body fights infection.  
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Zambian medical guidelines recommend an HIV test in all people who have TB. If you have not 
had this done, and would like one, you will be referred appropriately. An HIV test is not a 
compulsory part of this study and you can take part without having one.  
What are the possible disadvantages and risks of taking part? 
You may get a bruise from the blood test. The skin test involves a small injection under the skin. 
This may itch over the next week. You will have to spend about 30 minutes longer in the clinic 
today. 
What are the possible benefits of taking part? 
As we already know you have TB, there will be no benefit to you of having the new TB blood 
test. It will not affect your treatment. However by having the test you are helping us understand 
how well the test works which may benefit other people in the future who have TB that is 
difficult to diagnose. 
If you have HIV and your CD4 count is very low you would be likely to benefit from treatment for 
HIV and this will be offered to you. If your CD4 count is not very low, then you would be unlikely 
to benefit from HIV treatment at the moment. 
What will happen if I don’t want to carry on with the study?  
It is up to you whether or not you would like to take part in the study. If you agree to take part, 
you can change your mind at any time and leave the study. After leaving the study you will still 
receive all the usual care in the clinic. 
Will my taking part in this study be kept confidential? 
This consent form is the only thing that will have your name on. This form will be kept in a 
locked cabinet that only Dr Raby and Dr Banda will have access to. All other papers and samples 
will be identified only by a study number and will not have your name on. They will not be used 
for any other purpose than the present study. If the results of the study are published or 
presented they will not identify you by name. 
What if there is a problem? 
If you have questions about this research study you may contact Dr. Edward Raby by email at 
edward.raby@lshtm.ac.uk. 
Alternatively, contact Dr. Joseph Banda at ZAMBART offices based at the School of Medicine at 
Ridgeway Campus Telephone number 0211 254710 or mobile +26 0955905569 at any time. This 
study has been reviewed and approved by research ethics committees at both the University of 
Zambia and the London School of Hygiene and Tropical Medicine. 
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Appendix 18. : Consent form for QuantiFERON-TB Gold sensitivity and reproducibility 
studies.  
An Investigation into the Sensitivity and Reproducibility of the QuantiFERON-TB Gold In-Tube 
Assay in Zambian Adults with Smear-Positive Tuberculosis. 
Consent Statement 
I have read the provided information about this study, or it has been read and explained to me. I 
have been informed of the potential risks involved in participating in this study as the 
coordinator or doctor has carefully explained these to me. I have been given a chance to ask 
questions about any queries that I may have and I feel that all of my questions have been 
answered. I have been informed that participating in this study is my choice and that even if I 
choose to be in this study today, I may withdraw from it at any time in the future. I have been 
informed that if I participate now, or quit/withdraw from the study at a later time, this will not 
affect my care at this clinic in any way. I have been informed that all information about me, my 
illness and my family will be kept private at all times.  My signature below indicates that I agree 
to be in this study. 
 
Name of the Participant (Please Print) _______________________________________________ 
 
Signature of the Participant __________________________________ Date ________________ 
  
 
I have read this consent to the patient.   
 
Signature of Person who read consent __________________________ Date _______________ 
  
 
I have read this document to the patient in a language that they understand.  
 
Signature of Interpreter ______________________________________ Date ______________   
 
 
Using language that is understandable and appropriate, I have explained this research project 
to the person named above.  
 
 
Signature of Investigator______________________________________ Date _______________ 
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Appendix 19. :Questionnaire for QuantiFERON-TB sensitivity and reproducibility 
studies  
 
An Investigation into the Sensitivity and Reproducibility of the QuantiFERON-TB Gold In-Tube 
Assay in Zambian Adults with Smear-Positive TB. 
 
Study Number  
Date & Time of Enrolment (DD/MM/HR:MIN)  
Age (Years)  
Sex (M/F)  
Height (cm)  
Weight (kg)  
Mid Upper Arm Circumference(cm)  
Date of TB Diagnosis (DD/MM/YYYY)  
Grade of smear positivity (1+, 2+ or 3+)  
Date Started Treatment (DD/MM/YYYY)  
Previous TB (Year)  
BCG Scar (YES/NO)  
HIV Test (Pos/Neg/Unknown)  
Last HIV Test (DD/MM/YYYY)  
ART (Yes/No)  
ART Date Started (DD/MM/YYYY)  
Accepted HIV Test Today? (Yes/No)  
Diabetes (Yes/No)  
Other medical condition  
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Appendix 20. Published studies 
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